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People with type 2 diabetes are at increased risk of age-related cognitive impairment. 
Previous literature has focused on case-control studies comparing rates of cognitive 
impairment in patients with and without diabetes. Investigations of potential risk 
factors for cognitive impairment (including those with increased prevalence in 
diabetes, such as macrovascular disease, and diabetes-specific factors such as 
hypoglycaemia) in study populations consisting exclusively of patients with type 2 
diabetes have been largely neglected. Moreover, previous studies have failed to take 
advantage of the extensive characterisation and prospective nature of longitudinal 
cohort studies to investigate the relative predictive ability of a wider range of 
potential risk factors for cognitive decline. Using data from the prospective 
Edinburgh Type 2 Diabetes Study (ET2DS) the present thesis aimed (i) to determine 
associations of cognitive decline with macrovascular disease and with severe 
hypoglycaemia, and (ii) to compare a wider range of potential risk factors in their 
ability to predict cognitive decline.   
In 2006/2007, 1066 patients with type 2 diabetes (aged 60 to 75 years) attended the 
baseline ET2DS clinic and 831 returned for the follow-up at year 4. Subjects were 
extensively characterised for risk factor profiles at baseline, and at year 4 for 
incidence of severe hypoglycaemia. Socioeconomic status was estimated using 
postcode data. Scores on seven tests of age-sensitive ‘fluid’ cognitive function, 
which were administered at baseline and at year 4, were used to derive a general 
cognitive component (‘g’). A vocabulary-based test, administered at baseline, 
estimated pre-morbid ability. Findings are reported in three parts. 1.) Macrovascular 
disease and cognition: Subjects with higher levels of biomarkers indicative of 
subclinical macrovascular disease, including plasma N-terminal pro-brain natriuretic 
peptide and carotid intima-media thickness, had significantly steeper four-year 
cognitive decline, independent of traditional cardiovascular risk factors, stroke, 
socioeconomic status and estimated pre-morbid cognitive ability. For ankle-brachial 
pressure index, the association fell just short of statistical significance. Effect sizes 
were overall modest, with fully adjusted standardised beta coefficients ranging from 
0.06 to -0.12. Little evidence was found for associations of the symptomatic markers 
of macrovascular disease with four-year change in cognitive function that was 
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independent of participants’ pre-morbid ability and socioeconomic status. 2.) Severe 
hypoglycaemia and cognition: Subjects with lower cognitive ability at baseline were 
at two-fold increased risk of experiencing their first-ever incident severe 
hypoglycaemia during follow-up. The rate of four-year cognitive decline was 
significantly steeper in those exposed to hypoglycaemia compared with 
hypoglycaemia-free participants, independently of cardiovascular risk factors, micro- 
and macrovascular disease and of estimated pre-morbid cognitive ability. Effect sizes 
again were overall modest (Cohen’s d = 0.2 to 0.3 for statistically significant 
differences in four-year cognitive decline between subjects with and those without 
hypoglycaemia, following multivariable adjustment) 3.) Consideration of a wider 
range of risk factors and cognition: A stepwise linear regression model including a 
total of 15 metabolic and vascular risk factors identified inflammation, smoking and 
poorer glycaemic control (in addition to some of the subclinical markers of 
macrovascular disease) as predictive of a steeper four-year cognitive decline. Other 
traditional cardiovascular risk factors, diabetic retinopathy, clinical macrovascular 
disease and a baseline history of severe hypoglycaemia were not included in this 
model. The interpretation of the latter finding is limited, however, by the fact that the 
stepwise regression procedure may exclude true predictors from a model when they 
correlate with already included risk factors.  
This thesis has demonstrated associations of later-life cognitive decline in people 
with type 2 diabetes with markers of subclinical macrovascular disease and poor 
glycaemic control (including hypoglycaemia) as well as other cardiometabolic risk 
factors (inflammation, smoking). Findings suggest that associations are relatively 
weak and complex due to inter-relationships amongst risk factors, and indicate a role 
of pre-morbid ability and socioeconomic status (which as risk factors are difficult to 
modify) in the relationships of risk factors with cognitive decline. Future research 
including case-control studies to compare risk factor associations between people 
with type 2 diabetes and non-diabetic older adults and randomised controlled trials to 
evaluate potential causal effects of individual modifiable risk factors on cognitive 
decline, will help to evaluate the mechanisms underlying the observation that people 




Chapter 1: Introduction: Type 2 diabetes mellitus and 
cognition 
1.1 Diabetes Mellitus 
Glucose is the ‘fuel’ required for the body to function but becomes available as 
energy to its cells only through an interaction with the hormone insulin. When the 
glucose metabolism of a person is functioning correctly, insulin levels reflect the 
glucose levels present in the blood. In diabetes mellitus, or diabetes, this delicate 
balance is lost.  
1.1.1 Pathology and diagnosis 
In healthy glucose metabolism, preproinsulin is secreted from the β-cells of the 
pancreas and is converted to insulin when blood glucose levels rise. Insulin then 
stimulates glucose transport into muscle and adipose cells and reduces glucose 
production in the liver, overall reducing the glucose levels present in the blood 
(Rains & Jain, 2011). Diabetes is characterised by chronically raised blood glucose 
levels (hyperglycaemia) and mainly occurs as type 1, type 2 and a gestational form. 
It may also develop in response to medication (iatrogenic diabetes), due to genetic 
defects or diseases of the pancreas (ADA, 2011). Ninety to 95% of newly diagnosed 
cases are of type 2 (Centers for Disease Control and Prevention, 2011). This form of 
diabetes, also referred to as non-insulin dependent diabetes mellitus (NIDDM), is the 
focus of this thesis and ‘diabetes’ implies type 2 diabetes unless otherwise specified. 
Compared with patients with other types of diabetes, type 2 diabetes patients are 
typically older and are consequently more commonly affected by co-morbidities. In 
the development of the disease, the body gradually loses its ability to control blood 
glucose levels because insulin sensitivity declines due to progressive hypo-
responsiveness of the insulin receptors (IR) (Zhao & Townsend, 2009). Initially, this 
is compensated for by an increase in insulin secretion, but subsequent reduction in β-
cell function ultimately results in  hyperglycaemia  (Biessels, 2010). Common risk 
factors for type 2 diabetes include a family history of diabetes, South Asian or black 
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ethnicity and a prior history of gestational diabetes, as well as obesity, a 
hypercalorific diet and physical inactivity (Wild & Byrne, 2006).  
 
The specific diagnostic criteria for diabetes vary between institutions and are not 
undisputed (Resnick & Harris, 1999). According to the American Diabetes 
Association (ADA, 2011), a single reading of fasting glucose levels above 7.0 
mmol/L (no caloric intake for at least eight hours), a casual reading of above 11.1 
mmol/L (without regard to time since last meal), or a reading of above 11.1 mmol/L 
in an oral glucose tolerance test (OGTT) during which the effect of an ingested 
glucose solution on fasted blood levels is tested, is sufficient for diagnosis. The 
World Health Organisation (WHO) accepts fasting plasma glucose levels above 7.0 
mmol/l or plasma glucose above 11.1 mmol/l two hours following an OGTT (WHO, 
2006). Recently, both ADA (2011) and the WHO (2011) extended their criteria to 
accept glycated haemoglobin levels (HbA1c), which reflect average blood glucose 
levels over two to three months, of above 6.5% as indicative of diabetes.  
 
Disease onset in type 2 diabetes is gradual, and several pre-diabetic states have been 
described. Impaired glucose tolerance (IGT) occurs when fasting plasma glucose 
levels are below the diagnostic criteria for diabetes (<7 mmol/l), but two-hour post-
OGTT results are 7.8 mmol/l to 11.1mmol/l. Impaired fasting glucose (IFG) is 
defined as fasting glucose levels between 6.1 and 6.9 mmol/l, with two- hour post-
OGTT below 7.8 mmol/l if measured (WHO, 2006). Around one third of individuals 
with IGT or IFG remain pre-diabetic, one third revert to normoglycaemia, and one 
third progress to diabetes (Garber, 2012). A large proportion of people with diabetes 
remain undiagnosed because symptoms are relatively mild. Patients may experience 
excessive thirst, increased urination, weight loss, blurred vision, impairment of 
growth and susceptibility to certain infections (ADA, 2002). Diabetes has serious 
long-term complications, including retinopathy, chronic renal disease, autonomic and 
peripheral neuropathy, macrovascular disease (including coronary artery disease and 
stroke), sexual dysfunction and urinary incontinence (ADA, 2002; Centers for 
Disease Control and Prevention, 2011). Overall, quality of life is reduced and 
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activities of daily living are compromised (Bruce et al., 2003; Rubin & Peyrot, 
1999).  
1.1.2 Global Prevalence 
Diabetes is not a modern day occurrence - the condition was already alluded to by 
Hippocrates and Aristotle in ancient Greece. In the first century AD, diabetes was 
described in some detail by Aretaeus as “melting down of the flesh into urine” 
(Gemmill, 1972). Today, diabetes is a global health concern, following a rapid 
increase in prevalence which has resulted in a diabetes ‘epidemic’ (Olhansky et al., 
2005). Whereas in 1935, 15 million people worldwide were estimated to be suffering 
from a form of diabetes (1% of the world population of 2 billion), this number 
exploded to 220 million in 2010 (over 3% of a world population approaching 7 
billion) (Cahn & O'Brien, 1996; US Census Bureau, 2000b). Changes in diagnostic 
criteria since 1965 (WHO, 2006) and improved case ascertainment partly account for 
this development. However, actual increases in fasting plasma glucose levels in the 
Western world (Danaei et al., 2011) are undeniable. In the US, which some have 
labelled the ‘United States of Diabetes’, and which already sees any form of diabetes 
as the seventh most common cause of death (Centers for Disease Control and 
Prevention, 2011), prevalence of any type of diabetes is expected to rise from 12% in 
2010 to 15% by 2020 (United Health Center for Health Reform & Modernization, 
2010). In Scotland, estimated prevalence was 9% in 2008, following a rise from 5% 
in 2003 (Hamer, Kengne, Batty, Cooke, & Stamatakis, 2011). This development can 
be mainly attributed to an increasingly sedentary lifestyle and excessive consumption 
(F. B. Hu, Li, Colditz, Willett, & Manson, 2003), which has led to a decrease in the 
average age at diagnosis (Harron et al., 2011; Launer, 2009). At the same time, 
society is ageing rapidly. In the US, the proportion of over 65s has increased from 
4% to 12% since 1900 (US Census Bureau, 2000a, 2004, 2011; Warsch & Wright, 
2010) and life expectancy may reach 100 within the current century (Oeppen & 






1.2 Intelligence and g 
1.2.1 Introduction and terminology 
Because diabetes has been associated with intellectual deficits and this thesis aims to 
identify some of the underlying mechanisms, the concept of intelligence and its 
relationship with ageing is briefly introduced in the sections to follow.  
 
Intelligence is usually defined as the ability to learn, understand and deal with novel 
situations (W. Johnson & Bouchard, 2005), and is consequently required for 
automated as well as for higher order mental tasks. Individual differences in 
intelligence test scores are associated with occupational achievements, social 
mobility and longevity (Deary, Penke, & Johnson, 2010). It is understood that the 
genetic make-up of an individual strongly contributes to their performance on 
intelligence tests. Over 50% of variance in test scores at age 65 may be accounted for 
by genetic factors, for instance. Yet, the precise ‘locus’ of intelligence is unclear. 
Although researchers have attempted to identify potential distinct brain areas or 
networks responsible, the evidence overall suggests a higher general efficiency in the 
brains of individuals with higher compared with those with lower intelligence 
(Deary, 2012).  
 
The term intelligence, which today is often avoided (Deary, 2000), is sometimes used 
interchangeably with cognitive ability, cognitive function, mental ability or IQ. 
Interest in the quantification of cognitive ability arose in the late 19
th
 century. For 
instance, Galton (1869; cited in (Gould, 1981)) attempted to determine individual 
differences in and heredity of intelligence through anthropometry, including 
craniometry. Whereas physiological measurements to an extent indeed reflect 
individual differences in cognitive ability (Deary, 2012), this kind of research is 
vulnerable to subjective interpretation as well as the misuse for the justification of 
ethnic inferiority. Consequently,  the beginning of the 20
th
 century saw the 
development of more objective methods, which involved psychometric testing on 




1.2.2 Hierarchical structure of intelligence 
Spearman’s 2-factor theory of intelligence 
Scores on scales of cognitive abilities are typically normally distributed, with slightly 
wider distributions for males than for females (Deary, et al., 2010). Moreover, 
individuals who perform well on one test tend to also perform well on another. In his 
‘2-factor theory of intelligence’, Spearman (1904) identified this pattern, applied 
factor analysis to scores on a number of individual tests, and named the resulting 
shared factor ‘g’ - a measure of global cognitive ability. The use of psychometric 
scales of cognitive ability simply necessitated the presence and calculation of g, 
according to Spearman (Gould, 1981). As part of his theory, he further specified that 
each individual test resulted in an additional factor unique to that test. Consequently, 
individual differences in cognitive abilities would follow a hierarchical structure, 
with a test-specific first level, or stratum, and a global g stratum (Carroll, 1993). In 
support of Spearman’s account, g is indeed observed in virtually all cases when more 
than one cognitive test is administered and accounts for around 40% of variance 
when 10-15 individual tests are included. The highest ‘saturations’ or factor loadings 
on g are typically found for tests involving spatial ability and reasoning (Deary, et 
al., 2010). Until relatively recently, it was believed that the nature of g might differ, 
depending on the specific tests from which it was extracted (Carroll, 1993), but 
repeat testing of large samples have revealed strong correlations amongst g derived 
from different standardised test batteries, demonstrating that g in fact arises 
independent of the input (W. Johnson, Bouchard, Krueger, McGue, & Gottesman, 
2004; W. Johnson, te Nijenhuis, & Bouchard, 2008).  
 
Since their discovery, Spearman’s g and the assumed hierarchical structure of 
cognitive abilities have occasionally been contested despite this highly consistent 
evidence. In a theory which assumed a single stratum, the psychometrist Louis L. 
Thurstone initially suggested the presence of at least seven ‘primary mental abilities’ 
(PMA) in absence of an overarching stratum g, although he later acknowledged that 
g indeed became apparent in his own data sets (Carroll, 1993). The psychometrist 
Howard E. Gardner similarly proposed a number of intelligences in specific fields, 
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such as ‘musical intelligence’, which were also all placed on a single stratum. 
Importantly, Gardner based his account solely on studies of gifted individuals and of 
brain damage. He did not apply factor analysis to his data (Carroll, 1993), which 
would have revealed correlations of his specific ‘intelligences’ with a general ability 
factor g (Deary, 2012).  
Carroll’s 3-stratum theory of intelligence 
A majority of other theorists agreed with the evidence for a hierarchical structure of 
cognitive abilities, and based their own accounts on Spearman’s work. For instance, 
relatively early on it was suggested that Spearman’s 2-factor theory may be extended 
to include an additional ‘group factor’ level (Burt 1917; cited in (Carroll, 1993)). 
This notion was not formally conceptualised until 20 years ago, when in his ‘3-
stratum theory’ based on analyses of more than 460 individual data sets, Carroll 
(1993) added one stratum between the third general stratum g and the first stratum 
which (similar to Spearman’s test-specific factor) is relatively narrow and reflects 
specialisation in abilities dependent on individual’s experiences, learning 
opportunities and the adoption of specific strategies (W. Johnson & Bouchard, 2005). 
This novel intermediate stratum is based on general abilities in several broad 
‘cognitive domains’ (W. Johnson & Bouchard, 2005), and therefore constitutes the 
level at which variance is shared by a number of individual cognitive tests (Deary, 
2012). Despite the clear hierarchical structure, Carroll’s model does not imply that 
higher strata dominate over lower strata. Rather, each stratum partials out the 
respective higher strata, so that for instance the first stratum represents a test-specific 
level which is not accounted for by the second and third strata (Carroll, 1993). 
 
Carroll (1993) specified his second stratum (which accounts for relatively little 
variance when compared with the remaining two strata (Deary, 2012)), as the 
domains of memory and learning, general retrieval, visual and auditory perception, 
speediness, and fluid and crystallised intelligence. Herein, Carroll provided an 
alternative to a previous suggestion for a conceptual distinction of Spearman’s g into 
the domains of ‘v:ed’ (verbal fluency, divergent thinking, numerical abilities, 
scholastic knowledge) and ‘k:m’ (perceptual speed, psychomotor and physical skills, 
spatial and mechanical abilities) brought forward by the intelligence researcher 
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Philip E. Vernon (1964 cited in (W. Johnson & Bouchard, 2005). Instead, Carroll 
followed the earlier and more commonly employed distinction of g into fluid 
intelligence (gf) and crystallised intelligence (gc), which had been suggested in the 
mid-20
th
 century by Raymond Cattell and his student John L. Horn (1941 and 
unpublished; cited in (Cattell, 1963)). 
 
The domain of fluid intelligence describes a wide range of abilities required to solve 
and adapt to novel problems (Cattell, 1963). For each, specific brain areas and 
networks are recruited, although these may be difficult to separate out in 
neuroimaging studies due to common overlaps in test demands and due to individual 
differences in the adoption of strategies during test performance (Brancucci, 2012). 
 
Crystallised ability describes a person’s knowledge in a specific field which is 
consolidated over time through the application of general ability according to 
personal interest (Cattell, 1963). It is influenced by personality, motivation, cultural 
norms and education and cannot be built up on the basis of fluid ability alone 
(Cattell, 1963; W. Johnson & Deary, 2011). Additionally, crystallised ability also 
reflects abilities which are learned more passively, such as vocabulary abilities. This 
is useful given that vocabulary abilities are unlikely to be affected by personal 
circumstances, as is the case for other estimators such as a person’s knowledge in a 
specific field or their education. Due to this, crystallised ability (at least in English-
language studies) is commonly estimated using tests in which subjects either 
pronounce given words of various difficulty or identify synonyms of given words 
(Franzen, Burgess, & Smith-Seemiller, 1997). 
 
Fluid and crystallised abilities are highly correlated. It has been suggested that the 
strength of their relationship may peak in childhood, with subsequent decreases in 
effect sizes due to differences between individuals in the ‘willingness’ to invest their 
fluid abilities into attaining crystallised ability (W. Johnson & Bouchard, 2005). As 
aforementioned, Carroll (1993) positioned processing speed alongside fluid and 
crystallised intelligence at the second stratum of his model. Speed has been found to 
consistently and strongly correlate with fluid ability, and relatively weakly with tests 
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of crystallised ability (Sheppard & Vernon, 2008). However, correlational evidence 
is unable to establish whether or not Carroll’s positioning of speed is appropriate, or 
whether perhaps speed could causally influence fluid and crystallised abilities, as has 
since also been suggested (Deary, 2012).  
Other accounts 
Clearly, Carroll’s specification of his second stratum is not definitive. Researchers 
have yet to reach agreement with regard to the number, nature and labels of cognitive 
domains (Deary, 2012), although at least the Cattell-Horn distinction into fluid and 
crystallised intelligence appears relatively well-accepted. Carroll also notes that his 
list of three strata is not necessarily exhaustive. Indeed, Johnson and Bouchard 
(2005) recently suggested and empirically supported the existence of one further 
intermediate level between Carroll’s second and third strata. This level may be 
characterised by general verbal, perceptual and image rotation abilities, according to 
the account.  
 
Irrespective of the precise number of strata, the literature appears to have reached 
consensus with regards to a hierarchical structure of cognitive abilities. All 
hierarchical models have in common one general factor g at the highest level, and 
this will be used as the main outcome in the analyses described in this thesis.  
1.3 Cognitive ageing 
1.3.1 Patterns of cognitive ageing 
During ageing, we experience a global degeneration which becomes apparent in 
telomere shortening, mitochondrial mutations, depositions of waste products and 
oxidative damage, all of which equally affect the body and the brain, and their 
functions (Kirkwood, 2005; Liu & Mori, 1999). Crystallised abilities are relatively 
robust (although these may decline in advanced dementia) whereas fluid abilities are 
more vulnerable to age-related declines (Richards & Deary, 2005).  
 
There is some disagreement on the precise starting point of declines in fluid abilities, 
with arguments brought forward for a lifelong decline with onset in the twenties, or a 
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later onset around age 60. A majority of the evidence comes from studies with cross-
sectional designs which compare cognitive performance across age groups. These 
studies tend to reveal early cognitive declines, with variations in trajectories and rates 
between the different specific abilities. Relatively automated abilities such as short-
term memory may experience slower rates of decline when compared with reasoning 
abilities or visual and prospective memory, for instance (Hedden & Gabrieli, 2004; 
Logie & Maylor, 2009; Salthouse, 2009). Lifelong declines, with onset at least prior 
to age 60, is consistent with the observation that dementia may be preceded by two to 
three decades of increasing neuropathological burden (Singh-Manoux et al., 2011a).  
 
Yet, findings from cross-sectional studies may overestimate cognitive declines due to 
specific recruitment methods (for instance targeting low-functioning care home 
populations (Hedden & Gabrieli, 2004)), as well as cohort effects. Generational 
differences in social and cultural environments and disease prevalence tend to favour 
later born cohorts in terms of cognitive function and rates of cognitive decline 
(although this may not extend to the declines which occur shortly before death) (W. 
Johnson, et al., 2004; Schaie, 2009). Further speaking against early cognitive 
declines, cognitive impairment is a disease of older age and even subtle cognitive 
deficits typically do not become apparent until later in life. Yet, advocates of 
‘lifelong declines’ note that this may be due to compensatory processes involving 
increased crystallised abilities, motivation or persistence. Moreover, cognitive 
deficits may not become apparent earlier, because maximum cognitive performance 
is rarely required in everyday situations, which may additionally be modified to 
reduce cognitive demands (W. Johnson, et al., 2008).  
 
Unaffected by cohort effects and other between-subject confounding, prospective 
evidence has particularly high validity, but findings from prospective investigations 
directly contrast cross-sectional findings and typically show that cognitive abilities 
are in fact relatively preserved or even improve until around age 60 (Salthouse, 2009; 
Schaie, 2004) (although the evidence is mixed, with some reports of longitudinal 
declines during middle-age (Singh-Manoux, et al., 2011a)). Defenders of the 
‘lifelong decline’ contention note that practice effects and selective attrition may play 
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a role here, however, to under-estimate the degree of cognitive ageing (Hedden & 
Gabrieli, 2004; Salthouse, 2009). Furthermore, longitudinal studies on cognitive 
ageing are typically focused on middle-age or later life, so that it is more difficult to 
draw conclusions on earlier declines (Tucker-Drob, 2011). Most studies are also 
vulnerable to random intra-individual variability, because they involve only two 
waves of observation (Wilson et al., 2002).  
 
At around age 60, cross-sectional and prospective studies begin to demonstrate 
agreement, both providing strong evidence for cognitive decrements. Irrespective of 
the question of the precise ‘starting point’, it is therefore clear that fluid cognitive 
abilities are subject to an age-related decline. These declines appear to become 
sharpest after age 70 (Hedden & Gabrieli, 2004). Different mechanisms may be 
responsible, including increasing neuropathological burden (further described in 
Section 1.4) and increasing neglect of skills which engage and practice cognitive 
abilities (Schaie, 2004). Despite strong relationships with level of cognitive function, 
genetic factors do not appear to be major contributors to cognitive decline (Deary, 
2012).  
1.3.2 Continuum of cognitive decline and terminology 
Within individuals, the rates of declines in the various cognitive abilities appear to 
correlate to some extent, so that people who decline in one domain tend to also 
decline in another (Tucker-Drob, 2011; Wilson, et al., 2002). Most importantly, large 
inter-individual differences are observed in the rates and trajectories of cognitive 
declines, and these are the subject of this thesis. Individuals whose cognitive ability 
is preserved or even slightly improves with age, as well as ‘normatively declining’ 
individuals, who see their cognitive ability compromised but do not reach the level of 
dementia, and patients who experience various stages of impairment and are 
eventually diagnosed with dementia all lie on one continuum, as is illustrated in 
Figure 1.1. The three groups presented in the figure are only examples; cognitive 
trajectories may lie anywhere in the space between the two dashed lines, which 
reflect complete preservation of function and pathological cognitive ageing, 
respectively. The distinctions between the groups, as well as the distinctions between 
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the various clinical phases experienced by the pathological group (bottom dashed 
line), are all blurred.  
 
At the individual level, the trajectories of declines are also unlikely to be captured as 
consistent slopes. Phases of improvements and decrements are likely. As well as 
downward conversion (e.g., from ‘normative decline’ to the pathological pathway 
leading up to dementia), long-term recovery of cognitive function (e.g., transition 
from the pathological pathway to ‘normative decline’) is possible up to the point of 
dementia diagnosis.  
 
Figure 1.1: Cognitive trajectories spanning preserved cognitive function, 
‘normative decline’ and the clinical course of dementia (adapted from Sperling 
et al., 2011) 
 
Throughout this thesis, the terms ‘cognitive dysfunction’ as well as ‘poor’ or 
‘reduced cognitive function’ all describe a lower level of cognitive ability than would 
be expected at that age as a consequence of ‘normative declines’. This reduction in 
ability may or may not reach the level of impairment and dementia. Similarly, 
‘cognitive decline’ refers to a degree of decline or impairment which is accelerated 
relative to normative decline. When accelerated cognitive decline or impairment in 
the dementia-free range is referred to, this will be specified as such (‘cognitive 
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decline short of dementia’). The latter is at the focus of this thesis, because it predicts 
future risk of dementia (Amieva et al., 2005; M. F. Elias et al., 2000), represents the 
point at which interventions may be possible, affects a larger proportion of the 
population, and is independent of formal diagnosis, which is never entirely objective 
despite guidelines (e.g., Diagnostic and Statistical Manual of Mental Disorders, 4
th
 
edition (American Psychological Association, 1994)). Reflecting the notion that the 
entire cognitive continuum rather than thresholds for impairment should be 
investigated, one commentary recently argued that “the concept of dementia is 
obsolete” (Hachinski, 2008, p. 2172).  
 
1.3.3 Theories of cognitive ageing 
This section offers a brief summary of different accounts of age-related cognitive 
declines. Some centre on parallel declines or correlations between cognitive ability 
and physiological measures such as grip strength or sensory function (Anstey, Dear, 
Christensen, & Jorm, 2005; Clay et al., 2009; Grady & Craik, 2000; Li & 
Lindenberger, 2002) (although longitudinal studies have produced mixed evidence 
on this topic (Anstey, et al., 2005; Henderson et al., 2011)). The ‘sensory deprivation 
hypothesis’ suggests that such findings reflect effects of age-related ‘sensory 
underload’ restricting processing abilities and engagement in cognitively stimulating 
activities (Lindenberger & Baltes, 1994). Alternatively, a cognitive component of 
sensory functioning may increase in load with age (Baltes & Lindenberger, 1997). 
The ‘common-cause hypothesis’ assumes that age-related deterioration in the 
‘mechanics’ of the physiological system causes both physiological and cognitive 
declines (Lindenberger & Baltes, 1994). These ‘mechanics’ may include factors 
uniquely related to the central nervous system (e.g., dopaminergic functioning) or the 
entire organism (Li & Lindenberger, 2002). Shared resources between cognitive and 
physiological measures (Li & Lindenberger, 2002) and similarities between 
cognitive and physical tasks such as dependence on the ability to follow task 
instructions (Salthouse, Hambrick, & McGuthry, 1998) are both also possible 
‘common causes’. Finally, correlations between cognitive and physiological 
measures may be artefacts of higher-ability individuals engaging in behaviour which 
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ensures high sensory performance, such as bringing their spectacles to testing 
sessions (Henderson, et al., 2011). 
 
Other accounts of cognitive ageing focus on age-related declines in attentional 
resources (Craik & Rose, 2012) or speed of processing (Salthouse, 1996). According 
to the latter, reduced speed of processing puts constraints on a ‘limited time 
mechanism’ which allows the use of information for only a limited time during 
complex tasks, as well as a ‘simultaneity mechanism’ (Clay, et al., 2009). Age-
related increases in reaction time (Fozard, Vercruyssen, Reynolds, Hancock, & 
Quilter, 1994; Le Carret, Lafont, Mayo, & Fabrigoule, 2003), age-related delays in 
event-related potentials (ERP) during task performance (Dustman et al., 1990) and 
evidence for processing speed as a predictor or mediator for declines in other 
cognitive domains (Elgamal, Roy, & Sharratt, 2011; Finkel, Reynolds, McArdle, & 
Pedersen, 2007) may be seen to support this account of cognitive ageing. 
 
In contrast, the ‘executive function’ or ‘frontal lobe hypothesis’ assumes age-related 
declines initially in frontal and prefrontal abilities as the bases for later disruption of 
other cognitive domains (Dempster, 1992). The specific abilities prone to decline 
may include the ability to strategically encode and retrieve stimuli, or to resist 
interference from distractors (Buckner, 2004). This account of cognitive ageing finds 
support in evidence of loss of inhibitor function, and reduced task switching and 
planning abilities with advanced age (Span, Ridderinkhof, & van der Molen, 2004).   
 
Finally, the ‘depth of processing’ hypothesis suggests that processing becomes 
increasingly shallow due to under-recruitment of memory systems (Craik & 
Lockhart, 1972) and is, for instance, supported by reports of differences in 
hippocampal activation between younger and older individuals during deep versus 
shallow encoding tasks (Daselaar, Veltman, Rombouts, Raaijmakers, & Jonker, 
2003). The ‘effortfulness hypothesis’ very similarly posits that age affects task 
demands, and is consistent with age-related declines in dual task performance (Tun, 
McCoy, & Wingfield, 2009), as well as links between age-related declines in 




Because each account of cognitive ageing is supported by evidence, no one ‘correct’ 
version has been agreed on to date. Many of the theorists themselves acknowledge 
large overlaps between the accounts, and it is likely that cognitive ageing is a 
complex process with a number of different underlying mechanisms.  
1.4 Pathological cognitive ageing 
1.4.1 Impairment short of dementia  
As aforementioned and illustrated in Figure 1.1, the onset of dementia is not often 
sudden - brain pathology and symptoms appear to develop over the course of 
decades. In the 1980s, the need to identify patients in the ‘grey areas’ or ‘transitional 
phases’ between ‘normative’ cognitive decline and dementia became apparent, 
because clinicians were often faced with patients who exhibited clear cognitive 
deficits but did not (yet) meet the diagnostic criteria for dementia (Geda, 2012). A 
pre-clinical phase of dementia was identified during which individuals either 
experience very subtle cognitive symptoms or are symptom-free but have biomarkers 
consistent with dementia (e.g., beta amyloid in cerebrospinal fluid) (Sperling et al., 
2011). During another pre-dementia stage recently described as ‘subjective cognitive 
impairment’ symptoms begin to become apparent (Geda, 2012). This is then 
followed by a phase involving mild degrees of impairment. There is some 
disagreement in terms of terminology and diagnostic criteria for this phase. Widely 
used terms include cognitive impairment/ no dementia (CIND), age-associated 
memory impairment (AAMI) and mild cognitive impairment (MCI). CIND is 
commonly defined as impairment which does not meet criteria for dementia 
(irrespective of whether this impairment is in a memory or another cognitive domain) 
and often includes individuals with cognitive impairment due to other medical 
conditions, such as Parkinson’s disease. In contrast, AAMI typically rules out 
presence of other medical conditions and restricts impairment to a memory domain 
(Ward, Arrighi, Michels, & Cedarbaum, 2012).  
 
MCI may be amnestic (involving memory impairment) or non-amnestic (without 
memory involvement). For amnestic MCI, a large proportion of the literature uses 
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diagnostic criteria suggested by Petersen (1999). In absence of dementia, patients 
exhibit intact activities of daily living and normal general cognitive function, but 
have abnormal memory considering their age. For single-domain amnestic MCI, 
memory is the only domain affected; for multi-domain MCI several domains 
including memory are compromised (Geda, 2012). Additionally, patients must have a 
subjective memory complaint (R. C. Petersen, et al., 1999), although in practice, this 
criterion is often neglected (Ward, et al., 2012). Diagnosis made on the basis of a 
single assessment may also be complicated by the fact that some individuals may 
have long-standing memory problems which have not actually progressed up to the 
point of assessment (R. C. Petersen, et al., 1999). Prior to meeting the diagnostic 
criteria, MCI is usually preceded by detectable acceleration of cognitive decline 
(Sperling, et al., 2011).  
 
Once diagnosis is made, between 1% and 26% of patients progress to dementia 
annually (R. C. Petersen, 2004). Increased brain pathology that is typical of 
Alzheimer’s disease (Guillozet, Weintraub, Mash, & Mesulam, 2003) suggests that 
MCI may constitute a prodromal stage of Alzheimer’s disease (Hedden & Gabrieli, 
2004). Crucially, reversion to near-normal cognitive function is also possible in 
patients with MCI, particularly when patients are younger at the time of diagnosis 
(Koepsell & Monsell, 2012; Marioni et al., 2012).  
 
1.4.2 Dementia 
In contrast to MCI, recovery to near-normal functioning is impossible in dementia. 
The condition is associated not only with severe cognitive deficits, but also with 
behavioural and motor problems, overall contributing to a high risk of dependency 
and mortality. Dementia-typical symptoms were described as early as 2000 BC in 
Egyptian writings and were referred to as “being out of one’s mind” in 50 BC. Yet,  
dementia was not recognised as a disease until the 18
th
 century (Bourgeois & Hickey, 
2009). Today, pharmaceutical treatments may offer symptomatic relief and 
decelerate disease progression, but a cure is yet to be found (Farlow, Miller, & 
Pejovic, 2008). It is also unclear whether or not dementia shares a common cause 
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with normative age-related decline, or whether it has a distinct pathology (Buckner, 
2004). Thirty-three % of women and 16% of men over the age of 65 are currently 
expected to develop dementia (Gregg et al., 2000). Due to an ageing society, global 
incidence may double between 2010 and 2050 (Gustafson, 2006). This development 
exerts severe pressures and “if left unchecked (…) will destroy the health care 
system” (The Alzheimer’s Association in the USA, 2003; cited in (B. Wood, 2005, p. 
258)). Dementia is an extremely heterogeneous condition (Etgen, Sander, Bickel, 
Sander, & Forstl, 2010). Each patient with dementia is unique depending on their 
level of dependence, support from carers, and demands faced in everyday life. On the 
basis of patterns of symptoms and brain pathology, different types of dementia have 
been identified, including Alzheimer’s disease (AD), vascular dementia (VaD), 
fronto-temporal dementia (FTD), and dementia with Lewy bodies (DLB). Diagnosis 
is only certain following post-mortem examination, although even then precise 
guidelines on the extent of pathology required for diagnosis are lacked (J. A. 
Schneider, Arvanitakis, Bang, & Bennett, 2007). AD and VaD together account for 
around 80% of cases (J. A. Schneider, et al., 2007), although it is estimated that as 
many as 50% may be affected by mixed pathology (Woodward, Mackenzie, Hsiung, 
Jacova, & Feldman, 2010). Particularly the boundaries between VaD and AD 
pathology do not appear to be distinct. It has been suggested that a majority of AD in 
fact represents misdiagnosed VaD with a minimal component of AD (Román, 2005), 
or that any distinction between AD and VaD may be futile due to an atherosclerotic 
component of AD (Craft, 2009; Scheid & Voigt, 2005).  
Alzheimer’s disease (AD) 
Initial symptoms of AD include naming difficulty and executive dysfunction (R. G. 
Morris, 2004), as well as deficits in memory and reasoning (M. F. Elias, et al., 2000; 
B. J. Small, Fratiglioni, Viitanen, Winblad, & Backman, 2000). A family history is 
associated with early disease onset in middle-age whereas risk factors for the more 
common form of late-onset AD are less clear. AD is characterised by synaptic loss, 
neuronal death, as well as high densities of extracellular neuritic senile plaques (SP) 
and intracellular neurofibrillary tangles (NFT) (Arendash & Cao, 2010; Woodward, 
et al., 2010), which are further described below. Disease progression has been 
described in six stages, with initial development of beta amyloid and subsequent 
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development of NFT (H. Braak & Braak, 1991). This pathology at first contributes to 
a reduction in hippocampal volume and atrophy in medial temporal structures, and 
later to atrophy in the temporal neocortex, parietal and frontal lobes (T. C. Alves & 
Busatto, 2006).  The specific causes of AD are debated. According to the amyloid 
cascade hypothesis, beta amyloid deposition in the brain initiates the development of 
NFTs and neuronal death (Hardy & Higgins, 1992). Symptoms may first arise when 
accumulated NFT disturb frontal circuits responsible for executive function (Román, 
2005). Another view assumes that a decline in metabolic activity in the brain leads to 
both cognitive dysfunction and beta amyloid deposition without a causal relationship 
between the two (Struble, Ala, Patrylo, Brewer, & Yan, 2010). Environmental insults 
resulting in the degeneration of neurons and accumulation of cellular breakdown 
products, as well as increased production of inflammatory cytokines have also been 
implicated as possible causal factors (Armstrong, 2009; Clark, Atwood, Bowen, Paz-
Filho, & Vissel, 2012). Finally, insulin levels appear to play a role in the deposition 
of beta amyloid, because both insulin and beta-amyloid compete for degradation by 
the insulin-degrading enzyme (IDE) (Bourdel-Marchasson, Lapre, Laksir, & Puget, 
2010; Marlowe et al., 2006). This may contribute to the observation of an increased 
prevalence of (pre-)diabetes in AD (one US study found abnormal glucose levels in 
as many as 81% of AD patients (Janson et al., 2004)), and has led some to suggest 
the terms ‘type III diabetes’ (Lester-Coll et al., 2006), ‘neural diabetes’ (McNay & 
Recknagel, 2011) or ‘brain diabetes’ (Tomycz & Friedlander, 2011) to describe AD 
brain pathology. 
Vascular dementia (VaD) 
VaD is thought to be caused by cerebral micro- and macrovascular disease evident 
for example in ischemic or hemorrhagic strokes, micro-strokes and hyperperfusive 
ischemic injury (Román, 2005). Diagnostic criteria for VaD include memory loss and 
progressive impairment with detrimental effects on activities of daily living. Lesions 
in VaD are usually less localised compared with those seen in AD patients, and 
disease onset is relatively fast, with fluctuation in severity of symptoms (Erkinjuntti, 
2007). Several subtypes of VaD have been identified. Large-vessel VaD with highly 
variable symptoms arises following multiple infarcts or strategic infarcts in cortical 
or subcortical area. Symptoms depend on the location of the infarct (Kalaria & 
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Erkinjuntti, 2006). VaD may also occur as subcortical ischaemic VaD, cortical-
subcortical VaD, ischaemic-hypoperfusive VaD and haemorrhagic VaD (Erkinjuntti, 
2007; Strachan, Reynolds, Frier, Mitchell, & Price, 2008). Subcortical VaD, for 
instance, is characterised by early deficits in attention, executive function, processing 
speed and motor slowing, with initially only mild memory impairments (Kalaria & 
Erkinjuntti, 2006). 
Other types of dementia 
Other types of dementia include dementia with Lewy bodies (DLB), characterised by 
presence of α-synuclein proteins, which may develop into neurotoxic fibrils, as well 
as AD-typical SP in the limbic and/or neocortex. Patients experience a fluctuation in 
cognitive ability, hallucinations, as well as visuospatial and motor dysfunction 
commonly associated with Parkinson’s disease (PD) (Cairns, 2004; Kahle, 2008; 
Woodward, et al., 2010; C.-K. Wu, 2011). In fronto-temporal dementia (FTD), which 
has been linked to genetic factors (Van  Deerlin, Gill, Farmer, Trojanowski, & Lee, 
2003), frontal and anterior temporal areas show symmetric bilateral atrophy (Neary 
& Snowden, 1996). Patients commonly exhibit changes in social conduct and 
personality, stereotypical behaviour, personal neglect, disinhibition, impulsivity, 
hyperactivity and PD-typical motor symptoms. Perceptual, language and spatial 
skills are relatively preserved (Neary & Snowden, 1996; Van  Deerlin, et al., 2003). 
FTD is thought to be present in between 5% and 15% of dementia cases (Van  
Deerlin, et al., 2003). 
 
1.5 Age-related changes in the brain 
The cognitively unimpaired brain undergoes certain morphological and 
neurochemical changes during ageing, some of which are also typical of dementia. 
This section describes the typical hallmarks of brain ageing and their links to age-
related cognitive declines. 
1.5.1 Cerebral atrophy 
Cerebral atrophy involves a reduction in neocortical thickness and neuron number, 
and is the most visible sign of brain ageing. The brain appears shrunk and loses 
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weight and volume (Double et al., 1996; Enzinger et al., 2005). Brain atrophy has 
been linked to low level of cognitive function or cognitive decline in healthy older 
adults (Riley, Snowdon, & Markesbery, 2002), in older diabetes patients likely to 
suffer from type 2 diabetes (Akisaki et al., 2006; K. Hayashi et al., 2011; van Elderen 
et al., 2010) and in other patient populations (Egger et al., 2008; Lanz, Hahn, & 
Hildebrandt, 2007).  
1.5.2 Cerebral vascular changes 
Neuronal function in the brain is supported by a sophisticated vascular system which 
ensures the delivery of oxygen and nutrients. This system is apparent particularly in 
the white matter of the brain, which constitutes 40-50% of total brain volume. In 
unimpaired older adults, markers of integrity of the white matter have been found to 
correlate with cognitive ability (Kerchner et al., 2012), and some evidence suggests 
that processing speed may mediate this relationship (Deary, 2012). 
Disease of the white matter is termed leukoaraiosis and includes white matter 
hyperintensities (WMH) caused by ischaemic lesions, white matter lesions (WMLs) 
and white matter atrophy (Madden, Bennett, & Song, 2009). Prevalence of 
leukoaraiosis increases with age (Longstreth et al., 1996; Salat et al., 2009). It is 
virtually always present in VaD but also in 9% to 19% of unimpaired older adults 
(Moretti et al., 2008). Presence of leukoaraiosis predicts the risk of future cerebral 
infarction and dementia, and has been linked to poor cognitive function and cognitive 
decline short of impairment in general older populations (de Groot et al., 2000; 
Debette & Markus, 2010; Verdelho et al., 2007) and in patients with type 2 diabetes 
(Reijmer et al., 2011). Cognitively impaired individuals may also experience faster 
advancement of leukoaraiosis compared with unimpaired individuals (Meyer, Rauch, 
Rauch, & Haque, 2000). The underlying mechanisms may involve cerebral 
infarctions or intracerebral haemorrhages (ICH) causing microvascular damage (for 
instance through interactions of intravascular fibrin with platelets and astrocyte 
swelling around capillaries and neurons), tissue damage, disruption to the integrity of 
the basal lamina and the blood-brain-barrier (BBB) (which is further described 
below), or alterations in cerebral blood flow (Petty & Wettstein, 2001). The 
importance of cerebral blood flow, for instance, which is high relative to other organs 
32 
 
of the body (Moretti, et al., 2008), is evidenced in associations with cognitive decline 
and impairment (Kitagawa, 2010; Rombouts, Goekoop, Stam, Barkhof, & Scheltens, 
2005; Ruitenberg et al., 2005).  
1.5.3 Hippocampal changes  
The hippocampus is an evolutionarily old structure in the medial temporal lobe and 
in humans is primarily responsible for declarative memory (J. J. Kim & Diamond, 
2002). It is a site of neuronal plasticity and structural reorganisation, but is also 
vulnerable to ageing and stress (Artola, 2008). Small volume or atrophy of the 
hippocampus has been associated with poor cognitive function and cognitive decline 
including the presence of MCI and dementia (den Heijer et al., 2010; Golomb et al., 
1994; Shi, Liu, Zhou, Yu, & Jiang, 2009). The different hippocampal regions vary in 
their degrees of vulnerability to age-related pathology. The CA1 subfield appears 
susceptible to vascular disease, the entorhinal cortex is affected in AD, and 
normative age effects are typically evident in the dentate gyrus (S. A. Small, 
Schobel, Buxton, Witter, & Barnes, 2011).  
1.5.5 Neurofibrillary changes and senile plaques 
Neurofibrillary tangles (NFT) are irregularly-shaped intraneuronal inclusions made 
up of paired helical filaments (PHF) and straight filaments (Armstrong, 2009). NFT 
occur both in the nerve cell soma and in the extracellular space as ‘ghost tangles’ 
which may result from the death and dissolution of an affected neuron and are 
eventually degraded by astrocytes (H. Braak & Braak, 1991; Gasparini, Terni, & 
Spillantini, 2007). Senile plaques (SP) develop from accumulated beta amyloids 
within a cell, and occur in pre-amyloid, neuritic and dense-cored forms (Armstrong, 
2009). NFT and SP accumulate particularly in the hippocampus (Ryan & Geckle, 
2000), and from a relatively young age. In one study, around 20% of individuals 
aged <30 years had some neurofibrillary changes in the brain. For over 90 year olds, 
this was the case for close to 100% (E. Braak et al., 1999). Presence and density of 
NFT and SP have been linked to cognitive impairment as well as low level of 
cognitive function in both cognitively impaired and unimpaired older adults 
(Arvanitakis et al., 2006; Guillozet, et al., 2003; Savva et al., 2009). In one relatively 
small study of cognitively healthy older adults and MCI patients, patterns consistent 
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with NFT and SP on positron emission topography (PET) imaging also predicted 
rates of cognitive decline over the subsequent two years (G. W. Small et al., 2012).  
Beta amyloid  
Beta amyloid is a sticky, starchy plaque-like protein which develops from amyloid 
precursor protein (APP) (Rodrigue, Kennedy, & Park, 2009). Increased levels are the 
result either of an over-production or a failure of break-down processes due to a lack 
of beta-amyloid-degrading enzymes such as nephrilysin (NEP) and insulin-degrading 
enzyme (IDE) (Rodrigue, et al., 2009). Beta amyloid has synaptotoxic effects (Bell 
& Zlokovic, 2009) and in animal models leads to vascular oxidative stress and loss of 
vasodilatory function (Hamel, Nicolakakis, Aboulkassim, Ongali, & Tong, 2008). 
Beta amyloid imaged in PET has been negatively associated with cerebral blood flow 
(Buckner et al., 2005) and plasma beta amyloid may predict the risk of any dementia 
and AD in particular (Koyama et al., 2012). Amyloid is also accumulated during 
normal ageing. In one study, as many as half of 80 to 89 year olds with intact 
cognitive function had evidence of the protein in the brain (J. C. Morris et al., 2010). 
Overall, between 20% and 40% of older adults appear to have significant beta 
amyloid deposition (Jaworski et al., 2010), and particularly in medial prefrontal 
areas, the precuneus and posterior cingulate cortex (Rodrigue, et al., 2009). Evidence 
suggests associations of beta amyloid burden (determined in PET, cerebrospinal fluid 
or autopsy) with presence of MCI and AD, as well as with lower level of cognitive 
function in cognitively healthy older adults (DeCarli et al., 2012), although opposing 
results have also been reported. In two relatively small studies of healthy older adults 
and MCI patients, post-mortem beta amyloid burden was unrelated to cognitive test 
performance prior to death (Guillozet, et al., 2003; Mufson et al., 1999).  
Tau 
Tau is a phosphorylated protein with neurodegenerative effects. Accumulation 
occurs in neurons and neuroglial cells, such as oligodendrocytes and astrocytes. Tau 
is further present in PHF which contribute to NFT, as well as in isolated dendrites 
(neuropil threads) and in SP (Gasparini, et al., 2007). In contrast to beta amyloid, tau 
is present in all cases of AD (Jaworski, et al., 2010). Evidence of tau in cerebrospinal 
fluid or PET imaging has been linked to rate of cognitive decline and conversion to 
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AD in patients with MCI, and to the rate of cognitive decline in unimpaired older 
adults (Michell, 2009; Rolstad et al., 2013; G. W. Small, et al., 2012).  
1.5.6 Changes to the blood-brain barrier 
Brain and cerebrospinal fluid are separated from the circulating blood by the physical 
and chemical boundaries of the blood-brain barrier (BBB). The BBB allows passage 
of gaseous and small lipophilic molecules but prevents perfusion of components 
from the peripheral plasma, including red and white blood cells (Kojima et al., 2003; 
Zlokovic, 2008). Harmful molecules which breach the barrier may be actively 
exported (Shalev, Serlin, & Friedman, 2009).  
 
The BBB was first demonstrated in 1909 (Goldmann, 1909; cited in (Zlokovic, 
2008), but is still relatively poorly understood. Three layers have been identified: the 
cerebrovascular endothelium between blood and brain interstitial fluid, the choroid 
plexus epithelium and the arachnoid epithelium (Shalev, et al., 2009). Three types of 
‘junctions’ are present in the endothelia. Gap junctions allow intercellular 
communication and the movement of solutes, ions and water between cells (Kojima, 
et al., 2003). Tight junctions (TJ) are formed by various proteins including occludin, 
claudins (the primary ‘seal’ of TJ), the junctional adhesion molecule (JAM-1) and 
accessory proteins such as membrane-associated guanylate kinae-like proteins or 
cingulin. Finally, adherens junctions (AJ) are formed by adhesion proteins of the 
cadherin family (Dejana, Orsenigo, & Lampugnanl, 2008; Hawkins & Davis, 2005). 
TJ and AJ have been likened to ‘zippers’ and ‘fences’, and take on gating functions 
at the BBB (Hawkins & Davis, 2005). Transport proteins (such as GLUT1 for the 
transport of glucose), receptor-mediated transcytosis or adsorptive transcytosis 
enable the passage of hydrophilic molecules (Abbott, Rönnbäck, & Hansson, 2006).  
 
A breakdown by BBB function is characterised by the disruption of junctional 
components, transbarrier leakage, the secretion of immune factors, changes of 
astrocytes from a ‘resting’ to an ‘active’ status, necrotic changes in the endothelium 
and changes in the vascular basement membrane (Serlin, Levy, & Shalev, 2011; 
Shalev, et al., 2009). BBB functioning is altered in inflammatory states, hypoxia, 
35 
 
cerebral ischemia (Hawkins & Davis, 2005; Wolburg et al., 2003), as well as in 
dementia and normative ageing (Farrall & Wardlaw, 2009). Links of BBB function 
with cognition are also evidenced in associations with cerebral blood flow (Hawkins 
& Davis, 2005). One way in which BBB function may affect cognitive function is 
through an influx of beta amyloid into the brain caused by interactions of the protein 
with RAGE on the BBB endothelium. The active transport of beta amyloid across the 
BBB into the peripheral blood may also be reduced when BBB function is 
compromised (Zlokovic, 2008).  
1.6 Relative resistance to age-related pathology: cognitive and 
brain reserve 
When investigating patterns of cognitive ageing, it is important to consider that an 
individual’s late-life cognitive ability closely mirrors their peak pre-morbid ability 
achieved in young adulthood. In fact, between one quarter and one half  of variance 
in ability remains stable over the course of the lifetime (Deary, 2012). Individual 
differences in pre-morbid ability also predict risk of late-life disease and mortality. 
Consistent with the findings of this relatively new field of ‘cognitive epidemiology’ 
(Deary & Der, 2005; cited in (Deary, 2012)),  higher pre-morbid ability (McGurn, 
Deary, & Starr, 2008) and similarly high levels of education (Qiu, Bäckman, 
Winblad, Aguero-Torres, & Fratiglioni, 2001), high occupational complexity 
(Valenzuela & Sachdev, 2006), high socioeconomic status (SES) (Zeki Al Hazzouri 
et al., 2011) and high linguistic ability (Snowdon et al., 1996) are further related to 
reduced risk of cognitive impairment in later life, and particularly impairment due to 
vascular pathology (Deary, 2012). Although it is important to note that such findings 
are based on correlations and do not necessarily imply causation (Staff, 2012), these 
markers may be seen are proxies for a ‘reserve capacity’ protective of cognitive 
impairment. The relationship of a ‘reserve capacity’ with cognitive decline which is 
short of impairment is less clear. Whereas pre-morbid ability at age 11 did not 
predict the rate of late-life decline in the Lothian Birth Cohort of 1921 (Gow et al., 
2008), it did in the Aberdeen Birth Cohort of 1921 and 1936 (Bourne, Fox, Deary, & 
Whalley, 2007), as well as in the National Survey of Health and Development 
(NSHD) (Gow et al., 2012). Late-life level of cognitive ability also predicted the rate 
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of decline in the respective cognitive domain over annual examinations during six 
years of follow-up in the Religious Orders Study of non-demented Catholic clergy 
(Wilson, et al., 2002). However, due to occasional reports of even steeper cognitive 
declines in high- than in low-reserve individuals (Karlamangla et al., 2009; Singh-
Manoux et al., 2011b), there is overall some controversy on the relationship between 
markers of reserve and the rate of cognitive decline short of impairment (Deary, 
2012).  
 
Individual differences in an ability to buffer a certain neuropathological burden may 
form the basis for the apparent individual differences in the reserve capacity which 
may affect vulnerability to cognitive ageing (Stern, 2006). For instance, it has been 
shown that up to 25% of older adults who are free of dementia prior to death in fact 
have neuropathological burden sufficient for diagnosis with AD (Neuropathology 
Group. Medical Research Council Cognitive Function and Aging Study, 2001). The 
individual differences in the capacity to preserve cognitive function may involve 
active or passive processes which have been conceptualised in different non-
mutually exclusive accounts (Staff, 2012). The model of cognitive reserve (CR) 
emphasises active compensation for brain pathology (Stern, 2009). The brain 
counteracts age-related damage on the basis of its ‘neural reserve’, by engaging 
‘software’ processes which upregulate pre-existing brain networks or cognitive 
paradigms (‘working harder’) (Staff, 2012). This may involve an increase in synaptic 
efficiency (Whalley, Deary, Appleton, & Starr, 2004), a more elaborate encoding of 
information, improved representation of the problem, application of knowledge of 
past consequences or previous solutions, and the application of algorithms which 
reduce processing requirements (Salthouse, 2003 cited in (Tucker-Drob, Johnson, & 
Jones, 2009)). Alternatively, the brain may switch to engaging novel brain networks 
or areas usually involved in higher-demand tasks during  low-demand tasks, and 
thereby allow ‘neural compensation’ (‘doing different’) (Staff, 2012; Stern, 2002). 
Despite potentially equivalent anatomical bases, these kinds of compensatory 
processes would be more successful in a high-CR than in a low-CR individual. High-
CR individuals would tolerate and compensate for a higher degree of damage and 
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therefore reach the ‘point of inflection’, at which symptoms arise, only when a 
relatively higher neuropathological burden is reached (Stern, 2002, 2006, 2009).  
 
In support of the CR account, high-reserve individuals are at higher risk of mortality 
and experience steeper cognitive decline once the ‘point of inflection’ is reached 
(Marioni, et al., 2012; Stern, 2006). Moreover, cerebral metabolism may be lower in 
high- than in low-reserve patients with dementia (Alexander et al., 1997). Networks 
recruited by high-reserve older adults may also differ from those recruited by 
younger adults with the same background (Stern et al., 2005), and animal studies 
have demonstrated beneficial effects of enriched environments (comparable to high 
SES) on neurogenesis, cell proliferation and cognitive performance (Veena et al., 
2009). Overall, this evidence suggests a degree of active compensation and re-
organisation of processing networks.  
 
In contrast to CR, functional threshold models of brain reserve capacity (BRC) (Satz, 
1993; cited in (Stern, 2009)) assume that brain damage caused by neuropathology 
affects all individuals in the same way, with no individual differences in functional 
compensation. Susceptibility to clinical expression is instead caused by individual 
differences in passive processes and the anatomical ‘hardware’ of the brain, which 
may include synapse counts and connectivity, brain size and neural density(Richards 
& Deary, 2005; Stern, 2006). Progressive neuropathology gradually decreases BRC, 
but clinical expression only occurs once BRC is depleted, at a fixed threshold or cut-
off point that is identical for all individuals (Stern, 2006, 2009).  
 
For instance, symptoms may occur when synapse counts are reduced to a specific 
number insufficient to sustain normal functioning (Stern, 2009). It follows that, rates 
of cognitive decline would be equivalent in individuals with higher and those with 
lower reserve capacity. Individuals with higher initial ability simply reach the 
threshold for cognitive deficits at later time points compared with low-ability 
individuals due to higher ‘starting points’(Tucker-Drob, et al., 2009). This type of 
model is unable to account for the aforementioned individual differences in 
recruitment of brain networks (Stern, 2009), but finds support in evidence of higher 
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BRC-related markers such as brain size or neuronal density in individuals with high 
reserve (e.g., high pre-morbid ability; high SES) as well as in the aforementioned 
individuals with dementia-typical pathology who remain symptom-free (Staff, 2012). 
Given that both CR and BRC models are supported by evidence and that their 
distinctions are hardly clear-cut (Stern, 2009), it may be likely that both play a role in 
determining individuals’ susceptibility to cognitive ageing. In line with this, Richards 
and Deary (2005) recently proposed a dynamic lifecourse model of cognitive reserve, 
which incorporates the ‘software’ and the ‘hardware’ components of CR and BRC 
and further takes into account environmental, behavioural and genetic influences. 
1.7 Cognition in diabetes 
1.7.1 Brain pathology in diabetes 
The brains of patients who suffer from diabetes tend to have increased vulnerability 
to age-related pathology compared with those of healthy older adults. For instance, 
relative to non-diabetic controls, cerebral atrophy has been found to be more severe 
in older adults with type 2 or any type of diabetes (Kumar, Anstey, Cherbuin, Wen, 
& Sachdev, 2008; van Elderen, et al., 2010). A meta-analysis of brain imaging 
studies supported these observations and additionally established links of any type of 
diabetes with cerebral macrovascular disease evident in lacunar infarcts, as well as 
with regional alterations in cerebral blood flow (van Harten, De Leeuw, Weinstein, 
Scheltens, & Biessels, 2006). Diabetes patients are further prone to cerebral 
microvascular damage (Mankovsky, Metzger, Molitch, & Biller, 1996).  
 
Despite the aforementioned link of insulin with beta amyloid deposition (Bourdel-
Marchasson, et al., 2010), the evidence for AD-typical pathology in diabetes patients 
is somewhat less consistent. For instance, one small Spanish study reports more 
severe AD-typical pathology in AD patients with diabetes compared with non-
diabetic AD patients (Valente, Gella, Fernàndez-Busquets, Unzeta, & Durany, 2010), 
whereas such results were not found in the relatively larger US-based Religious 
Orders Study or in another US study, which compared general older patients with 
type 2 diabetes and diabetes of any type respectively to non-diabetic controls 




The hippocampus is the structure of the brain which appears to be most vulnerable to 
effects from disturbed glucose metabolism. Here, type 2 diabetes (Bruehl, Wolf, & 
Convit, 2009; K. Hayashi, et al., 2011) and even reduced glucose tolerance in non-
diabetic older adults (Convit, Wolf, Tarshish, & de Leon, 2003) have been associated 
with increased atrophy and reduced volume compared with non-diabetic and 
normoglycaemic controls, respectively. Hippocampal function may also be altered 
through a shift in postsynaptic depolarisation inhibiting long-term potentiation and 
facilitating long-term depression (Artola, 2008). 
 
Moreover, diabetes patients may suffer from disruption in blood-brain barrier (BBB) 
function. In rodents, the condition has also been associated with increased 
permeability, reduced occludin content and reduced occludin immunoreactivity in 
the BBB or the blood-retinal barrier which is thought to closely resemble the BBB 
(Antonetti et al., 1998; Barber, Antonetti, & Gardner, 2000; Hawkins, Lundeen, 
Norwood, Brooks, & Egleton, 2007).  
 
Patients with diabetes are further exposed to increased levels of oxidative stress 
resulting from increased formation of reactive oxygen species (ROS) and/or reduced 
levels of antioxidant scavengers. Oxidative stress contributes to damage of lipids, 
membranes, proteins and DNA (Rains & Jain, 2011). These processes, which are 
likely to equally affect the body and the brain, then result in endothelial dysfunction, 
vascular disease and the formation of advanced glycation endproducts (Pitocco et al., 
2010). Overall, the evidence suggests that many of the aforementioned normative 
age-related changes in the brain are more severely or more commonly expressed in 
patients affected by diabetes.  
1.7.2 Associations of diabetes with reduced cognitive function short 
of dementia 
Given the evidence for structural differences between the brains of individuals with 
and those without diabetes, associations of the disease with brain function are 
unsurprising. Such links were initially noted in the 17
th
 century (Willis, 1684; cited 
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in (Coker & Shumaker, 2003)), but were disregarded until the first half of the 20
th
 
century (Miles & Root, 1922). Since then, cross-sectional case-control studies of 
diabetic individuals (presumably mainly of type 2) and non-diabetic older individuals 
have reported reduced levels of global cognitive ability, as well as reduced memory 
and visuospatial ability, poorer executive function and slower processing speed, 
evident for instance in longer latencies on reaction time tasks in people with diabetes 
(Arvanitakis, Wilson, Bienias, Evans, & Bennett, 2004; Colberg, Somma, & 
Sechrist, 2008; Grodstein, Chen, Wilson, & Manson, 2001; Richerson, Robinson, & 
Shum, 2005; van den Berg, de Craen, Biessels, Gussekloo, & Westendorp, 2006), 
despite occasional null results (Arvanitakis, et al., 2004; Perlmutter et al., 1984; 
Rodrígyez-Saldana et al., 2002). In support of diabetes-associated cognitive deficits, 
diabetes has also been linked to longer latencies and lower amplitudes in the P300 
component of event-related potentials (ERP) thought to reflect cognitive processing 
(Andreadou, Mitrakou, Constantinides, & Triantafyllou, 2012; de Freitas Alvarenga 
et al., 2005). Numerous cohort studies (and more rarely, randomised controlled 
trials), which prospectively observe trajectories of cognitive decline over at least two 
(but usually more) years of follow-up in community-dwelling subjects, have been 
performed to assess diabetes associations with cognitive decline short of dementia. 
The findings of the key studies are summarised in Table 1.1. Prevalent or incident 
diabetes (presumably mainly of type 2) has been associated with an acceleration of 
decline in global ability (Gregg, et al., 2000; Hassing et al., 2004; Tilvis et al., 2004; 
Yaffe et al., 2012), processing speed (Arvanitakis, et al., 2004; Fontbonne, Berr, 
Ducimetière, & Alpérovitch, 2001; Gregg, et al., 2000; Knopman et al., 2001; 
Spauwen, Köhler, Verhey, Stehouwer, & van boxtel, 2013; Yaffe, et al., 2012), 
verbal and non-verbal memory (Fontbonne, et al., 2001; Spauwen, et al., 2013) and 
executive function (Fontbonne, et al., 2001; Gregg, et al., 2000; Kanaya, Barrett-
Connor, Gildengorin, & Yaffe, 2004; Knopman, et al., 2001; Spauwen, et al., 2013; 
van Elderen, et al., 2010). Occasionally, equivalent rates of cognitive declines have 
been reported for subjects with prevalent or incident diabetes and non-diabetics 
(Arvanitakis, et al., 2004; Fontbonne, et al., 2001; Kanaya, et al., 2004; van den 
Berg, et al., 2006; J. H. Wu et al., 2003; Yaffe, et al., 2012), or for individuals with 







Table 1.1: Prospective evidence linking diabetes with cognitive decline short of dementia 











Main finding in fully 
adjusted models 
























Diabetes patients declined 
more steeply on DSC and 
MMSE compared with others 
(for TMT-B p=0.06) 
Fontbonne 


























Diabetes patients at increased 
risk of ‘serious worsening’ in 
verbal learning/ DSC/ Faces/ 
finger tapping when adjusted 
for covariates except BMI. 
Only association with finger 
tapping survived adjustment 
for BMI 
Knopman 













any type of 
diabetes 








Diabetes patients declined 
more steeply on DSC and 
verbal fluency  
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Wu et al. 
(2003) 
SALSA project 
of US Latinos 
2-year 
prospective 



















1. Diabetes patients 
declined more steeply on 
MMSE/ word recall 
2. Diabetes patients at 
increased risk of ‘major 
decline’ on MMSE 
3. No relationship with 
major decline on word 
recall. 
Arvanitakis 





















1. Diabetes patients 
declined more steeply in 
perceptual speed (at 
additional 0.3SD/year) 
2. No relationship between 
diabetes status and 
decline in global function 
(p=0.06) or other 
cognitive domains.  
Hassing  











any type of 
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Diabetes patients declined 
more steeply on MMSE  
Kanaya 
































Diabetes patients (females 
only) at increased risk of 
‘major decline’ in verbal 











650 >75 years  101 (15.54%); 











Age, sex 1. Diabetes patients at 
increased risk of 
‘decline’ over 5 years 
(RR 2.2) 
2. Diabetes status unrelated 
to risk over 10 years  
Van den 






596 85 year 
olds 
96 (16.11%); 





Sex, education Diabetes patients declined 
more steeply on MMSE/ 









disease or at 

















Diabetes patients declined 
more steeply on Stroop and 
picture learning (immediate 
but not delayed) 
Rouch et 
al. (2012)  
PROOF study 2-year 
prospective 
163 Mean 66 
years 
26 (15.95%) 
had IFG; 12 
(7.34%) had 























Diabetes at baseline related 
to steeper decline on TMT-B 
and Stroop; IFG related to 
steeper decline on letter 
fluency 














any type of 
diabetes 
MMSE, DSC Age, sex, 
education, race 
1. Diabetes at baseline 
related to steeper decline 
on DSC/ MMSE.  
2. No relationship between 
incident diabetes and 
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cognitive decline.  
Spauwen 




























1. In crude analysis: 
baseline diabetes related 
to 3-fold steeper decline 
on DSC and 4-fold 
steeper decline in 
executive function over 6 
and 12 years.  
2. Findings attenuated in 
fully adjusted models.  
3. No relationship between 
incident diabetes and 
cognitive decline.  
DSC, Digit Symbol Coding; MMSE, Mini-Mental State Examination; TMT-B, Trail-Making Test-B; CDR, Clinical Dementia Rating Scale; BMI, body 




A systematic review of prospective studies determined an overall 1.2 to 1.5-fold 
accelerated rate of cognitive decline in older adults with any type of diabetes which 
are presumably mainly affected by type 2 diabetes (Cukierman, Gerstein, & 
Williamson, 2005). Similarly, younger adults with type 1 diabetes typically exhibit 
cognitive deficits when compared with age-matched controls (Brands, Biessels, De 
Haan, Kappelle, & Kessels, 2005). Mainly processing speed appears to be 
compromised in diabetes (McCrimmon, Ryan, & Frier, 2012). Type 2 diabetes in 
particular is additionally associated with deficiencies of moderate effect size in 
verbal memory, attention and executive function (Reijmer, van den Berg, Ruis, 
Kappelle, & Biessels, 2010).  
 
Patients with type 2 diabetes are also at increased risk of diagnosis with MCI 
(Bourdel-Marchasson, et al., 2010) and of cognitive impairment short of dementia 
which is defined using less robust measures. For instance, compared to non-
diabetics, patients have been found to be more likely to score in the lowest tenth 
percentile of cognitive test distributions (Gregg, et al., 2000) or below the cut-point 
<24 on the Mini-Mental-State Examination (MMSE) commonly applied to identify 
cognitively impaired individuals (Cartwright et al., 2012). Conversely, prevalence of 
impairment measured in this way may be raised in diabetic populations. For instance, 
20% of over 80 year olds participating in the Fremantle Cognition in Diabetes Study 
set in Australia obtained MMSE<24 (Bruce, et al., 2003) compared with prevalence 
of between 5% and 16% in the general older (80-84 years) Australian population 
(Anstey et al., 2010). 
1.7.3 Associations of diabetes with dementia 
In terms of  clinically diagnosed dementia, baseline diabetes (presumably mainly of 
type 2) predicted 65% increased risk of Alzheimer’s Disease (AD) over six-year 
follow-up in the Religious Orders Study (Arvanitakis, et al., 2004), in Taiwan 
predicted a 63% increased risk of any dementia over 7 years of follow-up (Cheng, 
Sy, Wu, Wang, & Chen, 2012), and in an early US study increased risk of any 
dementia by 66% over follow-ups of between 0 and 15 years (Leibson et al., 1997). 
Others report even larger effect sizes. In the Rotterdam Study, risk of any form of 
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dementia was almost two-fold in type 2 diabetes patients compared with non-diabetic 
controls (Ott et al., 1999). Similarly, patients with type 2 diabetes had relative risks 
of 1.8 for AD and 2.3 for vascular dementia (VaD) in the Honolulu-Asia Aging 
Study (Peila, Rodriguez, & Launer, 2002). In a Canadian cohort, diabetes 
(presumably mainly of type 2) also predicted a two-fold five-year risk of VaD, 
although associations were not found for AD or any dementia (MacKnight, 
Rockwood, Awalt, & McDowell, 2002). In contrast, an almost five-fold increased 
risk of incident AD in 70-year old diabetes patients (presumably mainly of type 2) 
compared with non-diabetic controls over a mean of 13 years of follow-up were 
found in the Framingham Study (Akomolafe et al., 2006). Oddly, one study 
established a reduced rate of two-year global decline in older diabetics with AD 
when compared to non-diabetics with AD (Sanz, Andrieu, Sinclair, Hanaire, & 
Vellas, 2009).  
 
A systematic review of cohort studies with prospective designs established a relative 
risk for any form of dementia of 1.5 and of 2.4 for VaD in older patients with 
diagnosed diabetes (which are presumably mainly of type 2) compared with non-
diabetic controls (Lu, Lin, & Kuo, 2009). Another systematic review (which also 
grouped type 1 and type 2 diabetes together) reports similar findings, with a risk of 
1.6 for any dementia (Cukierman, et al., 2005). The apparent larger effect sizes in 
associations for VaD than for any dementia could potentially reflect the 
aforementioned inconsistency in evidence for AD-like pathology contrasting the 
relatively well-established cerebral vascular damage in patients with diabetes. 
Overall, 6% to 8% of dementia risk in over 65 year olds has been attributed to 
diabetes (Kloppenborg, van den Berg, Kappelle, & Biessels, 2008), and this 
observation may not be restricted to diagnosed diabetes. In a study of non-diabetic 
older adults, early insulin response at baseline predicted risk of AD over twelve years 
of follow-up (Rönnemaa et al., 2009).  
 
At this point is should also be noted that although a majority of epidemiological 
research has focused on the investigation of selected clinical risk factors potentially 
contributing to the increased risk of cognitive impairment in people with type 2 
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diabetes (which is reviewed in the next chapter), some evidence suggests that 
diabetes-associated cognitive impairment may be driven by reverse causation. In a 
recent analysis of the Lothian Birth Cohort 1936, participants with diabetes had 
lower late-life cognitive ability short of dementia compared with the remaining 
subjects. However, the same individuals had also been tested for cognitive ability at 
age 11, and associations of diabetes with late-life ability disappeared following 
adjustment for childhood ability. Individuals with relatively lower cognitive ability at 
age 11 were therefore at increased risk of diabetes in later life, and had also carried 
their level of cognitive ability forward into later life (Mõttus, Luciano, Starr, & 
Deary, 2013). Similar findings were previously made in a relatively larger Dutch 
study. Here, participants with and those without diabetes were found to differ on four 
of six cognitive domains, but only the group differences in memory survived the 
adjustment for a vocabulary-based estimate of peak pre-morbid ability (Ruis et al., 
2009).  
 
To summarise, the literature provides robust evidence for an increased risk of 
cognitive impairment and accelerated cognitive decline in older patients with type 2 
diabetes. Cognitive function appears to have increased vulnerability to diabetes 
during the ‘crucial periods’ during which the brain undergoes change, i.e. in early 
adulthood and later life (Biessels, Deary, & Ryan, 2008). Cognitive deficits in early 
adulthood may also aid to refute a recent suggestion that associations between 
diabetes and cognitive dysfunction are plausible on statistical grounds alone, due to 
increasing prevalence of both conditions with age (Brito, 2009). Although, some 
recent evidence suggests that links of diabetes and cognitive impairment for patients 
with type 2 diabetes in particular may be confounded by reverse causation which 
predisposes low-ability individuals both to late-life diabetes and late-life cognitive 
impairment, a number of clinical risk factors which could potentially also contribute 





Chapter 2: Review of risk factors for cognitive decline 
This chapter presents evidence on risk factors for age-related cognitive decline. 
Although a few key risk factors relevant to type 2 diabetes are selected for analyses 
in the thesis, a general overview of potential risk factors is presented here. Most are 
inter-related and may be associated with cognitive decline through various dynamic 
pathophysiological pathways involving causation, mediation, interaction and 
cumulation of effects (previously referred to as a “chain of risks” (Anstey, 2008, p. 
284), but for the purposes of this review, each is considered individually in terms of 
their association with cognition, with a focus on populations with type 2 diabetes. 
Where evidence from populations with type 2 diabetes is limited, the literature on 
patients with type 1 diabetes or healthy older adults is also considered. The literature 
overall is inconsistent with respect to terminology and the use of cognitive 
instruments, with many studies relying on brief screening instruments for dementia 
(e.g., Mini-Mental State Examination, MMSE) despite potential unsuitability to 
detect subtle cognitive deficits (Tombaugh & McIntyre, 1992). Yet, any cognitive 
test, including screening instruments such as the MMSE, are considered equivalent 
for the purpose of this review. Because the various stages of age-related cognitive 
decline described in Chapter 1 are all seen to be part of the same process of cognitive 
ageing, these are also all reviewed together. The evidence for risk factor associations 
with dementia are described separately, because in contrast to cognitive decline short 
of dementia it is a clearly defined disease.  
2.1 Metabolic risk factors 
2.1.1 Obesity 
Obesity refers to ‘above normal’ accumulation of body fat, which may have adverse 
effects on human health.  Obesity is variously measured using body weight, body 
mass index (ratio of body weight to height with a BMI>30 often used to categorise 
‘obese’ individuals  (U. S. Department of Agriculture and U. S. Department of 
Health and Human Services, 2010)) or, less frequently, proportion of body fat. The 
accurate assessment of body fat using BMI or body weight is problematic, especially 
in older people,  due to a higher rate of weight loss in heavy than in lighter 
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individuals (D. K. Johnson, Wilkins, & Morris, 2006), age-related increases in 
adipose tissue in the absence of weight gain (Han et al., 2009), and because these 
measures do not capture the distribution of adipose tissue despite the fact that 
abdominal (or central, visceral) obesity is particularly linked to poor health outcomes 
(Boyko, Fujimoto, Leonetti, & Newell-Morris, 2000; Huxley, Mendis, 
Zheleznyakov, Reddy, & Chan, 2010). Attempts have been made to quantify 
abdominal obesity using the ratio of waist circumference to hip circumference, or 
waist-to-hip ratio (WHR>0.90 in males and >0.85 in females), with some success 
(Sundell, 2005). The prevalence of obesity is increasing, especially in developed 
countries.  In the US, 13% of adults were obese at the beginning of the 20
th
 century, 
compared with 33% in the 1960s (Ogden, Yanovski, Carroll, & Flegal, 2007). In 
Europe, current prevalence is between 4 and 28% for women and between 6 and 37% 
for men (Berghöfer et al., 2008). Around 10% of obese individuals suffer from type 2 
diabetes (Sundell, 2005), and 85% of diabetes patients living in Scotland are 
overweight (BMI>25) (Wild & Byrne, 2006).  
Obesity and cognition in the general population  
In older people selected from the general population, obesity has been associated 
with reduced levels of performance on detailed neuropsychological tests  (Dore, 
Elias, Robbins, Elias, & Nagy, 2009; Gunstad, Lhotsky, Wendell, Ferrucci, & 
Zonderman, 2010; Kilander, Nyman, Boberg, & Lithell, 1997). An association 
particularly with abdominal obesity has been supported by one study of over 8000 
older females in which links between BMI and cognitive test performance were 
limited to high-WHR individuals (Kerwin et al., 2010). Some evidence suggests a 
potential for confounding of cross-sectional links by initial pre-morbid ability. In a 
Scottish birth cohort followed between age 11 and later life, late-life BMI correlated 
inversely both with ability at age 11 and with two estimates of peak pre-morbid 
ability. Additional associations between BMI and level of cognitive test performance 
aged 70 became non-significant when ability at age 11 or social class were controlled 
for, potentially demonstrating causality in the direction of cognitive ability-body 




Yet, prospective investigations support a possible effect of obesity on subsequent 
cognitive decline and even on the development of brain atrophy (M. F. Elias, Elias, 
Sullivan, Wolf, & D'Agostino, 2003, 2005; Enzinger, et al., 2005; Gunstad, et al., 
2010; Han, et al., 2009). In one relatively large-scale analysis of hospital records, 
midlife obesity was associated with a 74% increased risk of later dementia (Whitmer, 
Gunderson, Barrett-Connor, Quesenberry, & Yaffe, 2005), although a review points 
out that this may be due to obese individuals having more contact with medical 
services and therefore being more likely to receive dementia diagnosis (Lawlor, 
Lean, & Sattar, 2006). Systematic reviews on this topic suggest a small to 
moderately-sized effect of obesity on increased risk of dementia and cognitive 
decline that is short of dementia (Profenno, Porsteinsson, & Faraone, 2010; van den 
Berg, Kloppenborg, Kessels, Kappelle, & Biessels, 2009).  
 
Such observations may be related to the release of free fatty acids (Qin, Knol, 
Corpeleijn, & Stolk, 2010), adipokines leptin, adiponectin and resistin, as well as 
cortisol, oestrogen, and inflammatory cytokines from adipose tissue (Abbatecola et 
al., 2010), some of which may pass the blood-brain barrier (Sundell, 2005). Obesity 
is further associated with poor nutritional habits and resulting hyperglycaemia and 
hyperinsulinemia (Sundell, 2005), and it functions as marker of systemic vascular 
disease (Lawlor, et al., 2006). 
Obesity and cognition in people with diabetes 
In people with type 2 diabetes, high abdominal obesity or body fat levels have also 
been linked to poorer late-life cognitive ability short of dementia (Abbatecola, et al., 
2010; E. Kim et al., 2008). In one of the investigations, the highest (versus lowest) 
tertile of total body fat mass at baseline was linked to a 68% increased risk of 
reduced cognitive function (MMSE<24) after two years of follow-up (Abbatecola, et 
al., 2010).  
 
Despite the overall body of evidence suggesting a detrimental effect of obesity on 
cognition, a few studies have demonstrated positive correlations between BMI and 
cognitive test performance (Gunstad, et al., 2010; Onem et al., 2009) or apparent 
protective effects of baseline overweight on cognitive ability and decline in the 
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general population and in people with diabetes (Kuo et al., 2006; Sturman et al., 
2008; Thilers, Macdonald, Nilsson, & Herlitz, 2010). For instance, in the Fremantle 
Diabetes Study of older adults with type 2 diabetes, 76% of individuals with normal 
cognitive function at eight-year follow-up had had central overweight or central 
obesity at baseline, whereas this applied to only 62% of participants with reduced 
cognitive function short of dementia and to 61% of participants with dementia 
diagnosis by the time of follow-up (Bruce, Davis, Casey, Starkstein, Clarnette, 
Foster, et al., 2008). The apparent duality of beneficial and detrimental effects of 
body weight has been described for a number of other health outcomes in diabetic 
and the general population (Doehner et al., 2011; Fogelholm, 2010; Sohn et al., 
2012) as an ‘obesity paradox’ (Florez & Castillo-Florez, 2012), although the positive 
correlations with of body weight and cognition in particular could potentially reflect 
weight loss as a consequence of early stages of dementia (Whitmer, 2007). Overall, 
the relationship between obesity and cognition appears to be complex.  
2.1.2 Dyslipidemia 
Dyslipidaemia is generally characterised by high levels of total cholesterol and 
triglycerides, low levels of circulating high-density lipoprotein (HDL) and raised 
levels of low-density lipoprotein (LDL) cholesterol and/or low HDL:LDL ratio. HDL 
cholesterol has protective effects on the body in terms of the development of vascular 
disease, whereas LDL and total cholesterol have detrimental effects, although 
specific associations with health outcomes may be complex (Burillo et al., 2010; L. 
K. Petersen, Christensen, & Kragstrup, 2010).   
Dyslipidemia and cognition in the general population  
High midlife cholesterol has been associated with lower cognitive ability short of 
dementia in later life as well as increased risk of dementia (Kivipelto et al., 2002; 
Polidori, Pientka, Nelles, & Griffiths, 2010), but the evidence is less clear for late-
life cholesterol. Some studies have reported higher cholesterol levels or a decreased 
rate of cholesterol absorption in individuals with poorer late-life cognitive test 
performance, in those with steeper cognitive decline, in those at increased risk of 
dementia (Stampfer, 2006; van den Kommer et al., 2011), and in individuals with 
hippocampal atrophy (Wolf et al., 2004). Cholesterol may be transported across the 
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blood-brain barrier (Polidori, et al., 2010), so that the basis for associations of 
cholesterol with poorer cognitive function may involve effects of lipids on increases 
in oxidative stress (Polidori, et al., 2010) and beta amyloid deposition in the brain 
(González-Gross, Ascensión, & Pietrzik, 2001). Raised cholesterol has further been 
associated with microvascular and macrovascular damage (González-Gross, et al., 
2001; Libby, Ridker, & Maeri, 2002). However, numerous other studies have failed 
to establish links between dyslipidemia and cognitive function in people with 
dementia or in older cohorts of the general population (den Heijer, Hofman, 
Koudstaal, & Breteler, 2005; Gillum & Obisesan, 2011; Orengo et al., 1996). 
Dyslipidemia and cognition in people with diabetes 
Although diabetes is characterised by high triglycerides, high LDL and low HDL 
(Ness, Aronow, & Ahn, 2000), studies of cholesterol and cognition in exclusively 
diabetic populations are rare. One small study of middle-aged to older type 2 
diabetes patients reported similar cholesterol levels in individuals with and those 
without reduced cognitive ability short of dementia (R. H. Chen et al., 2012), 
although an earlier investigation of a similar population had established cross-
sectionally significantly lower processing speed, reaction time and working memory 
in individuals with higher compared with those with lower triglyceride levels with 
medium to large effect sizes of associations (Cohen’s d=0.33 to 0.65) (J. Cohen, 
1992; Perlmutter et al., 1988). 
 
Because cholesterol levels are modifiable, a number of randomised controlled trials 
(RCTs) have been carried out on the topic in the general population, but a recent 
review of the evidence concludes that a reduction in cholesterol does not appear to 
positively impact late-life cognitive function (van Vliet, 2012), overall leading to 
lack of consensus on the role of cholesterol in human cognition (Stampfer, 2006; van 
Vliet, 2012).  
2.1.3 Hyperinsulinaemia 
Insulin is a growth promoting hormone secreted from the pancreas in response to 
food intake and regulates glucose metabolism (Lamport, Lawton, Mansfield, & Dye, 
2009). Through binding to receptors on the cell surface, particularly in skeletal 
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muscle, insulin enables the transport of glucose through translocation of the glucose 
transporter 4 (GLUT4) to the plasma membrane and transverse tubules (Choi & Kim, 
2010). Insulin resistance occurs when the normal response to insulin is reduced and 
higher levels of insulin are then required for normal glucose uptake (Clark, et al., 
2012). Hyperinsulinaemia and insulin resistance have been linked to poor lifestyle, 
hyperglycaemia and hypercholesterolemia (Mangrum & Bakris, 1997; Tomycz & 
Friedlander, 2011), and consequently have been associated with poor health 
outcomes even in non-diabetic populations (Ausk, Boyko, & Ionnou, 2010).  
Insulin and cognition in the general population and in people with 
diabetes 
Exogenous insulin has been shown to improve cognitive function at least in the short 
term and with sufficient glucose availability (Bourdel-Marchasson, et al., 2010). Yet, 
insulin resistance or chronically elevated endogenous levels (which are common in 
type 2 diabetes due to initial enhanced production in response to insulin resistance) 
have  been linked to  poorer late-life cognitive function short of dementia and steeper 
cognitive decline in observational studies of the general population and of people 
with diabetes (Bruehl, Sweat, Hassenstab, Polyakov, & Convit, 2010; Geroldi et al., 
2005; Heyer, Mergeche, Bruce, & Connolly, 2013; Kalmijn, Janssen, Pols, Lamberts, 
& Breteler, 2000; Kuusisto et al., 1993; Umegaki et al., 2008; Young, Mainous, & 
Carnemolla, 2006). In the Honolulu-Asia Aging Study, individuals in the highest 15
th
 
percentile of the baseline distribution of insulin had a 54% increased risk of dementia 
five years later (Peila, Rodriguez, White, & Launer, 2004). Null results have also 
been reported, however (Euser et al., 2010; Isik et al., 2007), and a systematic review 
of studies including both diabetic and non-diabetic individuals concluded that the 
observational evidence for an association of hyperinsulinaemia and/or insulin 
resistance with poor cognitive outcome was inconclusive (Lamport, et al., 2009).  
The observation that the risk of dementia is greater for insulin-treated than for orally 
or dietary treated type 2 diabetes patients (Ott, et al., 1999) may well be confounded 
by factors typically related to insulin treatment, such as disease stage. Results from 
intervention studies suggest that a reduction in insulin levels may improve cognitive 
function in older patients with diabetes (Yanagawa et al., 2011) and decelerate 
cognitive decline in diabetic and non-diabetic patients with AD (Plastino et al., 2010; 
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Reger et al., 2008). This could be seen to suggest causal effects of hyperinsulinaemia 
on cognitive function. Insulin is actively transported crosses the blood-brain barrier 
into the brain, where it interacts with widely expressed receptors (Ryan & Geckle, 
2000) and affects synaptic plasticity (McNay & Recknagel, 2011). Insulin further 
stands in relation to cortisol levels (McNay & Recknagel, 2011), and competes with 
beta amyloid for degradation by the insulin-degrading enzyme (IDE), so that higher 
insulin levels may indirectly lead to higher beta amyloid levels (Bourdel-
Marchasson, et al., 2010; Marlowe, et al., 2006). However, the aforementioned 
beneficial effects of a reduction in insulin levels could potentially also arise due to 
beneficial effects of improved glycaemic control on cognition (described below).  
2.1.4 Hyperglycaemia 
The brain has high energy requirements, but is unable to synthesise glucose. Its 
glycogen supply also lasts only for a few minutes (Cryer, Davis, & Shamoon, 2003). 
Consequently, glucose consumption enhances cognitive performance in the short-
term (Greenwood, Kaplan, Hebblethwaite, & Jenkins, 2003). To maximise 
performance, different areas of the brain are able to control their glucose levels 
locally (McNay, Fries, & Gold, 2000). Yet, in the short-term, abnormally elevated 
blood glucose levels, as present in diabetic ketoacidosis (DKA), can have severe 
detrimental effects on the brain. In one study of type 2 diabetes patients, 
experimentally induced hyperglycaemia (16.5mmol/l) reduced cognitive test 
performance compared to euglycaemic states in the same individuals. Effect sizes 
ranged between small and large for the individual cognitive tests, with 
hyperglycaemia accounting for between 2% and 56% of variance in performance, the 
largest of which was found for a reaction time task (Sommerfield, Deary, & Frier, 
2004). Consequently, diurnal intra-individual fluctuations in glucose levels appear to 
be linked to fluctuations in cognitive function in this type of patient (McCall, 2005; 
Rizzo et al., 2010). 
Chronic hyperglycaemia and cognition in the general population 
Evidence suggests similarly detrimental effects on cognition of chronic as for short-
term hyperglycaemia. Chronic hyperglycaemia can be identified in tests of fasting 
plasma glucose, glucose tolerance or glycosylated haemoglobin (HbA1c). The latter 
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is considered the ‘gold-standard’ (Lamport, et al., 2009), because it reflects the 
glucose which haemoglobin cells have been exposed to over their cell cycle of two to 
three months.  
 
A number of observational studies of general middle-aged to older populations have 
linked higher blood glucose levels to lower level of cognitive ability short of 
dementia (Cartwright, et al., 2012; Tournoy et al., 2010). In one non-diabetic old-old 
cohort, increases in HbA1c during mean 32-month follow-up were also related to 
concurrent cognitive decline (Ravona-Springer et al., 2012). Individuals with 
impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) are exposed to 
chronically (for IFG) or periodically (for IGT) elevated blood glucose levels, and 
both of these pre-diabetic states have also been related to lower level of late-life 
cognitive function short of dementia (Di Bonito et al., 2007; Yaffe, Blackwell, et al., 
2004). A systematic review of studies carried out in adults of any age supports these 
findings. Prospective analyses were less consistent. IGT appears to predict cognitive 
decline only when subjects remain in a pre-diabetic state in the long-term (Lamport, 
et al., 2009), and since publication of the review, an analysis of a Scottish cohort 
found that higher baseline fasting glucose predicted a trend for decelerated annual 
decline in memory (Euser, et al., 2010). 
 
The way in which hyperglycaemia may influence cognitive function may involve 
associations with micro- and macrovascular disease and with endothelial dysfunction  
(Brownlee, 2001; Lim, MacFayden, Bakris, & Lip, 2006). Basis for this may be an 
increased formation of advanced glycation endproducts (AGE), which are produced 
intra- and extracellularly in an irreversible reaction of glucose and other reducing 
sugars with protein amino groups (Brownlee, 2001; Semba, Nicklett, & Ferrucci, 
2010). In interaction with cell surface receptors (RAGE), AGE increase levels of 
inflammation and oxidative stress on vascular walls (Méndez, Xie, Aguilar-
Hernández, & Méndez-Valenzuela, 2010). Their role as a risk factor for cognitive 
decline was shown in associations of higher AGE with an increased rate of cognitive 
decline short of dementia in a prospective study of healthy older adults and of people 
with diabetes (Yaffe et al., 2011). AGE have also been identified within 
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neurofibrillary tangles and senile plaques, which has led to the suggestion of a 
potential role in the pathogenesis of Alzheimer’s Disease (Ryan & Geckle, 2000).  
Chronic hyperglycaemia and cognition in people with diabetes 
In  younger adults with type 1 diabetes (Northam & Lin, 2010) as well as in type 2 
diabetes (Cukierman-Yaffe et al., 2009; de Wet, Levitt, & Tipping, 2007; 
Greenwood, et al., 2003; Munshi et al., 2006), a number of observational studies 
have found associations of higher chronically elevated glucose levels with poorer 
level of cognitive function, typically with medium to large effect size. For instance, 
in one study of patients with type 2 diabetes, HbA1c ≥7 was associated with a 
significant odds ratio of 4.9 for presence of reduced executive function, which was 
identified using a screening test (de Wet, et al., 2007).  
 
Observational evidence is supplemented by intervention studies manipulating the 
level of glycaemic control. In the Action to Control Cardiovascular Risk in Diabetes-
Memory in Diabetes (ACCORD-MIND) RCT study of almost 3000 older patients 
with type 2 diabetes, a statistically non-significant trend for decelerated 20-month 
decline in processing speed (but no other age-sensitive cognitive domains) was 
observed for an intensive treatment group compared with a conventional treatment 
group. The former also showed significantly slower rates of decline in total brain 
volume (-13% versus -18%) during 40-month follow-up (Launer et al., 2011). A 
smaller RCT of patients with diabetes suggested an important role of post-prandial 
glucose levels in particular. Whereas both treatment groups achieved a reduction in 
HbA1c, only one achieved better post-prandial glucose control, and this was also the 
only group which did not cognitively decline over the one-year duration of the trial 
(Abbatecola et al., 2006). 
 
Overall, and consistent with some evidence which suggests that at least for people 
aged below 70 years, diabetes may only have a small effect on cognition when good 
glycaemic control is maintained (Messier, 2005), associations between raised blood 
glucose levels and poorer cognitive ability appear relatively well-established in 
general and in diabetic populations. Yet, the rare prospective observational analyses 
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and intervention studies have produced inconsistent findings, resulting in continued 
debate on the possible causal role of hyperglycaemia in age-related cognitive decline.  
2.2 Vascular risk factors 
2.2.1 Endothelial dysfunction and hypertension 
Normal endothelial function is important for the adaptation of blood vessels to 
changes in blood flow via the release of vasodilatory (e.g., nitric oxide; NO) and 
vasoconstrictive molecules (e.g., endothelin-1) in their endothelial surface (Sundell, 
2005). Endothelial function may be measured using soluble plasma biomarkers 
(Markus et al., 2005) or the change in brachial artery diameter following induction of 
mechanical ischemia (R. A. Cohen et al., 2009). Endothelial dysfunction may have a 
role to play in the development of atherosclerosis, in which lipids, fatty streaks and 
atherosclerotic plaques develop in the arterial endothelium. Arteries ultimately 
stiffen and calcify, narrowing the arterial lumen and thickening the intima layer 
(Robertson, Fowkes, & Price, 2012) and to compensate for a reduction in blood flow 
caused by atherosclerosis, blood pressure increases, sometimes to a level defined as 
hypertension (systolic pressure >140mmHg, diastolic pressure >90mmHg (World 
Health Organization, 2011)). Factors associated with obesity and metabolic 
derangement can contribute to this process (Sundell, 2005). Featuring the largest 
small-vessel and microcirculatory endothelial surface of the body (Román, 2005), the 
brain is vulnerable to these processes. Atherosclerosis, hypertension and endothelial 
dysfunction have been linked to white matter disease (R. A. Cohen, et al., 2009; Hoth 
et al., 2007; Kearney-Schwartz et al., 2009; Markus, et al., 2005), silent cerebral 
infarcts (Dempsey, Vemuganti, Varhese, & Hermann, 2010), cerebral hypoperfusion 
and hypoxia (Skoog & Gustafson, 2006).  
Endothelial dysfunction, hypertension and cognition in the general 
population  
A small number of studies have examined endothelial dysfunction in relation to 
cognition. In two cohorts of middle-aged to older adults with cardiovascular disease, 
endothelial dysfunction measured by brachial response was associated with lower 
level of cognitive function short of dementia (R. A. Cohen, et al., 2009; Forman et 
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al., 2008); one additionally reported inverse correlations with total brain volume (R. 
A. Cohen, et al., 2009).  
 
Hypertension and cognition in the general population has been researched more 
extensively. Associations of the potential risk factor with reduced cognitive function 
were reported as early as the 1950s (Apter, Halstead, & Heimburger, 1951) and are 
now supported by findings from prospective investigations (Swan et al., 1998; 
Wilkie & Eisdorfer, 1971). In one study, each 10mmHg increase in midlife systolic 
blood pressure predicted a 5% increased risk of poorer cognitive function in later life 
(Launer, Masaki, Petrovitch, Foley, & Havlik, 1995). Despite some conflicting 
evidence (Glynn et al., 1999; Yu, Ryan, Schaie, Willis, & Kolanowski, 2009), a 
systematic review of 24 cross-sectional and prospective studies  revealed consistent 
detrimental effects of small to medium effect size of hypertension on global 
cognitive function, memory, processing speed, executive function and attention, with 
similar results in the analysis of late-life hypertension and of mid-life hypertension 
(van den Berg, et al., 2009). Some studies also reported links of hypertension with 
presence of clinically diagnosed dementia (Hayden et al., 2006; Launer et al., 2000). 
Meta-analyses revealed odds ratios of 1.6 and even 4.8 for vascular dementia on the 
basis of prospective and cross-sectional studies, respectively (Sharp et al., 2011), 
although the risk of Alzheimer’s Disease appears to be relatively unrelated to 
hypertension (Guan et al., 2011). 
Hypertension and cognition in people with diabetes 
Atherosclerosis, arterial wall stiffening, hypertension and endothelial dysfunction are 
all common in people with type 2 diabetes (D'Souza et al., 2009; Jensen-Urstad, 
Reichard, Rosfors, Lindblad, & Jensen-Urstad, 1996; Stehouwer, Henry, & Ferreira, 
2008). The limited evidence on hypertension and cognition in such patients suggests 
similar associations as in the general population. In a cross-sectional analysis of the 
Framingham Study, patients with diabetes and hypertension were at 68% increased 
risk of poor visual memory and at 103% increased risk of low scores on a composite 
measure of cognitive function (relative to the sample) compared with normotensive 
patients (P. K. Elias et al., 1997). A Russian study of middle-aged women with type 
2 diabetes also reported higher prevalence of ‘abnormalities’ in executive function in 
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subjects with hypertension (Petrova, Prokopenko, Pronina, & Mozheyko, 2010), 
although the findings were limited by the relatively young age of the sample (mean 
age 56 years) and the unclear definition of cognitive outcomes. One cross-sectional 
study of type 2 diabetes patients, which treated cognition on as a continuous 
outcome, reported associations between hypertension and lower verbal memory, but 
statistical results were not reported (Mount, 2011). In a rare prospective investigation 
of 258 old-old dementia-free individuals, the presence of hypertension also 
exacerbated diabetes-related cognitive decline. Patients with diabetes declined by -
0.29 standard deviations on the MMSE during two-year follow-up, whereas patients 
with co-morbid diabetes and hypertension declined by 0.42 standard deviations. 
Nineteen % of patients with diabetes suffered incident dementia compared with 23% 
of individuals with co-morbid diabetes and hypertension (Hassing, et al., 2004). 
Antihypertensive therapy and cognition 
Studies on the effects of antihypertensive treatment (e.g., calcium channel blockers, 
diuretics, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin II-
receptor blockers) could potentially help resolve the question of whether 
hypertension has a causal role in old-age cognitive decline. However, to date, a 
mixture of RCTs and observational studies (which are much more likely to suffer 
from confounding), have produced mixed results, with all systematic reviews and 
meta-analyses (Chang-Quan et al., 2011; Feigin, Ratnasabapathy, & Anderson, 2005; 
Qiu, Winblad, & Fratiglioni, 2005) except one (K. Shah et al., 2009), as well as a 
recent review by the Cochrane group on evidence restricted to RCTs (McGuiness, 
Craig, Bullock, & Passmore, 2009), showing that the totality of evidence is 
inconclusive. One meta-analysis notes that should beneficial treatment effects on 
cognition indeed exist, these may be restricted to reductions in risk of vascular 
dementia (Chang-Quan, et al., 2011), consistent with treatment-induced reduction in 
risk of cerebral infarction (PROGRESS Collaborative Group, 2001). Since these 
meta-analyses were carried out, two prospective investigations have reported 
beneficial treatment effects on performance on the MMSE and detailed cognitive 
tests, but these were relatively small (n≤100) intervention studies with short follow-
up (Jaiswal, Bhavsar, Jaykaran, & Kantharia, 2010; Kennelly et al., 2011). One 
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observational study revealed no consistent relationship between antihypertensive 
treatment and six-year risk of dementia (P. Schneider et al., 2011).  
 
Investigations of antihypertensive treatment and cognition in populations with 
diabetes are rare. One US study of hospital records on almost 380 000 older diabetes 
patients found that antihypertensive treatment decreased the two-year risk of 
dementia diagnosis by between 4% and 24% depending on the specific treatment (M. 
L. Johnson et al., 2012).  
 
Importantly, any effects of antihypertensive medications on cognition may be 
unrelated to a reduction in blood pressure itself, rather reflecting their effect on 
biological pathways, such as the protective effect of calcium channel blockers on 
calcium build-up in neurons (Stampfer, 2006). Conversely, one report of improved 
cognitive test performance following non-pharmaceutical treatment of hypertension 
(Vanderploeg, Goldman, & Kleinman, 1987) would support direct effects of blood 
pressure reduction on cognition.  
2.2.2 Inflammation 
Systemic inflammation is associated with a wide range of morbidities and 
behaviours, including diabetes, hypertension, physical exertion, sleep disturbances, 
uremia, chronic fatigue, depression, adiposity, over-reactivity of the immune system, 
smoking, vascular injury, use of hormone replacement therapy and alcohol intake 
(Kushner, 2001; Schmidt et al., 2002). Inflammation is an adaptive mechanism, 
which becomes problematic when it persists long-term, and occurs as 
‘inflammaging’ during normal ageing. The body is increasingly burdened by chronic 
low-grade inflammation caused by infection, tissue damage or a deterioration of 
repair mechanisms (Singh et al., 2008).  
 
Observational and intervention studies in the general population on the effects of 
anti-inflammatory or anti-oxidant therapy have linked a reduction in systemic 
inflammation to improved cognitive outcome. For example, reviews of the literature 
on observational analyses have concluded that the evidence suggests a reduced risk 
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of dementia following the long-term use of steroidal and non-steroidal anti-
inflammatory drugs (NSAIDs) (McGeer, Schulzer, & McGeer, 1996 ) or high dietary 
antioxidant intake (Ancelin, Christen, & Ritchie, 2007). For instance, a higher 
antioxidant intake was associated with a higher level of cognitive function at age 70 
in a Scottish birth cohort. The effect sizes of the findings were small (McNeill et al., 
2011), but intervention studies lend support to significant contributions by 
inflammation. In one study of younger adults, bacterial infection caused both 
increased levels of inflammatory cytokines and declines in memory (C. Holmes, 
2013), and some RCTs have revealed beneficial effects of antioxidant treatment on 
cognitive function in animals, and in humans with or without dementia diagnosis, 
although a review of the literature notes that this type of evidence overall appears to 
be inconclusive (Ancelin, et al., 2007). 
 
The way in which inflammation may impact on cognitive function involves the 
initiation of Alzheimer’s Disease-typical pathology (Akiyama et al., 2000; Giunta et 
al., 2008). In one study inflammation even predicted whether or not such brain 
pathology manifests in symptoms of dementia (Arosio et al., 2011). Inflammation 
further appears to initiate neurodegeneration (Maier & Watkins, 1998; cited in 
(Marsland et al., 2006)), the activation of astrocytes and microglia (Shalev, et al., 
2009), and has a bidirectional relationship with vascular disease. Inflammatory 
proteins have been shown to contribute to atherogenesis and endothelial dysfunction 
(Kuo et al., 2005; Libby, et al., 2002), and damage to the vessel wall appears to lead 
to a pro-inflammatory response (Nash, 2005).  
 
Circulating markers of inflammation include c-reactive protein (CRP), interleukin-6 
(IL-6), fibrinogen and tumor necrosis factor alpha (TNF-α), all of which typically 
correlate strongly (Brunsgaard et al., 1999; Yudkin, Stehouwer, Emeis, & Coppack, 
1999). The observational evidence from general older and diabetic populations on 
associations of each marker with cognition is reviewed in the sections below. 
C-reactive protein (CRP) 
The pentraxin protein CRP is produced in the liver and in adipose tissue. It is a ‘first-
class’ acute phase reactant extremely sensitive to inflammation (Teunissen et al., 
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2003) and is regulated by IL-6 (Kuo, et al., 2005). Due to its ability to initiate cell 
lysis and phagocytosis of pathogens and cell debris, CRP is extremely important to 
the immune system (Schmidt, et al., 2002), but chronically raised levels have been 
linked to poor health outcomes (Harris et al., 1999).  
CRP and cognition in the general population  
Despite high intra-individual variability in CRP (de Maat et al., 1996), single-
measurement CRP has been associated with poorer level of cognitive function short 
of dementia assessed on detailed cognitive tests or screening instruments in several 
cohorts of middle-aged to older individuals  (Dik et al., 2005; Hogue et al., 2006; 
Luciano, Marioni, Gow, Starr, & Deary, 2009; Marioni, Deary, et al., 2010; Marioni 
et al., 2009; Ravaglia et al., 2005; Schram et al., 2007), but findings are not entirely 
consistent. In one recent study of old-old adults, a composite measure of CRP and 
TNF-α was associated with lower visuospatial ability, but was unrelated to other 
domains or to global cognitive function (Arfanakis et al., 2013). Observational 
studies assessing change in cognitive function have also produced mixed results. 
Cross-sectional analyses of one Scottish cohort (Aspirin for Asymptomatic 
Atherosclerosis Trial, AAA) and one Dutch cohort found that associations between 
CRP and cognitive function persisted when estimates of peak pre-morbid ability 
were controlled for (Marioni, Deary, Murray, Lowe, et al., 2010; Teunissen, et al., 
2003). This suggests steeper estimated lifetime decline in individuals with higher 
late-life CRP. However, associations between CRP and level of cognitive function 
did not survive or substantially attenuated following adjustment for (estimated) pre-
morbid ability or for its proxy education in another Dutch cohort (Dik, et al., 2005) 
and in three further Scottish cohorts (including one with data available on IQ at age 
11) (Luciano, et al., 2009; Marioni, Deary, Murray, Lowe, et al., 2010). This 
indicates a potential confounding role of peak pre-morbid ability in any cross-
sectional links between higher inflammation and lower late-life cognitive function.  
 
In terms of prospective analyses of late-life cognitive change, baseline CRP 
predicted the rate of five-year decline short of dementia on some cognitive domains 
in the AAA trial (Marioni, et al., 2009). Similar findings were reported for another 
similarly large cohort with two- to five-year follow-up (Yaffe, Kanaya, et al., 2004; 
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Yaffe et al., 2003). However, effect sizes in these studies appeared to be small, and 
other prospective studies failed to report similar findings (Dik, et al., 2005; Schram, 
et al., 2007; Teunissen, et al., 2003). Oddly, in one study, CRP was unrelated to 
decline in several age-sensitive cognitive domains, but predicted steeper decline on 
the Mill-Hill Vocabulary Scale - an estimate of pre-morbid ability which is typically 
relatively immune to decline (Gimeno, Marmot, & Singh-Manoux, 2008).  
 
CRP has also been linked to risk of dementia in several large-scale prospective 
analyses with two- to 25-year follow-ups (Schmidt, et al., 2002; G. Xu, Zhou, Zhu, 
Fan, & Liu, 2009; Yaffe, Kanaya, et al., 2004). For instance, in the Honolulu-Asia 
Aging Study, baseline CRP in the upper three (versus the lowest) quartiles was 
linked to a three-fold increased risk of dementia 25 years later (Schmidt, et al., 
2002). One investigation  failed to establish such an association (Licastro et al., 
2000). Importantly, in all studies which report significant findings, these were 
restricted to non-Alzheimer’s Disease types of dementia, in line with a number of 
cross-sectional analyses, which have consistently revealed equivalent CRP levels in 
Alzheimer’s Disease patients and controls (Engelhart et al., 2004; Giometto, 
Argentiero, Sanson, Ongaro, & Tavolato, 1988; Schmidt, et al., 2002; G. Xu, et al., 
2009). 
 
The interpretation of evidence on CRP and cognition is complicated by heterogeneity 
in sample characteristics. For instance, in studies of older adults without dementia, 
mean CRP levels reportedly ranged between 5.7 mg/l and 12.5 mg/l (Hogue, et al., 
2006; Teunissen, et al., 2003). Acknowledging this heterogeneity, two reviews of the 
literature note that meta-analysis was not possible, but that evidence overall suggests 
that higher CRP predicts steeper late-life cognitive decline as well as increased risk 
of dementia (Kuo, et al., 2005; Schram, et al., 2007). 
CRP and cognition in people with diabetes 
Type 2 diabetes is characterised by systemic inflammation, and some evidence 
suggests that elevated CRP in particular may increase the risk of future diabetes 
(Freeman et al., 2002). Yet, studies on CRP and cognition in this type of patient are 
rare. In a cross-sectional analysis of 115 type 2 diabetes patients undergoing surgery, 
64 
 
higher pre-operative CRP was associated with poorer cognitive function short of 
dementia one day after surgery (Heyer, et al., 2013). Patients with reduced cognitive 
function short of dementia also had higher mean CRP compared with higher 
functioning patients in a similarly small study of hospitalised type 2 diabetes 
patients, with medium effect size of the association (G. Chen et al., 2011). In a cross-
sectional analysis of the only population-based study investigating CRP in diabetes 
to date (the Edinburgh Type 2 Diabetes Study), CRP levels were associated with 
lower estimated peak pre-morbid ability and lower reasoning, with an additional 
trend short of statistical significance for lower global ability. However, findings did 
not survive adjustment for the estimate of peak pre-morbid ability, suggesting that 
the findings were driven by peak pre-morbid ability. Yet, in support of potentially 
causal CRP-cognition associations, genetic variants of a gene associated with raised 
levels of CRP were linked to lower level of ability in several cognitive domains in 
the same study (Marioni, Deary, Murray, Lowe, et al., 2010).  
Interleukin-6 (IL-6) 
IL-6 is secreted by monocytes, astrocytes, endothelial cells and neurons (amongst 
others) in response to TNF-α and endotoxin (Barkhudaryan & Dunn, 1999). Levels 
increase with volume of subcutaneous adipose tissue (Yudkin, et al., 1999) and have 
been associated with poor health outcomes (Harris, et al., 1999).  
IL-6 and cognition in the general population 
A number of cross-sectional studies have linked higher levels of circulating IL-6 to 
lower cognitive function short of dementia in general middle-aged or older cohorts 
(Gimeno, et al., 2008; Marsland, et al., 2006; Rafnsson et al., 2007; Weaver et al., 
2002; Wikby et al., 2005; Wright et al., 2006a) and in patients with multiple sclerosis 
(Pantanella et al., 2010).  IL-6 may also be raised in individuals with diagnosed 
dementia (Wada-Isoe, Wakutani, Urakami, & Nakashima, 2004), and has been 
related to functional status in dementia (Zuliani et al., 2007). 
 
With respect to cognitive change, higher IL-6 has been associated with steeper 
estimated lifetime cognitive decline in cross-sectional analyses with adjustment for 
estimates of peak pre-morbid ability (Marsland, et al., 2006; Rafnsson, Deary, Smith, 
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Whiteman, Rumley, et al., 2007). In prospective investigations, IL-6 in the highest 
tertile (versus the remaining two tertiles or versus the lowest tertile) predicted a 34% 
to 100% increased risk of ‘steep’ cognitive decline short of dementia (e.g., >5 point-
decline on MMSE) during 2.5 year, seven-year (Weaver, et al., 2002) or two-year 
follow-ups  (Yaffe, et al., 2003). In the Edinburgh Artery Study, higher baseline IL-6 
was associated with a steeper four-year decline in later life, although findings did not 
survive adjustment for cardiovascular disease, vascular risk factors, depression and 
diabetes status (Rafnsson, Deary, Smith, Whiteman, Rumley, et al., 2007). Another 
British study also failed to establish associations of IL-6 with cognitive decline short 
of dementia. An exception was the Mill-Hill Vocabulary Scale, which may be used 
to estimate peak pre-morbid ability. For this test, a decline was predicted by higher 
baseline IL-6 (as had also been found for CRP in the same study) (Gimeno, et al., 
2008). As for CRP, studies on IL-6 are heterogeneous, with mean IL-6 levels ranging 
between 1.6 pg/ml (Wright et al., 2006b) and 4.6 pg/ml (Weaver, et al., 2002), and 
the literature on IL-6 and cognition in the general population has not been meta-
analysed to date. 
IL-6 and cognition in people with diabetes 
Consistent with increased systemic inflammation in diabetes, endothelial expression 
of IL-6 appears to be increased in patients with diabetes (Hartge, Unger, & 
Kintscher, 2007). The limited evidence points to significant associations of IL-6 with 
cognition in patients with type 2 diabetes as in the general population. In the 
Edinburgh Type 2 Diabetes Study, higher IL-6 was linked to lower level of cognitive 
function short of dementia. Specifically, each two-fold increase in IL-6 was 
associated with 0.17 lower scores on a global ability factor. The finding survived 
adjustment for an estimate of peak pre-morbid ability, suggesting steeper estimated 
lifetime decline in individuals with higher late-life IL-6 (Marioni, Strachan, et al., 
2010).  
 
Finally, in support of an important role of IL-6 in cognition, knockout of the IL-6 
gene appears to improve learning ability in rodents (Braida et al., 2004). In the 
general human population, genetic variants associated with levels of IL-6 may also 
predict the level of cognitive function short of dementia in older age (Sasayama et 
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al., 2011), as well as the age at onset of Alzheimer’s Disease (Papassotiropolous et 
al., 1999), although the evidence overall is inconsistent (Baune et al., 2008; Eriksson 
et al., 2011; Mansoori et al., 2010; Marioni, Deary, Murray, Fowkes, & Price, 2010).  
Fibrinogen 
The acute-phase cytokine fibrinogen is produced in the liver (Schultz & Arnold, 
1990), and circulating levels are affected by sex, ethnicity, socioeconomic status and 
vascular risk factors (Fibrinogen Studies Collaboration, 2007).  
Fibrinogen and cognition in the general population 
Several cross-sectional analyses (Wada et al., 2011), including three of Scottish 
middle-aged to older cohorts (Luciano, et al., 2009; Marioni, et al., 2009; Rafnsson, 
Deary, Smith, Whiteman, Rumley, et al., 2007), have associated higher fibrinogen 
with lower late-life cognitive function short of dementia in the general population, 
although others have failed to establish such findings  (Elwood, Pickering, & 
Gallacher, 2001; J. Huang et al., 2011). In one Japanese study of older adults, higher 
fibrinogen was also associated with a higher grade of white matter lesion with small 
to medium effect size (r=0.19) (Wada, et al., 2011). In the Edinburgh Artery Study 
which adjusted for vocabulary-based estimated peak pre-morbid ability in cross-
sectional analyses and also had a prospective follow-up four years after baseline, 
higher fibrinogen was associated an increased rate of estimated lifetime decline in 
reasoning and with steeper actual late-life decline in verbal memory, although it was 
unrelated to decline in global ability (Rafnsson, Deary, Smith, Whiteman, Rumley, et 
al., 2007). One prospective Scottish study on actual lifetime cognitive change 
between childhood and older age, found that associations between higher late-life 
levels of fibrinogen and steeper lifetime cognitive decline were restricted to a 
measure of reaction time (Luciano, et al., 2009). Another prospective investigation 
carried out in middle-age to older adults found fibrinogen to be unrelated to five-year 
decline on a number of cognitive domains, with the exception of a test of executive 
function (Marioni, et al., 2009). Finally, fibrinogen has also been linked to future risk 
of dementia of any type, vascular dementia and Alzheimer’s Disease in several 
prospective investigations (van Oijen, Witteman, Hofman, Koudstaal, & Breteler, 
2005; G. Xu, Zhang, Zhang, Fan, & Liu, 2008). For instance, in one study each 
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standard deviation increase in fibrinogen increased the risk of dementia by 26% 
during six years (van Oijen, et al., 2005).  
Fibrinogen and cognition in people with diabetes 
Levels of fibrinogen are raised in type 2 diabetes (Dunn & Ariëns, 2004), but the 
investigation of their relationship with cognition has been neglected in this group of 
patients. In the Edinburgh Type 2 Diabetes Study, higher fibrinogen was associated 
with lower global ability. Each unit increase in fibrinogen was associated with a 
decrease by 0.09 on a global ability factor (Marioni et al., 2011).  Genetic variants 
associated with fibrinogen were further significantly related to late-life level of 
cognitive function (although the association between the genetic variant and 
fibrinogen levels were relatively weak in this cohort) (Marioni, et al., 2011). The 
latter finding was contrasted by investigations of fibrinogen polymorphism and 
cognition in the general population, which to date has been limited to analyses of 
three Scottish cohorts and have produced inconsistent results (Marioni, Deary, 
Murray, Lowe, et al., 2010; Marioni, et al., 2011). 
Tumor necrosis factor alpha (TNF-α) 
TNF-α is the ‘master cytokine’ which initiates the inflammatory cascade (Clark, et 
al., 2012)  and has been linked to chemical processes in the central nervous system. 
Beta amyloid deposition in AD initiates TNF-α production (Medeiros et al., 2010), 
and the cytokine acts on afferent fibres in the spinal cord and interacts with 
neurotransmitters, including glutamate (G. M. Holmes, Hebert, Rogers, & Hermann, 
2004). 
TNF-α and cognition in the general population  
The evidence on associations of TNF-α with cognition is mixed and with exception 
of a single study showing that serum levels were raised in people with cognitive 
impairment short of dementia as well as in patients with Alzheimer’s disease 
(Àlvarez, Cacabelos, Sanepro, Garcìa-Fantini, & Aleixandre, 2007), the literature to 
date has focused on dementia rather than on the spectrum of late-life cognitive 
function and decline. A number of relatively small cross-sectional studies reported 
raised plasma levels in patients with Alzheimer’s Disease relative to controls with a 
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medium effect size of unadjusted associations (Brunsgaard, et al., 1999; Fillit et al., 
1991). In direct contrast, two further investigations set in the Netherlands and Japan 
found equivalent levels of TNF-α in patients with Alzheimer’s Disease, in those with 
vascular dementia and in controls (Engelborghs et al., 1999; Yasutake, Kuroda, 
Yanagawa, Okamura, & Yoneda, 2006). Another study even reported lower levels in 
Alzheimer’s Disease and multi-infarct dementia than in age-matched controls 
(Cacabelos, Alvarez, Franco-Maside, Fernández-Novoa, & Caamaño, 1994), 
although the latter finding could reflect survival bias of patients with lower TNF-α. A 
rare prospective investigation reported a higher number of TNF receptors in plasma 
and cerebrospinal fluid of individuals who went on to develop dementia compared 
with a group who remained cognitively stable during four to six years. Effect sizes of 
unadjusted group comparisons were of medium size (Cohen’s d=0.33 to d=0.54; 
depending on the specific TNF receptor under investigation) (Buchhave et al., 2010; 
J. Cohen, 1992). 
 
In support of TNF-α associations with cognition, genetic variants coding for TNF-α 
have been found to predict the level of late-life cognitive function short of dementia 
(Baune, et al., 2008), as well as the presence or risk of dementia (Albani et al., 2012; 
Brunsgaard et al., 2004; Fung et al., 2005), although this type of evidence overall is 
also inconsistent (Pantanella, et al., 2010). Finally, causal effects of TNF-α on 
cognition are supported by beneficial effects of anti-TNF therapy on improved 
cognitive function in an intervention study of older adults with rheumatoid arthritis 
and by reduced beta amyloid deposition following such therapy in rodents (Y. M. 
Chen, Chen, Lan, & Chen, 2010; Medeiros, et al., 2010).  
 2.2.3 Smoking 
Smoking is a vascular risk factor with complex relationships to other risk factors. 
Smokers tend to come from lower socioeconomic backgrounds (Hiscock, 2007), 
have greater abdominal fat mass and diabetes risk, but also have lower BMI 
compared with non-smokers (Tonstad, 2009; Wild & Byrne, 2006). Smoking 
cessation is linked to weight gain (Wild & Byrne, 2006). Research into smoking and 
cognition is complicated, because data is particularly affected by survival bias, 
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selective attrition and recall bias. Overall, however, the literature has revealed 
relatively consistent findings of negative associations between smoking and 
cognition. 
Smoking and cognition in the general population  
Cross-sectional evidence from cohorts from the general population have revealed 
links between smoking and lower late-life cognitive function short of dementia 
(Corley, Gow, Starr, & Deary, 2012; Stewart, Deary, Fowkes, & Price, 2006). Such 
evidence may be restricted by observations that estimated or actually measured 
childhood ability predicts later smoking (Corley, et al., 2012; Richards, Jarvis, 
Thompson, & Wadsworth, 2003; Stewart, et al., 2006), but associations of smoking 
with lower late-life cognitive function in the Lothian Birth Cohort 1936 survived 
adjustment for IQ at age 11 showing that findings were independent of potential 
confounding by pre-morbid ability (Corley, et al., 2012).  
 
Instead, associations of smoking with poorer cognitive outcome are likely to involve 
a degree of causality. Although nicotine itself appears to facilitate neurotransmission 
in the cholinergic system and has neuroprotective and anti-oxidant properties (Swan 
& Lessov-Schlaggar, 2007), a total of 4700 compounds of smoke have toxic 
properties. Due to carboxyhemoglobin, smoking contributes to deficiencies in 
oxygen supply. It increases the vascular burden of the body through an increase in 
platelet aggregability and decreases HDL-cholesterol levels, initiating 
atherosclerosis, and contributes to reduced blood-brain barrier function, to oxidative 
stress, inflammation and reduced anti-oxidant levels  (R. S. Shah & Cole, 2010; 
Swan & Lessov-Schlaggar, 2007).  
 
In support of a causal relationship, prospective investigations have also revealed 
significant associations. For instance, in one English study of 3000 middle-aged 
adults, heavy smoking at age 53 (>20 cigarettes/day) was linked to a mean decline in 
memory since age 43 which was two words greater (4% of total words to be recalled) 
compared with non-smokers at age 53 (Richards, et al., 2003). A systematic review 
of prospective studies concluded that although having ever smoked does not appear 
to predispose individuals to steeper late-life cognitive decline short of dementia 
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compared to people who have never smoked, current smokers are at increased risk of 
cognitive decline compared with former smokers and those who never smoked 
(Anstey, von Sanden, Salim, & O'Kearney, 2007). Although another systematic 
review established only a non-significant trend for the latter association (R. Peters et 
al., 2008), two more recent investigations support the evidence for current smokers 
(compared with former/ never smokers) experiencing steeper late-life cognitive 
decline (N. Collins, Sachs-Ericsson, Preacher, Sheffield, & Markides, 2009; 
Nooyens, van Gelder, & Verschuren, 2008). One recent study, which revealed a 
three-fold lower ten-year risk of reduced cognitive function short of dementia in 
current/ past smokers compared with people who had never smoked seems to be at 
odds with the remaining literature (C.-C. Wang et al., 2010). 
 
Prevalence of smoking may be reduced in patients with diagnosed dementia (Lester, 
Lyubarova, Kirtani, Macina, & Kohen, 2011), but a number of prospective 
investigations have linked smoking to an increased risk of future dementia. One large 
US study reported linear dose-response relationships between the amount smoked 
(up to heavy smoking) and risk of Alzheimer’s Disease over several decades of 
follow-up, as well as with density of neurotic plaques (Tyas et al., 2003). A meta-
analysis of prospective studies overall reported 1.8-fold increased risks for both 
Alzheimer’s Disease and vascular dementia in current smokers versus former and 
never smokers. Risk of Alzheimer’s Disease was even increased for current smokers 
compared with former smokers, suggesting a potential for the brain to ‘recover’ from 
damage (Anstey, et al., 2007). Since the systematic review was completed, further 
prospective investigations of smoking and risk of dementia have supported this 
evidence (Rusanen, Kivipelto, Quesenberry, Zhou, & Whitmer, 2011; Rusanen et al., 
2010). 
Smoking and cognition in people with type 2 diabetes 
Smoking appears to be less prevalent in patients with type 2 diabetes compared with 
the general population (Schipf et al., 2009). Given that smokers are at increased risk 
of diabetes (Tonstad, 2009), this suggests that people may be likely to quit following 
diagnosis with diabetes. To date, studies have neglected the investigation of smoking 
and cognition in populations with diabetes. One early Dutch study of 489 men from a 
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general older population found that individuals with cardiovascular disease and/or 
diabetes declined by 1.3 points on the MMSE (maximum score 30) during three 
years, compared with a 0.2 point improvement in people free of both of these risk 
factors (Launer, Feskens, Kalmijn, & Kromhout, 1996). However, because 
cardiovascular disease and diabetes were grouped together, the specific role of 
diabetes in this association is unclear. In another study exclusively of older patients 
with type 2 diabetes, smokers were less efficient in diabetes self-management 
compared with non-smokers, which led the authors to suggest poorer cognitive 
function in the group of smokers (Gucciardi, Mathew, Demelo, & Bondy, 2011). 
 
Despite the overall lack of evidence, the findings for associations between smoking 
and poor cognitive outcome from the general population may well extend to people 
with diabetes. Because people with type 2 diabetes are less likely to smoke and 
because recent decreases in prevalence of smoking (R. S. Shah & Cole, 2010) 
contrasts the increasing prevalence of diabetes-associated cognitive dysfunction, 
smoking presumably does not account for the increased risk of poor cognitive 
outcome in diabetes. 
2.3 Microvascular disease 
2.3.1 Renal microvascular disease 
Microvascular disease, or disease of small blood vessels, is often symptomless but 
may affect renal and retinal function. Renal microvascular dysfunction is caused by 
glomerular and tubular endothelial damage, and becomes evident as 
microalbuminuria (measured in the albumin/creatinine ratio) (Weiner et al., 2009). 
Microalbuminuria is also associated with clinical and subclinical macrovascular 
disease (H. Kramer et al., 2004; Yuyun et al., 2004). In the general population and in 
patients with macrovascular disease, microalbuminuria or low serum albumin levels 
have been associated with poorer level of cognitive function short of dementia (Kuo, 
Lin, & Yu, 2007; Llewellyn, Langa, Friedland, & Lang, 2010; Mizrahi, Blumstein, 
Arad, & Adunsky, 2008; Ng, Feng, Niti, & Yap, 2008). In unadjusted analyses of 
one study, individuals in the lowest tertile of albumin were also at almost two-fold 
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increased risk of declines of ≥2 points on the MMSE during two year follow-up (Ng, 
Niti, Feng, Kua, & Yap, 2009).   
 
Although microalbuminuria is present in around 20% of type 2 diabetes patients 
(Macisaac & Jerums, 2011), studies on this topic are rarely carried out in people with 
diabetes. In an analysis of over 28 000 patients with any type of diabetes (37%) 
and/or vascular disease, baseline microalbuminura was associated with a lower level 
of cognitive function short of dementia at baseline, and with a 22% increased risk of 
≥3 point declines on the MMSE over five years (Barzilay et al., 2011). Overall, this 
suggests a similar association between renal microvascular disease and cognition in 
diabetic subjects as in the general population. 
2.3.2 Retinopathy  
Retinopathy is characterised by basement membrane thickening and loss of pericytes 
essential for retinal microvessel stability (Durham & Herman, 2011), and has been 
associated with metabolic derangements, including poor glucose control (Aso, 
Inukai, Tayama, & Takemura, 2000; WHO, 2011), dislipidemia and hypertension 
(Serlin, et al., 2011). Around 80% of insulin-treated patients with type 2 diabetes 
experience diabetic retinopathy (DR) within 20 to 25 years of disease onset (Durham 
& Herman, 2011), and DR accounts for around 5% of blindness globally 
(Chaturvedi, 2007). 
 
Due to homology between retinal and cerebrovascular cells, the state of retinal small 
vessels closely mirrors the state of the microvasculature of the brain (Patton et al., 
2005). This is reflected in associations between retinopathy and increased white 
matter hyperintensities (Ferguson et al., 2003), reduced grey matter volume (Musen 
et al., 2006) and increased number of silent brain infarcts (Kwon et al., 2007). In the 
general population, retinopathy has been associated with lower cognitive function 
short of dementia (M. L. Baker et al., 2007; Wong et al., 2002) and with presence of 




Consistent with evidence from the general population, a cross-sectional analysis of 
the Edinburgh Type 2 Diabetes Study associated presence and severity of retinopathy 
with a lower level of cognitive function short of dementia in type 2 diabetes patients, 
with a small effect size of associations following multivariable adjustment (Ding et 
al., 2010). In an analysis of younger patients with type 1 diabetes, retinopathy was 
also associated with lower performance on a number of cognitive tests with moderate 
to large effect size. Additionally, 33% of individuals with retinopathy had evidence 
of white matter lesions of the basal ganglia, compared with only 4% of a retinopathy-
free group (Ferguson, et al., 2003). Prospective analyses support these findings. One 
study of young to middle-aged type 1 diabetes patients reported that the development 
of DR over seven years was linked to steeper concurrent cognitive decline, although 
baseline DR was only weakly related to subsequent cognitive decline (Ryan, Geckle, 
& Orchard, 2003). A recent systematic review established a three-fold increased risk 
of poor cognitive outcome including dementia in patients with DR compared with 
those without (Crosby-Nwaobi, Sivaprasad, & Forbes, 2011), supporting results from 
a previous systematic review (Ding et al., 2008). Yet, more recently, evidence on 
associations between retinopathy and cognition from populations with diabetes and 
the general population has been mixed (de Bresser et al., 2010; Fergenbaum et al., 
2010; Qiu et al., 2010). 
2.4 Glucocorticoids 
Cortisol is a glucocorticoid secreted from the adrenal glands and has receptors in a 
range of organs. In the brain, receptors are most abundant in the hippocampus and 
cortex (McEwen & Seeman, 1999). Cortisol levels follow a diurnal slope and are 
affected by the hypothalamus-pituitary-adrenal (HPA) axis, which functions 
according to mood and sensual stimulation (Björntorp & Rosmond, 2000). In the 
short-term, cortisol provides energy and increases survival (Porter & Landfield, 
1998), but chronically raised levels due to disease (e.g., Cushing’s syndrome), stress, 
advanced age or obesity (Liu & Mori, 1999) are maladaptive. 
2.4.1 Glucocorticoids and cognition in the general population  
Cross-sectional analyses have linked high cortisol to ‘disorientation’ in stroke 
patients (Marklund, Peltonen, Nilsson, & Olsson, 2004), to lower prefrontal cortex 
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and left hippocampal volumes in patients with psychiatric illness (Carrion, Weems, 
Richert, Hoffman, & Reiss, 2010; Mondelli et al., 2010), and to lower level of 
cognitive function short of dementia in the general middle-aged to older population 
(Beluche, Carrière, Ritchie, & Ancelin, 2010; Franz et al., 2011; Kilander, et al., 
1997; Lara et al., 2013). Diurnal cortisol slopes may also be steeper in middle-aged 
individuals with higher cognitive function relative to those with lower cognitive 
function (Stawski et al., 2011). Although null results on cortisol and level of 
cognitive function short of dementia have occasionally also been reported (Schrijvers 
et al., 2011), one study reported higher cortisol in individuals with diagnosed 
dementia compared with dementia-free individuals (Lara, et al., 2013) 
 
In addition to potential effects of cortisol on neuronal vulnerability (Porter & 
Landfield, 1998) and beta amyloid deposition (L. D. Baker et al., 2012), cross-
sectional associations may be driven by associations of midlife cognitive ability with 
late-life cortisol levels (Franz, et al., 2011). However, several prospective 
investigations report similar evidence. In a French study, a flatter diurnal slope as 
well as higher morning cortisol predicted steeper four-year cognitive decline short of 
dementia, with odds ratios for scoring in the highest tertile of cognitive change 
scores ranging from 4.1 to 7.7 (Beluche, et al., 2010). Individuals with high or 
increasing cortisol levels over five to six-year follow-up also had lower cognitive 
function short of dementia, as well as 14% lower hippocampal volume at follow-up 
in a small Canadian study (Lupien et al., 1998). Yet, another prospective study of a 
relatively large cohort of older individuals from the general population found that 
baseline cortisol levels were unrelated to seven-year cognitive decline, or to the risk 
of dementia diagnosis during follow-up (Schrijvers, et al., 2011). Finally, higher 
baseline cortisol has been found to predict steeper cognitive decline in patients with 
diagnosed Alzheimer’s Disease (Csernansky et al., 2006; C. W. Huang, Lui, Chang, 
Wang, & Chang, 2009).  
2.4.2 Glucocorticoids and cognition in people with type 2 diabetes 
Type 2 diabetes is associated with increased cortisol levels (Z. S. Lee et al., 1999), 
but to date only one study has assessed cortisol and cognition in this type of patient. 
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In a cross-sectional analysis of the Edinburgh Type 2 Diabetes Study, higher 
morning cortisol levels predicted steeper estimated lifetime decline in global ability, 
processing speed and working memory between estimated peak pre-morbid ability 
and late-life ability at the time of the clinic visit. Apart from a statistically non-
significant trend for associations between higher cortisol and lower non-verbal 
memory, cortisol was entirely unrelated to current level of function at the clinic visit, 
however (R. M. Reynolds et al., 2010). In support of a link between cortisol and 
cognition in type 2 diabetes, one study reported that a blunted cortisol awakening 
response was linked to lower hippocampal volume in this type of patient. The 
unadjusted association was of large effect size (r=0.55) (Bruehl, et al., 2009).  
 
Finally, the observational evidence from the general population and people with 
diabetes is supported by an analysis of effects of therapeutic intervention. In a study 
of 55 patients with major depressive disorder, the use of anti-depressant medication 
reduced cortisol levels and concurrently improved cognitive function (Hinkelmann et 
al., 2011). The literature on cortisol and cognition to date does not appear to have 
been meta-analysed or reviewed. 
2.5 Apolipoprotein E 
Cognitive ability is highly heritable, with genetic factors accounting for 30-80% of 
variance in cognitive test performance (Deary, et al., 2010). Amongst the genes 
currently known, the apolipoprotein E (APOE) gene linked to cholesterol levels, beta 
amyloid deposition (Stampfer, 2006) and neurofibrillary tangle formation (Peila, et 
al., 2002) appears to be the most important determinant of late-life cognitive 
outcome. 
2.5.1 Apolipoprotein E and cognition in the general population 
A recent meta-analysis of studies carried out in dementia-free individuals revealed 
that the presence of the APOEe4 allele (compared with the e2 or e3 alleles) has 
adverse effects on late-life performance in a range of cognitive domains, including 
global ability, with small effect size. Some evidence suggested that increasing age 
may exacerbate the strength of this association (Wisdom, Callahan, & Hawkins, 
2011). Although genetic factors generally play less of a role in late-life cognitive 
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decline compared with their role in the level of ability (Deary, 2012), the e4 allele 
has also been associated with late-life cognitive trajectories. In the Lothian Birth 
Cohort 1921, it predicted an annual decline on a test of verbal memory which was 
0.5 points greater than was found for non-e4 carriers, and to a 0.3 point greater 
decline on a test of abstract reasoning (Schiepers et al., 2012).  
 
The e4 allele is also the most important determinant of late-onset Alzheimer’s 
Disease, alone accounting for around 20% of risk (Bookheimer & Burggren, 2009). 
One meta-analysis established odds ratios for Alzheimer’s Disease of 3.7 for the e4 
allele and 0.6 for the protective e2 allele relative to the e3 allele respectively 
(Williams, Plassman, Burke, Holsinger, & Benjamin, 2010).  
2.5.2 Apolipoprotein E and cognition in people with diabetes 
Presence of the e4 allele appears to exacerbate effects of diabetes on cognition. One 
cross-sectional analysis reports significant interactions between diabetes and e4 allele 
in their relationship with late-life level of cognitive function short of dementia (Dore, 
et al., 2009). These findings are supported by prospective cohorts of middle-aged to 
older adults which found that individuals with the e4 allele and diabetes (presumably 
of type 2) experienced steeper five- to seven-year cognitive decline compared with 
other combinations of APOE polymorphisms with diabetes status (Blair et al., 2005; 
Haan, Shemanski, Jagust, Manolio, & Kuller, 1999). Similar findings have been 
reported for risk of frank dementia. Several prospective studies have reported 
increased severity of Alzheimer’s Disease-typical pathology and two to five-fold 
increased risk of diagnosis with Alzheimer’s Disease in e4 carriers with type 2 
diabetes compared with individuals with neither risk factors (Alafuzoff, Aho, 
Helisalmi, Mannermaa, & Soininen, 2009; Irie et al., 2008; Peila, et al., 2002; W. L. 
Xu, Qiu, Wahlin, Winblad, & Fratiglioni, 2004). These estimates of risks are all 
substantially larger than those reported in Section 1.7.3 for diabetes without 
consideration of APOE.  
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2.6 Psychosocial and lifestyle risk factors 
2.6.1 Depression 
In the general population, depression has been linked to presence of brain atrophy 
(Cole, Costafreda, McGuffin, & Fu, 2011) and reduced volumes of frontal gray 
matter, orbito-frontal cortex and amygdala (Egger, et al., 2008). Meta-analyses and 
reviews of the literature further revealed significant associations with a lower level of 
cognitive function (Harvey, Reichenberg, & Bowie, 2006), and with presence of 
dementia. For instance, dementia patients were found to be 80% more likely to be 
suffering from depression compared with cognitively healthy older indiviudals (C.-
Q. Huang, Wang, Li, Xie, & Liu, 2011). A systematic review of prospective studies 
further revealed associations of depressive symptoms with steeper late-life cognitive 
decline which is short of dementia (Plassman, Williams, Burke, Holsinger, & 
Benjamin, 2010).  
 
Depression and diabetes appear to have a bi-directional relationship (Lustman & 
Clouse, 2007). A meta-analysis estimated that depressed individuals are at 60% 
increased risk of type 2 diabetes, and that diagnosis with diabetes increases the risk 
of depression by 15% (Mezuk, Albrecht, Eaton, & Golden, 2008). Diabetes may 
cause depression through the initiation of certain biochemical and cerebrovascular 
changes (Bruce et al., 2006; Renn, Feliciano, & Segal, 2011), as well as ‘diabetes-
associated distress’ stemming from perceived disability and psychological burden 
(Fisher et al., 2007). In support of importance of the latter, one study found that 
prevalence of depression was raised in individuals with diagnosed but not in people 
with undiagnosed type 2 diabetes (Nouwen et al., 2011). 
 
The evidence from cross-sectional studies comparing diabetes patients with and 
without depressive symptoms or clinical depression is mixed (Trento et al., 2011; 
Watari et al., 2006). Additive detrimental effects are suggested in a prospective 
analysis of a large US cohort which found that co-morbidity of diabetes and 
depression was linked to a 100% increased risk of dementia over three to five-year 
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follow-up when compared with presence of diabetes without depression (Katon et al., 
2012).  
2.6.2 Cognitive and social engagement 
In line with the concept of ‘use it or lose it’, a number of studies of the general 
population have shown that cognitively stimulating or leisure activities may protect 
from age-related cognitive decline and may facilitate cognitive improvement (Leung 
et al., 2011; Marioni, et al., 2012; Wilson et al., 2003). Social engagement has also 
been linked to a higher level of late-life cognitive function (Barnes, Mendes de Leon, 
Wilson, Bienias, & Evans, 2004), to a reduced rate of cognitive decline short of 
dementia (Andrew & Rockwood, 2010; Barnes, et al., 2004; Béland, Zunzunegui, 
Alvarado, Otero, & del Ser, 2005) and in two studies to around 40% to 50% lower 
risk of future dementia over three years (Fabrigoule et al., 1995; Fratiglioni, Wang, 
Ericsson, Maytan, & Winblad, 2000). Yet, the evidence overall is mixed for both 
cognitive (Helzner, Scarmeas, Cosentino, Portet, & Stern, 2007; Wilson et al., 2000) 
and for social engagement (Hultsch, Hertzog, Small, & Dixon, 1999; Stoykova, 
Matharan, Dartigues, & Amieva, 2011), and reviews of the literature have come to 
inconsistent conclusions (Fratiglioni, Paillard-Borg, & Winblad, 2004; Williams, et 
al., 2010). One of the main issues in the examination of evidence on this topic 
appears to be the uncertain direction of associations. While it is plausible that 
cognitive and social engagement protects from brain ageing, people with lower pre-
morbid ability or those already affected by early signs of cognitive declines may be 
less likely to engage in such activities.  
2.6.3 Physical activity 
Although a meta-analysis notes that the evidence for cross-sectional protective 
effects of physical activity on cognition overall is relatively weak (Etnier, Nowell, 
Landers, & Sibley, 2006), a review of prospective studies of humans and rodents has 
inked exercise to increased cerebral blood flow, changes in wave frequencies and 
amplitudes during cognitive processing, hippocampal neurogenesis, cell 
proliferation, cell survival (Hillman, Erickson, & Kramer, 2008), and in one study  
further to increased synaptic plasticity (A. Wu, Ying, & Gomez-Pinilla, 2008). Meta-
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analyses further reveal activity-associated reduction in risk of cognitive decline short 
of dementia (Sofi et al., 2011) and risk of dementia (Hamer & Chida, 2009) by 38% 
and 28%, respectively. Consequently, intervention programs in non-demented older 
adults may have beneficial effects on cognitive function, as was determined in a 
recent systematic review of twelve RCTs, eight of which reported significant 
findings (Tseng, Gau, & Lou, 2011).  
 
In type 2 diabetes, higher physical activity has been associated with a higher level of 
late-life cognitive function (Colberg, et al., 2008; Devore, Kang, Okereke, & 
Grodstein, 2009) and in one study of older females was linked to reduced rate of 
cognitive decline. A mean difference in decline in a measure of global ability of 0.14 
standard units was found between a high-activity compared with a low-activity group 
(Devore, Kang, et al., 2009).  The sedentary lifestyle typical of type 2 diabetes 
(Morrato, Hill, Wyatt, Ghushchyan, & Sullivan, 2007) undoubtedly contributes to the 
increased risk of poor cognitive outcome in diabetes patients, but the hypothesis by 
one researcher that low physical activity is the main cause of diabetes-associated 
cognitive decline (Brito, 2009) appears controversial.  
2.6.4 Nutrition 
A number of reviews of the literature have shown that high intake of saturated fats 
(Solfrizzi et al., 2005), high cholesterol and low antioxidant intake (Kanoski & 
Davidson, 2011; McNay & Recknagel, 2011; M. C. Morris, 2012), which are all 
typical of the ‘Western diet’, have been associated with poorer late-life cognitive 
outcome including dementia. Similar findings have been reported by individual 
studies on carbohydrate intake also linked to this type of diet (Miller, Bannerman, 
Daniels, & Crotty, 2006; Roberts et al., 2012). In contrast, high protein and high fat 
intake may be protective both in terms of level of cognitive function short of 
dementia and risk of dementia (Miller, et al., 2006; Roberts, et al., 2012). The 
Mediterranean diet combines beneficial patterns of micro- and macronutrient intake 
and a review of the literature concludes that it is consistently linked to reduced rates 





Intake of saturated fats is typically high in type 2 diabetes and may even predict risk 
of future diabetes (Lichtenstein & Schwab, 2000). In a prospective cohort study of 
females with type 2 diabetes, high baseline saturated and trans-fat intake predicted 
steeper two-year cognitive decline short of dementia (Devore et al., 2009). A rare 
RCT in older patients with type 2 diabetes also found that lifestyle intervention with 
dietary restriction and exercise improved cognitive function over similar length of 
follow-up. For instance, MMSE scores improved by 1.9 points (Yamamoto, 
Yamanaka, Takasugi, et al., 2009). Importantly, because type 1 diabetes patients are 
also cognitively affected (Brands et al., 2006; Ryan, Williams, Finegold, & Orchard, 
1993) despite not typically following detrimental dietary patterns, poor nutrition (as 
well as obesity) are presumably not the main contributors to the accelerated cognitive 
decline observed in type 2 diabetes. 
2.6.5 Socioeconomic status 
Peoples’ relative position in society and their access to resources define their 
socioeconomic status (SES), commonly estimated by educational achievement, 
parents’ SES, household income, occupation, number of assets or post code. SES is a 
largely non-modifiable risk factor which tends to remain relatively stable during the 
life course. Cross-sectional and prospective studies have linked lower SES to poorer 
late-life cognitive function short of dementia (Jefferson et al., 2011; Koster et al., 
2005; Marengoni, Fratiglioni, Bandinelli, & Ferrucci, 2011), as well as to an 
increased risk of cognitive decline short of dementia and of dementia diagnosis 
(Marengoni, et al., 2011; Zeki Al Hazzouri, et al., 2011). The mechanisms 
responsible may involve deprived backgrounds predisposing individuals to 
maladaptive behaviour and harmful lifestyles. However, associations of SES with 
late-life ability are also confounded by strong associations of SES with peak pre-
morbid ability, which become apparent in the aforementioned list of estimators. 
Patients with type 2 diabetes typically have lower SES than non-diabetic older adults 
(Tamayo, Herder, & Rathmann, 2010) and it has been suggested that low SES stands 
at the outset of the “chain of risks” (Anstey, 2008, p. 284) contributing to the 




Alcohol has both hypoglycaemic and hyperglycaemic effects. In the short-term, 
reactive hypoglycaemia may be caused by a rise in insulin and a decrease in release 
of glucose from glycogen stores, up to a depletion of these stores, and negatively 
affects cognitive function (van de Wiel, 2004). Moderate consumption has been 
associated with higher level of cognitive function, including in people with type 2 
diabetes  (Fan, O'Donnell, Singh, Pungan, & Perlmutter, 2008; Townsend, Devore, 
Kang, & Grodstein, 2009). Cross-sectional analyses may be restricted by ‘sick 
quitters’ who quit drinking due to poor health (Neafsey & Collins, 2011), but are 
supported by prospective investigations. A systematic review of 23 studies concluded 
that moderate consumption reduces the risk of any type of dementia by 37% and of 
Alzheimer’s Disease by 43% in the general population (R. Peters, Peters, Warner, 
Beckett, & Bulpitt, 2008), although associations with risk of vascular dementia 
appear to be more inconsistent (Anstey, Mack, & Cherbuin, 2009; R. Peters, Peters, 
et al., 2008). For instance, in two studies of the general population, moderate 
consumption or consumption of ≥1 drink/day was associated with 15% to 60% 
reduced risk of ‘steep’ late-life cognitive decline short of dementia over follow-ups 
of two to four years (Espeland et al., 2005; Stampfer, 2006). Yet, findings in another 
seven-year prospective investigation were mixed, with significant associations 
restricted to a single of six cognitive domains (Zanjani, Downer, Kruger, Willis, & 
Schaie, 2013), and one recent relatively large meta-analysis of 143 studies found that 
moderate drinking was unrelated to cognitive decline (Neafsey & Collins, 2011). A 
rare investigation in type 2 diabetes also did not establish significant associations of 
moderate drinking with subsequent rates of cognitive decline during four years of 
follow-up (Townsend, et al., 2009). Given that alcohol consumption appears to 
remain moderately stable over time (Hansell et al., 2008), this suggests that a 
moderate alcohol consumption has long-term protective effects on cognitive 
function, for instance due to a reduction in the risk of plaque deposits in arteries, 
improvements in insulin-sensitivity and protection from blood clotting (Zakhari, 
1997). Moderate levels of ethanol have also been linked in vitro to reduced beta 
amyloid concentrations (M. A. Collins et al., 2010), and the non-alcoholic 
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components of drinks may have antioxidant, anti-inflammatory and vasorelaxant 
effects (Gupta & Warner, 2008). 
 
Long-term excessive alcohol consumption appears to increase the risk of dementia 
(Deng et al., 2006; Saunders et al., 1991), although the evidence for effects on 
cognitive decline short of dementia has been mixed (Anstey, et al., 2009; Y. Lee et 
al., 2010). Excessive consumption increases the risk of type 2 diabetes (Pietraszek, 
Gregersen, & Hermansen, 2010) and a rare cross-sectional investigation of this topic 
reported that history of alcohol abuse in type 2 diabetes enhanced the detrimental 
effects of each condition on the level of mid-life cognitive function (Hudetz & 
Warltier, 2007).  
2.7 Chapter summary 
A number of factors have been identified in the literature as potentially contributing 
to increased risk of poorer cognitive outcome in later life in the general population 
and in people with diabetes. The differential prevalence of some of these risk factors 
in people with type 2 diabetes and the general population may in part account for the 
increased risk of cognitive decline in diabetes described in Chapter 1. Potentially 
modifiable risk factors for cognitive decline include factors associated with 
metabolic function, factors which contribute to vascular disease, and individual 
differences in behaviour. Other factors, such as genetic predisposition or 
socioeconomic status, are non-modifiable. Many are inter-related in various dynamic 
pathways, which may also evolve over the course of the lifetime. Consequently, 
research aimed at identifying potential causal determinants of cognitive ageing is 
extremely complex and difficult, and this applies both to the general population and 
to people with type 2 diabetes. This thesis will focus on two selected risk factors in 
their associations with cognitive decline. The evidence from the previous literature 







Chapter 3:  Association of macrovascular disease and 
hypoglycaemia with cognitive function: literature review 
and thesis aims 
In this chapter, evidence on the association of two of the main risk factors considered 
in this thesis (macrovascular disease and severe hypoglycaemia) with cognition is 
reviewed in detail, using a systematic approach to searching the literature for relevant 
epidemiological studies. Aims and objectives of the thesis are presented in the final 
part of the chapter.  
3.1 Hypoglycaemia 
3.1.1 Symptoms and consequences 
When insulin levels do not match food intake or activity, when insulin sensitivity is 
increased or insulin clearance is decreased, blood glucose drops to insufficient levels 
in people with diabetes. The risk of hypoglycaemia poses a considerable threat to 
people with diabetes. Biochemical hypoglycaemia occurs at around <3.8mmol/l, but 
symptoms do not arise until levels of around 3.3mmol/l (Graveling & Frier, 2010). 
These include tremulousness, palpitations, anxiety, excessive sweating, hunger, 
paresthesias, confusion, seizures or loss of consciousness resulting in diabetic coma 
(Cryer, et al., 2003). In patients with type 2 diabetes, ataxia and visual disturbance 
are particularly common (Graveling & Frier, 2010). Negative impacts of acute 
hypoglycaemia on cognitive function, as determined in studies experimentally 
inducing episodes of hypoglycaemia, appear well-established (Amiel et al., 1991; 
Bremer et al., 2006; Cox, Gonder-Frederick, Kovatchev, Julian, & Clarke, 2000; 
Hvidberg et al., 1996; Wirsén, Tallroth, & Lindgren, 1992). Cognitive deficits 
usually arise at peripheral glucose levels of around 2.6 to 3.0 mmol/l (Warren & 
Frier, 2005). Compared with younger patients with diabetes, symptoms are generated 
at lower blood glucose levels in older patients with type 2 diabetes, and cognitive 
symptoms arise at earlier time points. Consequently, cognitive deficits (limiting a 
patient’s ability to respond) and hypoglycaemia (demanding urgent action by the 




Severe hypoglycaemia (SH) is typically defined as a symptomatic episode which 
requires the help from another person to effect recovery. Two to 4% of such episodes 
result directly in the death of the patient (Diedrich, Sandoval, & Davis, 2002). 
Hypoglycaemia of any severity has further been estimated to account for five fatal 
road accidents per year in the UK alone (Amiel, Dixon, Mann, & Jameson, 2008). 
Consequently, recurrent episodes may heighten fear of hypoglycaemia and reduce 
quality of life (Barendse, Singh, Frier, & Speight, 2012). Particularly nocturnal 
hypoglycaemia may be a cause of worry (Munro, Barnett, Brod, & Peyrot, 2013).  
3.1.2 Difficulty of diagnosis, and prevalence 
Recurrent hypoglycaemia gradually induces a change in the glycaemic threshold for 
the generation of symptoms. This has been termed ‘impaired awareness of 
hypoglycaemia’ (IAH) (Cryer, 2001). Due to IAH, biochemical hypoglycaemia may 
then occur with reduced intensity of symptoms or changes in symptom profiles. 
Around 25% of patients with type 1 diabetes and around 8% to 10% of insulin-
treated patients with type 2 diabetes appear to be affected by either partial or absent 
awareness of hypoglycaemia (Graveling & Frier, 2010), which has been associated 
with a substantial increase in the risk of future hypoglycaemia (Bakatselos, 2011). 
 
In addition to IAH, recurrent episodes of hypoglycaemia cause a progressive 
deficiency in the ability of the autonomic central nervous system (CNS) to counter-
regulate hypoglycaemia. This has been termed ‘hypoglycaemia-associated autonomic 
failure (HAAF) (Cryer, 2001). In both humans and in animal models, even a single 
episode of hypoglycaemia without loss of consciousness has been found to reduce 
subsequent counter-regulation (Languren, Montiel, Julio-Amilpas, & Massieu, 2013; 
Tkacs, Pan, Raghupathi, Dunn-Meynell, & Levin, 2005). A vicious cycle of impaired 
symptom generation and increased risk of hypoglycaemia follows. Although both 
IAH and HAAF are initiated by recurrent hypoglycaemia, both are not always linked. 
Avoidance of hypoglycaemia may improve IAH while the counter-regulatory 




In addition to these issues, which complicate the response by patients to ensure 
reversion to normoglycaemia as well as the accurate identification of hypoglycaemia 
in studies using self-report data, many older patients may also lack knowledge of the 
specific symptoms of hypoglycaemia (Thomson, Masson, Leeming, & Boulton, 
1991). When symptoms are atypical, episodes may further be wrongly attributed to 
other age-related disorders, such as transient ischaemic attacks (TIA) (Jaap, Jones, 
McCrimmon, Deary, & Frier, 1998). Self-report is further limited by false positives 
when symptoms are wrongly attributed to hypoglycaemia by patients or physicians. 
Alternatives to self-report, such as continuous glucose measurement (UK 
Hypoglycaemia Study Group, 2007) or analysis of hospital records (Whitmer, Karter, 
Yaffe, Quesenberry, & Selby, 2009) are rarely used and have their own limitations. 
The use of hospital records, for instance, may not be advisable in research of 
associations with cognitive function, because hypoglycaemia is relatively common in 
hospital settings and particularly in seriously ill individuals (Graveling & Frier, 2009, 
2010). Data based on hospital records may further be subject to potential influences 
by physician-dependent tendency to record medical problems. A physician who is 
sensitive to a patient’s cognitive deficits may be more likely to also record the 
experience of hypoglycaemia compared with another physician who is less 
concerned with a patient’s state of cognitive function. Continuous glucose 
monitoring may offer an alternative method of ascertaining hypoglycaemia, but is 
difficult to apply to long-term investigations of large cohorts.  
 
Hypoglycaemia occurs less frequently in type 2 than in type 1 diabetes. However, 
with SH in people with type 2 diabetes most commonly occurring in those on insulin 
treatment (annual prevalence 3% to 15% depending on the duration of treatment (UK 
Hypoglycaemia Study Group, 2007)), prevalence is overall equivalent amongst 
people with type 1 and those with type 2 diabetes when groups are matched for 
duration of insulin treatment (Cryer, 2001). In one UK study, 84% of insulin-treated 
patients with type 2 diabetes self-reported at least one episode of any severity since 
diagnosis (Munro, et al., 2013). However, oral treatment with sulfonylureas also 
confers a considerable risk of SH (UK Hypoglycaemia Study Group, 2007). 
Hypoglycaemia occasionally occurs even in diet-controlled individuals in 
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postprandial or post-operative phases, with an annual prevalence of SH in this patient 
group of around 0.1% (UKPDS, 1998).  
3.1.3 Counter-regulation and brain response to hypoglycaemia  
The body responds to hypoglycaemia with an increase in heart rate and systolic 
blood pressure as well as secretion of glucagon, pancreatic polypeptide, cortisol, 
norepinephrine, epinephrine and growth hormone (Cryer, 2001; Cryer, et al., 2003). 
Glucagon, for instance, facilitates the production of glucose in the liver, which 
increases blood glucose levels. Epinephrine decreases insulin secretion, stimulates 
lipolysis and glucose synthesis (Languren, et al., 2013). Glucagon and epinephrine 
act in the short-term and at relatively mild hypoglycaemia (around 3.9mmol/l), 
whereas counter-regulation by cortisol and growth hormone occur at lower blood 
glucose levels and are delayed by around six hours (Cryer, 2001; Languren, et al., 
2013). 
 
Brain glucose levels are generally around 30% of those in the periphery (Convit, 
2005). Hypoglycaemia leads to an increase in glucose transport across the blood-
brain barrier, for instance through up-regulation of GLUT1 and GLUT3. 
Additionally, the brain uses glycogen stored in astrocytes, overall ‘super-
compensating’ for glucose deficits (McNay & Cotero, 2010). Consistent with the 
‘selfish brain theory’ (A. Peters et al., 2004), the remaining parts of the body limit 
their energy use by reducing insulin secretion and increasing lipolysis and 
proteolysis, which enable the degradation of fats and proteins (Cryer, 2001; Cryer, et 
al., 2003; Diedrich, et al., 2002). Consequently, and presumably because cortisol and 
norepinephrine act as cognitive enhancers (McNay & Cotero, 2010), hypoglycaemia  
has occasionally been linked to improved cognitive ability at least in rodents (McNay 
& Sherwin, 2004).  
 
In the long-term, recurrent episodes of hypoglycaemia are rarely linked to overt 
neural damage, changes in cerebral activity and sensory deficits in humans and 
rodents (Akyol, Kiylioglu, Bolukbasi, Guney, & Yurekli, 2003; Puente et al., 2010). 
When significant associations are reported, these typically become apparent only 
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following profound episodes of hypoglycaemia (blood glucose <1.5mmol/l) which 
often involve coma (Ryan, 2009).  
 
Despite this, long-term cognitive deficits, which may be caused by subclinical brain 
damage, are important to consider. In this chapter, evidence on the association of 
hypoglycaemia with cognition in people with diabetes is considered. This is done 
separately for type 1 and type 2 diabetes, because of differences between the two 
conditions; type 1 diabetes patients are typically less affected by co-morbidities 
(Plotnikoff et al., 2007) and are usually younger than people with type 2 diabetes, 
and so (in contrast to the latter) are not in a ‘crucial period’ at which the brain may 
have increased vulnerability to insults because it undergoes change (Biessels, et al., 
2008). Evidence from studies on type 1 diabetes is considered first, followed by a 
systematic review of studies on type 2 diabetes (the focus of subsequent analyses in 
this thesis).  
 
3.1.4 Hypoglycaemia and cognitive function in people with type 1 
diabetes 
Cross-sectional associations between a history of SH and lower level of cognitive 
function are well-established in children with type 1 diabetes (Blasetti et al., 2011). 
In adults, one relatively small investigation revealed no cross-sectional associations 
between a lifetime history of SH or frequency of SH and performance on a variety of 
cognitive tests in young people with type 1 diabetes. Even a history of coma due to 
SH was unrelated to cognitive function (Ferguson, et al., 2003).  
 
In terms of cognitive change, a small cross-sectional analysis of patients with type 1 
diabetes found that those who had a history of at least five episodes of SH 
experienced a steeper decline between estimated peak pre-morbid ability and current 
level of cognitive function (Langan, Deary, Hepburn, & Frier, 1991). In the same 
sample, frequency of SH was also significantly associated with the rate of estimated 
lifetime cognitive decline (Deary, Langan, Graham, & Hepburn, 1992). A trend just 
short of statistical significance was reported for associations of SH frequency and 
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estimated lifetime cognitive decline in a study of younger to middle-aged patients 
with any type of diabetes (Lincoln, Faleiro, Kelly, Kirk, & Jeffcoate, 1996). Another 
study further found that patients who had recently suffered an episode of SH had 
consistently lower processing speed and executive functioning when assessed 1.5, 9 
and 30 days following the episode compared with patients who had been free of SH 
in the previous year. Little evidence was found for cognitive improvement in the SH 
group over the course of the 30 day period (Strachan, Deary, Ewing, & Frier, 2000). 
In the Diabetes Control and Complications Trial (DCCT) of adults with type 1 
diabetes which investigated consequences of intensified glycaemic control, episodes 
of SH were unrelated to nine-year cognitive change (Austin & Deary, 1999). A re-
analysis of the data together with the follow-up Epidemiology of Diabetes 
Interventions and Complications (EDIC) similarly found no associations between SH 
and cognitive change over an 18-year period between young adulthood and middle-
age (The Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications (DCCT/EDIC) Study Research Group, 2007). The 
conclusions drawn on the basis of DCCT/EDIC may be limited by its selection for 
individuals with low risk of hypoglycaemia and the wide age range of participants 
(13 to 39 years at baseline), but are supported by a smaller Swedish trial, the Adults 
in Stockholm Diabetes Intervention Study (SDIS). Here, participants in two 
treatment arms differed in their frequency of SH, but had similar levels of cognitive 
function at the end of a ten-year follow-up (Reichard, Pihl, Rosenqvist, & Sule, 
1996).  
 
Overall, the evidence from adults with type 1 diabetes suggests that the experience of 
severe hypoglycaemia which is short of coma may be unrelated to cognitive function 
or cognitive change. This does not mean that older adults with type 2 diabetes, who 





3.1.5 Hypoglycaemia and cognitive function in people with type 2 
diabetes 
A systematic search of the literature was performed in order to identify all previous 
cross-sectional and prospective analyses of hypoglycaemia and cognition in older 
patients with type 2 diabetes investigating hypoglycaemia either as a risk factor for 
long-term poorer cognitive outcome or as a potential consequence of lower ability.  
Search strategy 
Titles, abstracts and keywords (.mp) of studies indexed in Medline between 1946 and 
the third week of April 2013 were searched. The terms “type 2 diabetes”, “non-
insulin-dependent” and “NIDDM” were combined with a Boolean OR operator, as 
were “hypoglyc*mia”, “low blood sugar”, “low blood glucose”. As the outcomes of 
interest, the keywords “cognit*”, “intelligence” and “abilit*” were again searched 
with an OR operator. The three searches were combined using the AND operator. 
Additionally, reference lists of key papers and reviews were examined, and experts 
in the field were consulted.  
Selection of studies  
Studies were selected for inclusion if they fulfilled the following criteria: a) original 
studies b) studies of human type 2 diabetes patients or older adults (mean age >55 
years) with unspecified diabetes, c) ascertainment of hypoglycaemic episodes of any 
severity and using any type of method, d) application of neuropsychological tests, 
brain imaging, clinical evaluation of dementia or self-report to ascertain cognitive 
function, and e) reporting of data linking hypoglycaemia and cognitive function. 
Case studies and reviews of the literature were excluded from the review.  
Data extraction 
The titles and abstracts of all studies identified by the search were screened. Full 
articles of those which appeared to meet the criteria or where this could not be 
ascertained on the basis of the abstract alone were obtained and reviewed for 
inclusion. Data from studies which were included in the review were extracted, with 
focus on the following topics: study design, total number of participants, age at 
baseline (range or mean), measurement of cognitive function, ascertainment of 
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hypoglycaemia, treatment of hypoglycaemia as an dependent variable or an 
independent variable, main findings including effect sizes and p-values or confidence 
intervals where available, and study limitations. Extracted data from all included 
studies were tabulated to provide an overview of the evidence.  
Results 
Following removal of duplicates the search resulted in 120 papers (Figure 3.1). All 
abstracts were evaluated, and the full texts of 19 studies were accessed. Of these, 12 
studies were found to meet the inclusion criteria. One additional study was published 
after the search had been performed (Yaffe et al., 2013) and is also included in this 
review. The designs and main findings of all included studies (total n=13) are 
summarised in Table 3.1 and Table 3.2. 
 
 









Table 3.1: Summary of studies identified in systematic search on hypoglycaemia and cognition in older adults with diabetes 
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Cross-sectional Yes  1047 >75 years 
(mean 81 
years) 
Self-reported history of ‘low 














Yes  2977 ≥ 55 years 
(mean 63 
years) 
Cites reference reporting 
that the intensive treatment 
arm had increased risk of SH 
1. MMSE, DSC, 
RAVLT 


















 Yes 15 404 >45 years 
(mean 64 
years) 
Codes for any 
hypoglycaemia from 
inpatient and outpatient 
medical records 
Codes for any dementia 




e et al. 
(2012) 
ACCORD-
MIND (type 2 
diabetes 
patients), 
Mean 3.5-year  
prospective 
 Yes 2957 ≥ 55 
(mean 62 
years) 
1. SH defined as self-
reported <2.8 mmol.l or 
symptoms that resolved 
with use of glucose or 
MMSE, RAVLT, 








2. HMA defined as 
episode requiring 
medical assistance 




3. HAA defined as episode 
requiring any assistance 






















Codes for hospital admission 
for hypoglycaemia on 
hospital records 
1. Codes for any type 





Hypo, hypoglycaemia; RCT, randomised controlled trial; MMSE, Mini Mental State Examination; IQCODE, Informant Questionnaire on for Cognitive 
Decline in the Elderly; CDR, Clinical Dementia Rating Scale; neuropsych., neuropsychological; MCI, mild cognitive impairment; MRI, magnetic 
resonance imaging; DSC, Digit Symbol Coding; RAVLT, Rey’s Auditory Verbal Learning Test; IV, independent variable; DV, dependent variable; ERP, 
event-related potential. *study investigated potential of hypoglycaemia as a risk factor for poorer cognitive function; **study investigated potential of poor 




Table 3.2: Main findings from studies identified in systematic search 
 Main findings Limitations 
Bruce et al. 
(2001) 
No difference in prevalence of ‘probable dementia’ in 
people with hypoglycaemia and others  (in separate 
analyses for hospital admission for hypoglycaemia 




Hissa et al. 
(2002) 
1. No difference in P300 between patients with 
history of hypoglycaemia and others (p=0.31) 
2. No relationship between P300 component and 
frequency of hypoglycaemic episodes (p=0.28) 
Small n; wide age range 
McGill et 
al. (2006) 
One treatment arm had beneficial effects on risk of 
hypoglycaemia over 5 months compared to the other 
group (p=0.02), but change in cognitive deficits was 
equivalent in both treatment groups (p=0.43; neither 
experienced change in cognitive deficits) 
Use of self-report for 
both predictor and 
outcome; wide age range 
Bruce et al. 
(2009) 
1. Cross-sectional unadjusted analyses: Increased 
prevalence of self-reported SH in patients with 
MCI (14%) and dementia patients (16%) 
compared with remaining sample (4%) (both 
p<0.05)Similar results for doctor-verified 
measures of hypoglycaemia (all p<0.05). Link 
between HSH and dementia (p<0.001) but not 
MCI 
2. Cross-sectional analyses adjusted for clinical and 
demographic covariates: for group with MCI, OR 
2.96, p=0.040 for self-reported SH, OR 5.10, 
p=0.011 for doctor-verified hypoglycaemia and 
OR 9.65, p=0.012 for HSH). Findings non-
significant for dementia (p>0.10) 
3. Prospective analyses: No association between any 
baseline hypoglycaemia measure and risk of 
‘cognitive decline’ (p=0.09 for all doctor-verified 
hypoglycaemia, in direction of higher prevalence 
of hypoglycaemia in ‘no decline’ (44%) than in 
‘decline’ group (26%)); baseline dementia 
predicted 202% increased risk of HSH during 
follow-up (p=0.037) 
Only n=33 ‘declined’ 
during follow-up; short 
follow-up; loss of power 
due to categorisation of 
cognitive outcome; 
potentially reduced 
validity of self-report in 
patients with dementia 
De Galan et 
al. (2009) 
1. ‘Mild’ and ‘severe’ dysfunction (versus ‘normal’) 
at baseline predicted 39% and 286% increased 
risk of SH (but not ‘mild’ hypoglycaemia) in 
unadjusted analyses (both p<0.0001). 
Significance was lost when age, sex, disease 
duration, education were controlled for in ‘mild 
dysfunction’ group (p=0.32) and attenuated to 
186% increased risk in ‘severe dysfunction’ 
group (p=0.003) 
2. Each 1 point lower baseline MMSE predicted  
10% increased risk of SH (p=0.001) 
3. Intervention led to increased frequency of SH in 
one treatment arm, but no difference between 
treatment arms in cognitive decline or risk of 
dementia (data not shown) 
4. Intervention increased risk of SH to similar 
extents in all 3 cognitive groups 
Only used MMSE with 
neuropsychological 
follow-up; low 
incidence of SH 
(baseline exclusion of 
patients requiring insulin 
treatment); 
hypoglycaemia only 
treated as an outcome; 
loss of power due to 
categorisation; ‘data not 
shown’ for some 
findings; did not report 
outcome of 
neuropsychological 
assessment of ‘severe 
dysfunction’ group so 






1. In both 5-year and 18-year analyses: 
hypoglycaemia (≥1 versus none) increased risk of 
subsequent dementia (e.g., for 5-year analysis: 
2.4% increased risk per year of follow-up, 95% 
CI 1.7%, 3.0%). Even greater risk for ≥2 episodes 
and ≥3 episodes 
2. Similar results when only including ICD codes 
from emergency departments 
Use of hospital records 
(hypoglycaemia may be 




No difference in prevalence of ‘hypo’ between 
‘cognitively impaired’ and ‘unimpaired’ individuals 
(p=0.08) 
Unclear definition of 
hypoglycaemia; assessed 
cognition only using 
MMSE 
Aung et al. 
(2011) 
1. Patients with ≥1 episode of SH had lower 
cognitive function compared with SH-free 
individuals 
2. These patients also experienced steeper estimated 
lifetime decline (determined by adjustment for 
estimate of peak pre-morbid ability) 
3. Linear relationship between number of episodes 
of SH and level of cognitive function 
 
Feil et al. 
(2011) 
Association between ≥1 episodes and increased 
prevalence of dementia and cognitive impairment 
(unadjusted OR 2.42 and 1.71 respectively compared 
with individuals free of both dementia and cognitive 
impairment). Adjustment for range of demographic 
and clinical covariates led to attenuation of OR to 
1.84 and 1.22 respectively) (all p<0.001) 
Use of hospital records; 
‘cognitive impairment’ 




1. No difference in 40-month cognitive decline 
between intensive treatment and standard 
treatment groups (p=0.23 to p=0.93 for individual 
cognitive tests), despite increased frequency of 
SH in intensive treatment group 
2. Trend for steeper 20-month decline on DSC in 
intensive treatment group (p=0.076) 
Failed to directly 
associate SH with 
cognitive decline 
Lin & Sheu 
(2012) 
1. Association between ≥1 episodes over 3 years and 
increased risk of subsequent dementia by 276% 
(p<0.001) in unadjusted analyses and by 60% 
(p=0.002) when adjusted for age, sex 
2. Number of episodes predicted risk of dementia 
(p<0.001; adjusted for age, sex) 
Use of hospital records; 
wide age range so may 
have included type 1 
diabetes 
Punthakee 
et al. (2012) 
1. HMA group had lower baseline cognitive test 
performance compared with group free of HMA 
(p<0.0001 to p=0.002 for individual cognitive 
tests) 
2. Lower baseline cognitive function predicts 
increased risk of first-ever HMA and HAA 
(largest effect observed for DSC: in largely 
unadjusted analyses, 5-point lower DSC predicted 
13% increased risk of HMA (95% CI 8% to 18%) 
Unclear reason for focus 
on DSC as main 
outcome, and for choice 
of the specific cut-point 
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and 11% increased risk of HAA (95% CI 7% to 
15%) 
3. Association between 20-month decline in DSC 
and risk of any first-ever hypoglycaemic episode 
in subsequent 22 months (for low baseline ability 
individuals only)  
Yaffe et al. 
(2013) 
1. Association between ≥1 episode and risk of 
dementia (adjusted for age, sex, education, 
ethnicity, diabetes prevalent at baseline, 
treatment, HbA1c, APOE e4 status, and baseline 
MMSE: OR 2.09, 95% CI 1.00, 4.35). Finding 
survived additional adjustment for change in 
MMSE scores prior to hypoglycaemic episode 
2. Patients with dementia at increased risk of 
subsequent hypoglycaemia (adjusted for age, sex, 
education, ethnicity, diabetes prevalent at 
baseline, treatment and baseline MMSE: OR 3.10, 
95% CI 1.46, 6.58) 
Use of hospital records 
DSC, Digit Symbol Coding; OR, odds ratio; APOE e4, apolipoprotein e4 allele; CI, confidence 
interval; SH, severe hypoglycaemia; MMSE, Mini Mental State Examination. 
 
Overview of included studies 
The 13 included studies reported data from 11 cohorts and a total of 536 585 
participants, a majority of whom (n=497 900; 89%) came from a single analysis of 
US Veterans (Feil et al., 2011). Seven studies included only patients with diagnosis 
of type 2 diabetes; the remaining 6 included individuals with any type of diabetes, 
but all had mean ages >55 years so that a majority of subjects will have suffered 
from type 2 diabetes. All studies included male and female participants. A total of 5 
studies had only cross-sectional designs, whereas the remaining 8 studies were 
prospective investigations. Three of the prospective studies were randomised 
controlled trials on the effects of antihypertensive or anti-diabetic treatment; all of 
the remaining investigations were observational cohort studies. Seven studies treated 
hypoglycaemia as an independent variable, i.e. a potential predictor of cognitive 
outcome, 3 studies investigated hypoglycaemia as a dependent variable, and 3 carried 
out both types of analyses. The studies were heterogeneous with respect to the 
assessment of hypoglycaemia. Measurements ranged from self-reported potentially 
very mild ‘hypos’ to hospital records of episodes requiring emergency treatment. The 
latter category may have included episodes resulting in coma, although none of the 
studies specifically set out to investigate such episodes. A total of 5 studies reported 
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data on clinically diagnosed dementia (most of which were based on hospital records, 
n=4) either with or without additional cognitive data, 1 study included a screening 
instrument which was followed up by neuropsychological assessment to identify 
people with ‘severe cognitive dysfunction’ (although prevalence of dementia in this 
group was unclear), 5 studies relied on cognitive tests or screening instruments 
without neuropsychological assessment or consultation of medical records, 1 
measured brain activity and 1 used a self-report measure of cognitive problems. Due 
to the described heterogeneity between the studies in terms of study design and 
cognitive outcome, a meta-analysis of data to derive overall effect sizes on 
associations between hypoglycaemia and cognitive function was not possible. 
Instead, the findings of the included studies are described with the aim to offer an 
overall picture of the evidence on links of hypoglycaemia with cognition.  
Findings from included studies 
Cross-sectional evidence on association between hypoglycaemia and cognitive 
ability 
The baseline analysis of the Edinburgh Type 2 Diabetes Study revealed statistically 
significant associations between a self-reported lifetime history of SH and lower 
global cognitive ability as well as lower scores on several cognitive domains (Aung 
et al., 2012).  A further UK study of around 1000 individuals reported statistically 
non-significant trends (p=0.08) for increased frequency of self-reported history of 
‘low blood sugar/ ‘hypo’’ in older adults with type 2 diabetes and reduced cognitive 
function (MMSE<24) compared with higher-functioning diabetes patients. The 
results may have been weakened by the measure of hypoglycaemia, which may have 
included mild episodes (Hewitt, Smeeth, Chaturvedi, Bulpitt, & Fletcher, 2011). In 
the Action to Control Cardiovascular Risk in Diabetes- Memory in Diabetes 
(ACCORD-MIND) trial, patients with a history of a hypoglycaemic episode which 
required medical assistance had a lower level of cognitive function compared with 
the remaining sample (Punthakee et al., 2012). Similar findings were reported in a 
cross-sectional study of almost 500 000 US veterans. Individuals with hospital 
records showing reduced cognitive function short of dementia were 71% more likely 
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to also have a record for hypoglycaemia compared with individuals without codes for 
either dementia or cognitive deficits (Feil, et al., 2011). 
 
The Fremantle Diabetes Study also found increased prevalence of a history of SH 
(self-reported or verified by a clinician) in patients with reduced level of late-life 
cognitive function short of dementia. For instance, the likelihood of a self-reported 
history of SH in this group was three-fold even after multivariable adjustment 
compared with cognitively unimpaired participants (Bruce et al., 2009). In contrast, 
an analysis of a relatively smaller baseline sample of the same cohort had failed to 
establish cross-sectional associations between a self-reported history of any 
hypoglycaemia or hospital admission for hypoglycaemia and the presence of reduced 
level of cognitive function (Bruce, Harrington, Davis, & Davis, 2001). In addition, 
one study found that the P300 component thought to reflect cognitive processing was 
unrelated to a self-reported history of or frequency of hypoglycaemia (Hissa, 
D'Almeida, Cremasco, & de Bruin, 2002). 
 
Compared with these slightly mixed findings, the evidence appears more consistent 
for associations with frank dementia. In the Fremantle Diabetes Study, a lifetime 
history of SH was more prevalent in patients with diagnosed dementia compared 
with dementia-free individuals at least in unadjusted analyses. For instance, 21% of 
the dementia patients had a doctor-verified severe episode compared with 3% of the 
cognitively ‘normal’ participants (Bruce, et al., 2009). In the study of US veterans, 
the prevalence of dementia in individuals who experienced a hypoglycaemic episode 
over a two-year period was also almost two-fold compared with hypoglycaemia-free 
individuals when demographics as well as anti-diabetic treatment, microvascular and 
macrovascular disease were controlled for (Feil, et al., 2011) 
Evidence on reduced cognitive ability as a risk factor for hypoglycaemia 
Cross-sectional evidence does not reveal the temporal relationship between risk 
factor and outcome, but studies with prospective designs can help to resolve this 
issue. The evidence for SH as a consequence of reduced cognitive ability in type 2 
diabetes appears relatively well-established. In the Action in Diabetes and Vascular 
Disease: Preterax and Diamicron Modified Release Controlled Evaluation 
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(ADVANCE) trial, ‘severe cognitive dysfunction’ at baseline (which may or may not 
have included patients with dementia) predicted 186% increased risk of SH over five 
years even when age, sex, disease duration and treatment mode were accounted for. 
Additionally, each one unit lower MMSE at baseline was associated with a 10% 
increased risk of SH during follow-up (de Galan et al., 2009). In ACCORD-MIND, a 
lower performance on a more detailed neuropsychological test battery also predicted 
increased risk of first-ever hospital admission for hypoglycaemia. Additionally, for a 
group with relatively low initial processing speed, a steeper rate of 20-month 
cognitive decline predicted increased risk of SH during the subsequent 22 months 
(Punthakee, et al., 2012). Clinical diagnosis with dementia at baseline also increased 
patients’ risk of hospital admission or emergency treatment for hypoglycaemia by 
around two-fold in the Fremantle Diabetes Study (Bruce, et al., 2009) and by three-
fold in the US Health, Aging and Body Composition Study (Health ABC) (Yaffe, et 
al., 2013). 
Evidence on hypoglycaemia as a risk factor for subsequent cognitive 
decline/dementia 
In terms of SH as a risk factor for cognitive decline, the balance of evidence is less 
clear. In the range of cognitive impairment short of dementia, the baseline analysis of 
the Edinburgh Type 2 Diabetes Study showed associations between a baseline 
history of SH and steeper estimated lifetime decline on a global ability factor and in 
several cognitive domains. This was determined in cross-sectional analyses of 
current late-life cognitive test scores with adjustment for an estimate of peak pre-
morbid ability (Aung, et al., 2012). These findings indicate at least an acceleration of 
cognitive decline pre- to post-hypoglycaemic episode, but are at odds with findings 
from the only three studies on prospectively ascertained late-life cognitive decline 
which is short of dementia (de Galan, et al., 2009; Launer, et al., 2011; McGill et al., 
2007). The relatively large-scale Glycemic Effect in Diabetes Mellitus: Carvedilol-
Metroprolol Comparison in Hypertensives (GEMINI) trial investigated effects of 
antihypertensive treatment on health outcomes. Here, no difference between two 
treatment arms in the change of self-reported cognitive deficits during a five-month 
follow-up was established, although incidence of hypoglycaemia over the same time 
101 
 
period favoured one treatment arm (McGill, et al., 2007). These findings are 
supported by evidence from ACCORD-MIND and ADVANCE, where patients in 
intensive treatment groups (with higher incidence of hypoglycaemia) cognitively 
declined at similar rates over 40-month and five-year follow-up, respectively, 
compared with the respective standard treatment (de Galan, et al., 2009; Launer, et 
al., 2011), despite an initial non-significant trend for steeper decline in speed of 
processing in the intensive treatment group of ACCORD-MIND between baseline 
and 20-month interim assessment (Launer, et al., 2011). Specific study designs may 
account for the apparent failure to establish associations in these studies. In GEMINI, 
both the change in cognitive function and incidence of hypoglycaemia were 
ascertained using self-report, so that the findings may be unreliable. ADVANCE and 
ACCORD-MIND actually measured change in cognitive function, but both were 
trials on the effects of strict glycaemic control on health outcomes. Because 
improvements in glycaemic control may alleviate cognitive dysfunction in poorly-
controlled type 2 diabetes (Ryan et al., 2006), it is plausible that detrimental effects 
of hypoglycaemia were counteracted by cognitive improvement associated with the 
assigned intervention. 
 
In contrast to the non-significant evidence on cognitive decline in the dementia-free 
range, two prospective investigations based on hospital records revealed an increased 
risk of dementia over four years of follow-up in individuals who had been admitted 
for one or more episodes of SH during previous periods of between three and 18 
years. Both studies further found dose-response relationships between the number of 
hospital admissions for SH and risk of dementia (Lin & Sheu, 2013; Whitmer, et al., 
2009). A baseline history of hypoglycaemia evidenced in hospital records also 
doubled participants’ risk of dementia over twelve years in the Health ABC Study. 
The finding persisted when adjusted for pre-dementia change in MMSE scores 
(Yaffe, et al., 2013), which may suggest a differential role of hypoglycaemia in 
dementia and cognitive decline. Contrasting these findings, a baseline history of SH 
failed to predict the five-year risk of conversion between normal functioning, 
reduced cognitive functioning and diagnosis with dementia in the Fremantle Diabetes 




Overall, cross-sectional evidence in type 2 diabetes suggests links between a history 
of hypoglycaemia and reduced level of cognitive function and the presence of 
dementia. These findings may mainly reflect associations in the cognition-
hypoglycaemia direction, which to date several studies have pointed to. Although 
prospective investigations in type 2 diabetes have consistently failed to reveal 
detrimental effects of a history of hypoglycaemia on cognitive decline short of 
dementia, all were limited by specific study designs and are at odds with some 
evidence suggestive of an increased risk of dementia following the experience of 
hypoglycaemia. A prospective investigation of the relationship between 
hypoglycaemia and the spectrum of age-related cognitive decline in an observational 




3.2 Macrovascular disease 
3.2.1 Symptomatic macrovascular disease 
Symptomatic macrovascular disease and its prevalence in diabetes 
Atherosclerosis results in macrovascular disease which affects the vasculature of the 
entire body. Cardiac macrovascular disease causes coronary heart disease (CHD) 
typically defined as myocardial infarction (MI) and/or presence of angina pectoris. 
Macrovascular disease of the brain may result in cerebral infarction, occurring either 
hemorrhagic or ischaemic. Intra-cerebral haemorrhage (ICH) results from a 
spontaneous rupture of a cerebral artery and causes accumulation of blood in brain 
tissue (Pleşea et al., 2005). In ischaemic strokes, which account for around 80% of 
all strokes, cerebral blood flow is interrupted due to the occlusion of a major artery 
(Sims & Muyderman, 2010). Transient ischemic attacks (TIA) are focal ischaemic 
strokes which remain episodic. Symptoms typically resolve within 24 hours, 
although for 30% to 50% of patients damage to the brain tissue is permanent (Easton 
et al., 2009; Poisson & Johnston, 2011), leading to the suggestion that a distinction 
between TIA and stroke may be futile (Easton, et al., 2009). Infarcts further occur in 
absence of symptoms as ‘silent’ microbleeds or ‘silent’ ischaemic strokes caused by 
leukoaraiosis, lacunar infarcts or territorial lesions (Gállego & Martínez-Vila, 2005). 
Silent infarcts are common, with prevalence of 20% even in healthy older adults 
(Vermeer, Longstreth, & Koudstaal, 2007). In 1998, for instance, around 11 million 
silent infarcts occurred in the USA, compared with only 200 000 to 500 000 TIAs 
(Easton, et al., 2009) and 770 000 strokes (Leary & Saver, 2003).  
 
Macrovascular disease also affects the lower limbs. Around 16% of 55 year-olds 
have atherosclerotic occlusive disease in this part of the body. In around one third of 
these individuals, circulatory deficits become symptomatic in intermittent vascular 
claudication (PAD stage II) through discomfort, pain, cramping or aching in calves 
thighs or buttocks. Symptoms typically occur during walking exercise and are 
relieved by rest. In two thirds of individuals with PAD, the disease remains 
asymptomatic (stage I); around 1% are affected by limb ischaemia causing rest pain, 
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tissue loss or gangrene (stage III-IV) (ADA, 2003; Waldstein et al., 2003). 
Symptomatic PAD has been linked to poor health outcomes, including a three-fold 
risk of cardiovascular events (Banerjee, Fowkes, & Rothwell, 2010).  
 
Diabetes is an important risk factor for symptomatic macrovascular disease, 
including CHD, cerebral infarction and PAD (ADA, 2003; Carneiro, 2004; Hopkins 
& Williams, 1981). For instance, diabetes has been linked to a two-fold increased 
risk of brain infarction (Centers for Disease Control and Prevention, 2011), and has 
been estimated to account for around 12% of strokes (Luitse, Biessels, Rutten, & 
Kappelle, 2012). Consequently, prevalence of cerebral infarction (Mankovsky & 
Ziegler, 2004), CHD (Chaturvedi, 2007) and PAD (ADA, 2003) are all increased in 
diabetes and potentially also in pre-diabetes (Rydén et al., 2007). For instance, PAD 
may be prevalent in between 10% and 29% of patients with type 2 diabetes, 
compared with only 4% in the general population (ADA, 2003; Potier, Khalil, 
Mohammedi, & Roussel, 2011). Conversely, diabetes is also common in people with 
macrovascular disease (Mukherjee, 2009). This section of the chapter is concerned 
with the evidence of associations between symptomatic macrovascular disease and 
cognitive function in people with type 2 diabetes. Where the evidence is lacking, the 
literature on the general population is consulted, although potential differences 
between patients with diabetes and the general population in the relationship of 
macrovascular disease with cognition are not at the centre of the present research 
question.  
Symptomatic macrovascular disease and cognition in type 2 diabetes 
In order to ascertain the evidence on the topic from patients with type 2 diabetes, a 
systematic search of the literature was carried out for cross-sectional or prospective 
investigations of symptomatic macrovascular disease and cognition, which were 
performed in populations either consisting entirely of people with type 2 diabetes (or 
older adults with unspecified diabetes) or which reported analyses of diabetic 






Titles, abstracts and keywords (.mp) of studies indexed by Medline and published 
between 1946 and the first week of May 2013 were searched for the terms “type 2 
diabetes” OR “NIDDM” OR “non-insulin dependent”, and “intelligence OR 
“cognitive function” OR “cognitive abilit*”, as well as “macrovascular disease” OR 
“stroke” OR “cerebral infarct*” OR “TIA” OR “transient isch*mic attack” OR 
“angina” OR “myocardial infarction” OR “MI” OR “PAD” OR “intermittent 
claudication”. The three separate searches were combined using AND. Additionally, 
reference lists of reviews and key articles were examined and experts in the field 
were consulted to identify additional publications.  
Selection of studies 
Studies were selected for inclusion if they fulfilled the following criteria: a) original 
studies b) cohort studies either exclusively of humans with type 2 diabetes, or 
unspecified diabetes and mean age >55 years, or studies reporting data for a diabetic 
subsample, c) ascertainment of symptomatic macrovascular disease, d) application of 
neuropsychological tests or clinical evaluation of dementia and e) reporting of data 
linking macrovascular disease and cognitive function. Although cerebral infarctions 
identified using brain imaging do not strictly imply symptomatic disease, studies 
which used this method were included with the aim to assess all of the evidence and 
because the causes of and damage associated with symptomatic and asymptomatic 
cerebral events are assumed to be identical. Analyses published on the basis of this 
thesis, as well as case studies and reviews of the literature were not included.  
Data extraction 
The titles and abstracts of all studies identified by the search were screened. For 
studies which appeared to meet the criteria, or where this could not be determined 
from the abstract alone, the full texts were obtained and reviewed for inclusion. Data 
from studies which were subsequently identified to meet the criteria were extracted, 
with focus on the following topics: study design, total number of participants, age at 
baseline (range or mean), measurement of cognitive function, the specific 
macrovascular disease under investigation and its measurement, main findings 
including effect sizes and p-values or confidence intervals where available, and 
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potential limitations. Extracted data from all studies included in the review were 
tabulated.  
Results 
The search yielded 108 studies. Full texts were accessed for 25 studies, 10 of which 
failed to meet the inclusion criteria mainly because data on macrovascular disease, 
diabetes and cognition were reported, but associations amongst these variables were 
not explored. 15 studies were eventually deemed to meet the inclusion criteria and 
were included in the review (Figure 3.2). Their designs and main findings are 
summarised in Table 3.3 and Table 3.4. 
 
Figure 3.2: Systematic literature search on symptomatic macrovascular disease 











Table 3.3: Summary of studies identified in systematic search on symptomatic macrovascular disease and cognition in older 
adults with diabetes 




Macrovascular disease and 
its measurement 
Measurement of cognitive 
function 
Fushimi et al. 
(1996) 
Patients with type 2 diabetes 
(80%) and non-diabetics, Japan 
Cross-
sectional 
194 68 years Lacunae on MRI Cube-drawing test (spatial 
ability) 
Bruce et al. 
(2001) 
Fremantle Diabetes Study 




63 ≥70 years 
(mean 75 
years) 




combination of MMSE and 
IQCODE 
Wu et al.  
(2003) 
SALSA (Latinos; 33% with any 
type of diabetes), USA 
2-year 
prospective 
1789 >60 years 
(mean 71 
years) 
Self-reported history of 
stroke 
MMSE; Delayed Word-List 





Manschot et al. 
(2006) 
Utrecht Diabetic Encephalopathy 
Study (113 type 2 diabetes 
patients, 51 controls; all free of 
dementia or disease affecting 







Self-reported history of MI, 
stroke or 
surgery/endovascular 
treatment for coronary, 
carotid or peripheral arterial 
disease. 
Lacunar/large cerebral 
infarcts on MRI 





construction. Dutch version 
of NART 
Manschot et al. 
(2007) 
Utrecht Diabetic Encephalopathy 
Study (112 type 2 diabetes 
patients, 56 controls; all free of 
dementia or disease affecting 







1. ‘Any PAD’ defined as 
intermittent claudication on 
Rose questionnaire or self-
reported history of 
surgery/endovascular 
treatment for peripheral or 
abdominal arterial disease 
2. ‘Ischaemic heart disease’ 
defined as self-reported 
Composite z score 
calculated from 11 









history of MI or 
surgery/endovascular 
treatment for CHD 
3. ‘Any vascular event’ 
define  
as self-reported history of 
MI, stroke or 
surgery/endovascular 
treatment for coronary, 
carotid or peripheral arterial 
disease. 
4. Lacunar/large cerebral 
infarcts on MRI 
Bruce et al. 
(2008) Diabetes 
Care 
Fremantle Diabetes Study 





205 ≥70 years 
(mean 75 
years) 
1. ‘Cerebrovascular disease’ 
defined as self-reported 
history of stroke/ TIA 
supplemented by scrutiny of 
hospital records  
2. ‘CHD’ defined as self-
reported MI/ angina/ 
coronary artery bypass/ 
evidence of MI on EEG 
 
1. MMSE, CDR, IQCODE 
2. neuropsychological 
assessment. 
MCI defined as CDR=0.5 
without dementia; 
‘cognitive decline’ defined 
as conversion between 
normal cognition, MCI and 
dementia 
Bruce et al. 
(2008) 
Diabetologia 
Fremantle Diabetes Study 





302 ≥70 years 
(mean 76 
years) 
1. ‘Cerebrovascular disease’ 
defined as self-reported 
history of stroke/ TIA 
supplemented by scrutiny of 
hospital records  
2. ‘CHD’ defined as self-
reported MI/ angina/ 
coronary artery bypass/ 
evidence of MI on EEG 
1. MMSE, CDR, IQCODE 
2. neuropsychological 
assessment. 
MCI defined as CDR=0.5 
without dementia; 
‘cognitive decline’ defined 
as conversion between 




et al. (2009) 
ACCORD-MIND (type 2 diabetes 
patients), North America 
Cross-
sectional 




2. ‘CVD’ defined as stroke/ 
MI/ angina with ischaemic 




changes/ coronary procedure 
De Galan et al. 
(2009)  





11 140 >55 years 
(mean 66 
years) 
1. Stroke (fatal or non-fatal) 
2. MI (fata or non-fatal) 
3. Major coronary event 
(non-fatal MI or death from 
coronary disease) 
4. Major CVD event ( non-
fatal MI/ non-fatal stroke/ 
cardiovascular death 
Macrovascular disease used 
as dependent variable. 
3. MMSE 
‘Normal’: >28 
‘Mild dysfunction’: 24-27 
‘Severe dysfunction’: <24 
4. Neurospsychological 
assessment of ‘severe’ 
group 
Ruis et al.  
(2009) 
Anglo-Danish-Dutch Study of 
Intensive Treatment in People 
with Sceen Detected Diabetes in 
Primary Care (ADDITION) (183 
patients with type 2 diabetes, 69 









defined as history of MI, 
stroke, surgery/endovascular 
treatment for carotid, 
coronary or peripheral 
arterial disease (presumably 
self-report data) 









2. Dutch version of 
NART 
Petrova et al.  
(2010) 
Type 2 diabetes patients (all with 








ascertained using ‘standard 
definitions’ 
MMSE, FAB, category 
fluency, Clock Drawing 
Test 
‘Cognitive impairment’ 
defined as MCI-free but 
‘decline’ on at least 1 
cognitive test 
Van Elderen et 
al. 
(2010) 
Prospective Study of Pravastatin 
in the Elderly at Risk (PROSPER) 
(89 patients with type 2 diabetes, 
438 subjects without diabetes), 







Cerebral infarcts on MRI Stroop, Picture Learning 





Imamine et al. 
(2011) 
Type 2 diabetes patients, Japan 3-year 
prospective 
67 >65 years 
(mean 75 
years) 
1. Presence of silent brain 
infarcts on MRI 
2. ‘Progression of silent 
brain infarcts’ defined 
as increase by at least 1 
between baseline and 
follow-up  
MMSE, DSC, Stroop, 
Word Recall; calculation of 
change scores 
Reijmer et al.  
(2011)  
Utrecht Diabetic Encophalopathy 
Study (68 type 2 diabetes patients; 











defined as MI or 








function); cognitive decline 
calculated using composite 
regression-based index 
(RBI) compared with non-
diabetic control group.  
‘Cognitive decline’ based 
on RBI averaged from the 3 
cognitive domains 
Umemura et al. 
(2011) 




219 >45 years 
(mean 63 
years) 
Silent brain infarcts on MRI. 
‘Progression of infarcts’ 
determined by blinded 
clinicians 
MMSE, DSC, Word Recall, 
Stroop administered to 90 
patients 
SALSA, Sacramento Area Latino Study of Aging; MRI, magnetic resonance imaging; TIA, transient ischaemic attack; MI, myocardial infarction; CHD, 
coronary heart disease; MMSE, Mini Mental State Examination; CDR, Clinical Dementia Rating Scale; IQCODE, Informant Questionnaire on for 
Cognitive Decline in the Elderly; DSC, Digit Symbol Coding; RAVLT, Rey’s Auditory Verbal Learning Test; FAB, Frontal Assessment Battery; NART, 







Table 3.4: Main findings from studies identified in systematic search 




Association between presence of lacunar infarcts and 
lower cognitive function in people with diabetes and non-
diabetics (r=0.63, p=0.0001 in diabetic group) 
 
Bruce et al.  
(2001) 
Prevalence of self-reported stroke similar in ‘probable 





Wu et al.  
(2003) 
1. Cross-sectional analysis of diabetes patients: 
association between history of stroke and lower level 
of cognitive function at year 2 (p<0.0001) 
2. Prospective analysis of entire sample: association 
between history of stroke and 2-fold increased risk of 
‘major cognitive decline’ on both cognitive tests (OR 
2.01, 95% CI 1.22, 3.32, for MMSE and OR 1.95, 
95% CI 1.22, 3.10, for word-list recall). Analyses 





1. Diabetic group: association between infarcts on MRI 
(infarcts found in 19% of patients) and lower 
processing speed (β -0.77; p<0.05) (adjusted for age, 
sex, NART). No association with other cognitive 
domains. 
2. Diabetic group: no association between ‘any 






1. Diabetic group: ‘any vascular event’ associated with 
lower cognitive function (for z score β -0.25; p=0.01; for 
processing speed β -0.46, p=0.008; for memory β -0.23, 
p=0.01) (finding ‘attenuated’ on exclusion of patients with 
stroke; data not shown) 
2. Diabetic group: association of infarct on MRI with 
lower cognitive function (for z score β -0.28; p=0.01; for 
processing speed β -0.77, p<0.001) (for z score, this did 
not survive adjustment for age, sex, NART) 
3. Diabetic group: ‘any PAD’ entered in regression model 
(following adjustment for age, sex, NART), but apparently 
not retained 
1. Findings for 
‘any PAD’ not 
reported. 
2. Unclear if 
‘attenuation’ 








Manschot et al. 
(2006) 
 




1. Whole sample: no association between CHD or 
cerebrovascular disease and risk of ‘decline’  
2. Similar results when analyses of cognitive decline 
restricted to individuals with ‘normal cognition’ at 
baseline 
 
Bruce et al.  
(2008)  
Diabetologia 
1. Cross-sectional: prevalence of stroke increased in 
MCI and dementia compared with unimpaired patients 
(unadjusted OR 3.18, p<0.001 for MCI/ dementia). 
Prevalence of CHD equivalent in all 3 groups 
(p=0.14) 
2. Prospective: Higher prevalence of cerebrovascular 
disease at baseline predicted poorer cognitive outcome 
at year 8 (prevalence 7% in ‘normal’, 10% in MCI 
Did not explore 
change in cognitive 
function between 
baseline and year 8 
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and 25% in dementia group; p=0.008 across groups); 
CHD unrelated to cognition at year 8 (p=0.15) 
Cukiermann
- 
Yaffe et al.  
(2009) 
1. Association between stroke and lower scores on 4 
cognitive tests (p<0.0001 to p<0.05). For instance, 
subjects with stroke had 8-point lower DSC scores 
and 0.6 unit lower MMSE scores 
2. Association between CVD (minus stroke) and lower 
RAVLT but higher MMSE (both p<0.05)(no 
association with DSC, Stroop) 
 
De Galan et 
al. (2009)  
1. Cross-sectional: Association between history of stroke 
and poorer cognitive group (history of stroke 
prevalent in 22% of individuals with dementia, 12% 
of individuals with ‘mild dysfunction’ and 8% of 
others, p<0.001 across groups); no association 
between MI and cognitive group (p=0.61) 
2. Prospective: Baseline ‘mild cognitive dysfunction’ 
and ‘severe cognitive dysfunction’ both associated 
with increased risk of major CVD event, stroke and 
major coronary event (e.g. with 31% and 70% 
increased risk of major coronary event with p=0.004 
and p=0.020 respectively when adjusted for age, sex, 
education, treatment) 






so prevalence of 
dementia is unclear 
Ruis et al.  
(2009) 
1. Diabetic group: association between macrovascular 
disease and lower processing speed (standardised β -
0.17; p<0.01) (adjusted for age, sex, NART). No 




were not explored.  









Increased prevalence of impairment on MMSE, FAB, 
category fluency in patients with cerebrovascular disease 
(23%, 63% and 24% respectively) compared with 
cerebrovascular disease-free individuals (8%, 21% and 8% 
respectively) (p<0.0001 to p=0.002). No group differences 





‘impairment’  and 
‘decline’ (study is 
cross-sectional) 
Van Elderen 
et al. (2010) 
Diabetic group: no association between baseline infarcts 
on MRI and change in cognitive function 
Data not shown 
Imamine  
et al. (2011) 
1. Cross-sectional: association between baseline number 
of silent infarcts and baseline MMSE, Word Recall, 
DSC, Stroop (r=-0.25 on MMSE, p<0.05 to r=-54, 
p<0.001 on Stroop), and follow-up Word Recall, 
DSC, Stroop (r=-0.37, p<0.005 on Word Recall to r=-
0.48, p<0.001 on Stroop) 
2. Prospective: trend for association between baseline 
number of silent infarcts and DSC change score (r=-
0.21, p<0.10) but not to change in other cognitive 
tests. Progression of silent infarcts unrelated to any 
cognitive outcome. All analyses adjusted for age, sex, 
education, treatment, vascular risk factors) 
 
Reijmer  
et al. (2011)  
1. Diabetic group: no association between baseline 





2. Diabetic group: no association between baseline CVD 
and ‘cognitive decline’ (95% CI including 0) 
Umemura et 
al. (2011) 
Individuals with 6-year progression of silent brain infarcts 
had lower level of DSC and Stroop compared with 
remaining participants (both Cohen’s d=3.97, p<0.01) (no 
association with MMSE or Word Recall)  
Cognitive function 
assessed at year 6 
only, and only in 
subsample  
MCI, mild cognitive impairment; MMSE, Mini Mental State Examination; DSC, Digit Symbol 
Coding; FAB, Frontal Assessment Battery; RAVLT, Rey’s Auditory Verbal Learning Test; 
CHD, coronary heart disease; CVD, cardiovascular disease; CI, confidence interval; NART, 
National Adult Reading Test. 
 
 
Overview of included studies 
The 15 studies reported data from 11 populations. All studies except 3, which were 
randomised controlled trials on the effects of intensified glycaemic control or lipid-
lowering drugs, had observational study designs. All reported data on cerebral 
infarctions; of these 7 had cross-sectional designs and 8 were prospective. Only 5 
studies (reporting results from 4 populations) investigated CHD. Of these, 3 had 
prospective designs and 2 were cross-sectional. One study on symptomatic PAD and 
cognitive function was identified. The total number of participants included in the 
review were 18 186. Eleven studies were on patients with type 2 diabetes; 4 included 
older patients with any type of diabetes. All studies included males and females. 
Mean age of participants ranged between 63 and 76 years. Two studies investigated 
clinical diagnosis with dementia, whereas all of the remaining studies administered 
neuropsychological tests or cognitive screening instruments. One of these 13 studies 
additionally included clinical interview of a ‘severe cognitive dysfunction’ group, 
although the outcome of the interview was not reported. With this overall 
heterogeneity between the studies, meta-analysis to derive overall effect sizes of 










Findings from included studies 
Coronary heart disease (CHD) and cognition 
Five studies which examined the association between CHD and cognitive function in 
people with type 2 diabetes were identified by the literature search (Bruce, Davis, 
Casey, Starkstein, Clarnette, Almeida, et al., 2008; Bruce, Davis, Casey, Starkstein, 
Clarnette, Foster, et al., 2008; Cukierman-Yaffe, et al., 2009; de Galan, et al., 2009; 
Reijmer, et al., 2011). In cross-sectional analyses of ACCORD-MIND, CHD was 
associated with lower memory performance, but was unrelated to processing speed 
or executive function measures. Unexpectedly, individuals with CHD had 
significantly higher MMSE scores compared with CHD-free subjects (Cukierman-
Yaffe, et al., 2009). All of the findings from the remaining cross-sectional studies 
identified in the search were non-significant. A baseline history of CHD was 
unrelated to the presence of reduced late-life cognitive function that was short of 
dementia in ADVANCE (de Galan, et al., 2009), and in the Fremantle Diabetes 
Study to either reduced cognitive function or to presence of diagnosed dementia. In 
the latter, baseline CHD was also unrelated to the cognitive outcome eight years 
later, although the cognitive trajectories between baseline and follow-up were not 
explored (Bruce, Davis, Casey, Starkstein, Clarnette, Foster, et al., 2008). The role of 
CHD in the reduced cognitive function observed in patients with ‘any vascular event’ 
in the Utrecht Diabetic Encephalopathy Study is unclear (Manschot et al., 2007).  
 
Results from the prospective analyses also consistently revealed non-significant 
associations between CHD and subsequent cognitive decline or risk of dementia. In a 
Dutch cohort, a history of MI or surgical/endovascular treatment of atherosclerotic 
arterial disease did not predict the risk of accelerated four-year cognitive decline 
(identified on the basis of eleven age-sensitive neuropsychological tests) relative to a 
non-diabetic control group (Reijmer, et al., 2011). Presence of CHD was also 
unrelated to the two-year risk of downward conversion between normal functioning, 
reduced cognitive function short of dementia and frank dementia, or to risk of any 
cognitive impairment (reduced cognitive function/dementia) in the Fremantle 




The only significant prospective findings have been reported in the cognition-CHD 
direction. In ADVANCE, the baseline presence of ‘mild cognitive dysfunction’ as 
well as ‘severe cognitive dysfunction’ (which may or may not have included 
individuals with frank dementia) increased the risk of a major coronary event (non-
fatal MI or death from coronary disease) during five years of follow-up by 31% and 
70% respectively after multivariable adjustment aimed at reducing the potential 
influence by confounding factors linked to both cognitive function and CHD (de 
Galan, et al., 2009). Overall, this evidence suggests that CHD may not play an 
important role in the determination of cognitive outcome in patients with type 2 
diabetes. Due to the currently limited evidence of associations in the cognition-CHD 
direction to a single study (which may or may not reflect causality), the role of 
cognitive function in the determination of risk of CHD in this patient is yet unclear. 
Cerebral infarcts and cognition 
Eleven studies were identified which investigated symptomatic or asymptomatic 
cerebral infarction and cognition in people with type 2 diabetes. In terms of cross-
sectional analyses, an early study of 56 older diabetes patients set in Japan revealed 
associations of large effect size between evidence of infarction on MRI and a lower 
spatial ability (Fushimi, Inoue, Yamada, Udaka, & Kameyama, 1996). In a more 
recent but similarly small Japanese study of stroke-free diabetes patients, a higher 
number of silent brain infarcts on MRI was linked to lower MMSE, memory, speed 
of processing and executive function, with relatively largest effect sizes for the latter 
(Imamine et al., 2011). In the diabetic subsample of the Utrecht Diabetic 
Encephalopathy Study, individuals with evidence of brain infarcts on MRI also had 
lower processing speed and global ability measured by scores on a composite 
measure derived from twelve cognitive tests. Additionally, links between a self-
reported history of ‘any vascular event’ and lower global ability, processing speed 
and memory were attenuated following exclusion of patients with stroke, 
demonstrating some contribution of stroke to the reduced cognitive function in this 
group (Manschot, et al., 2007). Individuals with self-reported history of stroke also 
had lower MMSE scores, as well as processing speed, executive function and verbal 
memory in ACCORD-MIND. For instance, stroke was linked to a 0.6-point lower 
score on the MMSE (maximum 30 points) (Cukierman-Yaffe, et al., 2009). A history 
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of stroke was more prevalent in individuals with reduced level of cognitive function 
in ADVANCE. Specifically, 22% of patients with ‘severe cognitive dysfunction’ 
(who may or may not have suffered from dementia) had a history of stroke, 
compared with 12% of ‘mildly impaired’ individuals and 8% of the remaining 
sample (de Galan, et al., 2009). Similarly, a smaller study performed in diabetes 
patients with memory complaint revealed increased prevalence of ‘impairment’ on 
the MMSE and tests of executive function in patients with a history of 
cerebrovascular disease. For instance, 23% of individuals with cerebrovascular 
disease were impaired on the MMSE compared with 8% of patients free of 
cerebrovascular disease, although the specific definitions of ‘impairment’ were 
unclear (Petrova, et al., 2010). Patients with diabetes and a history of stroke further 
had lower cognitive function compared with stroke-free diabetes patients in a 
diabetic subsample of the SALSA cohort of older Latinos in the US (J. H. Wu, et al., 
2003).  
 
Progression of silent brain infarcts during six years predicted lower processing speed 
and executive function at follow-up in a study of 219 middle-aged to older type 2 
diabetes patients, although results for other cognitive tests were non-significant 
(Umemura et al., 2011). Null results were also reported for links between a history of 
stroke and presence of reduced cognitive function identified on the basis of cognitive 
screening instruments in the Fremantle Diabetes Study (Bruce, et al., 2001). Yet, 
when screening was followed up by clinical interview in the same cohort, individuals 
with reduced cognitive function short of dementia and those with dementia diagnosis 
were found to be more likely to have had a prior history of cerebrovascular disease 
(stroke and/or TIA) compared with cognitively ‘normal’  individuals. In unadjusted 
analyses, stroke alone was associated with a three-fold increased risk of presence of 
reduced cognitive function or dementia. Baseline cerebrovascular disease further 
predicted poorer cognitive outcome (presence of impairment short of dementia or 
dementia) at year 8 in the same study, although associations with eight-year 
cognitive decline were not explored (Bruce, Davis, Casey, Starkstein, Clarnette, 




Findings from the diabetic subsample of the Utrecht Diabetic Encephalopathy Study 
of associations between infarction on MRI and lower global cognitive function  and 
processing speed (Manschot et al., 2006) (but not global ability (Manschot, et al., 
2007)) survived adjustment for an estimate of pre-morbid ability, suggesting that 
individuals with presence of infarction experienced accelerated decline between pre-
morbid speed in young adulthood and late-life post-stroke speed. This result was 
subsequently replicated in another Dutch cohort, although here all (presumably self-
reported) symptomatic macrovascular disease variables were grouped together. 
Consequently, the contribution of individual factors, such as stroke, to associations 
of macrovascular disease with a steeper estimated lifetime decline in processing 
speed remains unclear (Ruis, et al., 2009).  
 
In terms of prospective analyses, a higher number of infarcts on MRI at baseline 
predicted a trend short of statistical significance for steeper three-year decline in 
processing speed in the small Japanese study, although the change in other cognitive 
tests was entirely unrelated to baseline infarction and to the progression of silent 
brain infarcts over this time period (Imamine, et al., 2011). In an analysis of the 
entire SALSA cohort (a substantial proportion of which had diabetes), baseline 
history of stroke also predicted a two-fold increased risk of ‘decline’ on the MMSE 
and on a test of verbal memory, although the authors did not stratify by diabetes 
status (J. H. Wu, et al., 2003). Evidence of cerebral infarction on MRI was unrelated 
to the four-year cognitive decline short of dementia in the diabetes patients relative to 
non-diabetic controls in the follow-up of the Utrecht Diabetic Encephalopathy Study 
(Reijmer, et al., 2011) or to the three-year decline short of dementia in a diabetic 
subsample of a Dutch randomised controlled trial on the effects of cholesterol-
lowering drugs (van Elderen, et al., 2010). In the Fremantle Diabetes Study, baseline 
cerebrovascular disease was unrelated to conversion between ‘normal’ functioning, 
impairment short of dementia and frank dementia over two years of follow-up, both 
when the entire sample was considered and when analyses were restricted to 
individuals with initial ‘normal’ cognition at baseline (Bruce, Davis, Casey, 




The ADVANCE trial was identified as the only study of associations in the 
cognition-infarction direction in people with diabetes. After multivariable 
adjustment, individuals with ‘mildly reduced’ cognitive function at baseline were at 
34% increased risk of a major stroke during the subsequent five years compared with 
individuals with higher cognitive function; patients with ‘severe cognitive 
dysfunction’ were even at 71% increased risk (de Galan, et al., 2009). 
 
Overall, the review of the literature established that a prior history of cerebral 
infarction is relatively consistently linked to a poorer cognitive function (most 
frequently to poorer executive function and processing speed), and has increased 
prevalence in people with dementia in older adults with diabetes. The prospective 
evidence is less consistent, but points to potential bidirectional associations.  
Symptomatic peripheral arterial disease (PAD) and cognition 
In the only study identified in the systematic search with data on symptomatic PAD 
and cognitive function in patients with diabetes, PAD was entered into a regression 
model following adjustment for age, sex and estimated pre-morbid ability, but was 
not retained in the model. This suggests that PAD may not have been related to the 
estimated lifetime cognitive change in the sample, although neither statistical results 
nor findings from unadjusted analyses were reported by the authors (Manschot, et al., 
2007).  
Comparison of findings from the systematic search with evidence in the 
general population  
Because the evidence on symptomatic macrovascular disease and cognition in people 
with type 2 diabetes is relatively limited, the findings from the systematic review 
were put in context with the literature on the general population with the aim to offer 
an overall picture of the evidence and to address any inconsistency. 
CHD and cognition 
The systematic review showed that the presence of CHD appears to be relatively 
unrelated to cognitive function in people with type 2 diabetes. Yet, in the general 
population, several studies have revealed cross-sectional associations between a 
119 
 
presence of CHD and a low level of cognitive function short of dementia 
(Gharacholou et al., 2011; Rafnsson, Deary, Smith, Whiteman, & Fowkes, 2007; 
Roberts et al., 2008; Singh-Manoux, Britton, & Marmot, 2003). This contrasting 
evidence may be due to the limited literature available on people with diabetes. 
Alternatively, it may be the case that the health of people with diabetes is monitored 
more carefully compared with the general population, so that CHD is detected at 
earlier stages. The null findings for associations with cognitive function in diabetes 
could then arise due to a relatively lower severity of CHD in these patients; CHD 
patients in the general population may be affected more severely at the point of 
diagnosis so that any subtle associations between the presence of CHD and lower 
cognitive function may be more easily detectable in this group. Some of the studies 
of people with diabetes also had categorised their samples according to cognitive 
function (Bruce, Davis, Casey, Starkstein, Clarnette, Foster, et al., 2008; de Galan, et 
al., 2009), and so may have had reduced statistical power to detect associations when 
compared with the studies of the general population, many of which treated cognitive 
function as a continuous measure (e.g., (Rafnsson, Deary, Smith, Whiteman, & 
Fowkes, 2007)). 
 
Yet, in some support of the null findings from the two prospective investigations in 
people with type 2 diabetes, prospective investigations associating CHD with 
cognitive decline in the general population have produced mixed results (Almeida, 
Beer, Lautenschlager, Arnola, et al., 2012; Rafnsson, Deary, Smith, Whiteman, & 
Fowkes, 2007; Verhaegen, Borchelt, & Smith, 2003). For instance, one study which 
used EEG to identify CHD reported an association between a baseline history of MI 
and increased risk of dementia over up to 15 years, but the finding was restricted to 
males and to previously unrecognised MI (Ikram et al., 2008).  
 
Studies of interventions may help to resolve the contrasting evidence from cross-
sectional and prospective studies in the general population. In line with a potential 
causal relationship between cardiovascular disease and cognition, cardiac 
transplantation and pacemaker fitting appear to improve cognitive function, and to 
alter cerebral blood flow and the P300 component evoked by cognitive processing 
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(Bornstein, Starling, Myerowitz, & Haas, 1995; Grimm et al., 1996; Koide, 
Kobayaski, Kitani, Tsunematsum, & Nakazawa, 1994). Yet, non-significant results 
have also been reported (Rockwood, Dobbs, Rule, Howlett, & Black, 1992; Schall, 
Petrucci, Brozena, Cavarocchi, & Jessup, 1989) and a number of factors unrelated to 
cardiac surgery itself, such as improved quality of life, could contribute to the 
observations.  
 
Directly contrasting these beneficial effects of the aforementioned types of cardiac 
surgery on cognitive function, coronary artery bypass grafting (CABG) has been 
linked to post-surgery cognitive impairment in 30% to 80% of patients (Symes, 
Maruff, Ajani, & Currie, 2000). Importantly, diabetes appears to exacerbate this risk. 
In one Japanese study, pre- to post-CABG declines of >1 standard deviation on at 
least two of six cognitive tests over seven days was more common in patients with 
diabetes than in controls (Kadoi, Saito, Fujita, & Goto, 2005). Similar results were 
reported in another study of 127 older adults undergoing CABG. Patients with 
diabetes (but not non-diabetic patients) cognitively declined between pre-surgery 
assessment and assessments at one month and one year (Selnes et al., 1999).  
 
Overall, the balance of evidence suggests that, whereas CHD may be linked to 
reduced cognitive function, it is unclear whether this may be due to associations in 
the cognition-CHD direction or confounding by other risk factors associated both 
with CHD and with cognition. Coronary heart disease does not appear to predict 
cognitive decrements either in the general population or in people with diabetes. 
Despite some evidence which suggests that diabetes may exacerbate post-cardiac-
surgery cognitive deficits, the increased prevalence of CHD in type 2 diabetes is 
presumably unable to account for the increased risk of cognitive decline in people 
with diabetes.  
Cerebral infarcts and cognition  
Similar to the findings of studies carried out in people with diabetes as described in 
the systematic review, a self-reported history of cerebral infarction or imaging data 
consistent with infarction have frequently been linked to a lower scores on tests of 
fluid-type cognitive ability or screening instruments for dementia in the general 
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population (Arvanitakis, et al., 2006; Breteler, Claus, Grobbee, & Hofman, 1994; 
Maeshima et al., 2002; T. R. Price et al., 1997). For instance, in a Scottish cohort, a 
baseline history of stroke was associated with poorer executive function and verbal 
memory (Rafnsson, Deary, Smith, Whiteman, & Fowkes, 2007). Silent or 
symptomatic infarctions also increase the risk of ‘post-stroke dementia’, and 
particularly vascular dementia (Pendlebury & Rothwell, 2009; Vermeer et al., 2003). 
In one relatively large Italian study, stroke increased the likelihood of either 
clinically diagnosed reduced cognitive function short of dementia or diagnosis with 
dementia comparable to an additional ten years of age (De Ronchi et al., 2007). As 
many as 72% and 56% of patients with vascular dementia had a history of stroke and 
TIA respectively compared with prevalence of 10% and 14% of control subjects in a 
recent Finnish study of relatively old individuals (Hiltunen et al., 2013). 
 
The systematic review identified mixed prospective evidence of cerebral infarcts and 
cognitive function in people with diabetes, with four of five studies reporting non-
significant associations. The literature on the general population appears more 
consistent. In one Dutch study of older adults, a self-reported history of 
cerebrovascular disease at baseline was linked to almost five-fold increased the risk 
of ‘steep’ decline on the MMSE over three years (Kalmijn, Feskens, Launer, & 
Kromhout, 1996). Baseline stroke also predicted accelerated decline on the MMSE 
during seven years in the Cardiovascular Health Study (Haan, et al., 1999). Evidence 
of cerebral infarction on MRI as well as a self-reported or clinically evidenced 
history of stroke have further been found to predict steeper four- to seven-year 
decline in older age on more detailed neuropsychological tests in several cohorts 
(Haan, et al., 1999; Rafnsson, Deary, Smith, Whiteman, & Fowkes, 2007; Vermeer, 
et al., 2003).  
 
Similar to the findings of ADVANCE (de Galan, et al., 2009), studies in general 
older populations have also implicated a lower level of cognitive function with 
increased future risk of cerebral infarction (M. F. Elias et al., 2004). A review of the 
literature determined that pre-stroke dementia may be present in as many as 9% to 
14% of patients with stroke (Pendlebury & Rothwell, 2009). Yet, because dementia 
122 
 
occurs in around 20% of stroke patients three to six months after the event even 
when excluding people with a pre-stroke history of dementia (Pendlebury & 
Rothwell, 2009), some causation in the infarct-cognition direction is supported.  
 
Overall, the findings from prospective investigations suggest that, as well as 
potentially reflecting confounding by other risk factors, associations of cerebral 
infarction and cognitive decline may provide evidence that cerebral infarction 
negatively impacts cognitive function in people with type 2 diabetes and in the 
general population. The relatively stronger evidence in the latter compared with the 
former could be due to the relatively small number of prospective studies carried out 
in patients with diabetes or lower statistical power due to relatively smaller sample 
sizes. Differences in risk of incident infarction over the course of prospective 
investigations appear less likely to account for the observation, given that people 
with type 2 diabetes are at increased risk of stroke (Centers for Disease Control and 
Prevention, 2011) despite apparently showing less evidence of stroke associations 
with cognitive decline compared with the general population.   
 
Finally, some evidence suggests links between a lower cognitive ability and an 
increased risk of cerebral infarction in people with diabetes as well as in the general 
population. Thus, the relationship between cerebral infarction and cognition appears 
to be largely similar in people with diabetes and the general older population, and 
may be bidirectional. Considering that diabetes is a major risk factor for post-stroke 
dementia and reduced rate of cognitive recovery following stroke (Erkinjuntti, 2007; 
Pendlebury, 2009), it is plausible that cerebral infarction may play an important role 
in the increased risk of cognitive decline in people with diabetes.  
Symptomatic peripheral arterial disease (PAD) and cognition 
Although the literature on symptomatic PAD and cognition in people with type 2 
diabetes is limited to a single investigation, several studies carried out in the general 
population report significant findings. In the Helsinki Aging Study of 650 old-old 
individuals, those with intermittent claudication had around two-point lower mean 
MMSE scores (maximum 30 points) compared with claudication-free individuals 
(Tilvis, et al., 2004). Presence of claudication was also linked to lower level of 
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executive function, memory and reasoning with small to medium effect sizes in 5292 
middle-aged civil servants of the Whitehall II study (Singh-Manoux, et al., 2003), 
although another study of 1500 middle-aged to older men established similar 
cognitive function in individuals with intermittent claudication and a control group 
free of any vascular disease (Elwood, Pickering, Bayer, & Gallacher, 2002). A recent 
analysis reported significant differences in prevalence of PAD across groups between 
cognitively healthy individuals (11%), patients with Alzheimer’s Disease (2%), with 
vascular dementia (19%) and those with dementia with Lewy bodies (7%), although 
‘PAD’ was not specified and pairwise group comparisons were not applied 
(Hiltunen, et al., 2013). Cross-sectional associations are restricted by observations of 
lower estimated pre-morbid ability in individuals with intermittent claudication 
(Singh-Manoux, et al., 2003), but are supported by prospective evidence. In the 
Helsinki Aging Study, baseline claudication predicted a 70% increased risk of ‘steep’ 
(≥4-point) decline on the MMSE and/or an increase in the severity of dementia 
defined using the Clinical Dementia Rating scale during one-year follow-up, 
although it was not linked to risk of these outcomes during five-year follow-up of the 
same study (Tilvis, et al., 2004),  or to incidence of clinically diagnosed dementia 
during six years in a cohort of 201 old-old community-dwelling Australians (Piguet 
et al., 2003). Here, individuals with and those without baseline claudication also 
declined at similar rates on the MMSE over the course of the study. Overall, the 
evidence is relatively limited even in the general population and appears inconsistent. 
The contribution of intermittent claudication to cognition may become clearer in the 
consideration of the literature on asymptomatic PAD and cognition, which is 
described in section 3.2.2.  
Summary of the evidence on associations of symptomatic macrovascular 
disease with cognition 
In both people with type 2 diabetes and in the general older population, the presence 
of macrovascular disease manifesting in symptoms in various areas of the body has 
been associated with a reduced level of cognitive function including an increased 
likelihood of dementia. However, the direction of the associations and the role of 
potential clinical and demographic confounders, as well as pre-morbid ability, in any 
cross-sectional findings are unclear. For CHD and PAD, the evidence from 
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prospective analyses appears to be mixed in both people with type 2 diabetes and in 
the general population. Compared with this, the prospective evidence for links of 
infarction occurring directly in the brain, i.e. the ‘substrate’ of cognition, with 
cognitive decline is more consistent at least in the general population. This type of 
investigation has produced mixed results in studies of people with type 2 diabetes, 
but this may be due to fewer studies focusing on this type of patient.  
3.2.2 Potentially asymptomatic macrovascular disease 
Systemic atherosclerotic changes may not always result in symptoms, but may 
become apparent in, e.g., asymptomatic cardiac stress, asymptomatic PAD and in 
increased carotid intima-media thickness (cIMT). Such subclinical markers may be 
useful in the analysis of associations of macrovascular disease with cognition. Due to 
higher prevalence of asymptomatic than symptomatic disease, and because it does 
not require categorisation into binary ‘disease’ versus ‘no disease’ groups, statistical 
power to detect associations is possibly higher than is found with studies of 
symptomatic disease. This section summarises the evidence on links between these 
markers of macrovascular disease, which may or may not have reached the point of 
clinical expression, and cognition. 
Natriuretic peptides 
Congestive heart failure (CHF), diabetes and cognition 
CHF is a progressive condition and an end-stage of heart disease (Kannel, Hjortland, 
& Castelli, 1974). In addition to anecdotal evidence (Rogers et al., 2000), a number 
of quantitative studies have established links between symptomatic CHF or CHF 
severity and lower cognitive function (Almeida & Tamai, 2001; Antonelli Incalzi et 
al., 2003; Gorkin et al., 1993; Trojano et al., 2003; Zuccala et al., 1997), as well as 
reduced cerebral blood flow (T. C. T. F. Alves et al., 2005). A review of the literature 
notes that especially attention and memory may be compromised (Bennett & Sauvé, 
2003). Several prospective investigations have also revealed associations with a 
steeper decline on detailed neuropsychological tests of fluid-type ability (Almeida, 
Beer, Lautenschlager, Arnolda, et al., 2012; Hjelm et al., 2012). In its most severe 
form, CHF-associated cognitive impairment may result in ‘cardiogenic dementia’. 
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Some degree of impairment appears to be prevalent in 30 to 80% of CHF patients. 
This is independent of individual differences in education (i.e., pre-morbid ability) or 
co-morbidities (Bennett & Sauvé, 2003), although one recent report suggested that 
diabetes may exacerbate CHF associations with poorer cognitive function (Alosco et 
al., 2012a). This is important, because prevalence of CHF is increased in people with 
diabetes (Schainberg, Ribeiro-Oliveira, & Ribeiro, 2010), and diabetes is common in 
people with CHF. A systematic review found that 47% of US heart failure patients 
suffer from diabetes (Kamalesh & Nair, 2005). 
 
The inactive metabolite N-terminal pro-brain natriuretic peptide (NT-proBNP) is a 
biomarker of the cardiac stress caused by CHF and ventricular dysfunction in general 
older, in diabetic (J. Y. Kim et al., 2007) and in other patient populations (Ambrosi, 
Singerorzan, Oddoze, Argues, & Heim, 2010). Pre-proBNP is synthesised in the 
ventricles, and particularly the left ventricle, by the cardiac muscle and is modified 
into the pro-hormone proBNP, which is released in short bursts as a result of 
myocyte stretch. Subsequently, proBNP is cleaved into the 76 amino-acid peptide 
NT-proBNP and the 32 amino-acid peptide BNP (Ashley, Galla, & Nicholls, 2008). 
Consequently, NT-proBNP and BNP have been found to correlate (Castleberry et al., 
2010); plasma BNP>100 ng/l indicate established heart failure in clinical practice 
(Kondziella, Goethlin, Fu, Zetterberg, & Wallin, 2009). 
 
Raised natriuretic peptides have been linked to male sex, poor renal function and 
inflammation (Resl, Hülsmann, Pacher, & Clodi, 2009), and to increased risk of 
symptomatic macrovascular disease (Di Angelantonio et al., 2009) and mortality 
(Barents et al., 2008). Similar associations have been reported in patients with type 2 
diabetes (Gaede, Hildebrandt, Hess, Parving, & Pederson, 2005; Hamano, Abe, 
Komi, & Koboyashi, 2010; Vergès et al., 2005), who (consistent with increased 
prevalence of CHF) tend to have raised NT-proBNP (Andersen, Poulsen, Knudsen, 
Heickendorff, & Mogensen, 2005; Magnusson et al., 2004). Even in non-diabetic 
individuals, HbA1c may correlate with NT-proBNP (Clodi et al., 2009) and its 
correlate BNP (Suskin et al., 2000) (although one study implicated raised NT-
proBNP as protective of diabetes risk (Everett et al., 2011)). The mechanisms linking 
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diabetes with cardiac stress may involve hyperglycaemia and hyperinsulinemia, 
which contribute to increased left ventricular mass and reduced cardiac output. 
Hyperglycaemia further causes endothelial apoptosis and inflammation (which 
contributes to atherosclerosis), as well as oxidative stress and alteration in the nitric 
oxide metabolism, damaging the myocardium. Finally, raised insulin may activate 
the sympathetic nervous system and thereby affect heart function (Schainberg, et al., 
2010).  
Natriuretic peptides and cognition 
To ascertain the observational evidence from cross-sectional or prospective studies 
on associations between NT-proBNP or BNP and cognition in type 2 diabetes, a 
systematic search was performed. The atrial natriuretic peptide (ANP) or its inactive 
N-terminal form (NT-proANP) are also part of the natriuretic peptide family, but are 
not considered here. In the discussion of the findings presented in this thesis, the 
term ‘natriuretic peptide’ therefore refers specifically to NT-proBNP and BNP.  
Search strategy 
Titles, abstracts and keywords (.mp) of studies indexed in Medline and published 
between 1946 and the first week of May 2013 were searched for the terms “type 2 
diabetes” OR “non-insulin-dependent” OR “NIDDM”, “natriuretic peptid*” OR 
“*BNP”, and “cognitive function” OR “intelligence” OR “cognitive abilit*” were 
combined using AND. Additionally, other databases were searched, and reference 
lists of reviews and selected original articles were scanned. Experts in the field were 
consulted to identify additional articles. Because this search yielded no results (with 
exception of analyses published on the basis of this thesis), the search was widened 
to any studies of humans (diabetic or non-diabetic). The final search terms were 
“natriuretic peptid*” OR “*BNP”, and “cognitive function” OR “intelligence” OR 
“cognitive abilit*”, combined by an AND operator. Other databases were searched, 
and reference lists of reviews and selected original articles were scanned and experts 





Selection of studies 
Studies were selected for inclusion the following criteria were met: a) original 
studies, b) studies of any humans (either from the general population or from patient 
populations), c) measurement of BNP and/or NT-proBNP, d) application of 
neuropsychological test, brain imaging or clinical evaluation of dementia and e) 
reporting of data linking natriuretic peptides with cognitive function and/or brain 
imaging findings. Case studies, reviews of the literature and analyses published on 
the basis of this thesis were not included.  
Data extraction 
All titles and abstracts identified by the search were screened, and full texts were 
obtained for studies which appeared to meet the inclusion criteria or where this was 
uncertain. Data from studies which were found to meet the criteria were extracted, 
with focus on study design, total number of participants, age at baseline (range or 
mean), the specific natriuretic peptide (NT-proBNP and/or BNP), measurement of 
cognitive function, main findings including effect sizes and p-values or confidence 
intervals where available, and potential limitations. Although not part of the present 
research question, any available data on diabetes were also extracted. All data were 
tabulated.  
Results 
Following removal of duplicates, the search resulted in 50 articles. Full texts were 
accessed for 24 articles, and 19 of these were eventually found to meet the criteria 
for inclusion (Figure 3.3). The excluded 31 studies reported data from animal studies, 
had qualitative designs, were case studies or reported data presented in this thesis. 
The study designs and main findings of the 19 included studies are summarised in 












Table 3.5: Summary of studies identified in systematic search on natriuretic peptides and cognition in studies of the general or 
any patient population  




Measurement of cognitive function  
Gunstad et al. 
(2006) 
Adults with CVD 
(dementia-free), USA  
Cross-
sectional 




Mauro et al.  
(2007) 




72 Mean 66 years BNP MMSE, Corsi-Block-Tapping 




patients (47% have 
dementia; all free of 















1. CT scans (categorised as ‘infarctions and 
white matter lesion’ versus ‘white matter 
lesion only’ versus normal) 
2. Clinical diagnosis with dementia or 
reduced cognitive function short of 
dementia 
Suwa & Ito  
(2008) 




81 ≥65 years BNP MMSE (‘cognitive impairment’ defined as 
MMSE<24) 






950 ≥60 years 
(mean 77 
years) 




Patients with VaD, 




49 Mean 70 years  BNP Diagnosed dementia 
Naito et al.  
(2009) 
Patients with dementia 




42 Mean 74 years BNP HDS-R 
Vaes et al.  
(2009) 




274 90 years NT-proBNP   MMSE (‘poor cognitive function’ defined as 
MMSE<19) 
Kerola et al.  
(2010) 
Kuopio 75+(free of 




464 ≥75 years 
(mean 80 
years) 
BNP Diagnosed dementia; MMSE 
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452 Median 75 
years 









394 >55 years 
(mean 68 
years) 
BNP Randt Memory Test, Digit Span, Visual 
Reproduction, DSC, TMT-B.  
‘Post-operative cognitive dysfunction’ 
(POCD) defined as >1SD decrease in scores 
on at least 1 of the 4 cognitive domains 






950 ≥60 years 
(mean 77 
years) 
NT-proBNP MMSE, TMT-B, Category Fluency 
‘Low’ performance on each defined by ‘pre-
validated cut-points’: MMSE≤24, TMT-
B≥300 seconds; Category Fluency ≤12 
Van den Hurk 













DSC, TMT-A, TMT-B, Stroop (parts I to 
III), Corsi-Block Tapping, RAVLT, Rey 
Complex Figure, Location Learning Test, 
verbal fluency, forward/ backward digit span. 






controls with stable 
CHF and CHF-free 








60 Mean 61 years NT-proBNP Digit Span, Logical Memory, Stroop, DSC, 
Raven’s Standard Progressive Matrices Test 




patients (47% have 
dementia), Sweden  
Cross-
sectional 











1. MMSE;  
2. Diagnosis with dementia or MCI 




Hu et al. 
(2012) 
3 cohorts (267 from 
University of 
Pennsylvania ‘Penn’; 
333 from Washington 







1166 ≥50 years 
(means 65 to 






ADNI: BNP  
3. Diagnosis with MCI, AD or other 
dementias; cognitively healthy controls 
4. Measurement of beta amyloid and tau in 
CSF in ADNI cohort only 




Initiative (ADNI) (396 
patients with MCI, 112 
patients with AD and 
58 controls), North 
America 
Up to 4-year 
prospective  







Diagnosis with MCI, AD or cognitively 
unimpaired 
Vecchio et al. 
(2012) 
Older individuals (10 
patients with CHF, 20 




50 Mean 76 years BNP EEG recordings in resting state (authors note 
that high power of delta rhythms have been 
associated with cognitive impairment in the 
literature) 
Hiltunen et al.  
(2013) 
Kuopio 75+ (137 with 




601 75-96 years 




BNP Neuropsychological assessment at baseline 
and follow-up to diagnose normal cognitive 
function, AD, VaD, dementia with Lewy 
bodies, dementia due to medical condition  
CVD, cardiovascular disease; MCI, mild cognitive impairment; MMSE, Mini Mental State Examination; DRS, Dementia Rating Scale; HDS-R, Revised 
Hasegawa Dementia Scale; CHF, congestive heart failure; VaD, vascular dementia; AD, Alzheimer’s Disease; CT, computed tomography; DSC, Digit 
Symbol Coding; TMT-B, Trail-Making Test-B; RAVLT, Rey Auditory Verbal Learning Test; NT-proBNP, N-terminal pro-brain natriuretic peptide; BNP, 
brain natriuretic peptide; EEG, electroencephalograhy; CSF, cerebrospinal fluid.
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Table 3.6: Main findings from studies identified in systematic search 
 Finding Limitations 
Gunstad et 
al. (2006) 
Inverse association between BNP and DRS (r=-0.34, 
p=0.02); BNP explained 9% of unique variance in DRS 
(p=0.017; adjusted for age, sex, demographic, ‘clinical 
confounders’) 
 
Mauro et al. 
(2007) 
1. Higher mean BNP in MMSE≤24 versus MMSE>24 
(Cohen’s d=-0.44, p=0.05) 
2. (Apparently) inverse association between BNP and 
MMSE (r=0.25, p=0.02) 
3. Trend for inverse association between BNP and Corsi 










Nilsson et al. 
(2008)  
1. Median NT-proBNP higher in patients with any 
pathological finding on CT compared with remaining 
sample (p<0.001) 
2. No difference in NT-proBNP between group with 
cerebral infarction +/- white matter lesions and group 
with white matter lesions only; p>0.05) 
3. 74% of VaD patients had ‘elevated NT-proBNP’, 
compared with 51% of AD patients and 41% of 
patients with depression  
No statistical 








Suwa & Ito 
(2008) 
1. Mean BNP higher in group with ‘cognitive 
impairment’ than in remaining sample (Cohen’s d=-
0.72, p<0.007) 
2. BNP >40 pg/ml associated with OR 9.74 for 




Daniels et al. 
(2009) 
1. High NT-proBNP group  (≥450pg/ml) was at risk of 
low MMSE (OR 2.04, p=0.01), low TMT-B (OR 
1.83, p<0.01) and low Category Fluency (OR 1.54, 
p=0.048) when age and education were controlled for. 
Findings persisted for MMSE and TMT-B when 
vascular risk factors were additionally controlled for.  
2. Findings unchanged when patients with stroke were 
excluded 
Abstract only; 







Daniels et al., 
2011) 
Kondziella 
et al. (2009) 
Higher mean BNP in VaD group (but not AD group) 
compared with controls (Cohen’s d=0.62, p=0.03) 
 
Naito et al. 
(2009) 
Inverse association between BNP and HDS-R (r=-0.33, 
p=0.03) 
 
Vaes et al. 
(2009) 
1. 27% (n=72) had MMSE<19 
2. 18% (n=45) had diabetes 
3. No association between sex-specific tertiles NT-




4. No association between sex-specific tertiles NT-
proBNP and diabetes (p=0.88) 
Kerola et al. 
(2010) 
1. Cross-sectional analysis: Inverse association between 
BNP and MMSE (beta coefficient =-0.15, p=0.001) 
2. Prospective analyses: Association between higher 
baseline BNP and steeper 5-year decline on MMSE 
(beta coefficient =0.14, p=0.019). Association 
between higher baseline BNP and increased risk of 
AD and VaD (for each SD increase in BNP OR 1.53 
for any type of dementia, p=0.016 in model 
controlling for age, education, hypertension) 
(dementia total n=59) 
3. Results similar following exclusion of CHF patients 
or exclusion of subjects with a history of stroke 
4. No association between BNP and presence of diabetes 
 
Nilsson et al 
(2010) 
1. Inverse association between NT-proBNP and MMSE 
(r=-0.1, p<0.001) 
2. Lower MMSE in ‘high’ NT-proBNP group (>300 
ng/l) than in ‘low’ group (median MMSE scores 
22/30 versus 26/30, p<0.001) 
3. Groups with WML, cerebral infarction or both on CT 
each had higher mean NT-proBNP compared with a 
group without pathological findings (all p<0.001) 
 
McDonagh 
et al. (2010) 
No association between pre-surgery BNP and risk of 
POCD at either 6 weeks or 1 year after surgery (data not 
shown) 
 
Daniels et al. 
(2011) 
1. High NT-proBNP group (≥450pg/ml, n=198) group 
had increased risk of ‘low’ MMSE (OR 2.04, 95% CI 
1.18, 3.52), TMT-B (OR 1.84, 95% CI 1.26, 2.67); 
Category Fluency (OR 1.54, 95% CI 1.00, 2.36) in 
analyses controlling for age, sex, education.  
2. Adjustment for vascular risk factors, coronary heart 
disease and stroke, exclusion of patients with 
coronary heart disease and/or stroke or exclusion of 
patients with stroke did not change results for MMSE 
and TMT-B, but rendered finding for Category 
Fluency non-significant (p>0.05) 
3. High NT-proBNP group had lower scores on MMSE 
(Cohen’s d=0.48, p<0.001), TMT-B (Cohen’s d=-
0.36, p<0.001), Category Fluency (Cohen’s d=0.17, 
p=0.031) in analyses adjusted for age, sex, education 
compared with low NT-proBNP group (all except 
Category Fluency, p=0.08, survived adjustment for 






Hurk et al. 
(2011) 
1. Baseline BNP predicted 3.6% of variance in 
processing speed, 3.3% in memory and 12.4% in 
attention/executive function. Follow-up BNP 
predicted 2.8% and 6.5% in speed and 
attention/executive function respectively (all p<0.05; 
all adjusted for age, sex, estimated pre-morbid ability, 
pre-diabetes, diabetes)  
2. Association between an increase in BNP during 
follow-up and lower attention and executive function 
at follow-up (decline in BNP determined by 




et al. (2012) 
1.    Inverse association between NT-proBNP and Logical  
Memory, Digit Span, DSC, Stroop (range p<0.0001 to 
p<0.05) 
2.    Treatment (‘compensation’) improved cognitive 
function pre-test to post-test for the decompensated CHF 
group 
Did not report 
effect sizes 
Nilsson et al. 
(2012) 
1. Group with vascular disease and elevated NT-proBNP 
had lower MMSE and higher prevalence of 
pathological findings on CT compared with group 
free of vascular disease and with normal NT-proBNP 
(both p<0.001) 
2. Group free of vascular disease but with elevated NT-
proBNP had similar MMSE and prevalence of 
pathological findings on CT as group free of vascular 
disease with normal NT-proBNP (both p>0.05) 
3. Within MCI group (n=119), patients with vascular 
disease and elevated NT-proBNP had lower MMSE 
and higher likelihood of pathological findings on CT 
compared with patients free of overt vascular disease 
and normal NT-proBNP (both p<0.01) 
4. No associations between NT-proBNP groups and 
MMSE or pathological findings in VaD group (n=89) 
(all p>0.05) 
5. In AD group (n=77), association between elevated 
NT-proBNP (irrespective of overt vascular disease) 
and higher likelihood of pathological findings on CT 
(p<0.05), but no association with MMSE (p>0.05) 
 
Hu et al.  
(2012) 
1. Penn: No association of NT-proBNP with very mild 
dementia/MCI/AD (p=0.08) (adjusted for age, sex) 
2. WU: Association of NT-proBNP and very mild 
dementia/MCI/AD (OR 1.07, p<0.001) (adjusted for age, 
sex) 
3. ADNI: Association of BNP with very mild 





4.ADNI: Association of BNP with Aβ42 (<193 pg/ml) 
(OR 1.75, p<0.001) and t-tau/Aβ42 ratio (>39) (OR 1.11, 
p<0.001) (adjusted for age, sex) 
Soares et al. 
(2012) 
1. Cross-sectional at baseline: compared with 
controls, higher mean NT-proBNP in MCI (p<0.001)  
and AD (p<0.001) 
2. Cross-sectional at year 1: compared with controls, 
higher mean NT-proBNP in MCI (p=0.001)  and AD 
(p=0.003) 
3. In analysis of a screening tool to differentiate AD 
from healthy individuals, inclusion of plasma markers 
(including NT-proBNP) improved specificity from 
40% (on basis of age, sex, APOE e4 status) up to 80% 






data from same 
cohort as Hu et 







In CHF patients: Association between BNP and amplitude 











1. Cross-sectional: risk of any dementia associated with 
BNP was increased in youngest tertile (OR 1.44, 95% CI 
1.01, 2.07, p=0.047), non-significant in middle tertile 
(p=0.49) and reduced in oldest tertile (OR 0.57, 95% CI, 
0.32, 1.00, p=0.050) (adjusted for age, sex, medication, 
heart failure, blood pressure; findings similar when 
excluding subjects who die within 12 months of baseline) 
2. Prospective: in previously unimpaired subjects, 
baseline BNP predicted risk of dementia during follow-up 
in youngest tertile only (OR 1.89, 95% CI 1.07, 3.34, 






data from same 
cohort as 
Kerola et al. 
(2010) 
DRS, Dementia Rating Scale; MMSE, Mini Mental State Examination; DSC, Digit Symbol 
Coding; CHF, congestive heart failure; WML, white matter lesions; CT, computed tomography; 
POCD, post-operative cognitive dysfunction; VaD, vascular dementia; AD, Alzheimer’s Disease; 
SD, standard deviation; MCI, mild cognitive impairment; NT-proBNP, N-terminal pro-brain 
natriuretic peptide; BNP, brain natriuretic peptide; OR, odds ratio; CSF, cerebrospinal fluid; 
APOE e4, apolipoprotein e4 allele. 
 
Overview of included studies 
The 19 studies reported results from 14 cohorts, and reported data for a total of 7438 
participants. One study was in abstract form and was later followed by a full report; 
the remaining articles were full studies. All samples included both males and 
females. Seven studies assessed middle-aged to older cohorts form the general 
population, 6 recruited either patients with diagnosed dementia or recruited subjects 
from psychogeriatric facilities, 5 studies included individuals with cardiovascular 
disease and 1 was of patients undergoing non-cardiac surgery. All except 5 (with 6-
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month to 6-year follow-up) had cross-sectional designs. One additional prospective 
study on treatment effects had a 14-day pre-test to post-test period, but reports data 
on natriuretic peptides and cognitive test performance at pre-test phase only, i.e. 
cross-sectionally. Mean age of participants (where reported) ranged between 61 years 
and 84 years. Nine studies investigated NT-proBNP; 9 studies assessed its correlate 
BNP. One study reported data from 3 cohorts of which 2 measured NT-proBNP and 
1 measured BNP. Seven studies were on associations of natriuretic peptides with 
diagnosis of dementia (either with or without additional cognitive assessment on 
screening instruments). One of these 7 studies also measured beta amyloid and tau in 
participants’ cerebrospinal fluid. Eleven studies employed detailed 
neuropsychological tests, screening instruments for dementia and dementia rating 
scales, with brain imaging data (computed tomography, CT) additionally available in 
3 studies. Finally, 1 study related BNP to findings on EEG, but not to cognitive 
function. Due to the apparent heterogeneity between the studies identified in the 
search in terms of study design and cognitive outcome, meta-analysis to derive 
overall effect sizes of associations was not possible. Findings are therefore described 
in narrative form.  
Findings from included studies 
A majority of the studies identified in the search reported significant findings for 
associations between higher natriuretic peptides and worse cognitive outcome. In a 
Swedish cohort of dementia-free older adults and dementia patients, as well as in a 
study of patients with  heart failure, NT-proBNP or BNP correlated inversely with 
scores on the MMSE, each with small to medium effect sizes (Mauro et al., 2007; 
Nilsson, Gustafson, & Hultberg, 2010). Each unit increase in BNP was linked to a 
loss of 0.15 points on the MMSE in an analysis of the Finnish Kuopio 75+ cohort of 
relatively old dementia-free adults (Kerola et al., 2010). In a smaller study of heart 
failure patients and healthy individuals, NT-proBNP levels further correlated 
negatively with performance on a range of more detailed cognitive tests, although 
effect sizes were not reported and could not be derived on the basis of reported 
statistics (Kindermann et al., 2012). Significant differences in mean natriuretic 
peptide levels between higher cognitively functioning and lower functioning groups 
have also been reported in relatively small studies of patients with heart failure 
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(Mauro, et al., 2007) or cardiovascular disease (Suwa & Ito, 2009), with unadjusted 
medium to large effect sizes. Conversely, in a study of psychogeriatric patients, a 
group with elevated NT-proBNP also had lower cognitive function when compared 
with patients with NT-proBNP below a pre-specified cut-point (Nilsson, et al., 2010). 
Finally, BNP correlated strongly with the delta source amplitude on EEG, which had 
previously been linked to abnormal cerebral blood flow and reduced cognitive 
function (Vecchio et al., 2012).  
 
Age, which may affect both natriuretic peptide levels and cognitive function, was not 
controlled for in any of these investigations, but similar results have been reported in 
studies which apply adjustment. In one relatively small study of dementia-free 
cardiovascular disease patients, BNP correlated inversely with scores on a brief 
cognitive screening test with a medium effect size and accounted for as much as 9% 
of variance even after multivariable adjustment (Gunstad et al., 2006). Following 
adjustment for age, sex and education, a ‘high’ NT-proBNP group was at around 
two-fold increased risk of ‘low’ performance on the MMSE and on a trail-making 
test of executive function and visual attention when compared to a ‘low’ NT-proBNP 
group in the Rancho Bernardo Study. When cognitive test performance was treated 
as continuous, significant group differences of medium effect size were also 
reported, although findings for a verbal fluency test of executive function were less 
consistent (Daniels et al., 2009; Daniels et al., 2011). Because all significant results 
persisted when analyses were additionally adjusted for stroke and when 
cardiovascular disease patients were excluded (Daniels, et al., 2011), the study 
supports a role of NT-proBNP in late-life cognitive function which is over and above 
that of being a marker of symptomatic macrovascular disease.  
 
In contrast, results from the Swedish cohort showed confounding of associations 
between the peptide and cognition by symptomatic macrovascular disease. 
Individuals with pathological findings on CT had higher mean NT-proBNP 
compared with the remaining population (Nilsson, Gustafson, & Hultberg, 2008; 
Nilsson, et al., 2010), but a group with elevated NT-proBNP who was free of 
symptomatic macrovascular disease had similar MMSE scores and prevalence of 
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pathological findings on CT as a group with normal NT-proBNP who was also free 
of symptomatic disease. The only significant association between NT-proBNP and 
pathological findings which were independent of symptomatic macrovascular disease 
was reported for a group with Alzheimer’s Disease, and these findings did not extend 
to associations with cognitive test scores (K.  Nilsson, L.  Gustafson, & B. Hultberg, 
2012). Further speaking against associations with cognitive outcome, one relatively 
large study failed to establish cross-sectional associations between tertiles of NT-
proBNP and performance on the MMSE (Vaes, de Ruijter, Degryse, Westendorp, & 
Gussekloo, 2009). 
 
Yet, further cross-sectional analyses have associated natriuretic peptides with 
presence of dementia. In unadjusted analyses of one case-control study, individuals 
with diagnosed vascular-type dementia (but not those with Alzheimer’s Disease) had 
higher mean BNP levels compared with dementia-free individuals, with a medium 
effect size (Kondziella, et al., 2009). ‘Elevated’ serum NT-proBNP was prevalent in 
as many as 74% of patients with vascular dementia in the Swedish cohort, but 
statistical testing was not applied to a comparison with controls (Nilsson, et al., 
2008). In two US cohorts, BNP was found to be higher in patients with diagnosis of 
dementia or milder forms of impairment compared with controls (W. T. Hu et al., 
2012). In the North American Alzheimer’s Disease Neuroimaging Initiative (ADNI), 
subjects with dementia or milder forms of impairment both also had higher NT-
proBNP (Soares et al., 2012) and BNP (W. T. Hu, et al., 2012) compared with 
controls. Additionally, BNP levels were associated with presence of Alzheimer’s 
Disease-typical protein in cerebrospinal fluid (W. T. Hu, et al., 2012). Addition of a 
range of biomarkers (including NT-proBNP) to a statistical model attempting to 
identify patients with Alzheimer’s Disease versus dementia-free indiviudals further 
increased specificity, although the role specifically of NT-proBNP in this finding is 
unclear (Soares, et al., 2012). In a Japanese sample of patients with diagnosed 
dementia, BNP also correlated inversely with scores on a cognitive test aimed at 
determining the severity of dementia, with a medium effect size in the association 
(Naito, Naka, & Watanabe, 2009) A more complex picture of associations of 
natriuretic peptides with dementia emerged in the Kuopio 75+ cohort. Here, higher 
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BNP was linked to presence of dementia in the youngest tertile, but was associated 
with a reduced likelihood of dementia in the oldest tertile aged 83 to 96 years 
(Hiltunen, et al., 2013). The authors concluded that the development of cognitive 
impairment may decrease the levels of BNP, thereby implying causality, but did not 
back up this claim by specifying potential mechanisms.   
 
None of the studies identified in the search assessed peak cognitive ability in young 
adulthood as a potential determinant of late-life natriuretic peptides. If such 
associations exist (which is likely given that pre-morbid ability predicts risk of late-
life symptomatic macrovascular disease), these could account for any cross-sectional 
links between natriuretic peptides and cognition. Prospective evidence is currently 
limited to four investigations reporting data from three cohorts. In one study of 
dementia-free older adults, baseline BNP accounted for around 4% of variance in 
processing speed, for 3% of memory and 12% of attention and executive functioning 
at six-year follow-up when a number of covariates including diabetes and an estimate 
of peak pre-morbid ability were controlled for. This suggests a steeper estimated 
lifetime decline in cognitive function in individuals with higher late-life BNP. An 
increase in BNP between baseline and follow-up additionally predicted a lower level 
of executive function and attention at follow-up (van den Hurk et al., 2011). With 
respect to assessments of prospectively ascertained change in cognitive function, the 
literature has produced inconsistent findings. Higher baseline BNP predicted steeper 
subsequent decline on the MMSE over five years in Kuopio 75+. Additionally, each 
standard deviation increase in baseline BNP increased the risk of dementia during 
follow-up by 55% in initially non-demented individuals (Kerola, et al., 2010), 
although a re-analysis which stratified by age group found that the predictive ability 
of BNP was restricted to the youngest tertile of this relatively old cohort (Hiltunen, et 
al., 2013). A prospective investigation of around 400 older US adults, who were 
cognitively tested prior to, six weeks after and one year after non-cardiac surgery, 
baseline BNP was unrelated to the risk of ‘postoperative cognitive dysfunction’ 
defined as a decrease in at least one standard deviation compared to pre-operative 
assessment in at least one cognitive domain at either of the two follow-up 





In contrast to the remaining sections of this chapter, which focused on studies of 
older adults with diabetes, the systematic review of natriuretic peptides included 
studies of the general older and other patient populations, because although one study 
identified in the search controlled for presence of diabetes in their analyses of BNP 
and cognitive function, investigations of cohorts consisting of people with diabetes 
were previously neglected. In the studies identified in the search, the balance of 
evidence overall suggests a potential association between natriuretic peptide levels 
and poorer cognitive outcome both in terms of impairment short of dementia and 
frank dementia. Yet, the role of confounding in many of these studies, including by 
individual differences in peak pre-morbid ability, is unclear, and investigations with 
prospective designs have produced conflicting results.  
Potentially asymptomatic PAD and carotid intima-media thickness (cIMT) 
Potentially asymptomatic PAD and diabetes 
A low ABI calculated from systolic pressure in the ankle and brachial pressure 
indicates potentially asymptomatic PAD as well as generalised atherosclerosis (C. 
Hayashi et al., 2004). The measure is non-invasive, and has been found to be 95% 
sensitive and almost 100% specific in the identification of patients with PAD. The 
classification of PAD according to ABI is as follows (ADA, 2003): 
 
 Normal: 0.91 – 1.30 
 Mild obstruction: 0.70 – 0.90 
 Moderate obstruction: 0.40 – 0.69 
 Severe obstruction: <0.40 
 
Values >1.30 are common in diabetes, but indicate poorly compressed arteries in the 
lower limbs and are therefore unreliable measurements of ABI in this type of patient 
(ADA, 2003; Potier, et al., 2011). Low ABI and progressive worsening of ABI both 
predict poor health outcomes (Banerjee, et al., 2010). Individuals with ABI ≤0.90, 
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which was present in 9% of older individuals in one Scottish cohort (Fowkes et al., 
1991), are at two-fold risk of cerebral infarction (Banerjee, et al., 2010) and ten-year 
mortality (Ankle Brachial Index Collaboration, 2008). The less frequently used lower 
limb arterial duplex or the cardio-ankle vascular index (CAVI), which is calculated 
from the ankle and brachial pressures, a microphone for detecting heart beats and 
electrocardiograph electrodes placed on wrists, may be used as alternatives to the 
ABI to ascertain potentially asymptomatic arterial disease in the periphery. In 
contrast to ABI, higher CAVI values indicate higher severity of disease.  
 
Consistent with the aforementioned increased prevalence of symptomatic PAD in 
patients with type 2 diabetes, ABI is abnormal in around 15% of diabetes patients 
(Mukherjee, 2009), and some evidence suggests that CAVI may be higher in  
patients with diabetes than in non-diabetic individuals (H. Wang et al., 2013). 
Carotid artery intima-media thickness and diabetes 
Carotid arteries consist of three layers (innermost intima, media and outermost 
adventitia) and run along the axis of the neck at a depth of 2 to 4 cm (Molinari, Zeng, 
& Suri, 2010). The distance between the lumen-intima interface and the media-
adventitia interface defines cIMT; thickness >0.9 mm is considered indicative of 
atherosclerosis (Haley, Tarumi, Gonzales, Sugawara, & Tanaka, 2010). Carotid IMT 
can be visualised non-invasively in 2-dimensional images using ultrasound and 
predicts cardiovascular outcomes. One meta-analysis reports 15% increased risk for 
MI and 18% increased risk for stroke per 0.1 mm increase (Lorenz, Markus, Bots, 
Rosyall, & Sitzer, 2007). As well as increasing with age (Ludwig, von Petzinger-
Kruthoff, von Buguoy, & Stumpe, 2003), cIMT is raised in (pre-)diabetes. A 
systematic review found an average of 0.13 mm and 0.04 mm thicker cIMT in 
populations with diabetes and IGT respectively compared with normoglycaemic 
controls (Brohall, Odén, & Fagerberg, 2005).  
Potentially asymptomatic PAD, cIMT and cognition in type 2 diabetes 
A systematic search of the literature on cross-sectional or prospective studies with 
observational designs investigating potentially asymptomatic atherosclerosis 
determined by cIMT or by ABI, CAVI or lower limb arterial duplex and cognition in 
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type 2 diabetes was performed. Where the evidence from studies of people with 
diabetes is lacking, the literature on the general population was consulted. However, 
potential differences between people with diabetes and the general population in 
terms of atherosclerosis associations with cognition are not at the centre of the 
research question and are therefore not fully addressed.  
Search strategy 
The titles, abstracts and keywords (.mp) of studies indexed by Medline and published 
between 1946 and the first week of May 2013 were searched. The search terms were 
“type 2 diabetes” OR “non-insulin dependent” OR NIDDM, as well as “intelligence” 
OR “cognitive function” OR “cognitive abilit*”, and “carotid intima-media” OR 
“cIMT” OR “ankle-brachial pressure index” OR “ankle-brachial index” OR “ABI” 
OR “arterial duplex” OR “cardio-ankle vascular index”. The three separate searches 
were combined using AND. Reference lists of reviews of the literature on non-
diabetic populations and key papers were scanned, and experts in the field were 
consulted.  
Selection of studies 
Inclusion criteria were: a) original studies, b) cohort studies either exclusively of 
humans with type 2 diabetes, or unspecified diabetes and mean age >55 years, or 
studies reporting data for a diabetic subsample, c) measured cIMT and/or peripheral 
arterial disease using ABI, CAVI or lower limb arterial duplex, d) application of 
neuropsychological tests or clinical evaluation of dementia and f) reporting of data 
linking cIMT and/or peripheral arterial disease with cognitive function. Case studies 
and reviews of the literature were excluded from the review. 
Data extraction 
Titles and abstracts of all studies identified by the search were screened. Full texts 
were accessed for those which appeared to meet the inclusion criteria or where this 
could not be determined on the basis of the abstract. Data from studies which met the 
criteria were extracted. Information on study design, total number of participants, age 
at baseline (range or mean), the assessment of cIMT/ABI/CAVI/lower limb arterial 
duplex, the measurement of cognitive function, main findings including effect sizes 
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and p-values or confidence intervals where available, and potential limitations was 
tabulated.  
Results 
The search resulted in 10 studies and the full texts of 9 articles were accessed (Figure 
3.4). Of these, one described a study protocol and two studies reported data on cIMT 
and cognition, but failed to explore the data for associations and so were excluded. 
Consequently, a total of 6 articles were included in this review. The extracted data is 




Figure 3.4: Systematic literature search on cIMT or potentially asymptomatic 





Table 3.7: Summary of studies identified in systematic search on cIMT/ potentially asymptomatic PAD and cognition in type 2 
diabetes or older adults with any type of diabetes 










Encephalopathy Study (112 
patients with type 2 diabetes, 
56 controls; all free of 
dementia or disease affecting 
cognitive function), 
Netherlands 
Cross-sectional 168 55-80 years 
(mean 66 
years) 
cIMT Composite z score 
calculated from 11 







version of NART 
Bruce et al. 
(2008) 
Diabetologia 
Fremantle Diabetes Study 




302 ≥70 years 
(mean 76 
years) 
‘PAD’ defined as 
ABI ≤0.90 or lower-
limb amputations due 
to diabetes 




MCI defined as 
CDR=0.5 without 
dementia; ‘cognitive 
decline’ defined as 
conversion between 
normal cognition, MCI 
and dementia 
Bruce et al. 
(2008) 
Diabetes Care 
Fremantle Diabetes Study 




205 ≥70 years 
(mean 75 
years) 
‘PAD’ defined as 
ABI ≤0.90 or lower-
limb amputations due 
to diabetes 






MCI defined as 
CDR=0.5 without 
dementia; ‘cognitive 
decline’ defined as 
conversion between 
normal cognition, MCI 
and dementia 
Chen, G. et al. 
(2011)  
Hospitalised patients with type 
2 diabetes (free of central 
nervous system disease, head 
trauma, inflammatory disease, 
infectious brain disease, 
drug/alcohol abuse), China 
Cross-sectional 101 Mean 63 
years 
cIMT, ABI MoCA; ‘MCI’ defined 
as MoCA<26 
Amer et al. 
(2012) 
Patients with diabetes (any 
type) and PAD versus diabetes 
only versus controls (all 
MMSE>24), Egypt 
Cross-sectional 90 ≥60 years ‘PAD’ defined as 
presence of 
mild/moderate/severe 
stenosis on lower 
limb arterial duplex 
MMSE; self-reported 
education 
Chen, R.-H. et 
al. (2012)  
Patients with type 2 diabetes, 
China 
Cross-sectional 157 40-69 years 
(mean 55 
years) 
cIMT (average and 
maximum) 
‘MCI’ defined as 
MoCA<26 with CDR 
≥0.5 (n=93); ‘normal’ 
defined as MoCA≥26 
(n=64) 
MoCA, Montreal Cognitive Assessment, MCI, mild cognitive impairment; cIMT, carotid intima-media thickness; ABI, ankle brachial pressure index; PAD, 
peripheral arterial disease; NART, National Adult Reading Test. 
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Table 3.8: Main findings from studies identified in systematic search 
 Finding Limitations 
Manschot et 
al. (2007) 
Diabetic group: cIMT entered in regression model 
explaining cognitive test performance (adjusted for age, 
sex, NART), but apparently not retained in model  
Data not shown 
Bruce et al. 
(2008) 
Diabetologia 
1. Cross-sectional analysis: prevalence of PAD in 
cognitively normal (38%) < MCI patients (45%) < 
dementia patients (75%) (p=0.001 for trend) 
2. Cross-sectional analysis: PAD associated with OR 
2.03 for all MCI/dementia and OR 4.54 for all 
dementia (both p<0.05; PAD unrelated to MCI or 
AD alone)  
3. Prospective analysis: prevalence of baseline PAD in 
cognitively normal (21%) < MCI patients (27%) < 
dementia patients (57%) at follow-up (p=0.001 for 
trend) 
4. Prospective analysis: baseline PAD associated with 
OR 2.23 for any MCI/dementia (p<0.01) and 5.35 
for all dementia at follow-up (p<0.001) (PAD 
unrelated to risk of MCI or AD alone). All analyses 
unadjusted. 
Did not explore change in 
cognitive function 
between baseline and year 
8; did not adjust for 
potential confounders 




1. Prospective analysis of whole sample: prevalence of 
baseline PAD similar in patients who ‘declined’ and 
others (44% versus 36%; p=0.43)  
2. Similar results when analyses of cognitive decline 
restricted to individuals with ‘normal cognition’ at 
baseline 
Short follow-up period 
Chen, G. et 
al. (2011) 
1. Lower ABI in MCI group compared with others 
(mean 1.09 versus 1.17; Cohen’s d=-0.78, p<0.01) 
2. Higher cIMT in MCI group compared with others 
(mean 1.19 mm versus 1.05 mm; Cohen’s d=0.78, 
p<0.01 
1. Associations of ABI/ 
cIMT with age not 
reported; analyses not 
controlled for age (but 
age not significantly 
associated with MCI) 
2. High prevalence of 
MCI (n=58; 57%) 
considering young 
age  
Amer et al. 
(2012) 
1. Illiteracy in 67% of diabetics with PAD, in 63% of 
diabetics without PAD and 27% of non-diabetic 
controls (p<0.001 across groups) 
1. Did not report 
associations between 
PAD and MMSE 




et al. (2012) 
Group with MCI had higher average cIMT and max 
cIMT compared with remaining population (max cIMT 
0.91 mm versus 0.81 mm; Cohen’s d=0.67, p<0.001) 
Inverse correlation between MoCA scores and max 
cIMT (r=--0.25, p=0.005) 
High prevalence of MCI 




MoCA, Montreal Cognitive Assessment; MCI, mild cognitive impairment; cIMT, carotid intima-
media thickness; ABI, ankle brachial pressure index; AD, Alzheimer’s Disease; PAD, peripheral 
arterial disease. 
 
Overview of included studies 
The 6 studies included in the review reported findings from 5 cohorts. The total 
number of participants included in these studies was 1023 and all included both 
males and females. Mean age of participants (where reported) ranged between 55 
years and 75 years. Three of the studies included only patients with diagnosis of type 
2 diabetes. The remaining 3 studies included older patients with diabetes of any type, 
but given the advanced age of the samples may be assumed to have captured mainly 
people with type 2 diabetes. Three studies focused on PAD defined either by ABI or 
lower limb arterial duplex, two studies assessed cIMT and one study included data 
on both ABI and cIMT. CAVI was not measured in any of the studies. Three of the 6 
studies were cross-sectional and 2 (both of which reported data from the same 
cohort) were prospective with median follow-ups of 2 and 8 years respectively, 
although only the 2-year prospective study investigated cognitive change during the 
follow-up period. The 8-year prospective study associated baseline predictors with 
cognitive status at follow-up, and so essentially reports cross-sectional analyses. 
These 2 studies were also the only ones which included both cognitive screening 
instruments and clinical diagnosis of dementia. Of the remaining 4 studies, 3 were 
based on brief cognitive screening instruments and 1 applied more detailed 
neuropsychological tests. Due to the small number of studies identified in the 
systematic search and heterogeneity in terms of study design and cognitive 
outcomes, meta-analysis to derive average effect sizes of associations was deemed 
not possible and so findings from the included studies are described in narrative 
form.  
Findings from included studies 
Potentially asymptomatic PAD and cognition 
In the Fremantle Diabetes Study, which provided data for 2 of the 5 studies identified 
in the search 38% of cognitively ‘normal’ individuals, 45% of individuals with 
reduced cognitive function short of dementia and 75% of dementia patients suffered 
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from potentially asymptomatic PAD (ABI ≤0.90 or diabetes-related lower-limb 
amputation). Across groups, the difference in prevalence reached statistical 
significance, although the authors did not apply pairwise comparisons. Overall, 
presence of potentially asymptomatic PAD was associated with an unadjusted two-
fold likelihood of presence of any cognitive impairment and almost five-fold 
likelihood of presence of dementia. Results were similar in further cross-sectional 
analyses of baseline PAD and cognitive function assessed after a median of eight 
years. Baseline PAD was prevalent in 21% of individuals with ‘normal’ cognition at 
eight-year follow-up, in 27% of people with reduced cognitive function short of 
dementia and in 57% of individuals with dementia diagnosis by the time of the eight-
year follow-up; the risk of any cognitive impairment was again around two-fold and 
the risk of dementia was more than five-fold (Bruce, Davis, Casey, Starkstein, 
Clarnette, Foster, et al., 2008). The findings were supported by a Chinese study of 
hospitalised type 2 diabetes patients. Mean ABI was lower in a group with reduced 
cognitive function compared with a group with ‘normal’ cognitive function as 
defined on the basis of a screening instrument, with a large effect size in the 
unadjusted group difference in means (G. Chen, et al., 2011). 
 
Such reports may be driven by increased risk of both PAD and poorer late-life 
cognitive outcome in diabetes patients with lower peak ability in young adulthood 
compared with higher-ability patients. Findings from an Egyptian case-control study 
of older people with diabetes and non-diabetics support this possibility. Although the 
authors failed to associate cognitive function in the sample with evidence of PAD on 
a lower limb arterial duplex, links between PAD, diabetes and education were 
explored. Whereas 67% of diabetics with PAD were illiterate, this applied to 63% of 
diabetics without PAD and 27% of controls (Amer, Alsadany, Tolba, & Omar, 
2013). Pairwise comparisons were not carried out, but at least a trend for detrimental 






In support of confounding of cross-sectional associations between PAD and 
cognition, the only truly prospective investigation of PAD and cognitive decline 
reported non-significant associations. During two years of follow-up in the Fremantle 
Diabetes Study, potentially asymptomatic PAD at baseline (ABI ≤0.90 or diabetes-
related lower-limb amputation) was unrelated to risk of conversion between ‘normal’ 
cognition, reduced cognitive function short of dementia and diagnosis with dementia. 
Findings were similar when analyses were restricted to individuals with initially 
‘normal’ cognition at baseline, although the very short follow-up period clearly 
restricts the interpretations made on the basis of this finding (Bruce, Davis, Casey, 
Starkstein, Clarnette, Almeida, et al., 2008). 
Carotid IMT and cognition 
In two of the studies on cIMT and cognition identified in the search, participants 
were grouped according to performance on a brief cognitive screening instrument, 
the Montreal Cognitive Assessment (MoCA). In the analyses, which were both set in 
China and which appeared to differ mainly in terms of the mean age of the sample, 
the respective group with lower cognitive function had higher mean cIMT compared 
with the remaining participants, with medium effect size in the sample with mean 
age 55 years (R. H. Chen, et al., 2012) and medium to large effect size in sample 
with mean age 63 (G. Chen, et al., 2011). Additionally, MoCA scores also correlated 
negatively with cIMT with a small to medium effect size in the study with a mean 
age of 55 years (R. H. Chen, et al., 2012). Neither of the studies applied adjustment 
for potential confounding variables. The only study on cIMT and cognitive decline 
identified in the search was a cross-sectional analysis adjusting for an estimate of 
peak pre-morbid ability. Here, cIMT appeared to be unrelated to estimated lifetime 
cognitive decline, although the finding is severely limited in that no data or findings 









Comparison of findings from systematic search with evidence in the 
general population 
With the restriction of the evidence to five studies, the findings from the systematic 
search were extended through the consultation of the literature on the general 
population.  
Potentially asymptomatic PAD and cognition in the general population 
As was found in the cross-sectional studies of diabetes patients identified in the 
search, a low ABI has also been linked to lower late-life cognitive function short of 
dementia in the general population (W. Johnson, Price, Rafnsson, Deary, & Fowkes, 
2010; J. F. Price et al., 2006). In a Japanese study which categorised individuals 
according to cognitive function, ABI in the first versus the third tertile of the 
distribution was also linked to an odds ratio of 3.2 for presence of reduced cognitive 
function (MMSE<24), for instance. However, similar results were not found when 
analyses were unadjusted, or in comparison of the second to the third tertile of ABI 
(Sugawara et al., 2010). No significant associations between ABI<0.90 and 
performance on a battery of detailed neuropsychological tests were reported in a 
Dutch study of 400 middle-aged to older men (Muller, Grobbee, Aleman, Bots, & 
van der Schouw, 2007). Another study, which reports lower cognitive function in 
older adults with any PAD (ABI<0.97 after rest or <0.85 after treadmill test, or 
intermittent claudication identified using a questionnaire or on treadmill test) 
compared with controls who were free of PAD failed to stratify the analyses by PAD 
stage so that the role of potentially asymptomatic PAD as signified by the ABI is 
unclear in their results (Waldstein, et al., 2003).  
 
Evidence from prospective associations of potentially asymptomatic PAD in general 
older populations also appears mixed. In an early analysis of the Cardiovascular 
Health Study of over 5000 older adults, an ABI<0.90 was associated with steeper 
decline on a test of processing speed and on the MMSE during seven years of follow-
up (Haan, et al., 1999). Yet, mirroring the null findings of the only prospective 
investigation on the topic in people with diabetes (Bruce, Davis, Casey, Starkstein, 
Clarnette, Almeida, et al., 2008), baseline ABI was unrelated to change in cognitive 
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function during the subsequent ten years in the Edinburgh Artery Study of middle-
aged to older adults (W. Johnson, et al., 2010). This was in spite of previous 
evidence of steeper lifetime cognitive decline (estimated by adjustment for a test of 
vocabulary) in low ABI-individuals in this cohort (J. F. Price, et al., 2006). Despite 
equivalent baseline cognitive function in groups with lower or higher CAVI, scores 
on the MMSE and another dementia screening instrument for the ‘low CAVI’ group 
also declined at steeper rates relative to the ‘high CAVI’ group over four years in a 
Japanese study of over 75 year olds (Yamamoto, Yamanaka, Ishikawa, et al., 2009). 
In the Rotterdam Study, low ABI (<0.90) at baseline was unrelated to incidence of 
dementia during nine years of follow-up (van Oijen et al., 2007). Similar null 
findings were reported during eight-year follow-up in the Honolulu Asia Aging 
Study when ABI was treated as a continuous measure, but this finding may have 
been confounded by the aforementioned reduced validity of higher values of ABI. 
When individuals with ABI>1.20 were excluded from the analyses, ABI<0.90 
predicted a 66% increased risk of any type of dementia and a 125% increased risk of 
vascular dementia during follow-up when age, education and vascular risk factors 
were controlled for (Laurin, Masaki, White, & Launer, 2007). A review on 
symptomatic and asymptomatic PAD and a systematic review of PAD defined by 
ABI ≤0.90 both support associations with reduced cognitive function and cognitive 
decline (Guerchet et al., 2011; Rafnsson, Deary, & Fowkes, 2009). In further support 
of these conclusions, the presence of PAD (independently of pre-morbid ability) has 
been linked to lower amplitude of the P300 component in middle aged to older adults 
(Kügler, Vlajic, Funk, Raithel, & Platt, 1995).  
Carotid IMT and cognition in the general population 
In the general population, cIMT-cognition associations appear well-established. In a 
French study, cIMT correlated negatively with level of cognitive function, although 
the finding was of small effect size and restricted to males with a presence of plaques 
in the carotid artery (Auperin et al., 1996). Another relatively small cross-sectional 
investigation reported associations of small to medium effect size with processing 
speed, executive functioning and attention, but non-significant associations with 
other cognitive domains (R. A. Cohen, et al., 2009). Directly contrasting this pattern 
of results, a Dutch study of 400 middle-aged to older males established cross-
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sectional associations with memory ability (each mm increase in cIMT was 
associated with 1.3-point lower memory score), but cIMT was unrelated to 
processing speed or executive function (Muller, et al., 2007). An association with the 
latter has since been supported (Semplicini et al., 2011). In a large study of younger 
to older individuals (21 to 84 years), higher cIMT was related to lower MMSE, lower 
processing speed, executive function and psychomotor control. For instance, each 
mm increase in cIMT was associated with 0.6 lower points on the MMSE (Zhong et 
al., 2011). One cross-sectional investigation also associated cIMT with memory 
ability and processing speed measured twelve years later (Komulainen et al., 2007). 
Further associations have been reported between higher cIMT and lower cognitive 
test performance in middle-aged to older patients with HIV (Becker et al., 2009), 
cardiovascular disease (Haley et al., 2007), and major depressive disorder (P. J. 
Smith et al., 2007). It is noteworthy that many of these studies controlled for vascular 
risk factors and for presence cardiovascular disease.  
 
However, some studies have failed to establish such results (Auperin, et al., 1996; 
Romero et al., 2009; Yaldizli et al., 2006). Any cross-sectional associations may also 
be confounded by evidence of reduced peak pre-morbid ability or its proxies in 
individuals with higher cIMT (Knox et al., 2012; Singh-Manoux et al., 2008), but are 
supported by a number of prospective investigations. In the Baltimore Longitudinal 
Aging Study of middle-aged adults, baseline cIMT predicted (up to) eleven-year 
decline on some measures of verbal and non-verbal memory and executive function 
independent of covariates including education (indexing pre-morbid ability), 
although it was unrelated to trajectories in working memory or naming (Wendell, 
Zonderman, Metter, Najjar, & Waldstein, 2009). Two relatively small studies also 
reported links between baseline cIMT and rate of decline on screening instruments 
for dementia over one and two years in patients with Alzheimer’s Disease and an 






Higher cIMT further predicted increased risk of two-year incidence of reduced 
cognitive function (defined using a screening instrument) in a German study of over 
3000 older individuals (Sander, et al., 2010). In a smaller Greek study, each standard 
deviation increase in cIMT at baseline was associated with a two-fold risk of 
similarly defined reduced cognitive function one year after patients suffered their 
first-ever stroke (Talelli et al., 2004). Finally, subjects in the 5
th
 quintile of baseline 
cIMT were at 50% increased risk of dementia during the subsequent nine years in the 
Rotterdam Study (van Oijen, et al., 2007). A review of the prospective literature in 
the general population concludes that higher cIMT is relatively consistently 
associated with lower cognitive function and with increased risk of dementia 
(Arntzen & Mathiesen, 2011), and a systematic review reports that 14 of 20 studies 
(of which twelve were cross-sectional and of which most employed the MMSE) 
reported significant associations of higher cIMT and lower cognitive function (Saleh, 
2010). Yet, in the apparently only study of cIMT and cognition in people with type 1 
diabetes, the DCCT/EDIC, cIMT was unrelated to 18-year decline in any of eight 
cognitive domains, despite a non-significant trend linking higher cIMT to steeper 
decline in psychomotor speed (Jacobson et al., 2011).  
Conclusions  
Overall, potentially asymptomatic PAD appears to be relatively consistently 
associated with poorer cognitive outcome including steeper cognitive decline in the 
general population. Although the only prospective analysis of the topic in patients 
with type 2 diabetes to date failed to establish significant associations, it is likely that 
asymptomatic PAD has a similarly useful role as a potential marker of risk in this 
type of patient. 
 
Carotid IMT also appears to be a valuable marker predictive of late-life cognitive 
outcome in the general population. Despite a current lack of evidence, a similar role 
of cIMT as a marker for risk of cognitive decline in people with type 2 diabetes is 
plausible. Non-significant findings in the DCCT/EDIC trial of patients with type 1 
diabetes may in part be accounted for by the relatively younger age of these patients. 
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3.3 Aims and Objectives 
A number of potential risk factors for poorer late-life cognitive outcome have been 
identified in the general older population. Most studies treat presence of type 2 
diabetes as a single risk factor in comparisons with non-diabetic controls or 
adjustment of analyses for diabetes status, rather than exploring associations between 
risk factors and cognitive outcome in exclusively diabetic populations. As the 
systematic review of the literature presented in this chapter has shown, this is 
particularly the case for investigations of macrovascular disease and cognition. The 
literature has also neglected the study of the relationship of hypoglycaemia with 
cognitive decline in people with type 2 diabetes. Finally, despite inter-relationships 
between the various factors, a majority of studies investigate individual risk factors 
in isolation in terms of their links with cognition and have failed to compare a wider 
range of risk factors in their predictive ability for cognitive decline.  
3.3.1 Aims 
The aim of the analyses presented in this thesis is to extend the current knowledge on 
risk factors for cognitive decline in type 2 diabetes. For this purpose, risk factor 
associations with trajectories of late-life cognitive change will be investigated in a 
population consisting exclusively of diabetes patients. Data from the baseline, the 
year 1 and year 4 follow-up waves of the prospective Edinburgh Type 2 Diabetes 
Study (ET2DS) of community-dwelling patients with type 2 diabetes will be used to 
statistically test associations between baseline risk factors and cognition. The main 
outcome of interest is the rate of cognitive change between baseline and year 4 of the 
study. Additionally, cross-sectional associations with estimated peak pre-morbid 
ability, with level of cognitive function measured at year 4, with estimated lifetime 
cognitive change between pre-morbid ability and year 4, and with presence of 
diagnosed dementia will be explored. Both specific cognitive domains and global 
cognitive function will be assessed. In the first part of the thesis, the relationship of 
the main risk factors under investigation, including one which is unique to diabetes 
(severe hypoglycaemia) and one which is linked to the condition but (at lower 
prevalence) also occurs in non-diabetic populations (macrovascular disease), with 
cognitive outcome will be determined in detail. Multivariable adjustment will be 
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applied with the aim to evaluate potential mechanisms underlying any statistically 
significant associations. In the second part of the thesis, exploratory analyses will 
consider and compare a wider range of vascular and metabolic risk factors in their 
ability to predict cognitive outcome in slightly less detail. Finally, the usefulness of a 
summary ‘allostatic load’ measure derived from a number of individual risk factors 
in its relationship with cognitive decline will be determined. 
3.3.2 Objectives 
1. To determine the associations of baseline macrovascular disease with: (i) 
estimated peak pre-morbid cognitive ability, with (ii) level of late-life 
cognitive ability measured at follow-up, with (iii) four-year late-life cognitive 
change between baseline and follow-up, and with (iv) estimated lifetime 
cognitive change between estimated peak pre-morbid ability and late-life 
ability in a sample of older people with type 2 diabetes.  
2. To determine the potential bidirectional relationship between hypoglycaemia 
and cognitive function in the same sample by associating a baseline history of 
severe hypoglycaemia and severe hypoglycaemia during follow-up: with (i) 
estimated peak pre-morbid cognitive ability, with (ii) level of late-life 
cognitive ability, with (iii) four-year cognitive change and with estimated 
lifetime cognitive change, and by (iv) associating cognitive function at 
baseline with the risk of severe hypoglycaemia during follow-up. 
3. To compare the predictive ability of a wider range of risk factors measured at 
baseline: with respect to (i) level of late-life cognitive ability at follow-up, 
with (ii) four-year cognitive change, and with (iii) estimated lifetime 
cognitive change. In addition to macrovascular disease and severe 
hypoglycaemia, risk factors considered in this part of the analyses will 
include:  
(i) Conventional cardiovascular risk factors 







4. To determine the usefulness of an ‘allostatic load’ measure constructed from 
a number of baseline risk factors and (if applicable) its prediction of late-life 
cognitive outcome.  
 
In order to achieve these objectives, a series of tasks will be undertaken: 
1. Test participants in the ET2DS for cognitive ability, four years after they 
were recruited into the study, and analyse change in cognitive function 
over the four-year period. 
2. Assess the representativeness in terms of demographic, clinical and 
cognitive characteristics of ET2DS participants who returned to year 4 
follow-up.  
3. Collect data on the incidence of dementia in the ET2DS and repeat key 
analyses with exclusion of subjects with dementia in order to evaluate the 
independence of overall findings from a contribution by dementia. 
Analyse statistically the associations of pre-selected risk factors, 
measured at baseline or during follow-up, with: (i) estimated pre-morbid 
ability, with (ii) level of cognitive function at year 4, with (iii) four-year 
cognitive change, and with (iv) estimated lifetime cognitive change.  
4. Determine whether or not ‘allostatic load’ derived on the basis of a 
number of pre-selected risk factors is a useful summary measure, and, if 











Chapter 4: Methods 
This chapter describes the design of the Edinburgh Type 2 Diabetes Study (ET2DS) 
and the data relevant to this thesis which were collected at the baseline and year 1 
waves of the study. These phases of data collection were completed before I joined 
the study. Data collection, data cleaning and derivation of variables are also 
described for the four-year follow-up phase of the study, in which I was integrally 
involved. The statistical analyses included in this thesis as well as their theoretical 
background are specified in the final sections of the chapter.  
4.1 The Edinburgh Type 2 Diabetes Study: study design 
The ET2DS was set up in 2006/2007 with funding from the Medical Research 
Council (MRC) and the primary objective to investigate associations between 
modifiable risk factors and cognitive decline, in order to inform the future 
development of strategies and therapeutic agents to protect cognitive function in type 
2 diabetes (J. F. Price, Reynolds, et al., 2008). Additional outcomes of interest were 
fatty liver disease as well as micro- and macrovascular disease (J. F. Price, Reynolds, 
Frier, & Strachan, 2008). 
A large sample of older patients with type 2 diabetes who were living in the Lothian 
area of Scotland, UK, were recruited, extensively phenotyped and followed up over 
several waves. The study is a population-based cohort study investigating exposure-
outcome relations in a population defined by geographic boundaries and group 
membership in an observational fashion (Szklo, 1998). Although retrospective cohort 
studies are possible, the ET2DS has the preferred prospective design, which allows 
the addition and exclusion of measurements during follow-up and enables 
observation of incidence and prognosis of disease as well as continuous change in 
outcomes. Although this type of study does not allow conclusions regarding causality 
underlying any associations, the temporal relationship between exposure and 
outcome may be inferred when both occur at different time points. Ultimately, 
conclusions drawn on the basis of prospective investigations may be more reliable at 
least when compared with cross-sectional or case-control studies (Mann, 2003). This 
may provide important information for the design of future studies aimed at 
identifying causality in associations, although the view that evidence from this type 
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of study is of a quality comparable to that from ‘gold-standard’ randomised 
controlled trials (Micha & Mozaffarian, 2010) appears exaggerated.  
A majority of cohort studies of cognitive ageing, such as the Framingham Study 
(Akomolafe, et al., 2006) or the Rancho Bernardo Study (Kanaya, et al., 2004), 
recruit large samples from older general populations and investigate type 2 diabetes 
as a secondary predictor of cognitive outcome. Rarely are individual differences in a 
range of different risk factors associated with cognitive outcome in populations 
consisting exclusively of older patients with type 2 diabetes. The ET2DS follows 
precisely this approach. By targeting risk factors within this high-risk group will 
enable an investigation of the relationship of individual differences in risk factor 
prevalence or severity with cognitive decline and will thereby exceed simple 
description of diabetes-associated cognitive decline by allowing the investigation of 
the specific underlying causes of these well-established associations. The study 
therefore offers a novel contribution to the research literature on diabetes-associated 
cognitive decline. To date, two main waves have been completed.  
4.2 Study population 
Details of recruitment have been described in the study protocol (J. F. Price, 
Reynolds, Mitchell, et al., 2008). Participants were recruited from the Lothian 
Diabetes Register (LDR) which captures almost all patients with diabetes diagnosed 
according to WHO criteria living in the Lothian region of Scotland (n=~20 000). 
5454 individuals on the LDR who were between 60 and 74 years of age on 1
st
 
August 2006 were randomly selected by sex and five-year age bands and were 
contacted by post; 1252 individuals replied and expressed interest. The baseline 
clinic in 2006/2007 was subsequently attended by 1077 subjects. Participants with 
the entire spectrum of severity of diabetes were recruited: mode of treatment ranged 
from diet-controlled to insulin-controlled. Individuals with poor corrected visual 
acuity (distance vision <6/36 or unable to read large print text) were excluded from 
the study, because some cognitive tests were paper-based. Non-native speakers of 
English were also excluded. This limitation was applied due to language 
requirements of cognitive tests, but is unlikely to restrict generalisation of the study 
results to the general Scottish population, considering that only around 3% of Scots 
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are born outside of the UK and therefore likely to be non-native speakers (General 
Register Office for Scotland, 2008).  
 
Following completion of the baseline clinic, medical records were assessed by the 
study team in order to exclude any patients erroneously recorded on the LDR as 
having type 2 diabetes. Type 2 diabetes status was taken as confirmed if a patient 
was treated with oral anti-diabetic agents and/or insulin, or had HbA1c levels >6.5%. 
Individuals who were not receiving treatment, had HbA1c ≤6.5%, had started on 
insulin within one year of diagnosis, had self-reported pancreatic surgery or disease, 
or  who were on insulin-treatment and aged <35 years  at the time of diagnosis were 
reviewed by a consultant diabetologist.  
The overall temporal structure and subject participation of the ET2DS are shown in 
Figure 4.1. Of all participants attending the baseline clinic in 2006/2007 (n=1077), 
subjects with questionable type 2 diabetes diagnosis or a history of pancreatic disease 
(n=7) and those who were not cognitively tested or physically examined due to 
refusal or physical disability (n=4) were excluded from the study. This resulted in a 
total baseline population of 1066. Around one year after the baseline clinic, all 1066 
participants were invited to return for further assessments, predominantly of liver 
abnormalities. 939 individuals attended this clinic and 898 consenting subjects were 
there enrolled in a 6-month survey of severe hypoglycaemia (SH). In the time period 
between baseline and year 4, 88 (8.3%) participants died (mortality was the cause of 
37.4% of attrition between baseline and year 4), nine (0.8%) declined further 
attendance and 26 (2.4%) were deemed unfit to continue with the study. Reasons for 
withdrawal or non-attendance included poor health (including dementia), 
responsibilities as a carer, and other personal reasons. Following the baseline clinic, 
one participant was identified as failing to meet WHO diagnostic criteria for 
diabetes. The remaining 943 participants of the total baseline population (n=1066) 
were invited for the year 4 follow-up. In 2010/2011, and 831 participants attended 
the clinic; 828 of these provided cognitive data. Physical examination procedures and 
cognitive test batteries were largely identical at baseline and year 4, with additional 
assessment for cIMT undertaken at the year 1 clinic. Details of these examinations 





Figure 4.1: Subject participation in the ET2DS 
 
4.3 Ethical approval 
The study had full ethical approval from the Lothian Medical Research Ethics 
Committee and assessments complied with the Declaration of Helsinki. Informed 
consent was obtained from all participants at each point of data collection. 
4.4 Physical and cognitive examination 
Clinical examination was carried out by four to six members of the research team on 
each weekday morning between August 2006 and September 2007 (at baseline) and 
between May 2010 and May 2011 (at year 4) in the Wellcome Trust Clinical 
Research Facility at the Western General Hospital, Edinburgh. A taxi service to the 
clinic was offered; appointments affected by severe weather conditions were 
rescheduled.  Patients were fasted overnight and instructed to collect morning urine 
samples. Physical and cognitive assessments were completed between morning and 
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noon, although the specific order of examinations varied. All members of the 
research team were trained in their respective assessments. 
4.4.1 Questionnaires 
Baseline questionnaires 
Baseline questionnaires collected self-reported information on educational 
attainment, occupation, current employment status of the participant and their 
spouse, marital status, ethnicity, years since diagnosis of diabetes and current 
diabetes treatment. Information on previous doctor’s diagnosis of cardiovascular 
disease, including myocardial infarction and angina, and history of surgical 
operations were also self-reported. Deprivation was determined by the Scottish Index 
of Multiple Deprivation (SIMD) determined on the basis of participants’ postcodes; 
this was represented in quintiles (first quintile- most deprived; fifth quintile- least 
deprived). 
Severe hypoglycaemia (SH) was defined as an episode which required the 
intervention by another person for recovery. In order to ascertain participants’ 
lifetime history of SH, an initial question asked if the participant had ever 
experienced an episode of low blood glucose which required treatment by another 
person, for instance using a sugary drink or glucagon. It was noted that such episodes 
are commonly termed ‘hypoglycaemia’. Possible responses to the item were ‘yes’, 
‘no’ and ‘I don’t know’. A positive response to the item was followed-up by 
questions on the number of such episodes that had been experienced in total over the 
course of their lifetime (possible responses ‘1-2’, ‘3-4’, ‘5 or over’), and in the year 
prior to the clinic visit (possible responses ‘1-2’, ‘3-4’, ‘5 or over’). Uncertainty in 
subjects who selected ‘I don’t know’ was followed up and resolved by research staff 
if possible.  
The Edinburgh Claudication Questionnaire (Leng & Fowkes, 1992) assessed 
presence of intermittent claudication, which for the purpose of this thesis is referred 
to as ‘PAD’. Administration of the World Health Organisation (WHO) Chest Pain 
Questionnaire aided the identification of individuals with cardiovascular disease. 
Alcohol intake over the past week was self-reported (number of spirits/wines on each 
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day), as was a doctor’s diagnosis of alcohol abuse. Current smoking habits (number 
of cigarettes/cigars or ounces of tobacco per day) and history of smoking for ex-
smokers (years/months since cessation) were ascertained.  
Six-month survey of severe hypoglycaemia 
Of all subjects attending the year 1 clinic (n=939), 898 agreed to participate in a 6-
month survey of severe hypoglycaemia (SH) carried out immediately after year 1 
clinic visit. The questionnaire was based on the Edinburgh Hypoglycaemia Scale 
(Deary et al., 1993) and included items on symptoms, date and time of any 
hypoglycaemic episode, loss of consciousness, details on help from another person, 
details of treatment and blood glucose values if measured (Appendix H). Subjects 
self-completed the questionnaires and returned one every two months over a six 
month period (total of three questionnaires per person) irrespective of whether they 
had experienced SH or not. Participants who reported SH and those who failed to 
return a given questionnaire were contacted by telephone by a clinically qualified 
member of the research team in order to ensure data accuracy and completeness. 
Year 4 questionnaire  
Year 4 self-completion questionnaires collected up-dated information on marital 
status, current occupation of participants and his/her spouse, diabetes history and 
treatment, cardiovascular disease, alcohol intake over the past week, history of 
alcohol abuse, and history of smoking, including number of cigarettes/cigars or 
ounces of tobacco smoked per day and months/years since cessation. The 
questionnaire also included items on whether or not subjects had experienced SH 
during the past four years (i.e., since baseline) and during the past year. Responses 
again were ‘yes’, ‘no’ and ‘I don’t know’. Positive responses were followed by items 
on the number of episodes which had been experienced during the past four years 
(possible responses ‘1-2’, ‘3-4’, ‘5 or over’), and during the year prior to this clinic 
visit (possible responses ‘1-2’, ‘3-4’, ‘5 or over’), and participants who expressed 
uncertainty were followed up by the research team where possible. Again, the 
Edinburgh Claudication Questionnaire (Leng & Fowkes, 1992) determined possible 
intermittent claudication, and the World Health Organisation’s (WHO) Chest Pain 
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Questionnaire was administered to aid identification of individuals with 
cardiovascular disease.  
Hospital Anxiety and Depression Scale (HADS) 
At both baseline and four-year follow-up, two subscales of the self-administered 
Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) measured 
anxiety (HADS-A) and depression (HADS-D). On each, participants self-report 
symptoms of depression and anxiety over the last few days, respectively, by selecting 
‘most of the time’, ‘a lot of the time’, ‘from time to time’ and ‘not at all’ in response 
to statements describing symptoms (e.g., ‘I feel tense or wound up’, HADS-A). 
Maximum score is 21 for each scale, minimum scores are zero. High scores indicate 
a high number of symptoms. A recent systematic review established high validity for 
the HADS in general and in patient populations, as well as a two-factor structure 
consistent with HADS-A and HADS-D (Bjelland, Dahl, Haug, & Neckelmann, 
2002). The subscales also have high sensitivity and specificity (Bjelland, et al., 2002; 
Olssøn, Mykletun, & Dahl, 2005), and have further been shown to have high 
reliability and a robust factor structure in diabetic populations (Reddy, Philpot, Ford, 
& Dunbar, 2010). Scores may be used as continuous measures or with cut-off ≥8 to 
indicate suspected clinical depression and anxiety, respectively. Both applications are 
common in the literature. Copies of all questionnaires can be found in Appendix H.  
4.4.2 Physical  assessment 
Physical examination 
At both baseline and four-year follow-up, systolic blood pressure was taken in two 
readings from left and right brachial, posterior tibial and dorsalis pedis arteries using 
Doppler in a supine position and following a five minute rest unless this was 
undesirable or impossible. Additionally, systolic and diastolic blood pressure was 
taken from the right arm. Height to the nearest millimeter, body weight to the nearest 
0.1 kg, twelve-lead ECG, waist circumference and hip circumference were recorded. 
For waist and hip circumference, two readings were carried out to the nearest 0.5 cm 
and averaged. Duplication of all recorded values over a pre-specified period of time 
during the clinics determined that inter-individual differences between testers in the 
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precision of measurement were acceptably low at both baseline and at year 4. For all 
participants, ECG was rated for possible cardiovascular disease by a single rater. In 
addition to these assessments, distance and near vision and % body fat content were 
measured at baseline only. Three readings of body fat content were averaged.  
Blood and urine assessments 
At baseline, fasting blood samples were taken for measurement of low-density 
lipoprotein (LDL), high-density lipoprotein (HDL), inflammatory markers (c-
reactive protein, CRP; interleukin-6, IL-6; tumor necrosis factor-alpha, TNF-α, 
fibrinogen), HbA1c, plasma glucose, red and white cell counts, platelet counts, 
creatinine and cortisol. Plasma N-terminal pro-brain natriuretic peptide (NT-
proBNP) concentrations were determined using the Elecsys 2010 
electrochemiluminescence method (Roche Diagnostics, Burgess Hill, UK) calibrated 
using the manufacturer's reagents. Manufacturer's controls were used with limits of 
acceptability defined by the manufacturer. Low control coefficient of variation (CV) 
was 6.7% and high control CV was 4.9%. At year 4, fasting blood samples 
determined fasting blood glucose, HbA1c, lipids, apolipoprotein A1 and B, creatine 
and cortisol. All blood and urine samples were frozen at -80º C for storage.  
Diabetic retinopathy (DR) 
Two to three weeks following their initial baseline visit to the clinic, 1046 patients of 
the total baseline population returned for digital retinal photography. Seven-field 
non-stereoscopic colour photographs were taken of both eyes using a high resolution 
digital retinal camera and were graded independently by two trained optometrists. 
Grading was carried out according to a scale used by the Early Treatment Diabetic 
Retinopathy Study (ETDRS) (1991). Scores ranged between 10 (no retinopathy) and 
81 (advanced proliferative retinopathy), and were categorised into ‘no DR’, ‘mild 
DR’ and ‘moderate/severe DR’. Discrepancies between the graders was resolved by 
discussion, and if unresolved were reviewed by an ophthalmologist. For each 
participant, severity of retinopathy in the eye more severe affected was used for all 
analyses. Data from two participants was excluded due to low image quality, so that 
overall retinopathy data was available for 1044 participants. A detailed description of 
the photography procedure has been published previously (Ding, et al., 2010).  
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Carotid intima-media thickness 
Approximately one year later, all baseline participants (n=1066) were invited to the 
year 1 clinic. 939 participants attended the clinic and there had carotid intima-media 
thickness (cIMT) examined, a procedure which was repeated again at four-year 
follow-up. At both year 1 and year 4, carotid IMT was visualised bilaterally in three 
separate images of the common carotid artery, one to two cm below the bifurcation 
and in areas free of plaque using a Sonoline Elegra Ultrasound Imaging System 
(Siemens Medical Systems Inc, Washington). Mean cIMTs were calculated for left 
and right carotid arteries and the larger of the two values was used for analyses.  
4.4.3 Record linkage 
Participants gave full written consent to allow access to their medical records. 
Historical data on any blood pressure readings and HbA1c collected between 1988 
and September 2007 was collected from the Lothian Diabetes Register (LDR) for all 
participants. At baseline and again at year 4, records of acute hospital admissions on 
the SMR01 scheme of the Information and Services Division of NHS Scotland were 
also consulted for the entire baseline population. These records included information 
on dates of hospital admission, medical conditions, operations and cause of death 
from 1981 up to September 2007 (end of baseline clinic) and from September 2007 
(end of baseline clinic) to July 2011) (end of year 4 clinic). Any ICD-9 and ICD-10 
codes for cardiovascular disease, cerebrovascular disease or dementia were identified 
from this database and used in combination with self-report data and findings from 
the chest pain questionnaire and the ECG to identify individuals with a history of 
myocardial infarction, angina, stroke, transient ischaemic attacks or dementia 
according to pre-specified criteria described below.  
4.4.4 Cognitive assessment 
With exception of the Deary-Liewald reaction time task which was only 
administered at year 4, the same battery of cognitive tests was used at baseline and 
follow-up. Seven neuropsychological tests of fluid-type cognitive ability, a test 
screening for dementia and a test estimating crystallised-type pre-morbid ability were 
administered in a single session lasting approximately one hour. Cognitive 
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assessment was performed following food intake and measurement of plasma 
glucose levels. Individuals with levels <4 mmol/L were not cognitively tested but 
first offered food. Following a brief period of rest, blood glucose was re-tested to 
ensure that values exceeded 4 mmol/L. Prior to the clinic appointment, participants 
had been reminded to bring their reading glasses, and testers ensured that these were 
worn during the testing session if possible. Subjects who did not perform any of the 
cognitive tests at baseline due to either refusal, physical disability or because they 
were deemed unfit (n=4) were excluded from the baseline population of the ET2DS 
and were not invited to return for any subsequent waves of the study. Participants 
without any cognitive data at year 4 (n=3) were not excluded. The seven tests of fluid 
ability tapped a variety of cognitive domains, and were selected on the basis of 
common use in the literature, evidence of validity and/or susceptibility to decline in 
diabetes. Within each cognitive testing session, a strict order of administration was 
followed where possible. Copies of some of the paper-based cognitive tests can be 
found in Appendix G.  
Borkowski Verbal Fluency Test  
Tests of verbal fluency load on executive function processes and involve the 
production of words from a phonemic or semantic category which are pre-
determined by the tester (Klumpp & Deldin, 2010). The phonemic Borkowski Verbal 
Fluency Test (BVFT) (Borkowski, Benton, & Spreen, 1967) was used in the ET2DS. 
Subjects name as many words as possible beginning with C, F and L, excluding 
proper nouns, within 3 x 60 seconds. One point is given for each word with no upper 
limit in achievable scores. Performance relies on the maintenance of tasks sets, the 
initiation of multiple response alternatives and monitoring of responses to avoid 
repetition. Verbal fluency is affected by age (Salthouse, Atkinson, & Berish, 2003), 
mild cognitive impairment (Cunje, Molloy, Standish, & Lewis, 2007) and mood 
disorders (Klumpp & Deldin, 2010). Temporal and frontal areas, including Broca’s 
speech area and the dorsolateral pre-frontal cortex, are recruited during performance 
(Amunts et al., 2004; Klumpp & Deldin, 2010; Libon et al., 2009). The validity of 
tests of verbal fluency to measure frontal lobe and executive function was shown by 
a study which reported correlations of verbal fluency with relative/carer-reported 
everyday executive function (Burgess, Alderman, Evans, Emslie, & Wilson, 1998). 
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However, verbal fluency is also strongly related to level of education (Tombaugh, 
Kozak, & Rees, 1999; van der Elst, van Boxtel, Van Breukelen, & Jolles, 2006) and 
to prior experience with crosswords or other word games (Phillips, 1997 cited in 
(Crawford, Bryan, Luszcz, Obonsawin, & Stewart, 2000)). 
Trail-Making-Test-B 
The Trail-Making-Test-B (TMT-B) measures mental flexibility, processing speed, 
visual attention and executive function (Salthouse, et al., 2003). Participants are 
presented with an A4 sheet of paper with dots with numbers and letters and connect 
dots alternating between numbers and letters (e.g., A-1-B-2…). Following a short 
practice of seven connections, completion of the trial involving 26 connections is 
timed. Higher TMT-B scores indicate poorer performance. The test’s high executive 
function demands caused by inhibition of prepotent responses (A-B-C…) are 
reflected in the involvement of frontal areas during task performance (O'Sullivan et 
al., 2001; Oosterman et al., 2010). The TMT-B is well-validated (Burgess, et al., 
1998), is sensitive to age effects as well as cognitive impairment and impaired 
activities of daily living (ADL) (Cook et al., 2002; Mitrushina, Boone, Razani, & 
D'Elia, 2005) and may be immune to mood disorders (Misdraji & Gass, 2010). 
However, due to the wide range of cognitive functions involved in TMT-B 
performance, poor performance is a non-specific finding. Education and 
graphomotor skills also affect performance (Misdraji & Gass, 2010; Mitrushina, et 
al., 2005). Indeed subjects in the ET2DS occasionally experienced physical 
difficulty. A difference score between the TMT-B and a simpler version (TMT-A; 
connection of dots 1-2-3…) helps to eliminate effects of graphomotor skills, but 
TMT-A in practice is rarely administered, including in the ET2DS. Although cut-
points may be applied (Kilander, Nyman, Boberg, Hansson, & Lithell, 1998), the 
present analyses will use all TMT-B measurements in order to reflect the entire 
breath of performance in the population.  
Wechsler Memory Scale 3rd Edition 
Two subtests of the Wechsler Memory Scale 3
rd
 Edition (WMS-III) (Wechsler, 




In the Logical Memory (LM) subtest of verbal declarative memory, participants 
listen to a short story with 25 story units and recall the story immediately after 
presentation and again following a delay of around 40 minutes. One point is given 
for each correctly recalled unit. As immediate and delayed recall of the task correlate 
highly (Tulsky, Ivnik, Price, & Wilkins, 2003), both scores typically correlate highly 
and may be summed to represent overall verbal memory (maximum score 25). 
Performance appears to involve prefrontal and parietal areas (Simensky & Abeles, 
2002). Previous studies have shown age-related declines in verbal memory and in 
Logical Memory scores in particular (D. K. Johnson, Storandt, & Balota, 2003; L. 
Price, Said, & Haaland, 2004; Simensky & Abeles, 2002), with some evidence for  
differential effects on immediate and delayed recall (D. K. Johnson, et al., 2003). 
Performance on the test may be able to dissociate normative cognitive ageing, MCI 
and dementia (Cunje, et al., 2007).  
Faces 
The Faces subtest assessed nonverbal memory. Twenty-four pictures of faces are 
first exposed, each for around two seconds. Subjects then identify the familiar faces 
out of a sample of 48, which include 24 novel pictures, through verbal responses 
‘yes’ (I have seen this face before) and ‘no’ (I have not seen this face before). 
Instructions specify that for each item the initial best guess should be verbalised. The 
procedure is repeated both immediately following presentation of the target stimuli 
(immediate recall), and with a delay of around 20 minutes (delayed recall). On both 
occasions, maximum score is 48. Scores may be summed to obtain a composite score 
of non-verbal memory (maximum score 96). Due to high complexity and intra-class 
similarity, faces are somewhat ‘special’ when compared with other visual stimuli 
(Werheid & Clare, 2007). The Faces test is therefore immune to strategies such as 
verbal encoding which would mask subjects’ actual nonverbal memory abilities. 
Despite this advantage, the validity of the test has been questioned on the basis of 
low correlations with other tests of visual memory, which may be caused by a unique 
hard-wired memory for this ‘special’ stimulus (Tulsky, et al., 2003). Moreover, 
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women may have advantages in memory for faces over men (Bengner et al., 2006; 
Weirich, Hoffman, Meissner, Heinz, & Bengner, 2011).  
Wechsler Adult Intelligence Scale 3rd Edition  
Subtests of the Wechsler Adult Intelligence Scale 3
rd
 Edition (WAIS-III) (Wechsler, 
1997) were included in the cognitive test battery. The WAIS-III is a well-validated 
group of measures shown to have high reliability and high loadings on the general 
ability factor g (Kaufman, 2000; Lichtenberger & Kaufman, 2009; Shelton, Elliott, 
Hill, Calamia, & Gouvier, 2009). 
Digit Symbol Coding 
The paper-and-pencil based Digit Symbol Coding (DSC) subtest of the WAIS-III 
assesses speed of information processing. A table is presented at the top of an A4 
page linking specific arbitrary symbols to digits 1 to 9.  Rows with digits but missing 
symbols are printed below the table, and participants are instructed to match symbols 
to their respective digits. Maximum score is 133. A time limit of 120 seconds 
minimises ceiling effects. Test performance involves visual search, attention and 
constant updating of working memory. Recruitment of frontal, prefrontal and parietal 
areas reflect the wide variety of processing demands of the task (Usui et al., 2009). 
Digit Symbol Coding performance declines with age but is relatively unaffected by 
education (Hoyer, Stawski, Wasylyshyn, & Verhaeghen, 2004). However in the light 
of the advanced age of the ET2DS population influences of visual acuity and motor 
coordination on performance (Lichtenberger & Kaufman, 2009) must be considered. 
Individual differences in incidental learning of the digit-symbol combinations may 
affect results (Joy, Kaplan, & Fein, 2003) although opposing findings have also been 
reported (Erber, Botwinick, & Storandt, 1981).  
Letter Number Sequencing 
In the Letter Number Sequencing (LNS) subtest - which is used to assess working 
memory-participants are verbally presented with sequences of numbers and letters at 
a rate of around one item per second. The sequence is then mentally manipulated into 
alphabetic and numeric order and is verbalised to the tester. Eight blocks of 
sequences (each with three trials) have increasing length. The initial block includes 
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three numbers and letters and this increases by one number/letter with each new 
block. Successful completion of each trial counts as one score. Maximum score is 21. 
Performance is terminated following unsuccessful completion of all three trials 
within a given block. Working memory is defined as a temporary storage system 
responsible for information processing (Baddeley, 1981). According to one popular 
model (Baddeley & Hitch, 1974 cited in (Baddeley, 1981)), it comprises of a central 
executive, an articulatory loop rehearsing verbal information, and a visuo-spatial 
scratchpad which enables the visualisation of processed content. Consequently, 
attentional abilities affect Letter-Number Sequencing performance. The test has been 
shown to have high construct validity as a test of working memory (Shelton, et al., 
2009); evidence of right hemisphere activation during performance (Haut, 
Kuwubara, Leach, & Arias, 2000) could potentially reflect involvement of the 
hypothesised visuo-spatial scratchpad. 
Matrix Reasoning 
The Matrix Reasoning subtest (MR) of non-verbal reasoning is presented in a 28-
page booklet. Several pictures are printed on each page and subjects identify the one 
picture out of five choices which best completes a geometric sequence. Following 
two practice items, 26 trial items are completed, with a maximum score of 26. 
Performance is terminated when choices are incorrect on either four consecutive or 
four out of five consecutive items. The test relies on visual acuity, visuo-spatial 
construction and the ability to use trial and error, and assesses non-verbal and 
abstract perceptual reasoning abilities with high loading on the general ability factor 
g (Salthouse, et al., 2003). Reliance on working memory resources and executive 
function is evident in activation of pre-frontal areas during abstract reasoning tasks 
(V. Prabhakaran, Smith, Desmond, Glover, & Gabrieli, 1997) as well as in poor 
reasoning abilities in patients with frontal atrophy (Yoshiura et al., 2011). Abstract 
reasoning declines with age and is reduced in dementia (Cronin-Golomb, Rho, 
Corkin, & Growdon, 1987). The Matrix Reasoning test has high face validity and 
correlations with Raven’s Progressive Matrices of abstract reasoning indicate high 
construct validity (Kohutek, 1999). Due to reliance on concentration skills and 
motivation, reasoning performance may be vulnerable to mood disorders. The use of 
the test is further complicated by the fact that although the tester is informed that 
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performance should not exceed 15 minutes, the test is not strictly timed and time is 
not mentioned during instructions. Evidence suggests that the resulting confusion 
over instructions may affect subjects’ reasoning test scores (Knight, 2003).  
Deary-Liewald reaction time task 
The Deary-Liewald reaction time task (Figure 4.2), which measures processing 
speed, was administered only at the year 4 clinic. It was performed on a conventional 
computer at the end of each testing session in order to ensure that performance on 
other cognitive tests was unaffected by task-associated psychological distress. The 
test measures simple reaction time (SRT) and four-choice reaction time (CRT) in two 
paradigms: in the SRT, participants respond to the appearance of a stimulus on the 
computer screen by pressing the spacebar on the keyboard as quickly as possible. 
Performance does not involve evaluation of content other than presence or absence 
of the stimulus (W. Johnson & Deary, 2011). In the CRT, a target stimulus is 
detected in one of four possible squares on the screen. Responses are made by 
pressing a key corresponding to the square (‘Z’, ‘X’, ‘comma’, ‘full stop’). Thus, for 
both the CRT and SRT, response times are the sum of the speed of processing of the 
stimulus, and the movement time required to carry out the response. For each task, 
subjects initially performed eight practice trials, before completing 20 trials in the 
SRT and 40 trials in the CRT. Inter-stimulus intervals ranged between 1000 and 
3000 milliseconds for both tasks. Latency between stimulus presentation and 
response was measured and recorded automatically by the computer program for 
each trial. In addition to average latency of each participant, their intra-individual 






Figure 4.2: Screenshot of the Deary-Liewald task for the SRT (left) and CRT 
(right), reproduced from Deary et al. (2011) 
 
The Deary-Liewald task was recently validated against other measures of reaction 
time across age groups (Deary, et al., 2011). Its use offers great advantages over 
traditional paper-and-pencil tasks, including the output of absolute values (rather 
than scores on arbitrary scales), a high precision in the recording of responses, as 
well as quickness and consistency in task administration. This allows completion of a 
large number of trials for each participant and performance is immune to 
experimenter expectancy. However, task performance may be affected by subjects’ 
proficiency in computer use, which may linked to crystallised-type ability (Nair, 
Czaja, & Sharit, 2007). Sex differences in reaction time are also well-established 
(Roivainen, 2011).  
Mill Hill Vocabulary Scale  
The Junior and Senior form A of the Mill Hill Vocabulary Scale (MHVS) (Raven, 
Raven, & Court, 1998) measures crystallised-type intelligence by estimating best-
ever pre-morbid cognitive ability. Throughout this thesis, scores on the MHVS will 
be referred to as pre-morbid cognitive ability despite reflecting estimation and not 
measurement.  Participants are presented with 43 groups of words, and instructed to 
identify the one word out of a choice of six which is a synonym of a target word 
printed above each group of words. One point is obtained for each correctly 
identified word (maximum score 43). The MHVS may be preferable over self-
reported education as an estimate of pre-morbid ability, because education is affected 
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by circumstantial factors, particularly in currently older populations. The National 
Adult Reading Test (NART), which involves the verbalisation of words with 
increasing difficulty, is often preferred over the MHVS to estimate peak pre-morbid 
ability on the basis of vocabulary, but in contrast to NART, the MHVS allows self-
completion. In the light of the relatively large and time-intensive battery of cognitive 
tests and relatively large sample size of the ET2DS, the MHVS was therefore seen as 
advantageous. Its use is supported by observations of typically strong correlations of 
scores on the MHVS with scores on other estimates of peak pre-morbid ability 
including NART (O'Carroll & Gilleard, 1986; Yuspeh & Vanderploeg, 2000). For 
instance, in one early investigation of dementia patients and healthy older adults, the 
correlation coefficient of MHVS with NART was 0.69 (O'Carroll & Gilleard, 1986). 
Both tests also appear to be relatively immune to age-related declines or dementia 
(Deary, Whalley, & Crawford, 2004; McGurn et al., 2004), overall showing that both 
appear to be similarly valid representations of crystallised-type cognitive ability.  
Mini-Mental-State-Examination 
Due to a quick and easy administration, the Mini-Mental-State-Examination 
(MMSE) (Folstein, Folstein, & McHugh, 1975) is a popular test of global cognitive 
ability and is used by clinicians and in the research literature alike. The test includes 
items on orientation to time and place, immediate and short-term memory, attention, 
calculation, language and praxis, and has overall good reliability, construct validity 
and specificity (Lancu & Olmer, 2006; Tombaugh & McIntyre, 1992). Maximum 
score is 30. Some studies, for instance the Preterax and Diamicron Modified Release 
Controlled Evaluation (ADVANCE) trial (de Galan, et al., 2009) employ the MMSE 
as the main cognitive outcome variable in their analysis. Due to severe imprecision 
of this approach, as well as the neglect of some cognitive abilities such as processing 
speed which may be particularly susceptible to decline in diabetes (Cukierman, et al., 
2005), the ET2DS instead relied on a battery of detailed neuropsychological tests on 
the basis of which a measure of global cognitive ability was derived. In line with its 
initial design, the MMSE only serves as a screening tool for cognitive impairment. 
Scores <24 are commonly used to indicate cognitive impairment (Lancu & Olmer, 
2006). However neuropsychological follow-up is essential; the cut-point alone 
appears to have low reliability and validity (O'Connor et al., 1989). For instance, in 
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two studies only 40% and 55% of subjects with MMSE<24 were eventually 
identified as suffering from dementia respectively (O'Connor, et al., 1989; Truelsen, 
Thudium, & Grønbæk, 2002).  
 
Items on the MMSE also vary between different English-language versions, 
complicating a cross-study comparison of scores and the use of a cut-point to 
indicate cognitive impairment. For instance, versions vary in the specific words to be 
recalled following a brief interruption (e.g., ‘lemon’, ‘key’, ‘ball’). Some also include 
an item of serial sevens (counting down from 100 in steps of seven) (Chatfield, 
Matthews, Brayne, & Study, 2007), whereas other versions, including the one used in 
the ET2DS, replace this with backwards spelling of the word ‘world’. If a subject is 
unable to complete this item, five points (17% of total scores) are lost. Indeed, some 
participants of the ET2DS who self-reported being dyslexic (and who may have been 
illiterate) were unable to spell the word at all despite apparent good overall cognitive 
ability. In line with this observation, MMSE scores have been linked to education as 
well as cultural and socioeconomic backgrounds (Lancu & Olmer, 2006; Tombaugh 
& McIntyre, 1992). The cut-point indicative of cognitive impairment may be 
changed according to such factors (Bachman et al., 1992), but this is rarely applied in 
practice. Sex differences in MMSE scores have also been reported (de Galan, et al., 
2009), and sensitivity and specificity of the test may be affected by mood disorders 
(Milian et al., 2012; Rajji et al., 2009). Finally, the test is unable to record changes in 
severity of dementia (Lancu & Olmer, 2006), although this does not apply to its use 
in the ET2DS.  
Summary of cognitive test battery  
A summary of the cognitive tests and their respective measured cognitive domains is 
provided in Figure 4.3 with the aim to provide the reader with a rough guide to the 
cognitive test battery used by the ET2DS and reported throughout this thesis. Note 
that the list of specific cognitive abilities assigned to each test is not exhaustive. For 
instance, visual attention also contributes to the performance of the Trail-Making 
Test-B. The MMSE is not included in the diagram, because it was used only as a 
screening instrument. Finally, a summary of the abbreviations for cognitive tests 




Figure 4.3: Cognitive tests used in the ET2DS. With exception of the Deary-






Table 4.1: List of abbreviations for cognitive tests 
MHVS Mill-Hill Vocabulary Scale 
MMSE Mini-Mental State Examination 
LM Logical Memory 
Faces Faces 
MR Matrix Reasoning 
DSC Digit Symbol Coding  
TMT-B Trail-Making-Test B 
LNS Letter Number Sequencing 









The participants of the ET2DS live independently in the community, were required 
to schedule appointments and attended the research clinic(s). A majority is therefore 
assumed to be cognitively healthy. The identification of individuals with dementia is 
important nonetheless, because cognitive impairment is the end-point of age-related 
cognitive decline and even a few cases could skew the study’s results. Although in 
practice dementia is only diagnosed following neuropsychological interview by a 
clinician, suspected cases (in both attenders and non-attenders of year 4) were 
identified in the ET2DS using information from a number of different available 
sources. These included MMSE performance at baseline and year 4, record linkage 
to hospital data, assessment of death records, self/relative report of dementia, self-
reported use of medication for dementia, local old age psychiatry records and 
communication with patients’ GPs. Specific findings from each of these sources are 
summarised in Appendix A. Because information on the time of diagnosis was not 
always available, and because disease onset may precede formal diagnosis by many 
years, no distinction was made between dementia that was prevalent at baseline and 
four-year incident dementia. The following criteria, which had been developed in co-
operation with a consultant old age psychiatrist, were applied to identify participants 
who were likely to be suffering from dementia. It is understood that this method does 
not represent a substitute for neuropsychological assessment.  
Either: 2 of (1) (2) (3) (4) (6)  
or (5) plus 1 of (1) (2) (3) (4) (7) 
(1) On medication for dementia (self-reported or GP reported use of 
donepezil, rivastigmine, galantamine, memantine) 
(2) Hospital discharge code for dementia (ISD data) (ICD-10 codes F00, F01, 
F02, F03, G30; FXX or GXX were additionally checked) 
(3) GP report of psychiatrist diagnosis of dementia 
(4) Psychiatrist diagnosis of dementia obtained from psychiatry/hospital 
notes (PiMS) 
(5) Mini-Mental-State Examination score <24 at baseline or year 4 or missing 
at year 4 
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(6) Self-reported and/or relative-reported dementia 
(7) Code for dementia on death certificate 
 
On the basis of these criteria, 19 individuals with suspected dementia were identified. 
For nine, the year of diagnosis was available. For all of these except one (who was 
diagnosed in 2004) diagnosis was made after completion of the baseline clinic 
(between 2008 and 2011; see Appendix A), suggesting that overall the 19 cases 
predominantly reflect four-year incident rather than prevalent dementia. Participants 
with suspected dementia were less likely to attend the year 4 clinic (n=4; retention 
rate 21.1%) compared with the remaining population (n=827; retention rate 78.7%; 
p<0.001). Although all dementia cases were retained in the database for the analyses 
presented in this thesis, some of the final multivariable analyses will be repeated with 
their exclusion in order to show that overall findings of risk factor associations with 
the cognitive continuum are not driven by dementia. Findings from these analyses 
are presented in Appendix E.   
4.4.6 Summary of data collection 




Figure 4.4: Data collection in the ET2DS 
 
4.5 Data analysis 
4.5.1 Cleaning of data  
This section describes the process of data cleaning on the data from the four-year 
follow-up. Similar procedures had been carried out at baseline and year 1, as 
described in brief by Marioni et al. (2010). 
Double data entry 
Data was recorded in paper files for each participant and entered into a central 
Microsoft Access database securely stored at the University of Edinburgh. All 
cognitive data were entered on an on-going basis immediately following clinic 
appointments; entries were later checked by another member of the research team. 
Following completion of the year 4 data collection, the accuracy of information in 
the database was determined. For this purpose, data on cognitive and physical 
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measurements as well as questionnaire data were re-entered into a separate database 
for a random group of participants (n=80; 9.6% of attenders). All entries were then 
checked against their original entries and any discrepancies were resolved. This 
procedure identified an error rate of 0.017% in the original database. When factors 
which could easily result in an error such as medication names were excluded, this 
rate attenuated to 0.004%.  
Treatment of outliers 
Following completion of all year 4 data entry, descriptive analyses were run on 
physical and cognitive measurements. Any ‘implausible’ physical outliers were 
resolved by the medically trained members of the research team through consultation 
of paper records and individual case assessment. For cognitive data, outliers were 
defined as scores >1.5 of the interquartile range of distributions. For each outlier, 
paper records were consulted and occasional data entry errors were resolved. Any 
outliers which were identical in database and paper records but were impossible were 
deleted and treated as missing. Any outliers which were identical in database and 
paper records but which were deemed plausible remained in the database and were to 
be excluded or included on an individual basis by the researchers who were using the 
data. In the analyses reported in this thesis, plausible outliers were retained with the 
aim to preserve statistical power, and because their analysis may be informative with 
respect to the research question. For the Deary-Liewald reaction time task, the 
computer automatically detected very long and very short response times (reflecting 
distraction or guessing prior to stimulus presentation, respectively), and excluded 
these from the final dataset. Response times between 150 and 1500 milliseconds 
were accepted as plausible in the SRT. For the CRT, acceptable response times 





4.5.2 Use of clinical variables   
Temporal pattern of clinical measurements  
With exception of severe hypoglycaemia (data on which were used from baseline 
and from year 4 follow-up), only physical measurements and questionnaire data 
collected at baseline were used as exposure variables for the purpose of the analyses 
presented in this thesis. Because only one year passed between the baseline and the 
year 1 clinic, year 1 measurement of cIMT will be interpreted as equivalent to any 
baseline measurements.  
Physical variables and blood measurements 
Distribution of body fat mass was represented by the waist-hip-ratio (WHR) 
calculated from waist and hip circumferences. Ankle brachial pressure index (ABI) 
was determined by dividing the lowest of the lower limb blood pressures by the 
higher value of brachial pressure. Lower ABI values reflect higher degree of 
peripheral arterial disease. Because very high values may indicate arterial stiffness in 
diabetic populations (Potier, et al., 2011) data from participants with ABI >1.3 
(n=26) was recoded as ‘missing’. The ratio of low-density lipoprotein to high-density 
lipoprotein (LDL:HDL)  measured dyslipidaemia.  
Diabetic retinopathy 
Severity of diabetic retinopathy (DR) was used as a binary variable (‘DR’, ‘no DR’) 
in descriptive analyses (to allow calculation of point bi-serial correlation 
coefficients), but was used in its original categorical form (‘no DR’, ‘mild DR’, 
‘moderate/severe DR’) in all further analyses.  
Historical data for blood pressure and HbA1c 
Historical data collected since 1988 on the Lothian Diabetes Register (LDR) was 
used to derive average long-term HbA1c and systolic blood pressure measurements. 
For HbA1c, participants had between one and 59 readings available (median 13 
readings; interquartile range 9 to 17). For systolic blood pressure, between one and 
65 readings (median 19 readings; interquartile range 14 to 25) had been recorded. 
Readings for HbA1c and systolic blood pressure were summed and averaged for 
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each participant. The resulting variables are referred to as ‘historical HbA1c’ and 
‘historical systolic blood pressure’ throughout this thesis. The use of historical data 
has added to the validity of the present analyses, because HbA1c from blood samples 
collected at the clinic may be a poor indicator of long-term glycaemic control. 
Historical data on blood pressure avoided potential effects of clinic-associated 
psychological stressors, such as anticipation of cognitive testing, on measurements.  
Questionnaire data 
At baseline and year 4 follow-up, questionnaire data from individuals who expressed 
uncertainty over their experience of severe hypoglycaemia (which had not been 
resolved by research staff during data collection) were not used and so was treated as 
‘missing’. Self-reported smoking history was transformed to a continuous  
‘packyears’ variable using a procedure which has been described in detail by a 
member of the research team involved in the baseline analysis of the ET2DS 
(Conaglen, 2009). In brief, packyears were calculated on the basis of self-reported 
number of cigarettes smoked per day. Smoking of cigars and pipes was relatively 
rare. When self-reported, the numbers of cigars/pipes were converted to cigarettes on 
the basis of estimated tobacco content (one cigar equivalent to four cigarettes; pipe 
smoking was self-reported in Oz. of tobacco) for each participant. The number of 
cigarettes was then transformed to number of packs (20 cigarettes in one pack) and 
multiplied by the number of years that the participant had smoked. One packyear is 
equivalent to 20 cigarettes smoked every day for one year, or 7300 grams of tobacco 
(Prignot, 1987, cited in (Conaglen, 2009)). Self-reported alcohol consumption during 
the week prior to clinic attendance was transformed to alcohol units/year. This 
continuous variable was used for the calculation of Pearson correlation coefficients, 
but all further analyses used the categorical variable. Categorisation was made to 
derive one group of abstainers, and quartiles of the subjects who consume alcohol 














0 (abstainers) 0 0 
1 14 53 
2 54 314 
3 319 817 




Presence of intermittent claudication was indicative of symptomatic peripheral 
arterial disease (PAD) and was determined from responses on the Edinburgh 
Claudication Questionnaire (Leng & Fowkes, 1992). Claudication codes were 
identified on the basis of the location of an X placed by participants on a diagram of 
their legs from a front and back viewpoint to indicate the location of pain. Grades 
were assigned according to responses on the item ‘Do you get [pain or discomfort in 
your legs] when you walk at an ordinary pace on the level?’. ‘Yes’ represented Grade 
2; ‘no’ was defined as Grade 1. For the purpose of the present analyses, codes 1 to 7 
in Table 4.3 indicated claudication; participants with code 8 were free of 
claudication.  
Table 4.3: Coding from the Edinburgh Claudication Questionnaire 
1 = Definite, Grade 1 
2 = Definite, Grade 2 
3 = Definite, Grade unknown 
4 = Atypical, Grade 1 
5 = Atypical, Grade 2 
6 = Atypical, Grade unknown 
7 = Possible claudication 






Cardiovascular and cerebrovascular disease 
The presence of cardiovascular and cerebrovascular disease was determined using a 
combination of self-report, record linkage and ECG data.  
History of myocardial infarction was indicated when: 
(i) 2 of the following 3 criteria were fulfilled: 
Self-reported heart attack in questionnaire 
Myocardial infarction indicated on WHO Chest Pain Questionnaire 
Ischaemia indicated by ECG 
Or  
(ii) Both of 2 criteria were fulfilled: 
Self-reported heart attack in questionnaire 
ICD code consistent with myocardial infarction (I21-I23, I252) 
 
Angina was indicated when 
 
(i) 2 of the following 3 criteria were fulfilled: 
Self-reported doctor-diagnosed angina or regular use of medication for 
angina 
Angina indicated on WHO Chest Pain Questionnaire  




(ii) Both of 2 criteria were fulfilled: 
Self-reported doctor-diagnosed angina or regular use of medication for 
angina 
ICD code consistent with angina or other ischaemic heart disease (IHD) 
(I20, I24, I25) 
 
History of cerebrovascular disease (stroke and/or TIA) was indicated when 2 of the 
following 3 criteria were fulfilled:  
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(i) Self-reported doctor-diagnosed stroke or TIA 
ICD code consistent with stroke or TIA (I61, I63, I64, G45) 
Confirmation by review of clinical notes 
 
Presence of any symptomatic macrovascular disease (‘any MVD’; a binary variable) 
was indicated by a baseline history of TIA, stroke, MI, baseline presence of angina 
and/or baseline presence of intermittent claudication. Levels of NT-proBNP as well 
as cIMT and ABI measurements are all indicators of subclinical macrovascular 
disease, although the term ‘subclinical’ does not necessarily imply an absence of 
symptoms. Rather, it is used as a continuous quantification of the relative severity of 
damage to the vascular system, which may or may not have reached the level of 
clinical expression.  
4.5.3 Use of cognitive variables 
Calculation of sum scores 
Cognitive data from baseline and the four-year follow-up will be used. Due to 
relatively strong correlations between the immediate and delayed components of the 
Faces and the Logical Memory tests respectively (Table 4.4), these were summed for 
each test and at each time point. Throughout this thesis, the labels ‘Faces’ and 
‘Logical Memory’ will be used to refer to these sum scores.  
 
Table 4.4: Bivariate correlations of immediate and delayed components of Faces 
and Logical Memory tests 
 Baseline Year 4 
Faces (immediate) and Faces (delayed) 0.55 0.58 
LM (immediate) and LM (delayed) 0.87 0.85 
Values are Pearson correlation coefficients.  
LM, Logical Memory. All p<0.001; n=1050 (LM) and 1059 (Faces) at baseline;  
n=820 (LM) and 822 (Faces) at year 4.  
 
Imputation of missing cognitive data  
As is common in the literature on cognitive ageing (J. F. Price, Stewart, et al., 2008), 
missing data on the seven cognitive tests of fluid-type ability which were 
administered at both baseline and at year 4 (LM, Faces, LNS, MR, DSC, TMT-B, 
BVFT) were imputed. Specifically, accounting for age and sex, missing cognitive 
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test scores were imputed for any participant with missing data on one, two or three 
out of these seven cognitive tests. This procedure was performed separately for 
cognitive test scores at baseline and at year 4 follow-up. For participants with 
missing data on Faces or Logical Memory, the sum scores on the respective test were 
imputed. A potential for an underestimation of error following imputation may be 
problematic (Nair, et al., 2007), but in the present analyses was seen to be 
outweighed by the increased statistical power particularly in the analysis of the 
global ability factor g. The calculation of the factor, which is further described 
below, requires that data is available on each contributing test, so that any missing 
data on individual tests would severely restrict the number with participants with a 
value of g. The number of cases with data was imputed is shown separately for each 
cognitive test in Table 4.5.  
 
Table 4.5: Imputation of cognitive test data at baseline and at year 4 
 Baseline  Year 4 


















Matrix Reasoning 9 0.28 1 0.72 
Digit Symbol Coding 4 0.47 21 0.96 
Trail-Making 9 0.47 21 0.96 
Logical Memory 12 0.38 5 0.72 
Faces 2 0.47 3 0.72 
Letter-Number 13 0.47 32 0.84 
Verbal Fluency 2 0.38 4 0.60 
Log-transformed values were used for Trail-Making. Trail-Making, Trail-Making Test-B; Verbal 
Fluency, Borkowski Verbal Fluency Test, Letter-Number, Letter-Number Sequencing. 
a
total 
includes three subjects who did not perform any of the cognitive tests at year 4.  
 
Latent variables 
A latent variable is a theoretical concept which is not directly accessible to the 
researcher. It is inferred on the basis of several observed, or manifest, variables 
assumed to all reflect one underlying construct (Penke & Deary, 2010). For instance, 
a person’s personality may be inferred on the basis of their actions (Borsboom, 
Mellenbergh, & van Heerden, 2003). Latent variables were first used by Spearman 
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(1904) who determined the general ability factor g on the basis of several individual 
cognitive tests, but in theory may be applied to any set of correlating variables. . 
Weighted sumscores of the extracted latent variable constitute an ‘operational latent 
variable’, which enables its visualisation as well as its use in further analyses 
(Borsboom, et al., 2003). Because the variance of the latent variable is shared by all 
contributing observed variables, latent variables are immune to measurement error, 
and interpretations of analyses based on latent variables may have higher reliability 
compared with analyses of observed variables (Penke & Deary, 2010). Following 
extraction of the latent variable, only test-specific and error variance remains in the 
individual manifest variables, and correlations amongst these variables is reduced.  
 
Principal component analysis (PCA) and common factor analysis are methods to 
derive principal components and latent factors respectively. Both reduce the number 
of variables, but whereas common factor analysis has a confirmatory approach, PCA 
may be either confirmatory or exploratory. Factor analysis further assumes that 
observed variables have a causal influence on the latent variable; latent variables 
derived from PCA are assumed to exert causal influence on the observed variables 
(Albright & Park, 2009).  
 
The present analyses applied PCA both on cognitive data (to derive the global ability 
factor g) and on risk factor data to derive an ‘inflammation’ factor. As is common in 
the literature (Widaman, 1993), components with Eigenvalues>1 will be extracted. 
Standardised regression scores were saved and used as ‘operational latent variables’ 
in further analyses of the respective latent construct. 
General ability factor ‘g’  
In order to derive a construct similar to Spearman’s g (1904), a PCA was applied to 
the imputed data on the seven fluid-type neuropsychological tests (LNS, BVFT, MR, 
DSC, TMT-B, Faces, LM) which are all assumed to reflect general cognitive ability 
to some extent. Log-transformed values were used for any cognitive test originally 
identified to be non-normally distributed (described below). The MHVS was not 
included in the PCA, because its scores are assumed to reflect a crystallised-type 
ability, which is largely immune to age-related declines, rather than current fluid-
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type ability, which is the main outcome of interest in the present thesis. The MMSE 
was also excluded due to its role as a screening instrument for dementia. Baseline g 
and year 4 g must reflect the same underlying construct in order to allow investigate 
change in g between the two time points. Therefore, the Deary-Liewald reaction time 
task was omitted from the PCA on year 4 data.  
 
At baseline, the internal consistency amongst the seven cognitive tests (following 
imputation of missing data) was found to be acceptable (Cronbach’s α = 0.63), and 
so a PCA was performed. All seven of the imputed cognitive tests loaded on a single 
component, with loadings ranging from 0.47 (Faces) to 0.80 (-TMT-B) (Table 4.6). 
The derived g factor explained 44.74% of total variance. A standardised regression 
score of the factor was saved, creating a value of baseline g for each participant, 
which was based on imputed cognitive test data.  
 
 
Table 4.6: Factor loadings of baseline cognitive tests on g 
Cognitive test Factor loadings 
-Trail-Making 0.80 




Matrix Reasoning 0.67 
Verbal Fluency 0.67 
Logical Memory 0.54 
Faces 0.47 
N=1060. The log-transformed variable was used for Trail-Making. Trail-Making, Trail-Making 
Test-B; Verbal Fluency, Borkowski Verbal Fluency test. Data from each cognitive test were 




The procedure was repeated on the year 4 follow-up cognitive tests (following 
imputation of missing data) in order to also obtain one value of follow-up g for each 
‘attender’ of the follow-up clinic. Initially, internal consistency of the seven year 4 
cognitive tests was assessed and found to be acceptable (Cronbach’s α = 0.66), 
before all seven cognitive tests were entered into a PCA and again a single 
component was identified which captured performance on all seven cognitive tests. 
Factor loadings ranged between 0.51 (Faces) and 0.81 (-TMT-B) (Table 4.7). The 
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component explained 47.44% of total variance in follow-up cognitive test 
performance.  
Table 4.7: Factor loadings of follow-up cognitive tests on g 
Cognitive test Factor loadings 
-Trail-Making 0.81 
Digit Symbol Coding 0.79 
Letter-Number Sequencing 0.75 
Matrix Reasoning 0.69 
Verbal Fluency 0.62 
Logical Memory 0.61 
Faces 0.51 
N=823. The log-transformed variable was used for Trail-Making. Trail-Making, Trail-Making 
Test-B; Verbal Fluency, Borkowski Verbal Fluency test. Data from each cognitive test were 
imputed prior to the extraction of g.  
 
 
Because the decision to impute missing cognitive data was not made immediately at 
the beginning of this project, two PCA were initially performed to extract baseline g 
and follow-up g on the basis of original data, i.e. without imputation of missing 
values. These were used for analyses reported in the first publication made on the 
basis of this thesis (Feinkohl et al., 2012). The overall differences in cognitive test 
variables (original versus imputed data) used in this thesis and in publications are 
summarised in Table 4.8. Note that because little cognitive data was imputed for 
individual cognitive tests (Table 4.5), results at least for analyses of individual 
cognitive tests are close to identical when using imputed and when using original 
data throughout.  
Table 4.8: Cognitive data in present thesis and in publications 
 Seven cognitive tests used 
to extract g 
G 
Feinkohl et al. 2012 Original data (non-imputed) Original data (non-imputed) 
Thesis Original data (non-imputed) Imputed 
Feinkohl et al., 2013 Imputed Imputed 








A comparison of the number of subjects with data available on g when this was 
extracted from imputed cognitive data and when it was extracted from original, non-
imputed cognitive data shows that the imputation of missing data led to a substantial 
increase in statistical power (Table 4.9). This was particularly the case for the 
analyses of four-year change in g, which requires data on both baseline g and follow-
up g. Here, data from 91 participants (11.1% of ‘attenders’) would have been ‘lost’, 
had analyses been restricted to original data.  
 
Table 4.9: Number of participants with data on g prior to and following 
imputation of scores on individual cognitive tests then used to calculate g 
 N based on original non-
imputed cognitive data 




 1021 1060 
Follow-up g
b
 758 823 
Four-year change in g
b
  731 822 
a
for all baseline participants (total n=1066) 
b
for attenders of year 4 follow-up (total n=831) 
 
Latent inflammation factor  
Because all four inflammatory markers (c-reactive protein, CRP; interleukin-6, IL-6; 
tumor necrosis factor-alpha, TNF-α; fibrinogen) measured at baseline are expected to 
be highly correlated, it was anticipated that a PCA of these observed variables would 
extract components which reflect the shared variance amongst the inflammatory 
markers. As is common practice in the literature, the first unrotated component from 
this analysis was used in further analyses. All four inflammatory markers loaded on a 
single principal component (Table 4.10), which explained 49.68% of variance. The 
standardised regression score was saved and used as an ‘inflammation factor’ in 
further analyses, although the label ‘factor’ is not strictly correct. In support of the 
application of a PCA to the four inflammatory markers, the internal consistency of 











N=1038. Log-transformed values were used for CRP, IL-6 and TNF-α. 
CRP, c-reactive protein; IL-6, interleukin-6; TNF-α, tumor necrosis factor α.  
 
 
4.5.4 Statistical Analyses 
Description of data 
Means and standard deviations are reported for continuous cognitive and risk factor 
variables. Histograms of distributions are visually examined for non-normality; 
variables with skewed distributions were selected for transformation to their natural 
logarithmic values or square roots. Instead of means, geometric means (means 
calculated on the log-transformed scale which are then back-transformed to the 
original scale of measurement) are reported for these variables in the description of 
data. Categorical variables are described in terms of frequency of their levels. 
Patterns of missing data (prior to imputation) are summarised for cognitive data from 
baseline and year 4 and for baseline risk factor data.  
Cut-point for statistical significance  
As is common practice in the literature, the statistical cut-point p<0.05 is used 
initially to reject the null-hypothesis, reflecting a <5% probability that the null-
hypothesis is rejected despite being true. However, the risk of this type of error 
(Type I error) increases with increasing number of individual analyses. Analyses 
may be adjusted for multiple comparisons in order to account for this type of error. 
In a Bonferroni correction, the level of significance sufficient to reject the null-
hypothesis is divided by the number of the individual analyses. For instance, 100 
individual analyses requires p<0.0005 to reject the null hypothesis. This method is 
commonly used in exploratory post-hoc analyses, but not when a priori hypotheses 
are tested (Perneger, 1998). Moreover, Bonferroni correction increases the risk of 
Type II error- the rejection of a false null-hypothesis. As Perneger (1998) notes, if a 
strict Bonferroni correction was applied to all analyses, the level at which to halt 
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would be arbitrary. Researchers could apply correction to analyses in a single paper, 
to a single study or to their entire scientific career. Due to these issues, and because a 
priori hypotheses which are not independent from one another are tested, the results 
presented in this thesis are not corrected for multiple comparisons. Instead, the total 
number of individual analyses described in the main text is kept to a reasonable 
minimum. Caution is exercised in the interpretation of results with significance 
marginally below the 5% level; significance levels marginally above this cut-point 
are interpreted strictly as non-significant. 
Outcomes 
The overall temporal pattern of the cognitive outcome variables is illustrated in 
Figure 4.5. The change in cognitive function between baseline and year 4 serves as a 
‘snapshot’ of trajectories of late-life cognitive change of the sample. Its relationship 
to risk factors measured at baseline is the key interest in this thesis. 
 
Figure 4.5: Temporal order of cognitive outcome in the ET2DS. Note that in 
contrast to baseline and follow-up assessments, peak pre-morbid ability was not 
assessed (estimated) at a fixed time point. Adapted from Glymour, Weuve, 





Estimated pre-morbid ability 
Baseline scores on the vocabulary-based MHVS are used as estimates of 
participants’ pre-morbid cognitive ability, which is likely to have peaked some time 
in young adulthood following the completion of education.   
Level of cognitive ability 
Cognitive test performance and g at year 4 represent the outcome in analyses of 
cross-sectional relationships between late-life risk factors and late-life level of 
cognitive function. 
Estimated lifetime cognitive change 
Adjustment of follow-up cognitive test scores and g for baseline MHVS scores 
enables the estimation of change in cognitive ability over the course of the lifetime, 
between peak pre-morbid ability and late-life ability. Results of analyses which use 
this type of method have previously been found to correlate with actual measures of 
lifetime cognitive change (Deary, et al., 2004). 
Four-year cognitive change 
A number of different approaches may be taken to the analysis of longitudinal 
change in cognitive ability. Consensus on the preferred method is lacked (C. A. 
Reynolds, Gatz, & Pedersen, 2002), which is important when considering that 
different approaches may produce conflicting results (Gow, et al., 2008). As a 
prerequisite to the measurement of change in cognitive function, the cognitive tests 
must measure identical constructs at both time points (Rogosa, Brandt, & Zimowski, 
1982), which necessitated the exclusion of the Deary-Liewald reaction time task 
from the calculation of year 4 g. 
One option for the identification of individuals with decline in cognitive test scores is 
the application of subjective or objective cut-off points. These may be made on the 
basis of the distribution of scores in the population (e.g., change from top quartile at 
baseline to bottom quartile of the distribution at follow-up), or when individuals 
score at least one standard deviation or standard error of measurement (SEMEAS) 
below their baseline scores at follow-up.  The latter method may be advantageous 
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because it is able to account for practice effects (C. A. Reynolds, et al., 2002). 
However, categorisation of participants into those who decline in cognitive ability 
and those who do not results in a loss of statistical power, and may be unable to 
capture the complexity of patterns linking risk factors with cognitive decline.  
 
Analyses of change measured on the basis of continuous variables avoid such issues. 
In one approach, ‘change scores’, or ‘gain scores’, between two waves of a study are 
calculated for each participant. These reflect pre- to post-exposure change or change 
between two randomly chosen time points. ‘Annual rate of change’ scores (ARC) are 
a type of change scores based on the ratio of observed change and the number of 
years over which the change occurred (C. A. Reynolds, et al., 2002). Due to their 
simplicity, calculation of change scores were initially appealing in psychological 
research, but lost popularity in the 1960s and 1970s (Willett, 1994).  
 
The approach is flawed because change is continuous, and when based on two 
randomly chosen time points change scores are essentially only ‘snapshots’ of 
change. Problems arise when change correlates with initial status, meaning that 
individuals with high initial status may have high gains (or low declines) between the 
two waves (Willett, 1997). Willett (1997, p. 216) describes such correlations as “an 
almost inevitable fact of life”, which may apply to cognitive ageing research in 
particular because some evidence suggests that cognitive reserve may influence the 
rate of late-life decline (Gow, et al., 2012). Furthermore, when change occurs at 
similar rates for all individuals of the sample, reliability of change scores is low 
(Willett, 1997). This is reflected in the observation that cognitive ARC are typically 
zero or even positive in samples of cognitively unimpaired older adults (C. A. 
Reynolds, et al., 2002). Change scores are also affected by regression to the mean 
(RTM). At each point of observation, random error distorts the true mean of the 
sample. Values then approach the true value during repeated measurement. Thus, 
following relatively high or low cognitive test scores at time one, it is likely that a 
participant performs closer to the true mean at time two (Barnett, van der Pols, & 
Dobson, 2005; Krum & Tonkin, 2003), so that the change scores then do not reflect 
the actual cognitive change at all. The use of change scores is further complicated by 
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the observation that RTM is more likely to cause high-ability individuals to perform 
poorly than it is to cause low-ability individuals to perform better than expected 
(Gow, et al., 2012). A commonly cited real-life example of RTM is the observation 
that tall parents tend to have shorter children and vice versa. Repeated measurements 
of blood pressure, cholesterol or body weight also regress to the mean (Bland & 
Altman, 1994);  ‘regression to the truth’ describes the observation that initially 
successful drug trials typically become unsuccessful in later trials (Bland & Altman, 
1994; Krum & Tonkin, 2003).  
 
Yet, change scores are unbiased, and reliability may be high at least when individual 
differences in true change is large (Rogosa & Willett, 1983). Reliable change indices 
(RCI), which are effect sizes based on the ratio of observed change and the standard 
error of the change, may also avoid risk of RTM and measurement error (Stein, 
Luppa, Brähler, König, & Riedel-Heller, 2010). Due to these advantages, it has been 
suggested that “the difference score is not the outcast that many critics have claimed” 
(Willett, 1994, p. 673). 
 
Adjustment of follow-up scores for baseline scores (‘adjustment method’) rivals 
change scores as a continuous representation of change. The approach models 
change over time under the assumption that each participant started out with equal 
initial scores (Willett, 1994) and is common in the literature on cognitive ageing 
(Gow, et al., 2008) as well as other health outcomes (Yanez, Kronmal, & Shemanski, 
1998). The adjustment method and change scores typically lead to identical 
conclusions (Willett, 1994). Due to the aforementioned flaws of change scores, the 
former method is chosen for the analyses presented in the main text of this thesis. 
Year 4 cognitive test scores are adjusted for baseline scores on the respective 
cognitive test. The analysis of change in g requires a different approach to the 
assessment of the individual tests. Because g is not an absolute value, it is not 
possible to adjust follow-up g standardised on attenders of year 4 follow-up for 
baseline g standardised on baseline participants. In order to allow application of the 
adjustment method, both baseline g and year 4 g must be standardised on the same 
population. For this purpose, a third separate PCA was carried out which follows a 
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procedure previously described in Gow et al. (2008): (i) cognitive data of all 
attenders of the year 4 clinic were arranged in the statistical program so that each of 
seven columns include cognitive scores obtained at baseline and at follow-up, (ii) a 
single PCA was performed, (iii) saved regression scores of the first principal 
component were separated into two columns according to time point. This resulted in 
baseline g and follow-up g with identical factor loadings, which ranged between 0.43 
(Faces) and 0.79 (-TMT-B) (Table 4.11). The factor accounted for 43.41% of 
variance in the data.  
 
Table 4.11: Factor loadings of baseline and year 4 follow-up cognitive 
tests on g used to calculate ‘four-year change in g’ variable 
Cognitive test Factor loadings 
-Trail-Making 0.79 
Digit Symbol Coding 0.75 
Letter-Number Sequencing 0.72 
Matrix Reasoning 0.67 
Verbal Fluency 0.65 
Logical Memory 0.55 
Faces 0.43 
The log-transformed variable was used for Trail-Making. Trail-Making, Trail-Making Test-B; 
Verbal Fluency, Borkowski Verbal Fluency Test. Data from each cognitive test were imputed. 
 
 
Finally, the standardised residual from a linear regression of follow-up g on baseline 
g derived in this method was saved, and is used to represent ‘four-year change in g’ 
for each attender of the four-year follow-up. 
Main analyses 
Univariate analyses 
In initial univariate analyses, baseline cognitive test performance, demographics and 
risk factors are compared between participants lost to attrition between baseline and 
year 4 and attenders of year 4 follow-up, and between participants with suspected 
dementia and the remaining sample. The various baseline predictor variables are also 
associated with each other in order to ascertain relationships amongst risk factors. 
Correlation coefficients are calculated for cognitive tests scores at baseline and year 
4, and mean cognitive test scores are compared between baseline and year 4 for 
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attenders. Further analyses determine associations of age, sex, socioeconomic status 
and duration of diabetes with predictors and cognitive outcome in order to determine 
their potential use as covariates in multivariable analyses. The univariate statistical 
methods include Pearson correlations, point bi-serial correlations, t-tests, chi
2
 tests 
and analyses of variance (ANOVAs). All analyses are two-tailed. 
Multivariable analyses linear regression analyses 
For completeness, all individual risk factors as well as the ‘inflammation’ factor are 
then associated with all cognitive outcomes (estimated pre-morbid ability, baseline 
ability, four-year cognitive change and estimated lifetime cognitive change, with the 
latter three outcomes represented both in terms of g and all seven individual 
cognitive tests) in linear regression analyses. Results from these analyses are 
presented in Appendix D. Analyses associating risk factors with four-year cognitive 
change are additionally selected as an example analysis which are repeated using raw 
scores of cognitive change instead of the adjustment method (Appendix E). Although 
all further analyses presented in this thesis on four-year cognitive change employ the 
adjustment method, a comparison of the findings in Appendix D and Appendix E 
demonstrate an overall similarity of findings (particularly with respect to effect sizes) 
following both of these approaches.  
In the main part of the multivariable analyses, linear regression analyses and analyses 
of covariance (ANCOVA) determine associations of baseline subclinical and 
symptomatic macrovascular disease variables, of baseline history of severe 
hypoglycaemia (SH), and of incident SH between baseline and year 4 with cognitive 
outcome (estimated peak pre-morbid ability, baseline ability, four-year cognitive 
change and estimated lifetime cognitive change). Due to evidence of hypoglycaemia 
as a consequence of poorer cognitive ability, incident SH between baseline and year 
4 is additionally investigated as a potential outcome of poorer baseline cognitive 
ability in ANCOVAs and in logistic regression analyses is used to calculate odds 
ratios.  
A total of 15 metabolic and vascular risk factor variables measured at baseline/ year 
1 are  then associated with the level of late-life cognitive function, with estimated 
lifetime cognitive change and with four-year cognitive change with the aim to 
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compare relative predictive ability with respect to late-life cognitive outcome. For 
this purpose, stepwise linear regression analyses, which are further described in 
Chapter 8, sees the addition of all 15 risk factors into models of follow-up g, 
estimated lifetime change in g and four-year change in g, with retention of those with 
associations with p<0.05 in each step. All analyses are performed in SPSS version 





















Chapter 5: Results I: Characteristics of study population 
and descriptive statistics for risk factor and cognitive 
test variables 
This chapter describes the characteristics and representativeness of the ET2DS study 
population, presents descriptive statistics for the risk factor variables included in 
subsequent analyses and describes the cognitive test results from baseline and 
follow-up.  
5.1 Study population 
5.1.1 Baseline socio-demographic characteristics 
The participants of the baseline clinic of the ET2DS (n=1066) were on average 67.9 
years old, and 547 (51.3%) participants were male. One hundred and twenty-seven 
(11.9%) were in the first quintile (most deprived), 208 (19.5%) were in the second 
quintile, 188 (17.6%) were in the third quintile, 194 (18.2%) were in the fourth 
quintile and 349 (32.7%) were in the top quintile (least deprived) of the Scottish 
Index of Multiple Deprivation (SIMD). A majority of participants (n=581; 54.6%) 
self-reported secondary school as their highest educational attainment, 307 (28.8%) 
obtained other professional or technical qualifications after leaving school, 171 
(16.0%) had a University degree, and seven individuals (0.7%) had terminated 
education following primary school.  
5.1.2 Representativeness 
Representativeness of the recruited sample (n=1066) as successfully capturing older 
adults with type 2 diabetes living in the Lothian area was determined by researchers 
involved in the baseline phase of the study through comparison of clinical and socio-
demographic characteristics of the study population recorded on the Lothian 
Diabetes Register with those of individuals who had been invited to participate but 
declined or did not respond (‘non-responders’; n=4386) (Marioni, Strachan, et al., 
2010). The recruited sample and non-responders were found to be similar in social 
class (SIMD) (p>0.05) and age (67.9 years ± 4.2 versus 67.9 years ± 4.4; p>0.05). In 
the recruited sample, 516 individuals (48.4%) had a diabetes duration of ≤5 years 
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compared with 2135 (48.7%) of non-responders (p>0.05). Mean HbA1c was 
identical for the two groups (7.4% ± 1.12 versus 7.4% ± 1.36; p>0.05). Of the 
recruited sample, 185 (17.4%) were treated with insulin, compared with 704 (16.1%) 
of the non-responders (p>0.05). However, the recruited sample was more likely to be 
male (n=547, 51.3% versus n=1839, 41.9%; p<0.001), and had higher mean total 
cholesterol (4.2 mmol/l ± 0.96 versus 4.3 mmol/l ± 0.90; p<0.001) and lower systolic 
blood pressure (137.2 mmHg ± 18.2 versus 133.3 mmHg ± 16.4; p<0.01) compared 
with non-responders, although differences were not large (Marioni, Strachan, et al., 
2010).  
 
In order to determine the representativeness of the ET2DS sample relative to other 
older populations with type 2 diabetes, prevalence of disease categories and mean 
values of continuously assessed clinical measures (Table 5.2) were compared with 
those reported in previous studies.  
 
Similar to the prevalence of stroke in the ET2DS (5.8%), the Utrecht Diabetic 
Encephalopathy Study of patients with a similar mean age (mean 66 years) and 
duration of diabetes (mean 8.7 years) compared with the ET2DS (mean age 68 years; 
mean duration of diabetes 8.1 years at baseline), had reported a similar prevalence of 
6% (Manschot et al., 2007). However, prevalence of MI and/or angina appeared to be 
lower in this study (31%) compared with the ET2DS (42%).  
 
With 6.1%, the ET2DS had apparently lower prevalence of PAD than reported in 
previous studies (11%, Manschot et al., 2007; 10% Potier et al., 2007; 29%, Hirsch et 
al., 2001) although the latter two investigations defined PAD on the basis of ABI 
which may have affected levels of prevalence reported in the studies. ABI appeared 
to be somewhat lower in the ET2DS (mean 0.98) than in a Chinese study which was 
comparable in terms of demographic characteristics (mean 1.12) (Chen et al., 2011).  
 
Very similar to the ET2DS (32.5%), retinopathy was prevalent in 33% of subjects in 
the Dutch study (Manschot et al., 2007). Mean HbA1c measured at the baseline 
clinic (7.4%) appeared to be similar to those reported for the Utrecht Diabetic 
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Encephalopathy Study (6.9%) (Manschot et al., 2007) and those reported for the 
Anglo-Danish Dutch Study of Intensive Treatment in People with Screen Detected 
Diabetes in Primary Care (ADDITION) Study (6.1%) (Ruis et al., 2009). Similar 
findings were made when comparing BMI in the ET2DS (mean 31.4) with the 
Utrecht Diabetic Encephalopathy Study (mean 28.1) (Manschot et al., 20078) and 
with ADDITION (mean 30.4) (Ruis et al., 2009). Relatively large apparent 
differences in BMI to the Chinese study (mean 23.7) could potentially be due to 
cultural differences between Scottish and Chinese older adults with type 2 diabetes 
which may influence their clinical characteristics (Chen et al., 2011) 
 
With 14%, prevalence of current smoking was notably lower in the ET2DS 
compared with the Utrecht Diabetic Encephalopathy Study (22%) (Manschot  et al., 
2007), ADDITION (21%) (Ruis et al., 2009) and the Chinese cohort (19%) (Chen et 
al., 2011). Finally, cholesterol levels and systolic blood pressure appeared to be 
relatively lower in the ET2DS compared with other samples (e.g., mean HDL 
cholesterol 4.3 mmol/l in Manschot et al., 2007; mean systolic blood pressure 143 
mmgH in ADDITION, Ruis et al., 2009).  
 
Of those subjects who were treated with insulin at year 4, 4.9% reported incident 
severe hypoglycaemia since baseline, resulting in an annual incidence of around 
1.3%. This incidence is relatively lower than that reported by the Hypoglycaemia 
Study Group for older participants with type 2 diabetes who are on insulin. Here, 
prevalence was estimated to be around 3-15% depending on the duration of treatment 
(UK Hypoglycaemia Study Group, 2007). It may be the case that participants of the 
ET2DS were selected for a shorter duration of insulin treatment, adherence to 
treatment or for cognitive ability, all of which may have offered protection from 
severe hypoglycaemia. 
 
Comparisons of the ET2DS sample with other key population-based cohorts with 
type 2 diabetes were not made due to differences in demographic characteristics, 
such as age and disease duration (Bruce, Davis, Casey, Starkstein, Clarnette, Foster, 
et al., 2008; Wu et al., 2003). Comparisons with ADVANCE (de Galan et al., 2009) 
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and ACCORD-MIND (Punthakee et al., 2012) were also neglected due to specific 
selection criteria having been applied during recruitment to these trials. ADVANCE 
selected subjects with presence of major macrovascular or microvascular disease 
disease and/or increased vascular risk, for instance. Consequently, their samples may 
not be representative of the general older population living with type 2 diabetes.  
 
Overall, the participants of the ET2DS appeared to be relatively representative in 
terms of lifestyle and clinical characteristics both to the population with type 2 
diabetes living in the Lothian area of Scotland (as far as the data on the Lothian 
Diabetes Register showed), and to other populations-based studies of older adults 
with type 2 diabetes as reported in the literature.   
5.2 Risk factor distributions and inter-correlations    
For all risk factors (except severe hypoglycaemia), only data collected at baseline or 
at year 1 were used in the analyses reported in this thesis and so are described here. 
This section reports missing risk factor data and distributions, inter-correlations 
amongst risk factors, and their associations with age, sex and duration of diabetes.  
5.2.1 Missing data 
As shown in Table 5.1, a majority of risk factor variables had very little missing data 
(<4%). Data was complete for age and all binary disease variables (TIA, stroke, 
angina, MI, PAD, dementia), because only individuals with evidence for the 
respective disease or event were recorded; all remaining individuals constitute the 
respective ‘no disease/event’ group. However, some may have been included in this 
group due to missing data despite having suffered the disease or event. This is likely 
to weaken findings in ‘disease/event’ versus ‘no disease/event’ analyses, but is 









Table 5.1: Missing data on risk factors measured at baseline or year 1 
 N  Missing in % of 
baseline sample  
Reason (if available) 
Current anti-diabetic 
treatment     
1065 0.09%  
HADS-A 1065 0.09%  
HADS-D 1065 0.09%  
Body Mass Index 1065 0.09%  
Systolic bp at clinic visit 1064 0.19%  
IL-6 1064 0.19%  
TNF-α 1063 0.28%  
Fibrinogen 1063 0.28%  
Historical systolic bp  1063 0.28%  
Cortisol 1062 0.38%  
Historical HbA1c  1062 0.38%  
Waist-hip ratio 1061 0.47%  
ABI 1059 0.66% Amputations 
LDL:HDL 1057 0.84%  
Duration of diabetes  1053 1.22%  
NT-proBNP  1050 1.50% Secondary analysis of blood 
samples 
Diabetic retinopathy 1044 2.06% Retinal photographs taken at 
separate appointment 
CRP  1043 2.16%  
Inflammation ‘factor’ 1038 2.63% Required data on all four 
inflammatory markers  
History of severe 
hypoglycaemia 




1032 3.19%  
HbA1c at clinic visit 1028 3.56%  
Packyears 1019 4.41%  
Carotid IMT 917 14.0%
a
  Measured at year 1 




 Carried out following year 1 
clinic; some non-responders 
a
data missing for 2.34% of year 1 sample. 
b
data missing for 4.37% of year 1 sample.  
HADS-A, Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D, Hospital Anxiety 
and Depression Scale- Depression subscale; ABI, ankle brachial index; bp, blood pressure; IL-6, 
interleukin-6; TNF-α, tumor necrosis factor α; CRP, c-reactive protein; LDL:HDL, low-density 
lipoprotein: high-density lipoprotein ratio; NT-proBNP, N-terminal pro-brain natriuretic peptide; 













Because a relatively large proportion of data was missing for packyears, cIMT and 
the 6-month survey of severe hypoglycaemia (SH) (all >4%), individuals with and 
those without data on these measures were compared in terms of socio-demographic 
characteristics (age, sex, education, SIMD) and baseline global cognitive ability 
measured by g. Compared with the respective remaining baseline populations, the 
group with missing data on packyears was more likely to be male (p=0.003) and had 
lower baseline g (mean -0.31 ± 0.85 versus 0.01 ± 1.00; p=0.032). The group with 
missing cIMT data was of lower social class (SIMD; p=0.030) and had lower 
baseline g (mean -0.44 ± 1.05 versus 0.07 ± 0.97; p<0.001). The group who did not 
participate in the 6-month survey of SH had lower baseline g (mean -0.34 ± 1.09 
versus 0.07 ± 0.97; p<0.001). All of the remaining socio-demographic parameters 
were similar in the groups with missing data and the respective remaining 
populations (all p>0.05).  
It is plausible that the findings for cIMT and 6-month SH directly reflect the attrition 
of lower-cognitive-ability individuals between baseline and year 1 (at which point 
cIMT was measured and participants were enrolled in the 6-month survey of SH). 
Overall, the tendency for lower cognitive ability in individuals with missing data on 
packyears, cIMT and 6-month SH has the potential to affect the results of analyses of 
these risk factors and cognitive outcome, and will therefore be considered in the 
interpretation of the results.  
5.2.2 Risk factor distributions  
Descriptive statistics for baseline and year 1 risk factors 
Mean ± SD, median (quartile range) or n (%) for risk factor variables are presented 
in Table 5.2. Note that the table reports data on risk factors which are not always 
used in any subsequent analyses in this thesis, but they describe important general 








Table 5.2: Baseline and year 1 risk factor data  
 Mean ± SD, 
median (quartile 
range) or n (%) 
Minimum  Maximum  
Duration of diabetes (years) 6 (3 – 11) 0 43 
Current treatment 
    Insulin +/-tablets    
    Tablets alone  






HbA1c at clinic visit (%) 7.4 ± 1.1 5.0 14.9 
Average historical HbA1c 
(%) 
7.4 ± 0.9 4.9 11.6 
Plasma glucose (mmol/L) 7.2 (6.2 – 8.5) 2.1 22.2 
Systolic bp at clinic visit 
(mmHg)  
133.3 ± 16.4 90 210 
Diastolic bp at clinic visit 
(mmHg)  
69.1 ± 9.0 20 110 
Average historical systolic 
bp (mmHg) 
138.3 ± 10.2 105 185 
Macrovascular disease  
     Myocardial infarction 
     Angina  
     Stroke 
     TIA 
     Claudication 










   None 
   Mild 






Carotid IMT (mm) 1.00 ± 0.17 0.63 1.70 
Ankle brachial index 0.98 ± 0.21 0.27 2.34 
NT-proBNP(pg/ml) 75 (37 – 169) 5 2926 
Body Mass Index (kg/m
2
) 31.43 ± 5.69 18.40 55.44 
Waist-hip ratio 0.97 ± 0.08 0.74 1.22 
Total cholesterol (mmol/L) 4.3 ± 0.9 2.3 9.4 
HDL cholesterol (mmol/L) 1.3 ± 0.4 0.4 3.3 
LDL:HDL ratio 3.5 ± 1.1 1.7 10.7 
Smoking 
   Current smoker 
   Ex-smoker 






Packyears 7.20 (0.0 – 32.0) 0.0 180.0 
Alcohol units/year groups 
    0 (abstainers) 
    1 
    2 
    3 








CRP (mg/l) 1.86 (0.87 – 4.38) 0.10 160.00 
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Fibrinogen (g/l) 3.65 ± 0.74  0.70 7.14 
IL-6 (pg/ml) 2.87 (1.96 – 4.47) 0.49 34.18 
TNF-α (pg/ml) 1.07 (0.69 – 1.62) 0.10 28.00 
Inflammation ‘factor’ 0.00 ± 1.00 -2.39 4.67 
Cortisol (nmol/l) 722.2 ± 196.3 49.5 1447.8 
MMSE 29 (28 – 30) 14 30 
MMSE<24 30 (2.8)   
Dementia 19 (1.8)   
HADS-A 5 (3 – 8) 0 20 
HADS-D 3 (1 – 6) 0 16 
Total n=1066. Carotid IMT and 6-month incident SH measured at year 1.  
Any MVD, any symptomatic macrovacular disease; TIA, transient ischaemic attack; HADS-A, 
Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D, Hospital Anxiety and 
Depression Scale- Depression subscale; MMSE, Mini-Mental-State Examination; bp, blood 
pressure; IL-6, interleukin-6; TNF-α, tumor necrosis factor α; CRP, c-reactive protein; 
LDL:HDL, low-density lipoprotein: high-density lipoprotein ratio; NT-proBNP, N-terminal pro-
brain natriuretic peptide; DR, diabetic retinopathy; SH, severe hypoglycaemia; carotid IMT, 
carotid intima-media thickness.  
 
Distributions of continuous baseline and year 1 risk factor variables 
Histograms of the continuous risk factor variables were visually inspected (Figure 
B.1 to B.28 in Appendix B). Positively skewed distributions were identified for NT-
proBNP, packyears, alcohol units/year, HADS-D, HADS-A, diabetes duration, 
plasma glucose, CRP, IL-6 and TNF-alpha; all of the remaining risk factor variables 
were approximately normally distributed. Prior to their use in further analyses, the 
variables with skewed distributions (except packyears) were each transformed to 
their natural logarithms. Because HADS-D, HADS-A, alcohol units/year and disease 
duration could each have values of 0 (which cannot be log-transformed), 1 was 
added to each HADS-D, HADS-A, alcohol units/year, and disease duration value 
prior to transformation. Subsequent log-transformation achieved approximately 
normal distribution for all variables with previously skewed distributions (Figure 
B.29 to B.37 in Appendix B). The packyears variable was transformed to its square 
root, because this led to a distribution which was closer to normal compared with its 





Descriptive statistics for severe hypoglycaemia (SH) 
Data on SH were used in terms of prevalence of a lifetime history at baseline (self-
reported at baseline), incidence between baseline and year 4 (self-reported at year 4), 
and incidence within the 6-month survey carried out immediately after the year 1 
clinic. The reporting of SH over the course of the study is shown in Figure 5.1. At 
baseline, 112 participants (10.5% of baseline population) reported a lifetime history 
of SH. A majority of these individuals (n=57; 50.9%) had experienced 1 or 2 
episodes, 28 (25.0%) reported 3 to 4 episodes, and 27 (24.1%) had experienced 5 or 
more episodes. Of the 112 participants with a baseline history of SH, 51 (45.5%) 
were on insulin treatment, 53 (47.3%) were on tablets, and 8 (7.13%) were treated by 
diet alone at the time of the baseline assessment. 
 
 





At the year 4 clinic, 85 participants (10.2% of the year 4 population) reported 
incident SH between baseline and year 4 follow-up (Figure 5.1). Of these, most 
(n=44; 51.8%) again had been affected by 1 or 2 episodes since the baseline clinic 
visit, 19 (22.4%) had experienced 3 to 4 episodes and 22 (25.9%) suffered 5 or more 
episodes. Of the 85 participants with incident SH, 40 (47.1%) were on insulin 
treatment at the time of the year 4 clinic, 41 (48.2%) were on tablets alone, and 4 
(4.7%) were treated by diet. Twenty-seven (31.8%) of the 85 participants with 
incident SH had also been in the group with a lifetime history of SH reported at 
baseline. In the 6-month survey of SH, 30 participants (3.3% of individuals enrolled 
in the survey) reported a total of 45 episodes. For 18 of these, blood glucose readings 
were self-reported. All but one of 14 measurements made prior to treatment were 
below 3.0mmol/l. Of the 30 participants reporting SH in the 6-month survey, 25 
recovered following treatment with sugary drink or food, one required injection with 
glucagon and three required intravenous glucose (data missing for one subject). 
Twenty-three of the 30 subjects attended the year 4 follow-up. 
 
5.2.3 Associations of risk factors with age, sex and disease duration 
To summarise the statistically significant associations of risk factors with age, sex 
and disease duration (Table 5.3), age correlated positively with disease duration, 
blood pressure, HDL cholesterol, cIMT, NT-proBNP and HbA1c, and with all 
inflammatory markers except CRP, as well as with the derived inflammation ‘factor’, 
and correlated negatively with alcohol consumption, total cholesterol and LDL:HDL. 
Longer disease duration predicted higher inflammatory marker levels (except CRP) 
and higher values on inflammation ‘factor’, and was further associated with higher 
waist-hip ratio, higher NT-proBNP and higher HbA1c. Females tended to have 
higher HbA1c, lower waist-hip ratio, LDL:HDL, ABI and cIMT and had fewer 
packyears and lower yearly alcohol consumption compared with males. Males had 
lower levels of fibrinogen and CRP, and lower overall inflammation.  
As shown in Table 5.4, individuals with any symptomatic macrovascular disease, 
myocardial infarction and angina were older and had longer disease duration 
compared with the respective remaining populations. Additionally, patients with a 
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history of stroke, those with symptomatic PAD and those with diabetic retinopathy 
tended to have longer disease duration. Males were more likely to suffer from any 
symptomatic macrovascular disease and angina and to have suffered myocardial 






Table 5.3: Age, sex and disease duration associations with continuous baseline and year 1 risk factors 
 Age Duration of 
diabetes 
Sex 
   Males Females p-value 
Duration of diabetes (years) 0.07 (0.018) -- 6 (4 – 11) 6 (3 – 10) 0.16 
Historical HbA1c (%) -0.07 (0.023) 0.28 (<0.001) 7.34 ±0.86 7.47 ±0.93 0.019 
HbA1c at clinic visit (%) -0.06 (0.044) 0.28 (<0.001) 7.36 ± 1.13 7.43 ± 1.10 0.31 
Waist-hip ratio -0.05 (0.11) 0.12 (<0.001) 1.00 ± 0.06 0.92 ± 0.07 <0.001 
Total cholesterol (mmol/L) -0.08 (0.013) -0.12 (<0.001) 4.15 ± 0.84 4.48 ± 0.94 <0.001 
HDL cholesterol (mmol/L) 0.06 (0.050) -0.03 (0.29) 1.21 ± 0.35 1.38 ± 0.35 <0.001 
LDL:HDL -0.11 (<0.001) -0.05 (0.11) 3.65 ±1.09 3.42 ± 1.06 <0.001 
Historical systolic bp (mmHg) 0.05 (0.10) 0.03 (0.37) 137.8 ± 10.0 138.9 ± 10.4 0.09 
Systolic bp at clinic visit (mmHg) 0.08 (0.013) -0.01 (0.79) 133.8 ± 15.9 132.8 ± 17.0 0.35 
Diastolic bp at clinic visit (mmHg) -0.13 (<0.001) -0.11 (0.001) 70.5 ± 8.8 67.5 ± 9.0 <0.001 
Packyears  -0.04 (0.21) 0.00 (0.96) 10.45 ± 5.42 4.05 ± 5.16 <0.001 
Alcohol (units/ year) -0.07 (0.031) -0.06 (0.08) 111.93 ± 14.25 15.11 ± 12.63 <0.001 
Cortisol (nmol/l) 0.03 (0.34) 0.02 (0.46) 726.3 ± 183.4 717.9 ± 209.3 0.49 
ABI -0.02 (0.60) -0.03 (0.32) 1.01 ± 0.24 0.95± 0.16 <0.001 
Carotid IMT (mm) 0.15 (<0.001) 0.09 (0.72) 1.03 ± 0.17 0.96 ± 0.16 <0.001 
NT-proBNP (pg/ml) 0.25 (<0.001) 0.15 (<0.001) 68 (35 – 175) 87 (42 – 166) 0.41 
TNF-α (pg/ml) 0.10 (0.002) 0.15 (<0.001) 1.0 (0.7 – 1.6) 1.1 (0.8 – 1.6) 0.13 
Fibrinogen (g/l) 0.07 (0.022) 0.11 (0.001) 3.5 ± 0.8 3.8 ± 0.7 <0.001 
CRP (mg/l) -0.02 (0.52) -0.04 (0.25) 1.4 (0.7 – 3.5) 2.4 (1.2 – 5.6) <0.001 
IL-6 (pg/ml) 0.09 (0.003) 0.13 (<0.001) 2.8 (1.9 – 4.4) 2.9 (1.9 – 4.5) 0.52 
Inflammation ‘factor’ 0.08 (0.016) 0.11 (0.001) -0.17 ± 0.95 0.18 ± 1.01 <0.001 
Analyses are two-tailed Pearson correlations and t-tests. Values for age and disease duration are correlation coefficients (p-values); for sex are 
means ± SD or median (interquartile range). NT-proBNP, TNF-α, CRP, IL-6. Square root transformed values were used for packyears. Bp, blood 
pressure; IL-6, interleukin-6; TNF-α, tumor necrosis factor α; CRP, c-reactive protein; LDL:HDL, low-density lipoprotein: high-density lipoprotein 
ratio; NT-proBNP, N-terminal pro-brain natriuretic peptide; carotid IMT, carotid intima-media thickness. 






Table 5.4: Age, sex and disease duration associations with categorical baseline risk factors 
 Age (years) Duration of diabetes (years) Sex in disease group 
 Mean ± SD 
in disease 
group 
Mean ± SD 
in ‘no 
disease’ 






range) in ‘no 
disease’ 





Any MVD 68.45 ± 4.33 67.60 ± 4.09 0.001 7 (4-11) 6 (3-11) 0.003 242 (44.2) 151 (29.1) <0.001 
Stroke 68.72 ± 3.84  67.86 ± 4.22 0.12 8 (6 – 16) 6 (3 – 11) 0.001 43 (7.9) 19  (3.7) 0.003 
Transient ischaemic 
attack 
67.97 ± 4.68 67.91 ± 4.19 0.94 7 (4 – 11) 6 (3 – 11) 0.89 19 (3.5) 12 (2.3) 0.26 
Myocardial 
infarction 
68.87 ± 4.13 67.76 ± 4.20 0.003 7 (4 – 12) 6 (3 – 11) 0.051 115 (21.0) 35 (6.7) <0.001 
Angina 68.67 ± 4.23 67.20 ± 4.08 <0.001 7 (4 – 11) 6 (3 – 11) 0.021 182 (33.3) 116 (22.4) <0.001 
Peripheral arterial 
disease 
68.24 ± 4.41 67.89 ± 4.19 0.52 8 (4 – 14) 6 (3 – 11) 0.027 39 (7.1) 26 (5.0) 0.15 
Diabetic 
retinopathy 
67.94 ± 4.24 67.90 ± 4.18 0.87 10 (5 – 15) 5 (3 – 9) <0.001 188 (18.0) 151 (14.5) 0.06 
Analyses are two-tailed t-tests and chi
2
 tests. Values are means ± SD or medians (interquartile range). Disease groups are compared to all other participants.  
‘Any MVD’, any symptomatic macrovascular disease. Log-transformed values were used for t-tests comparing duration of diabetes between disease groups. 
Diabetic retinopathy is a binary variable.  
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5.3 Characteristics of follow-up population and prevalence of 
dementia  
The risk factor and demographic characteristics of the year 4 follow-up population 
(‘attenders’) versus those lost to attrition between baseline and year 4 (‘non-
attenders’) and the demographic characteristics of individuals with dementia at year 
4, are described here. 
5.3.1 Attrition between baseline and year 4 
Of the total study population (n=1066), 831 returned for the year 4 follow-up 
(retention rate 78.0%). An overview of the reasons for attrition is presented in Figure 
4.1 of the Method chapter. Two-tailed t-tests and chi
2 
tests revealed that non-
attenders were overall older and were of lower social class compared with attenders 
(Table 5.5).  
Table 5.5: Baseline demographic characteristics of ‘attenders’ and ‘non-








Age (years) 67.7 ± 4.2 68.7 ± 4.3 0.001 
Male sex 430 (51.7) 117 (49.8) 0.60 
Education 
   University degree 
   Professional  
   qualification 
   Secondary school 















   1
st
 quintile 
   2
nd
 quintile 
   3
rd
 quintile 
   4
th
 quintile 























5.3.2 Risk factors in attenders and non-attenders 
Participants who returned for year 4 follow-up also tended to have lower blood 
pressure, lower levels of inflammation, lower NT-proBNP and lower packyears and 
alcohol consumption, had lower prevalence of symptomatic macrovascular disease 
and experienced fewer symptoms of anxiety and depression at baseline compared 
with non-attenders (Table 5.6). Attenders and non-attenders were similar on all of the 
remaining risk factor parameters.  
 
Table 5.6: Baseline risk factors in attenders and non-attenders of year 4 follow-
up 
 Attenders Non-attenders  
 Total 
N 
Mean ± SD, 
median (quartile 
range) or n (%) 
Total 
N 
Mean ± SD, 
median (quartile 




Duration of diabetes 
(years) 
824 6 (3 – 11) 229 7 (3 – 12) 0.39 
Current treatment 
    Insulin +/-tablets    
    Tablets alone  


















Historical HbA1c (%) 825 7.39 ± 0.90 230 7.45 ± 0.87 0.35 
HbA1c at clinic visit 
(%) 
804 7.39 ± 1.13 224 7.41 ± 1.08 0.87 
Severe hypoglycaemia 816 77 (9.4) 225 35 (15.6) 0.009 
Historical Systolic bp 
(mmHg) 
825 138.2 ± 10.0 231 138.9 ± 10.8 0.35 
Systolic bp at clinic visit 
(mmHg) 
829 132.5 ± 15.9 235 136.1 ± 18.1 0.003 
Diastolic bp at clinic 
visit (mmHg) 
829 69.0 ± 8.9 235 69.4 ± 9.5 0.46 
Macrovascular disease  
     MI 
     Angina  
     Stroke 
     TIA 
     Claudication 




































NT-proBNP (pg/ml) 820 71 (35 – 158) 230 102 (48 – 216) 0.004 
Carotid IMT (mm) 775 1.00 ± 0.17 142 0.99 ± 0.17 0.41 
ABI 824  0.99 ± 0.20 235 0.95 ± 0.23 0.009 
Waist-hip ratio 828 0.97 ± 0.08 233 0.97 ± 0.08 0.97 
Total cholesterol 
(mmol/L) 
826 4.34 ± 0.90 231 4.23 ± 0.91 0.10 
HDL cholesterol 
(mmol/L) 
826 1.29 ± 0.36 231 1.31 ± 0.38 0.52 
LDL:HDL ratio 826 3.57 ± 1.11 231 2.09 ± 0.98 0.06 
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Packyears 803 6 (0 – 30) 231 15 (0 – 40) 0.019 
Smoking  
   Current smoker 
   Ex-smoker 












    0 (abstainers) 
    1 
    2 
    3 





















CRP (mg/l) 817 1.7 (0.83 – 3.89) 226 2.75 (1.10 – 6.77) 0.002 
Fibrinogen (g/l) 829 3.61 ± 0.71 234 3.78 ± 0.83 0.003 
IL-6 (pg/ml) 829 2.72 (1.87 – 4.29) 235 3.40 (2.36 – 5.39) 0.002 
TNF-α (pg/ml) 828 1.05 (0.68 – 1.61) 235 1.17 (0.78 – 1.68) 0.24 
Inflammation ‘factor’ 813 -0.08 ± 0.97 225 0.29 ± 1.07 <0.001 
DR severity 
   None 
   Mild 


















Cortisol (nmol/l) 829 727.1 ± 203.7 233 720.8 ± 194.3 0.67 
MMSE 830 29 (28 – 30) 233 28 (27 – 29) <0.001 
MMSE<24 830 13 (1.6) 233 17 (7.3) <0.001 
HADS-A 831 5 (3 – 8) 234 6 (4 – 9) 0.007 
HADS-D 831 3 (1 – 5) 234 4 (2 – 6) 0.004 
Values are means ± SD, median (interquartile range) or n (%). Any MVD, any symptomatic 
macrovascular disease; MI, myocardial infarction; TIA, transient ischaemic attack; HADS-A, 
Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D, Hospital Anxiety and 
Depression Scale- Depression subscale; MMSE, Mini-Mental-State Examination; bp, blood 
pressure; IL-6, interleukin-6; TNF-α, tumor necrosis factor α; CRP, c-reactive protein; 
LDL:HDL, low-density lipoprotein: high-density lipoprotein ratio; NT-proBNP, N-terminal pro-
brain natriuretic peptide; DR, diabetic retinopathy; carotid IMT, carotid intima-media thickness. 
Log-transformed or square root transformed values were used for analyses of duration of 












5.3.3 Prevalence of dementia 
Although the ET2DS aimed to recruit cognitively healthy older individuals, 19 
subjects met the criteria for dementia specified in Section 4.4.5 at the end of the four-
year follow-up (2011). Of these, only four had attended the year 4 clinic; 15 had been 
lost to attrition following baseline. The dementia group was overall older and of 
lower education compared with the remaining baseline population, but was of a 
similar social class (Table 5.7). For full baseline risk factor characteristics in the 
dementia group versus subjects without dementia diagnosis, see Appendix A.  
 
Table 5.7: Demographic characteristics of dementia patients and the remaining 
baseline sample 







Age 71.1 ± 3.4 67.9 ± 4.2 0.001 
Male sex 11 (57.9) 538 (51.2) 0.56 
Education 
   University degree 
   Professional  
   qualification 
   Secondary school 
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st
 quintile 
   2
nd
 quintile 
   3
rd
 quintile 
   4
th
 quintile 
























5.4 Cognitive test descriptive statistics 
Both baseline and four-year follow-up cognitive test results were used in subsequent 
analyses  and are described here, including inter-correlations, correlations with age, 
sex and duration of diabetes, and correlations between baseline and year 4. 
5.4.1 Baseline 
Missing data 
A majority of the seven cognitive tests which contributed to g (Logical Memory, 
LM; Faces; Matrix Reasoning, MR; Digit Symbol Coding, DSC; Trail-Making-Test 
B,  TMT-B; Letter Number Sequencing, LNS; Borkowski Verbal Fluency Test, 
BVFT) were completed by all participants at baseline. Data was missing 
predominantly due to physical difficulty rather than test refusal and was missing for 
below 2% of participants on all cognitive tests (for between 18 participants or 1.7% 
of the total baseline population on Letter-Number Sequencing, and six participants, 
or 0.06%, on Verbal Fluency).  
 
Because calculation of g required completion of all seven of the aforementioned 
cognitive tests (excluding MHVS and MMSE as an estimate of pre-morbid ability 
and a screening instrument for dementia, respectively), g was derived on the basis of 
data which had been imputed separately for each of the cognitive tests at both 
baseline and year 4, as described in Section 4.5.3 of the Method. Consequently, g had 
relatively little missing data at baseline (n=6; 0.6% of baseline population). Data on 
the MHVS was missing for 19 (1.8%) participants and MMSE data was missing for 








Mean ± SD or median (interquartile range) cognitive test performances at baseline 
are presented in Table 5.8. Note that the minimum values ‘0’ for Logical Memory 
test of verbal memory and Letter-Number Sequencing test of working memory do 
not represent missing data; one participant and two participants were willing to 
perform these two tests respectively, but following test administration were unable to 
recall any of the target information despite prompting by the tester.  
Table 5.8: Baseline cognitive test scores 
 N Mean ± SD or median  
(interquartile range) 
Min Max 
MMSE 1063 29 (28 – 30) 14 30 
MHVS 1049 30.93 ± 5.23 9 44 
Logical Memory 1050 25.24 ± 8.17 0 46 
Faces 1059 65.82 ± 7.88 40 88 
Matrix Reasoning 1052 12.81 ± 5.28 3 25 
Digit Symbol Coding 1057 49.21 ± 14.77 9 99 
Trail-Making (s) 1052 104 (81 – 139) 38 570 
Letter Number Sequencing 1048 9.67 ± 2.75 0 19 
Verbal Fluency 1060 36.93 ± 12.83 5 79 
g 1060 0.00 ± 1.00 -3.36 3.07 
Total n = 1066. Data for g have been imputed; for remaining cognitive tests are non-imputed. G 
was arbitrarily standardised through principal components analysis, resulting in mean = 0 and SD 
= 1. This variable was not used to represent four-year cognitive change in g in the adjustment 
method.  
MMSE, Mini-Mental-State Examination; MHVS, Mill-Hill Vocabulary Scale ; Verbal Fluency, 
Borkowski Verbal Fluency Test; Trail-Making, Trail-Making Test-B; s, seconds; max, maximum 
score; min, minimum score.  
 
Histograms of the cognitive test scores obtained at baseline were also visually 
inspected (Figure B.37 to B.45 in Appendix B). The distribution for the Trail-Making 
Test was positively skewed and for MMSE was negatively skewed. Prior to further 
analyses, the Trail-Making Test was transformed to its natural logarithm to achieve 
approximately normal distribution (Figure B.46 in Appendix B). Despite skewed 
distribution, MMSE scores were not log-transformed as the test was not used as a 
continuous outcome measure, but as a screening instrument for dementia. All 





Inter-correlations amongst baseline cognitive tests 
The correlations amongst the cognitive tests and g at baseline are shown in Table 5.9. 
All cognitive tests and g correlated significantly with all other cognitive tests. 
Relatively weaker correlations were found for some of the measures of memory 
(Logical Memory, Faces); correlations were particularly strong amongst the 
measures of processing speed (Trail-Making Test-B, Digit Symbol Coding). Note 
that correlations for Trail-Making Test-B are negative, because in contrast to the 
remaining cognitive tests, higher values represent a worse performance. 
Table 5.9:  Bivariate associations amongst baseline cognitive test scores 
 LM Faces MR DSC TMT-B LNS BVFT g* 
MHVS 0.38 0.28 0.45 0.37 -0.37 0.40 0.44 0.58 
LM -- 0.24 0.28 0.27 -0.28 0.31 0.25 0.54 
Faces  -- 0.24 0.29 -0.26 0.20 0.22 0.47 
MR   -- 0.38 -0.46 0.40 0.36 0.67 
DSC    -- -0.63 0.40 0.40 0.75 
TMT-B     -- -0.50 -0.39 0.80 
LNS      -- 0.46 0.72 
BVFT       -- 0.67 
Data for g have been imputed, for remaining cognitive tests are non-imputed. *Values for 
associations of g with the seven cognitive tests (except MHVS) are factor loadings on basis of 
imputed cognitive test data. Values for all individual cognitive tests are correlation coefficients 
from two-tailed Pearson correlations. All p<0.001. MHVS, Mill-Hill Vocabulary Scale; LM, 
Logical Memory; MR, Matrix Reasoning; DSC, Digit Symbol Coding; TMT-B, Trail-Making-
Test B; LNS, Letter Number Sequencing; BVFT, Borkowski Verbal Fluency Test  
 
 
Associations of baseline cognitive test performance with age, sex and 
disease duration 
Higher age was associated with lower performance on all seven cognitive tests 
contributing to g and with lower g (Table 5.10). Disease duration correlated 
negatively with Faces, Digit Symbol Coding, Trail-Making Test-B, Letter-Number 
Sequencing, Verbal Fluency and g. Performance on the MHVS was unrelated to age 
or disease duration. Males tended to have higher scores on the MHVS and Matrix 
Reasoning; females outperformed males on Logical Memory, Faces and Digit 







Table 5.10: Baseline cognitive test associations with age, sex and disease duration 






Males Females p-value 
MHVS 0.01 (0.67) -0.02 (0.60) 31.37 ± 5.33 30.48 ± 5.09 0.006 
Logical Memory -0.10 (0.001) -0.01 (0.72) 24.45 ± 7.85 26.07 ± 8.43 0.001 
Faces -0.16 (<0.001) -0.12 (<0.001) 64.46 ± 7.46 67.25 ± 8.08 <0.001 
Matrix Reasoning -0.17 (<0.001) -0.02 (0.44) 13.47 ± 5.22 12.12 ± 5.26 <0.001 
Digit Symbol Coding -0.21 (<0.001) -0.15 (<0.001) 46.80 ± 14.08 51.73 ± 15.07 <0.001 
Trail-Making (s) 0.20 (<0.001) 0.12 (<0.001) 108 (83 – 140) 102 (78 – 135) 0.13 
Letter Number Sequencing -0.16 (<0.001) -0.09 (0.007) 9.75 ± 2.86 9.59 ± 2.64 0.34 
Verbal Fluency -0.07 (0.020) -0.09 (0.002) 37.13 ± 12.87 36.71 ± 12.80 0.60 
g -0.23 (<0.001) -0.13 (<0.001) -0.06 ± 0.98 0.06 ± 1.02 0.06 
Analyses are two-tailed Pearson correlations and t-tests. Data for g have been imputed, for remaining cognitive tests are non-imputed. MHVS, Mill-Hill 
Vocabulary Scale; LM, Logical Memory; Trail-Making, Trail-Making-Test-B; LNS, Letter Number Sequencing; Verbal Fluency, Borkowski Verbal 
Fluency Test. Log-transformed values were used for Trail-Making Test-B and duration of diabetes. Values for age and disease duration are correlation 
coefficients (p-values); for sex are means ± SD or medians (interquartile range).  
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Baseline cognitive test performance in people with dementia by year 4 
Participants who were identified to suffer from dementia following the year 4 clinic 
had consistently lower baseline test performance on tests of fluid-type cognitive 
ability as well as on the MHVS compared with the individuals who remained 
dementia-free (Table 5.11). This may or may not reflect cognitive deficits due to 
early signs of dementia, given that the data used to identify subjects with dementia 
was not limited to the study period. Consequently, participants in the dementia group 
may have been received diagnosis prior to the baseline assessment.  
Table 5.11: Baseline cognitive test scores in the dementia group and the 
remaining sample 
 Dementia  
(total n=19) 




Mean ± SD or 
median  
(quartile range)  
Total 
N 
Mean ± SD or 
median  
(quartile range)  
MMSE 19 26 (23 – 28) 1044 29 (28 – 30) 
MHVS 19 27.05 ± 6.71 1030 31.01 ±5.18 
Logical Memory 16 15.81 ± 6.99 1034 25.38 ± 8.11 
Faces 19 58.58 ± 5.80 1040 65.95 ± 7.86 
Matrix Reasoning 19 8.16 ± 4.15 1033 12.90 ± 5.26 
Digit Symbol Coding 18 31.44 ± 14.17 1039 49.52 ± 14.60 
Trail-Making (s) 18 177 (154 – 230) 1034 104 (81 – 136) 
Letter Number 
Sequencing 
19 6.89 ±3.02 1029  9.72 ± 2.72 
Verbal Fluency 19 30.05 ± 11.51 1041 37.05 ± 12.82 
g 19 -1.51 ± 0.92 1041 0.03 ± 0.98 
Data for g have been imputed, for remaining cognitive tests are non-imputed. All group 
comparisons p<0.001 except Verbal Fluency (p=0.018), MMSE (p=0.002) and MHVS (p=0.001). 
MMSE, Mini-Mental State Examination; MVHS, Mill-Hill Vocabulary Scale; Trail-Making, 








5.4.2 Four-year follow-up 
Missing data 
The greatest proportion of missing cognitive data at follow-up was due to non-
attendance at the research clinic. Attenders of the year 4 follow-up clinic were found 
to have consistently higher baseline cognitive test performance compared with non-
attenders (Table 5.12). To illustrate, the difference between attenders and no-
attenders in baseline g was of medium effect size (Cohen’s d = 0.56) (J. Cohen, 
1992), for instance.  
Table 5.12: Baseline cognitive test performance of attenders and non-attenders 
of the year 4 clinic 
 Attenders Non-attenders 








MHVS 820 31.45 ± 5.07 229 29.07 ± 5.37 
Logical Memory 822 25.86 ± 7.95 228 23.02 ± 8.57 
Faces 827 66.34 ± 7.66 232 63.95 ± 8.40 
Matrix Reasoning 822 13.36 ± 5.23 230 10.87 ± 5.00 
Digit Symbol Coding 828 50.42 ± 14.34 229 44.81 ± 15.47 
Trail-Making (s) 823 101 (79 – 132) 229 124 (94 – 161) 
Letter Number 
Sequencing 
822 9.93 ± 2.66 226 8.74 ± 2.89 
Verbal Fluency 828 37.77 ± 12.53 232 33.95 ± 13.47 
g 829 0.13 ± 0.93 231 -0.44 ±1.11 
Data for g have been imputed, for remaining cognitive tests are non-imputed. All p<0.001 
for group comparisons. MHVS, Mill-Hill Vocabulary Scale; DSC, Digit Symbol Coding; 
Trail-Making, Trail-Making-Test B; LNS, Letter Number Sequencing; Verbal Fluency, 




Completion of at least part of the cognitive test battery was part of the inclusion 
criteria for the ET2DS, but this did not apply to the year 4 follow-up. Three 
participants attending the follow-up clinic did not complete any of the cognitive tests 
(due to physical disability or refusal). Missing data on the individual cognitive tests 
(including these three individuals) generally ranged between 30 (3.6% of total year 4 
population) on Digit Symbol Coding and Trail-Making Test-B and 7 (0.8%) on 
Matrix Reasoning. The Letter-Number Sequencing stood out with a relatively higher 
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proportion of data missing for 39 (4.7%) participants, which may be attributable to 
the year 4 testers offering to omit this test more freely compared with the baseline 
testers. Additionally, 34 (4.1%) participants did not perform the Simple Reaction 
Time (SRT) component of the Deary-Liewald Reaction Time Task and 83 (10.0%) 
participants had missing data on the Choice Reaction Time (CRT) component.  Data 
on the MHVS was missing for eleven (1.3%) participants and MMSE data was 
missing for seven participants (0.8%). 
As at baseline, imputation of cognitive test data for the purpose of calculating g 
resulted in a relatively low proportion of missing data for follow-up g (n=8; 1.0% of 
year 4 sample). Data on a ‘four-year change in g’ variable derived through 
adjustment of follow-up g for baseline g was missing for nine attenders (1.1% of year 
4 sample).  
Distributions 
Mean ± SD or median (interquartile range) for year 4 cognitive test performances are 
presented in Table 5.13 and 5.14. As had also been found for one subject at baseline, 
one participant attending the year 4 follow-up was unable to recall any of the target 
material of the Logical Memory test of verbal memory despite prompting, resulting 
in ‘0’ as the minimum score on this test.  
Table 5.13: Year 4 cognitive test scores for attenders 




MMSE 824 29 (28 – 30) 18 31 
MHVS 820 30.71 ± 4.94 10 43 
Logical Memory 820 27.28 ± 8.27 0 46 
Faces 822 69.23 ± 8.39 44 92 
Matrix Reasoning 824 11.56 ± 5.22 2 24 
Digit Symbol Coding 801 50.18 ± 14.04 13 103 
Trail-Making (s) 801 106 (83 – 142) 43 681 
Letter-Number Sequencing 792 8.92 ± 2.89 1 20 
Verbal Fluency 822 36.85 ± 12.76 5 97 
g 823 0.00 ± 1.00 -2.99 2.92 
Total n=831. Data for g have been imputed, for remaining cognitive tests are non-imputed. G is 
arbitrarily standardised through principal components analysis, resulting in mean = 0 and SD = 1. 
This variable was not used to represent four-year cognitive change in g in the adjustment method.  
MMSE, Mini-Mental-State Examination; MHVS, Mill-Hill Vocabulary Scale; Trail-Making, 
Trail-Making-Test B; Verbal Fluency, Borkowski Verbal Fluency Test; s, seconds; max, 











Correct count - 39 (38 – 40) 
Mean (ms) 305 (276 – 344) 632 ± 123 
Standard Deviation (ms) 59 (43 – 90) 157 ± 50 
Values are means (SD) or medians (interquartile range). ‘CRT correct count’ is number of correct 
trials during CRT (only correct CRT trials were included for calculation of means and standard 




Histograms of the cognitive test scores obtained at year 4 were also visually 
inspected (Figure B.47 to B.60 in Appendix B). As at baseline, the distribution for 
Trail-Making Test-B was positively skewed and for MMSE was negatively skewed. 
The ‘SRT mean’ and ‘SRT standard deviation’ were also positively skewed. ‘CRT 
correct count’ describing the number of trials during which a participant responded 
by pressing the correct key on the keyboard (maximum n=40) was negatively 
skewed. Prior to further analyses, Trail-Making Test-B, SRT mean, SRT standard 
deviation and CRT correct count were transformed to their natural logarithms to 
achieve approximately normal distributions (Figure B.61 to B.64 in Appendix B). 
Again, MMSE scores were not log-transformed (despite skewed distributions) as the 
test was again used only as a screening instrument for dementia. All of the remaining 
cognitive test variables appeared approximately normally distributed. 
Inter-correlations amongst follow-up cognitive tests 
Correlations amongst cognitive test scores and g at year 4 are shown in Table 5.15. 
Mirroring the pattern found for baseline, scores on Faces and Logical Memory 
correlated relatively weakly; correlations appeared particularly strong for the tests of 










Table 5.15: Bivariate associations amongst year 4 cognitive test scores 
 LM Faces MR DSC TMT-B LNS BVFT g* 
MHVS 0.43 0.29 0.45 0.34 -0.33 0.40 0.42 0.55 
LM -- 0.26 0.32 0.37 -0.38 0.37 0.41 0.61 
Faces  -- 0.29 0.29 -0.31 0.22 0.27 0.51 
MR   -- 0.44 -0.48 0.46 0.29 0.69 
DSC    -- -0.65 0.47 0.41 0.79 
TMT-B     -- -0.53 -0.37 0.81 
LNS      -- 0.41 0.75 
BVFT       -- 0.62 
*Data for g have been imputed, for remaining cognitive tests are non-imputed. Values for 
associations of g with the seven cognitive tests (except MHVS) are factor loadings on basis of 
imputed cognitive test data. Values for all individual cognitive tests are correlation coefficients 
from two-tailed Pearson correlations. All p<0.001. MHVS, Mill-Hill Vocabulary Scale; LM, 
Logical Memory; MR, Matrix Reasoning; DSC, Digit Symbol Coding; TMT-B, Trail-Making-
Test B; LNS, Letter Number Sequencing; BVFT, Borkowski Verbal Fluency Test. Log-
transformed values were used for Trail-Making Test-B. 
 
 
All of the CRT measures correlated with one another and with performance on the 
SRT, with the exception of a non-significant association between CRT correct count 
and SRT mean (Table 5.16). Compared with the remaining variables, effect sizes 
were relatively small for associations of CRT correct count. A weak positive 
association between CRT correct count and CRT mean could reflect a trade-off 
between speed and accuracy on the task. The different SRT measures were all highly 
correlated.  
 
Table 5.16: Univariate associations amongst Simple Reaction Time (SRT) and 
Choice Reaction Time (CRT) measures 








CRT mean 0.10 (0.006) -   
CRT 
SD 
0.07 (0.051) 0.62 (<0.001) -  
SRT mean -0.02 (0.623) 0.50 (<0.001) 0.22 (<0.001) - 
SRT 
SD 
-0.08 (0.030) 0.28 (<0.001) 0.18 (<0.001) 0.70 
(<0.001) 
Values are correlation coefficients from two-tailed Pearson correlations (p-values). SRT, simple 
reaction time; CRT, choice reaction time; ‘SRT SD’, standard deviation in SRT component; 
‘CRT SD’, standard deviation in CRT component; ‘CRT correct count’ is number of correct trials 
during CRT (only correct CRT trials were used to calculate  means and standard deviations; 
maximum n = 40). SRT mean, SRT SD and CRT correct count were log-transformed. Higher 
values of SRT mean and CRT mean represent worse performance, whereas higher values of CRT 




All further analyses on reaction time were carried out only for SRT mean and CRT 
mean as the main reaction time variables of interest. The associations of these 
measures with performance on the remaining cognitive tests at year 4 are shown in 
Table 5.17. Individuals who performed well on the CRT and SRT tended to also 
perform well on the remaining cognitive tests and g. 
 
Table 5.17: Simple and Choice Reaction Time associations with year 4 cognitive 
test scores 
 CRT mean SRT mean 
MHVS -0.17 -0.20 
Logical Memory -0.16 -0.13 
Faces -0.17 -0.14 
Matrix Reasoning -0.25 -0.22 
Digit Symbol Coding -0.39 -0.28 




Verbal Fluency -0.20 -0.19 
g -0.38 -0.30 
Analyses are two-tailed Pearson correlations. Trail-Making and SRT mean were 
log-transformed. Data for g have been imputed, for remaining cognitive tests are 
non-imputed. Values are correlation coefficients. All p<0.001. Higher values of 
Trail-Making, SRT mean and CRT mean represent worse performance; for all 
remaining cognitive tests higher values represent better performance.  Trail-
Making Test-B and SRT mean were log-transformed. MHVS, Mill-Hill 
Vocabulary Scale; Trail-Making, Trail-Making-Test B; Verbal Fluency, 























Associations of follow-up cognitive test performance with age, sex and 
disease duration 
Similar to baseline, age correlated negatively with performance on all individual 
cognitive tests contributing to g, except Verbal Fluency (Table 5.18). Longer disease 
duration was associated with lower performance on Faces, Digit Symbol Coding, 
Trail-Making Test-B, Verbal Fluency and g. Males outperformed females on the 
MHVS and Matrix Reasoning, and had lower mean reaction time (i.e. better 
performance) on both components of the reaction time task compared with females; 
females on average scored higher or performed better than males on Logical 
Memory, Faces, Digit Symbol Coding, Trail-Making Test-B and g. None of the 
remaining associations of cognitive test performance with age, disease duration or 
sex reached statistical significance. The non-significant relationship between MHVS 
and age as well as disease duration supports the measure as an estimate of 








Table 5.18: Year 4 cognitive test associations with age, sex and disease duration 
 Age  Duration of diabetes  Sex 
 Correlation coefficient 
 (p-value) 
Correlation coefficient  
(p-value) 
Males Females p-value 
MHVS <0.01 (0.99) -0.01 (0.72) 31.26 ± 4.88 30.12 ±4.95 0.001 
Logical Memory -0.12 (0.001) -0.03 (0.40) 26.32 ± 8.47  28.29 ± 7.93 0.001 
Faces -0.20 (<0.001) -0.11 (0.003) 68.02 ± 7.88 70.51 ± 8.72 <0.001 
Matrix Reasoning -0.17 (<0.001) -0.07 (0.07) 12.13 ± 5.21 10.96 ±5.16 0.001 
Digit Symbol Coding -0.22 (<0.001) -0.09 (0.008) 47.99 ± 13.73 52.53 ± 14.01 <0.001 
Trail-Making (s) 0.25 (<0.001) 0.08 (0.020) 108 (85 – 145) 105 (81 – 136) 0.052 
Letter-Number Sequencing -0.16 (<0.001) -0.06 (0.09) 8.98 ± 2.94 8.86 ± 2.85 0.56 
Verbal Fluency -0.05 (0.13) -0.09 (0.008) 36.76 ±12.92 36.95 ± 12.60 0.83 
g -0.24 (<0.001) -0.11 (0.002) -0.07 ± 0.99 0.07 ± 1.01 0.039 
CRT mean (ms) 0.15 (<0.001) 0.04 (0.305) 624 ± 122 642 ± 122 0.050 
SRT mean (ms) 0.16 (<0.001) 0.04 (0.232) 297 (269 – 342) 310 (284 – 347) 0.011 
Analyses are two-tailed Pearson correlations and t-tests. MHVS, Mill-Hill Vocabulary Scale; Trail-Making, Trail-Making-Test B;; Verbal Fluency, 
Borkowski Verbal Fluency Test; SRT, Simple Reaction Time; CRT, Choice Reaction Time; ms, milliseconds; s, seconds.  Log-transformed values were 
used for Trail-Making, SRT mean and duration of diabetes. Values for age and disease duration are correlation coefficients (p-values); for sex are means ± 
SD or medians (interquartile range). Data for g have been imputed, for remaining cognitive tests are non-imputed. Higher values for Trail-Making Test-B, 






5.4.3 Correlations between cognitive test scores at baseline and 
follow-up 
All cognitive tests showed high stability of individual differences between baseline 
and year 4 (Table 5.19). Performance on the MHVS was the most stable of all 
cognitive tests, further supporting its usefulness to estimate crystallised-type ability, 
although some severe cases of decline (e.g., from 31 out of 43 at baseline to 19 at 
year 4) or strong improvements (e.g., from 11 at baseline to 19 at year 4) were 
observed for this test (these were not explained by non-nativeness, error in data entry 
or dementia). The tests of memory (Letter-Number Sequencing, Logical Memory, 
Faces) correlated relatively weakly between the two time points compared with the 
remaining cognitive tests (although still with large effect sizes); tests of speed of 
processing and executive function (Verbal Fluency, Digit Symbol Coding, Trail-
Making Test-B) as well as g correlated particularly strongly. For g as the main 
cognitive variable of interest, the correlation between baseline and follow-up scores 
is illustrated in Figure 5.2. 
 
 





Verbal Fluency 0.81 
Digit Symbol Coding  0.75 
Trail-Making 0.69 
Matrix Reasoning 0.67 
Logical Memory 0.63 
Faces 0.61 
Letter-Number Sequencing 0.54 
Analyses were two-tailed Pearson correlations. All p<0.001. MHVS, Mill-Hill Vocabulary Scale; 
Trail-Making, Trail-Making-Test B; Verbal Fluency, Borkowski Verbal Fluency Test. Log-
transformed values were used for Trail-Making. Data for g have been imputed, for remaining 












5.4.4 Change in cognitive test scores during follow-up 
Change in cognitive test performance between baseline and year 4 follow-up was 
analysed for attenders of the year 4 clinic. Mean scores decreased significantly on 
MHVS, Matrix Reasoning, Letter-Number Sequencing, Verbal Fluency and g and 
the mean time required by participants to complete the Trail-Making Test-B 
increased (Table 5.20). Performance on Faces and Logical Memory improved 
although this does not necessarily imply improved ability, because memory for the 
specific stimuli between the clinic visits could potentially have affected scores. A 
decline in Digit Symbol Coding performance approached statistical significance.  
 
As described in section 4.5.2, original data for the seven cognitive tests contributing 
to g were used for all analyses presented in this thesis. A comparison of the four-year 
change in scores on the individual cognitive tests using original, non-imputed data 
(Table 5.20) with the same analysis using imputed data (Appendix C) shows that 
findings were close to identical when imputed data and when originally measured 






Table 5.20: Cognitive change between baseline and year 4 for attenders 
  Baseline  Year 4    
 N Mean ± SD or 
median 
(interquartile range) 




MHVS 810 31.53 ± 5.02 30.70 ± 4.95 <0.001 
Logical Memory 812 25.88 ± 7.96 27.37 ± 8.14 <0.001 
Faces 819 66.42 ± 7.63 69.21 ± 8.39 <0.001 
Matrix Reasoning 816 13.38 ± 5.22 11.58 ± 5.22 <0.001 
Digit Symbol Coding 801 50.86 ± 14.08 50.18 ± 14.04 0.06 
Trail-Making (s) 795 101 (79 – 132) 106 (83 – 142) <0.001 
Letter-Number 
Sequencing 
784 10.01 ± 2.64 8.93 ± 2.89 <0.001 
Verbal Fluency 819 37.84 ± 12.53 36.87 ± 12.77 <0.001 
g 822 0.07 ± 0.95 -0.06 ± 1.04 <0.001 
MHVS, Mill-Hill Vocabulary Scale; Trail-Making, Trail-Making-Test B;  Verbal Fluency, 
Borkowski Verbal Fluency Test; s, seconds. Log-transformed values were used for analyses of 
Trail-Making. Data for g have been imputed; for individual cognitive tests are non-imputed. The 




5.4.5 Unviariate associations between demographic variables, 
estimated peak pre-morbid ability and four-year change in g 
An analysis of variance (ANOVA) revealed a statistically significant association of 
SIMD quintile with peak pre-morbid ability estimated at baseline (MHVS) 
(F(4,1044) = 26.26; p<0.001). Pairwise comparison then determined that the first 
(most deprived) quintile had a significantly lower mean MVHS (28.69, 95% CI 
27.81, 29.57) compared with the third (mean 30.12, 95% CI 29.40, 30.83), fourth 
(mean 31.57, 95% CI 30.84, 32.28) and fifth (least deprived; mean 32.84, 95% CI 
32.31, 33.38) quintile. The second (mean 29.29, 95% CI 28.60, 29.97) as well as the 
third quintile groups both had significantly lower mean MHVS scores compared with 
the fourth and fifth quintiles. Subjects in the fifth quintile (highest socioeconomic 
status) had significantly higher mean MHVS scores compared with all of the 





Figure 5.3: Mean baseline MHVS scores according to SIMD quintile (error bars 
show 95%CI) 
 
Unadjusted linear regression analyses investigated the relationship of age, sex, 
disease duration and MHVS with the four-year change in cognitive function. To 
summarise, advanced age and a lower score on the MHVS (indicating lower peak 
pre-morbid ability) were both associated with a steeper decline in cognitive ability 
between baseline and year 4 assessments in terms of all individual cognitive tests as 
well as global ability measured by g (Table 5.22). For analyses of MHVS, 
associations were of relatively largest effect size for g, and for working and verbal 
memory (Letter-Number Sequencing; Logical Memory) and reasoning (Matrix 
Reasoning). For age, findings of a relationship with a steeper decline appeared 
relatively strongest for non-verbal memory (Faces) and for executive function (Trail-
Making Test-B). Sex and disease duration were relatively unrelated to the change in 
cognitive test performance between baseline and year 4, both in terms of individual 
tests and g. An exception was a steeper decline in Matrix Reasoning score in 










Table 5.22: Univariate associations of baseline Mill-Hill Vocabulary Score, age, 
sex and disease duration with four-year change in cognitive function 
 Age Sex Duration of 
diabetes 
MHVS 




































































Analyses are linear regression analyses of follow-up cognitive test scores adjusted for baseline 
scores. Values are correlation coefficients (p-values). MHVS measured at baseline. MHVS, Mill-
Hill Vocabulary Scale; Trail-Making, Trail-Making Test-B; Verbal Fluency, Borkowski Verbal 
Fluency Test; data for g has been imputed, for individual cogntiive tests is non-imputed. Higher 
values of Trail-Making Test-B indicate worse performance. Duration of diabetes and Trail-
Making Test-B are log-transformed. Sex coded as 1 = male; 2 = female. For analyses of age and 
sex, n = 784 to 822; for analyses of duration of diabetes, n = 777 to 815; for analyses of MHVS, 
n = 777 to 811.  
 
 
Analyses of the relationship of education and social class with four-year cognitive 
change were restricted to g (rather than the seven individual cognitive tests) for 
reasons of brevity. As shown in Table 5.23 and illustrated in Figure 5.4, subjects 
with a lower socioeconomic status tended to experience steeper cognitive decline 
between baseline and year 4, although post-hoc pairwise comparison showed that 
only the difference in four-year decline in g between the fifth and the first (p=0.001) 
as well as the third quintile (p=0.004) reached statistical significance. A similar trend 
short of statistical significance was observed for associations of the level of 








Table 5.23: Univariate associations of education and deprivation with four-year 
change in g 
 Mean standardised residual 
of follow-up g adjusted for 




   University degree 
   Professional qualification 
   Secondary school 
   Primary school 
 
0.13 (-0.04, 0.92) 
0.05 (-0.07, 0.18) 
-0.06 (-0.16, 0.03) 
-0.66 (-1.53, 0.22) 
0.07 
SIMD rank 
   1
st
 quintile 
   2
nd
 quintile 
   3
rd
 quintile 
   4
th
 quintile 




-0.22 (-0.42, -0.02) 
-0.16 (-0.32, 0.00) 
-0.11 (-0.27, 0.06) 
0.03 (-0.13, 0.19) 
0.19 (0.07, 0.30) 
<0.001 
Analyses are analyses of variance (ANOVA) of follow-up g adjusted for baseline g. CI, 











Figure 5.4: Mean four-year change in g according to SIMD quintile (error bars 
show 95% CI) 
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Chapter 6: Results II: Macrovascular disease and 
cognition  
This chapter presents results on the association between baseline macrovascular 
disease (MVD) and cognition in the ET2DS. Variables representing MVD are further 
categorised as measures of ‘symptomatic’ disease (myocardial infarction, angina, 
stroke, transient ischaemic attack, peripheral arterial disease of the lower limbs) and 
‘subclinical’ disease (NT-proBNP, ankle brachial index and carotid intima medial 
thickness). Cognitive outcomes for these analyses include vocabulary (MHVS 
measured at baseline; an indicator of peak prior cognitive ability), late life cognitive 
ability (cognitive function at year 4), estimated relative lifetime cognitive change 
(year 4 cognitive ability adjusted for MHVS), four-year cognitive change (year 4 
cognitive ability adjusted for baseline ability) and presence of dementia by year 4 
(n=19). In order to determine whether or not the findings presented in this chapter 
were driven by patients with dementia, selected analyses (those of MHVS and of 
four-year cognitive change – the main outcome of interest) were repeated with their 
exclusion. Results from these analyses, which did not alter statistical significance or 
effect sizes compared with the analyses presented in the current chapter, are shown 
in Appendix E. In addition to potential confounders included in each analysis, data 
from the Scottish Index of Multiple Deprivation (SIMD) was controlled for in a final 
modelling step in analyses of MHVS and of g in order to evaluate the role of 
socioeconomic status in associations of estimated pre-morbid cognitive ability with 
late-life risk of macrovascular disease as well as between late-life macrovascular 
disease and late-life cognition. 
6.1 Macrovascular disease and estimated peak pre-morbid 
ability 
To determine the association of macrovascular disease with estimated peak pre-
morbid ability at baseline, linear regression analysis of MHVS on each 
macrovascular risk factor was used. For each symptomatic disease category, 
comparisons were made both against subjects without disease in that specific 
category, and against subjects without any symptomatic disease (n=673). A lower 
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peak pre-morbid ability, as estimated by lower baseline MHVS scores, was 
significantly associated with the presence of stroke, myocardial infarction (MI) and 
angina, with relatively largest effect sizes for the association with angina (Table 6.1; 
Figure 6.1). The restriction of comparisons to individuals who were free of any 
symptomatic disease increased effect sizes throughout. ABI was significantly 
associated with MHVS: each standard deviation decrease in ABI was associated with 
a 0.09 standard deviation decrease in MHVS. Associations of MHVS with NT-
proBNP and cIMT were not statistically significant. Adjustment for SIMD rendered 
all associations except that for angina statistically non-significant. For angina, the 
association was also severely weakened (close to halved) in this modelling step. 
Overall, the findings show that subjects with a lower (estimated) cognitive ability in 
young adulthood were at an increased risk of having experienced a stroke and to be 
suffering from coronary heart disease and peripheral atherosclerotic disease at the 
time of attending the baseline clinic of the ET2DS, but the findings were largely 
driven by individual differences in SES. It may be plausible that subjects with a 
relatively lower socioeconomic status were exposed to environments which did not 
stimulate the accumulation of cognitive abilities (for instance, people from lower 
socioeconomic status may have been more concerned with survival than with 
cognitively engaging activities such as reading). At the same time, such 
environments may have had detrimental effects on the risk of late-life macrovascular 
disease, although of course the specific relationship of socioeconomic status, pre-
morbid ability and later atherosclerosis does not become apparent on the basis of the 
present data. A mediatory role of socioeconomic status may also be possible, with 
relatively lower cognitive ability in young adulthood predisposing to a lower 
socioeconomic status and then to an increased risk of late-life macrovascular disease. 
The survival of angina associations with MHVS following adjustment for covariates 
including socioeconomic status could potentially be attributed to a relatively higher 



































    

































Comparison with participants free of any symptomatic MVD (n=673) 
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Outcome measure is baseline MHVS. Analyses adjusted for age, sex. Values are standardised β coefficients (p-values). 
a
for symptomatic MVD predictors, 
analyses compared to all other participants. MHVS, Mill-Hill Vocabulary Scale; MVD, macrovascular disease; TIA, transient ischaemic attack; MI, 
myocardial infarction; PAD, peripheral arterial disease; NT-proBNP, N-terminal pro-brain natriuretic peptide; carotid IMT, carotid intima-media 

















Figure 6.1: Mean MHVS scores in subject with and those without angina at baseline (error bars show 95% CI)
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6.2 Macrovascular disease and cognitive function at year 4 
6.2.1 Symptomatic disease 
The associations of symptomatic macrovascular disease at baseline with the level of 
cognitive function at year 4 were investigated in multiple linear regression analyses 
of the global ability factor g and scores on the individual cognitive tests at year 4 on 
each of the five measures of symptomatic macrovascular disease. For each model, an 
initial step controlled for age and sex, followed by additional adjustment for a range 
of established cardiovascular risk factors. Results for g and the majority of the 
individual tests are shown in Table 6.2 with results for reaction time in Table 6.3. As 
for other analyses in this chapter, comparisons for each symptomatic disease 
category were made both against subjects without disease in that specific category, 
and against subjects without any symptomatic disease (n=538). For g, which was the 
main cognitive outcome of interest, SIMD was controlled for in a final modelling 
step to determine the independence of findings from socioeconomic status. 
 
A prior history of stroke was significantly associated with lower performance or 
trends for lower performance on a majority of cognitive tests and g at year 4, but the 
results for TIA tended to be non-significant (Table 6.2; Table 6.3). Consistent with 
MI and angina as manifestations of coronary heart disease, patterns of findings were 
similar for each of these disease categories, with both associated with lower working 
memory (Letter-Number Sequencing), executive function (Trail-Making Test-B), 
reasoning (Matrix Reasoning) and processing speed (Digit Symbol Coding). With 
exception of an association with longer mean Choice Reaction Time latencies, the 
presence of PAD was unrelated to cognitive function at year 4 in the analysis of the 
entire sample; statistically significant associations were present only when 
comparisons were made with participants free of all symptomatic MVD. 
 
Almost all of the significant associations of symptomatic macrovascular predictors 
with cognitive test scores and g survived adjustment for conventional vascular risk 
factors, but were weakened following adjustment for SIMD to the extent that all 
associations with g except those for stroke, and for MI and angina (when compared 
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with MVD-free individuals) became statistically non-significant. This also reflects 
the observation that generally, results were similar when comparing the disease 
categories to all of the remaining participants, and when restricting the comparison to 
individuals free of all symptomatic MVD, although in the latter analyses effect sizes 
tended to be increased and significance levels improved. 
 
Associations of baseline symptomatic macrovascular disease with the risk of 
dementia diagnosis by year 4 were investigated using age-and sex-adjusted logistic 
regression analyses of presence of dementia on each of the measures of symptomatic 
macrovascular disease. A baseline history of stroke (age- and sex-adjusted OR 1.65, 
95% CI 0.36, 7.57, p=0.52) and angina (age- and sex-adjusted OR 0.68, 95% CI 
0.24, 1.96, p=0.48) were found to be both unrelated to dementia diagnosis, but trends 
were observed for increased prevalence of TIA and MI in the dementia group. Two 
individuals with TIA (6.5%) suffered from dementia compared with 17 individuals 
without TIA (1.6%; age- and sex-adjusted OR 3.89, 95% CI 0.83, 18.23, p=0.09). A 
history of MI was prevalent in 31.6% (n=6) of the subjects in the dementia group 
(31.6%) whereas only 13.8% (n=144) of the remaining sample had suffered MI (age- 
and sex-adjusted OR 2.40, 95% CI 0.85, 6.79, p=0.10). None of the 19 individuals 










Table 6.2: Linear regression analyses of associations between symptomatic macrovascular disease and cognitive function (g and 
individual cognitive tests) at year 4  













 Vs. no stroke Vs. no 
symptomatic 
MVD 
Vs. no TIA Vs. no 
symptomatic 
MVD 
Vs. no MI Vs. no 
symptomatic 
MVD 






























     Multi-adjusted
a
 -0.08 (0.031) -0.12 (0.004) 0.01 (0.75) -0.01 (0.88) -0.03 (0.41) -0.07 (0.07) -0.10 (0.005) -0.12 (0.001) -0.05 (0.17) -0.09 (0.038) 
Faces 
 





















   
    Multi-adjusted
a
 -0.05 (0.17) -0.08 (0.06) -0.04 (0.26) -0.07 (0.12) -0.04 (0.32) -0.07 (0.07) -0.05 (0.19) -0.07 (0.06) -0.06 (0.09) 0.09 (0.025) 
Letter Number    
























 -0.07 (0.06) -0.11 (0.011) -0.03 (0.34) -0.06 (0.18) -0.07 (0.050) -0.10 (0.015) -0.09 (0.016) -0.11 (0.006) -0.06 (0.10) -0.09 (0.032) 
Trail-Making
 





















   Multi-adjusted
a
 0.14 (<0.001) 0.18 (<0.001) 0.01 (0.71) 0.03 (0.47) 0.06 (0.07) 0.10 (0.09) 0.07 (0.07) 0.09 (0.021) 0.05 (0.17) 0.07 (0.08) 
Verbal Fluency
 





















   Multi-adjusted
a
 -0.11 (0.003) -0.15 (0.001) 0.01 (0.83) -0.01 (0.85) -0.03 (0.40) -0.06 (0.12) -0.04 (0.22) -0.07 (0.06) -0.05 (0.16) -0.08 (0.07) 
Digit Symbol Coding
 





















   Multi-adjusted
a
 -0.14 (<0.001) -0.19 (<0.001) -0.01 (0.67) -0.04 (0.37) -0.08 (0.019) -0.12 (0.003) -0.14 (<0.001) -0.15 (<0.001) 0.00 (0.99) -0.03 (0.46) 
Matrix Reasoning
 





















   Multi-adjusted
a
 -0.06 (0.08) -0.09 (0.033) -0.11 (0.002) -0.14 (0.001) -0.09 (0.009) -0.11 (0.005) -0.07 (0.07) -0.08 (0.034) 0.01 (0.81) -0.01 (0.79) 
g 
























 -0.15 (<0.001) -0.21 (<0.001) -0.04 (0.30) -0.07 (0.10) -0.08 (0.017) -0.14 (0.001) -0.11 (0.002) -0.14 (<0.001) -0.05 (0.13) -0.10 (0.020) 
    
+SIMD
b
 -0.13 (<0.001) -0.17 (<0.001) -0.01 (0.71) -0.03 (0.42) -0.05 (0.11) -0.10 (0.014) -0.06 (0.08) -0.09 (0.013) -0.04 (0.21) -0.07 (0.07) 
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Values are standardised β coefficients (p-values). Outcome variables are year 4 follow-up cognitive test scores. Data for individual cognitive tests are non-imputed; 
for g are imputed. Trail-Making Test-B is log-transformed. For each independent variable, comparisons are made with the respective remaining sample and with 
participants free of any symptomatic MVD (n=538).MVD, macrovascular disease; TIA, transient ischaemic attack; MI, myocardial infarction; PAD, peripheral 
arterial disease; SIMD, Scottish Index of Multiple Deprivation (quintiles); Trail-Making, Trail-Making Test-B; Verbal Fluency, Borkowski Verbal Fluency Test; 
Letter Number, Letter Number Sequencing.  
a
adjusted for age, sex, total cholesterol, smoking (current/ex/never), systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit 
b




Table 6.3: Linear regression analyses of associations between symptomatic 
macrovascular disease and reaction time at year 4 
 Simple Reaction Time 
(SRT) mean 
Choice Reaction Time 
(CRT) mean 




















   vs. no symptomatic MVD 0.11 (0.001) 0.11 (0.008) 0.05 (0.32) 0.07 (0.14) 
TIA 









    vs. no symptomatic MVD 0.02 (0.60) 0.02 (0.59) 0.02 (0.70) 0.02 (0.68) 
MI 









   vs. no symptomatic MVD 0.00 (0.93) 0.00 (0.99) 0.01 (0.80) 0.01 (0.87) 
Angina 









    vs. no symptomatic MVD 0.05 (0.17) 0.04 (0.27) 0.08 (0.06) 0.07 (0.09) 
PAD 









    vs. no symptomatic MVD  0.01 (0.87) 0.01 (0.87) 0.09 (0.046) 0.11 (0.010) 
Values are standardised β coefficients (p-values). Simple Reaction Time mean is log-transformed. 
MVD, macrovascular disease; TIA, transient ischaemic attack; MI, myocardial infarction; PAD, 
peripheral arterial disease. 
 a
adjusted for age, sex, total cholesterol, smoking (current/ex/never), systolic blood pressure at clinic 
visit, diastolic blood pressure at clinic.  






6.2.2 Subclinical disease 
The associations of ABI, cIMT and NT-proBNP with level of cognitive function at 
year 4 were investigated using multiple linear regression analyses of g and scores on 
the individual cognitive tests at year 4 on ABI, cIMT and NT-proBNP. Again, initial 
adjustment was made for age and sex, followed by additional adjustment for a range 
of established cardiovascular risk factors, and, for g, for SIMD quintiles measuring 
participants’ socioeconomic status as well as for a prior history of stroke in separate 
steps. Results for g and the majority of the individual tests are shown in Table 6.4, 
with results for reaction time in Table 6.5.   
 
All three subclinical measures were relatively weakly but significantly associated 
with follow-up g. Each standard deviation lower ABI, higher cIMT and higher NT-
proBNP were associated with a 0.12 standard deviation, a 0.09 standard deviation 
and a 0.10 standard deviation lower g, respectively. In terms of individual cognitive 
tests, findings were largely similar for NT-proBNP and ABI, although effect sizes 
overall were somewhat larger for ABI than for NT-proBNP. Higher NT-proBNP and 
lower ABI were both associated with lower verbal memory (Logical Memory) and 
processing speed (Digit Symbol Coding), with some lesser suggestion of additional 
associations with non-verbal and working memory measures (Faces, Letter-Number 
Sequencing; Table 6.4, Table 6.5). Higher cIMT was associated with lower non-
verbal memory (Faces), reasoning (Matrix Reasoning) and particularly with lower 
processing speed as measured by reaction time. For instance, each standard deviation 
increase in cIMT was associated with a 0.12 standard deviation longer mean Choice 
Reaction Time latency. Findings were relatively unchanged following multivariable 
adjustment for conventional vascular risk factors (Table 6.4; Table 6.5), but for g lost 
statistical significance following addition of SIMD as a covariate in the final models 
(Table 6.4). Additional adjustment for stroke further attenuated the strength of 
associations.  
 
The subclinical markers therefore appeared to have a relationship with late-life level 
of cognitive function which was driven by socioeconomic status and by stroke. A 
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contribution of a relatively lower socioeconomic status and/or a prior history of 
stroke to a lower level of late-life cognitive ability as well as to an increased risk of 
concurrent presence of subclinical atherosclerosis may be plausible  
 
In contrast to these significant findings for late life cognitive ability assessed as a 
continuous variable (at least in largely unadjusted analyses), the subclinical markers 
of macrovascular disease were unrelated to dementia diagnosis. Subjects  with 
dementia had similar NT-proBNP (age- and sex-adjusted geometric means 92.9 
pg/ml, 95% CI 54.2, 158.9 versus 81.3 pg/ml, 95% CI 75.8, 87.3, p=0.63), ABI (age- 
and sex-adjusted mean 0.95, 95% CI 0.85, 1.04 versus 0.98, 95% CI 0.97, 0.99; 
p=0.45) and cIMT (age- and sex-adjusted mean 0.97 mm, 95% CI 0.88, 1.06 versus 
1.00 mm, 95% CI 0.98, 1.01; p=0.58) at baseline compared with participants who 






















Table 6.4: Linear regression analyses of associations between measures of 
subclinical macrovascular disease and late-life cognitive function (g and 
individual cognitive tests) at year 4  













   Multi-adjusted
a
 -0.09 (0.010) 0.11 (0.003) -0.05 (0.22) 
Faces 







   Multi-adjusted
a
 -0.06 (0.11) 0.06 (0.13) -0.08 (0.025) 
Letter Number Sequencing  







   Multi-adjusted
a
 -0.06 (0.09) 0.05 (0.22) 0.02 (0.70) 
Trail-Making  







    Multi-adjusted
a
 0.06 (0.09) -0.09 (0.021) 0.05 (0.15) 
Verbal Fluency  







    Multi-adjusted
a
 -0.06 (0.09) 0.03 (0.49) -0.03 (0.47) 
Digit Symbol Coding  







   Multi-adjusted
a
 -0.07 (0.07) 0.10 (0.006) -0.04 (0.31) 
Matrix Reasoning  







   Multi-adjusted
a
 -0.03 (0.42) 0.03 (0.38) -0.08 (0.026) 
g  







   Multi-adjusted
a
 -0.09 (0.012) 0.10 (0.007) -0.08 (0.043) 
   +SIMD
b
 -0.06 (0.07) 0.05 (0.13) -0.07 (0.07) 
   +stroke
c
 -0.05 (0.14) 0.04 (0.30) -0.05 (0.13) 
Values are standardised β coefficients (p-values). Outcome variables are year 4 follow-up 
cognitive test scores. Data for individual cognitive tests are non-imputed; for g are imputed. 
Trail-Making Test-B is log-transformed. NT-proBNP, N-terminal pro-brain natriuretic 
peptide; Carotid IMT, carotid intima-media thickness; SIMD, Scottish Index of Multiple 
Deprivation (quintiles). Trail-Making, Trail-Making Test-B; Verbal Fluency, Borkowski 
Verbal Fluency Test. 
a
adjusted for age, sex, total cholesterol, smoking (current/ex/never), systolic blood pressure at 
clinic visit, diastolic blood pressure at clinic visit. 
b
adjusted for age, sex, total cholesterol, smoking (current/ex/never), systolic blood pressure at 
clinic visit, diastolic blood pressure at clinic visit, SIMD (quintiles). 
c
adjusted for age, sex, total cholesterol, smoking (current/ex/never), systolic blood pressure at 
clinic visit, diastolic blood pressure at clinic visit, SIMD (quintiles), stroke 









Table 6.5: Linear regression analyses of associations between  measures of 







Simple Reaction Time (SRT) 
mean 







   Multi-adjusted
a
 -0.01 (0.75) -0.06 (0.11) 0.09 (0.016) 
Choice Reaction Time (CRT) 
mean  







   Multi-adjusted
a
 0.02 (0.60) -0.06 (0.11) 0.10 (0.008) 
Values are standardised β coefficients (p-values). Simple Reaction Time mean is log-
transformed. NT-proBNP, N-terminal pro-brain natriuretic peptide; Carotid IMT, carotid intima-
media thickness;  
a
adjusted for age, sex, total cholesterol, smoking (current/ex/never), systolic blood pressure at 
clinic visit, diastolic blood pressure at clinic visit. NT-proBNP max. n=1050; ABI max. n=1033; 




6.3 Macrovascular disease and estimated lifetime cognitive 
change 
6.3.1 Symptomatic disease  
The relationship between symptomatic macrovascular disease and the estimated 
lifetime cognitive change between young adulthood and later life was also 
investigated. For this purpose, multiple linear regression analyses of g and scores on 
the individual cognitive tests was performed on the each of the measures of 
symptomatic macrovascular disease, with initial adjustment for age, sex and 
estimated peak pre-morbid ability (MHVS). In a subsequent step, conventional 
vascular risk factors were added as covariates into the model, before, for analyses of 
g, SIMD representing socioeconomic status was additionally controlled for. The 
results from analyses of g and a majority of individual cognitive tests are shown in 
Table 6.6 and for reaction time measures are shown in Table 6.7. All symptomatic 
disease groups were relatively unrelated to lifetime cognitive change; significance at 
the 5% level was typically restricted to a small number of individual cognitive tests 
rather than g and effect sizes were relatively small throughout. An exception to this 
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was stroke, which was consistently associated with a steeper decline between peak 
pre-morbid ability (which was presumably the level of ability prior to stroke) and 
post-stroke late-life cognitive function, with effect sizes which appeared somewhat 
reduced compared with the analyses of year 4 level of cognitive function (Table 6.2; 
Table 6.3). For instance, a history of stroke was associated with a 0.12 standard 
deviation lower g with age, sex and estimated peak pre-morbid ability held constant. 
Overall, the finding shows that even several (at least four) years following the event, 
potential post-stroke cognitive recovery had not achieved a level of cognitive 
function which would be expected given an individual’s pre-morbid ability in young 
adulthood. Multivariable adjustment for conventional vascular risk factors or for 






Table 6.6: Linear regression analyses of associations between symptomatic macrovascular disease and late-life cognitive 
















 Vs. no stroke Vs. no 
symptomatic 
MVD 
Vs. no TIA Vs. no 
symptomatic 
MVD 
Vs. no MI Vs. no 
symptomatic 
MVD 
































    Multi-adjusted
b
 -0.05 (0.15) -0.06 (0.10) 0.03 (0.31) 0.03 (0.40) -0.01 (0.81) -0.02 (0.54) -0.03 (0.43) -0.03 (0.32) -0.04 (0.27) -0.05 (0.18) 
Faces 
 























   
   Multi-adjusted
b
 -0.03 (0.41) -0.04 (0.29) -0.04 (0.29) -0.05 (0.20) -0.02 (0.60) -0.04 (0.33) 0.00 (0.91) -0.02 (0.59) -0.06 (0.09) -0.08 (0.06) 
Letter Number
 























   
  Multi-adjusted
b
 -0.05 (0.15) -0.07 (0.10) -0.01 (0.69) -0.02 (0.62) -0.05 (0.15) -0.05 (0.18) -0.02 (0.66) -0.02 (0.50) -0.03 (0.38) -0.04 (0.33) 
Trail-Making
 























    Multi-adjusted
b
 0.12 (<0.001) 0.14 (<0.001) 0.00 (0.97) 0.00 (0.95) 0.04 (0.26) 0.05 (0.20) 0.00 (0.96) 0.02 (0.62) 0.03 (0.32) 0.04 (0.31) 
Verbal Fluency 























    Multi-adjusted
b



























   Multi-adjusted
b
 -0.12 (<0.001) -0.14 (<0.001) 0.01 (0.89) 0.00 (0.97) -005 (0.13) -0.06 (0.10) -0.07 (0.025) -0.08 (0.020) 0.02 (0.64) 0.01 (0.88) 
Matrix Reasoning
 























   Multi-adjusted
b
 -0.03 (0.36) -0.03 (0.38) -0.08 (0.009) -0.09 (0.012) -0.08 (0.017) -0.07 (0.052) 0.01 (0.77) 0.01 (0.89) 0.02 (0.57) 0.02 (0.61) 
g 


























 -0.12 (<0.001) -0.14 (<0.001) -0.02 (0.58) -0.03 (0.44) -0.05 (0.10) -0.06 (0.054) -0.02 (0.63) -0.03 (0.28) -0.03 (0.27) -0.04 (0.20) 
   +SIMD
c
 -0.11 (<0.001) -0.13 (<0.001) -0.01 (0.75) -0.02 (0.63) -0.04 (0.19) -0.05 (0.12) 0.00 (0.95) -0.02 (0.60) -0.03 (0.33) -0.04 (0.28) 
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Values are standardised β coefficients (p-values). Outcome variables are year 4 follow-up cognitive test scores. Data for individual cognitive tests are non-
imputed; for g are imputed. Trail-Making Test-B is log-transformed.  For each independent variable, comparisons are made with the respective remaining sample 
and with participants free of any symptomatic MVD (n=538). MVD, macrovascular disease; TIA, transient ischaemic attack; MI, myocardial infarction; PAD, 
peripheral arterial disease; SIMD, Scottish Index of Multiple Deprivation (quintiles); Trail-Making, Trail-Making Test-B; Verbal Fluency, Borkowski Verbal 
Fluency Test; MHVS, Mill-Hill Vocabulary Test; Letter Number, Letter Number Sequencing. 
a
adjusted for age, sex, baseline MHVS. 
b
adjusted models adjusted for age, sex, baseline MHVS, total cholesterol, smoking (current/ex/never), systolic blood pressure at clinic visit, diastolic blood 
pressure at clinic visit. 
c




Table 6.7: Linear regression analyses of associations between symptomatic 
macrovascular disease and late-life reaction time at year 4 adjusted for 
estimated peak pre-morbid ability (MHVS)  
 Simple Reaction Time 
(SRT) mean 
 


























   vs. no symptomatic  
   MVD  
0.09 (0.039) 0.09 (0.039) 0.04 (0.36) 0.04 (0.35) 
TIA  









   vs. no symptomatic  
   MVD  
0.01 (0.74) 0.02 (0.71) 0.01 (0.83) 0.01 (0.74) 
MI  









   vs. no symptomatic  
   MVD  
-0.02 (0.60) -0.02 (0.55) -0.03 (0.55) -0.02 (0.66 
Angina  









   vs. no symptomatic  
   MVD  
0.01 (0.85) 0.00 (0.97) 0.04 (0.36) 0.03 (0.41) 
PAD  









   vs. no symptomatic     
   MVD  
-0.01 (0.88) 0.00 (0.92) 0.07 (0.08) 0.08 (0.052) 
Values are standardised β coefficients (p-values). Outcome variables are year 4 follow-up 
reaction time scores. Simple Reaction Time mean is log-transformed. MVD, macrovascular 
disease; TIA, transient ischaemic attack; MI, myocardial infarction; PAD, peripheral arterial 
disease.   
a
adjusted for age, sex, baseline MHVS. 
b
adjusted models adjusted for age, sex, baseline MHVS, 
total cholesterol, smoking (current/ex/never), systolic blood pressure at clinic visit, diastolic 
blood pressure at clinic visit.  






6.3.2  Subclinical disease 
Multiple linear regression analyses of g and of scores on the individual cognitive 
tests at year 4 on ABI, cIMT and NT-proBNP were performed. Each initial model 
controlled for age, sex and baseline MHVS (estimating peak pre-morbid ability) to 
represent associations of the respective predictor with estimated lifetime cognitive 
change. A second model additionally controlled for conventional vascular risk 
factors. For g, two further models controlled for SIMD and for stroke in separate 
steps in order to show potential confounding of overall findings by socioeconomic 
status or by stroke. Table 6.8 shows the results for g and a majority of individual 
cognitive tests and Table 6.9 shows the results for the reaction time measures. 
 
Increased severity of subclinical macrovascular disease as measured by ABI, cIMT 
and NT-proBNP was associated with steeper estimated lifetime decline in g, with the 
specific cognitive domains as well as relative effect sizes mirroring those which had 
been identified as significant for the level of cognitive function at year 4 (Table 6.4; 
Table 6.5). The finding shows that late-life atherosclerosis was linked to an 
accelerated cognitive decline between younger adulthood and older age. Carotid IMT 
stood out as the only predictor of estimated lifetime decline in reaction time (Table 
6.5). The association had the relatively largest effect size amongst all analyses of the 
subclinical markers and the estimated lifetime change in the various cognitive tests. 
Each standard deviation increase in cIMT was associated with a 0.12 standard 
deviation increase in mean Choice Reaction Time with age, sex and estimated peak 
pre-morbid ability (MHVS) held constant. Again, the results were largely unchanged 
when vascular risk factors were controlled for. Associations with g remained 
statistically significant for NT-proBNP and cIMT, but not for ABI, following 
adjustment for SIMD; additional adjustment for stroke then rendered all findings 
except that for cIMT statistically non-significant (Table 6.8).- Overall, the 
association of late-life atherosclerosis of the carotid artery but not of the periphery or 
of the heart appeared to be related to the decline between estimated peak ability in 





Table 6.8: Linear regression analyses of associations between subclinical 
macrovascular disease and late-life cognitive function at year 4 (g and 
individual cognitive tests) adjusted for estimated peak pre-morbid ability 
(MHVS) 

















 -0.08 (0.014) 0.09 (0.007) -0.06 (0.08) 
Faces 









   Multi-adjusted
b
 -0.05 (0.17) 0.04 (0.24) -0.09 (0.011) 
Letter Number Sequencing  









   Multi-adjusted
b
 -0.05 (0.15) 0.02 (0.58) 0.00 (0.97) 
Trail-Making  









   Multi-adjusted
b
 0.05 (0.16) -0.06 (0.07) 0.06 (0.08) 
Verbal Fluency  









   Multi-adjusted
b
 -0.05 (0.14) 0.00 (0.92) -0.04 (0.26) 
Digit Symbol Coding  











 -0.05 (0.14) 0.08 (0.014) -0.05 (0.17) 
Matrix Reasoning  









   Multi-adjusted
b
 -0.02 (0.52) 0.01 (0.81) -0.10 (0.005) 
g  









   Multi-adjusted
b
 -0.07 (0.017) 0.07 (0.020) -0.09 (0.005) 
   +SIMD
c
 -0.06 (0.038) 0.04 (0.20) -0.08 (0.006) 
   +stroke
d
 -0.05 (0.08) 0.02 (0.42) -0.07 (0.014) 
Values are standardised β coefficients (p-values). Outcome variables are year 4 follow-up 
cognitive test scores. Data for individual cognitive tests are non-imputed; for g are imputed. 
Trail-Making Test-B is log-transformed. NT-proBNP, N-terminal pro-brain natriuretic peptide; 
Carotid IMT, carotid intima-media thickness; SIMD, Scottish Index of Multiple Deprivation 
(quintiles); Trail-Making, Trail-Making Test-B; Verbal Fluency, Borkowski Verbal Fluency 
Test. 
a
adjusted for age, sex, baseline MHVS. 
b
adjusted models adjusted for age, sex, baseline MHVS, total cholesterol, smoking 
(current/ex/never), systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit. 
c
adjusted for age, sex, baseline MHVS, total cholesterol, smoking (current/ex/never), systolic 
blood pressure at clinic visit, diastolic blood pressure at clinic visit, SIMD (quintiles). 
d
adjusted for age, sex, baseline MHVS, total cholesterol, smoking (current/ex/never), systolic 
blood pressure at clinic visit, diastolic blood pressure at clinic visit, SIMD (quintiles), stroke 





Table 6.9: Linear regression analyses of associations between subclinical 
macrovascular disease and late-life reaction time at year 4 adjusted for 
estimated peak pre-morbid ability (MHVS) 




Simple Reaction Time mean 









   Multi-adjusted
b
 -0.03 (0.47) -0.05 (0.16) 0.09 (0.012) 
Choice Reaction Time mean  









   Multi-adjusted
b
 0.01 (0.78) -0.04 (0.29) 0.11 (0.005) 
Values are standardised β coefficients (p-values). Outcome variables are year 4 follow-up 
reaction time scores. Simple Reaction Time mean is log-transformed. NT-proBNP, N-terminal 
pro-brain natriuretic peptide; carotid IMT, carotid intima-media thickness. 
a
adjusted for age, sex, baseline MHVS. 
b
adjusted for age, sex, baseline MHVS, total cholesterol, smoking (current/ex/never), systolic 
blood pressure at clinic visit, diastolic blood pressure at clinic visit.  




6.4 Macrovascular disease and four-year cognitive change 
6.4.1 Symptomatic disease 
Multiple linear regression models of follow-up g and scores on the seven cognitive 
tests contributing to g on each of the macrovascular predictors with adjustment for 
the respective baseline scores tested associations between symptomatic 
macrovascular disease and the change in cognitive function between baseline and 
year 4. Because participants’ change in cognitive function between baseline and year 
4 follow-up is the main outcome of interest in this thesis, unadjusted associations of 
each of the macrovascular disease categories (compared with all remaining 
participants) with the four-year change in g are illustrated in Figure 6.2 to 6.6. Note 
that comparison of observation between graphs is not possible due to varying scales 
used on the Y-axis.  
 
 
Figure 6.2: Mean follow-up g adjusted for baseline g in subjects with angina and 




Figure 6.3: Mean follow-up g adjusted for baseline g in subjects with a baseline 




Figure 6.4: Mean follow-up g adjusted for baseline g in subjects with a history 






Figure 6.5: Mean follow-up g adjusted for baseline g in subjects with a history 
of TIA and those without a history of TIA at baseline (error bars show 95% CI) 
 
 
Figure 6.6: Mean follow-up g adjusted for baseline g in subjects with 
claudication and those without claudication at baseline (error bars show 95% 
CI) 
 
In linear regression models exploring these observations, an initial model controlled 
for age and sex, before conventional vascular risk factors were entered as covariates. 
Baseline MHVS was controlled for in a next model with the aim to show the 
independence of findings from individual differences in peak pre-morbid cognitive 
ability. For g, a final model then additionally controlled for SIMD measuring 
participants’ socioeconomic status. Analyses compared the symptomatic disease 
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variables with the respective remaining sample and with participants free of any 
macrovascular disease (n=538). Results are shown in Table 6.10.  
 
Similar to the analyses of estimated lifetime cognitive change presented in the 
previous section (Table 6.6, Table 6.7), stroke was the only symptomatic disease 
group consistently associated with four-year cognitive change in later life. The 
remaining symptomatic disease groups were only occasionally significantly related 
to declines on individual cognitive tests and with relatively limited effect sizes; 
findings for PAD were consistently non-significant. In addition to g, stroke at 
baseline appeared to accelerate particularly the decline in processing speed (Digit 
Symbol Coding) and executive function (Trail-Making Test-B). A majority of the 
significant findings for stroke were not attenuated following adjustment for vascular 
risk factors. 
 
Although data on the specific time at which the cerebral infarction occurred in 
subjects identified to have a history of stroke, it appears to be likely that it had 
occurred months or years prior to the baseline clinic, considering that clinic 
attendance was required for inclusion in the study. The finding on first inspection 
therefore suggests that cerebral infarction has lasting effects on subsequent 
trajectories of cognitive ageing. The effect sizes, however, were notably smaller 
compared with the associations of stroke with estimated lifetime cognitive decline. 
For instance, stroke was associated with a 0.07 standard deviation lower score on 
year 4 g with age, sex and baseline g held constant (Table 6.10), whereas it was 
associated with a 0.12 standard deviation lower g with age, sex and MHVS held 
constant (Table 6.6). Some confounding by individual differences in pre-morbid 
ability and by socioeconomic status was also indicated by an attenuation of the 
results following adjustment for MHVS and for SIMD, overall demonstrating that 
lasting effects of stroke on post-stroke cognitive change which were independent of 







Table 6.10: Linear regression analyses of associations between symptomatic macrovascular disease and four-year cognitive 
















 Vs. no stroke Vs. no 
symptomatic 
MVD 
Vs. no TIA Vs. no 
symptomatic 
MVD 



































    
Multi-adjusted
b
 -0.03 (0.28) -0.06 (0.07) 0.01 (0.84) -0.01 (0.84) -0.03 (0.24) -0.06 (0.06) -0.06 (0.043) -0.07 (0.014) -0.05 (0.10) -0.07 (0.024) 
    
+MHVS
c
 -0.02 (0.42) -0.04 (0.21) 0.02 (0.41) 0.02 (0.56) -0.02 (0.47) -0.03 (0.28) -0.02 (0.40) -0.03 (0.25) -0.04 (0.18) -0.05 (0.10) 
Faces 























    
Multi-adjusted
b
 -0.01 (0.76) -0.02 (0.60) -0.04 (0.21) -0.05 (0.13) 0.01 (0.84) -0.02 (0.60) -0.02 (0.43) -0.04 (0.23) -0.04 (0.13) -0.06 (0.07) 
    
+MHVS
c
 0.00 (0.98) 0.00 (0.91) -0.03 (0.25) -0.04 (0.20) 0.01 (0.69) 0.00 (0.89) 0.00 (0.93) -0.01 (0.68) -0.04 (0.13) -0.04 (0.13) 
Letter Number 























      
Multi-adjusted
b
 -0.03 (0.29) -0.06 (0.12) -0.01 (0.65) -0.03 (0.46) -0.07 (0.031) -0.08 (0029) -0.05 (0.12) -0.06 (0.07) -0.04 (0.23) -0.06 (0.13) 
   +MHVS
c
 -0.03 (0.35) -0.04 (0.26) -0.01 (0.77) -0.01 (0.71) -0.05 (0.09) -0.05 (0.16) -0.01 (0.66) -0.02 (0.53) -0.01 (0.63) -0.02 (0.58) 
Trail-Making    























   Multi-adjusted
b
 0.06 (0.032) 0.08 (0.015) 0.01 (0.74) 0.02 (0.58) 0.03 (0.24) 0.05 (0.10) 0.03 (0.19) 0.05 (0.10) 0.01 (0.85) 0.02 (0.62) 
   +MHVS
c
 0.05 (0.037) 0.07 (0.034) 0.00 (0.96) 0.00 (0.98) 0.02 (0.37) 0.03 (0.29) 0.01 (0.68) 0.02 (0.48) 0.00 (0.91) 0.01 (0.83) 
Verbal Fluency  























    Multi-adjusted
b
 -0.04 (0.07) -0.05 (0.031) 0.00 (0.91) -0.01 (0.64) -0.01 (0.68) -0.02 (0.42) -0.03 (0.14) -0.04 (0.08) -0.01 (0.62) -0.02 (0.38) 
    +MHVS
c
 -0.03 (0.10) -0.05 (0.07) 0.01 (0.78) 0.00 (0.93) -0.01 (0.82) -0.01 (0.68) -0.02 (0.42) -0.02 (0.30) -0.01 (0.55) -0.02 (0.43) 
Digit Symbol Coding 























   Multi-adjusted
b
 -0.06 (0.012) -0.07 (0.014) -0.01 (0.72) -0.01 (0.63) -0.02 (0.50) -0.03 (0.35) -0.06 (0.020) -0.06 (0.026) 0.03 (0.25) 0.02 (0.43) 
   +MHVS
c
 -0.06 (0.015) -0.06 (0.028) 0.01 (0.83) 0.01 (0.84) -0.01 (0.72) -0.01 (0.70) -0.04 (0.12) -0.04 (0.17) 0.03 (0.19) 0.03 (0.26) 
Matrix Reasoning  

























    Multi-adjusted
b
 -0.03 (0.19) -0.04 (0.23) -0.08 (0.002) -0.10 (0.002) -0.05 (0.08) -0.04 (0.19) 0.00 (0.93) -0.01 (0.81) 0.01 (0.66) 0.01 (0.74) 
   +MHVS
c
 -0.02 (0.35) -0.02 (0.52) -0.07 (0.005) -0.08 (0.009) -0.05 (0.07) -0.03 (0.30) 0.03 (0.36) 0.02 (0.40) 0.02 (0.50) 0.03 (0.43) 
g 























   Multi-adjusted
b
 -0.07 (0.037) -0.10 (0.016) -0.05 (0.18) -0.07 (0.10) -0.04 (0.28) -0.06 (0.16) -0.04 (0.29) -0.06 (0.14) -0.01 (0.70) -0.03 (0.45) 
   +MHVS
c
 -0.06 (0.07) -0.08 (0.07) -0.03 (0.39) -0.04 (0.33) -0.03 (0.44) -0.03 (0.47) -0.01 (0.74) -0.02 (0.54) 0.01 (0.83) 0.00 (0.97) 
   +SIMD
d
 -0.06 (0.10) -0.07 (0.11) -0.02 (0.49) -0.03 (0.45) -0.02 (0.62) -0.02 (0.66) 0.00 (0.94) -0.01 (0.82) 0.01 (0.76) 0.01 (0.85) 
Values are standardised β coefficients (p-values). Outcome variables are year 4 follow-up cognitive test scores. Data for individual cognitive tests are non-
imputed; for g are imputed. Trail-Making Test-B is log-transformed.  For each independent variable, comparisons are made with the respective remaining 
sample and with participants free of any symptomatic MVD (n=538). MVD, macrovascular disease; TIA, transient ischaemic attack; MI, myocardial 
infarction; PAD, peripheral arterial disease; MHVS, Mill-Hill Vocabulary Scale; Trail-Making,  Trail-Making Test-B; Verbal Fluency, Borkowski Verbal 
Fluency Test; Letter Number, Letter Number Sequencing.  
a
adjusted for age, sex, baseline scores.  
b
adjusted models adjusted for age, sex, baseline scores, total cholesterol, smoking (current/ex/never), systolic blood pressure at clinic visit, diastolic blood 
pressure at clinic visit. 
c
adjusted for age, sex, baseline scores, total cholesterol, smoking (current/ex/never), systolic blood pressure at clinic visit, diastolic blood pressure at clinic 
visit, baseline MHVS.  
d
adjusted for age, sex, baseline g, total cholesterol, smoking (current/ex/never), systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, 







6.4.2 Subclinical disease 
The analyses of four-year cognitive change for the subclinical markers of 
macrovascular disease were also performed using multiple regression models of 
follow-up g and scores on the individual cognitive tests contributing to g on ABI, 
NT-proBNP and cIMT. Unadjusted associations are illustrated in Figures 6.7 to 6.9.  
 
 
Figure 6.7: Scatterplot illustrating association of baseline NT-proBNP (prior to 
log-transformation) with four-year change in g 
 
Figure 6.8: Scatterplot illustrating association of baseline ABI with four-year 





Figure 6.9: Scatterplot illustrating association of cIMT measured at year 1 with 
change in g between baseline and year 4 
 
In analyses exploring the observation of associations based on graphical presentation, 
the respective initial linear regression model controlled for age and sex; conventional 
vascular risk factors and estimated peak pre-morbid ability (baseline MHVS) were 
subsequently controlled for in two separate steps, with additional adjustment for 
socioeconomic status (SIMD) and stroke in separate steps for the analyses of g only. 
Results of these analyses are shown in Table 6.11. Increased severity of subclinical 
macrovascular disease (as measured by ABI, NT-proBNP and cIMT) predicted an 
accelerated decline in g between baseline and year 4. Effect sizes were similar for 
ABI and NT-proBNP, and relatively largest for cIMT. Higher cIMT was associated 
with steeper decline on a majority of cognitive tests, some of which (verbal memory, 
processing speed) were shared with ABI and NT-proBNP. Additionally, higher cIMT 
was also linked to steeper decline in non-verbal memory (Faces) and reasoning 
(Matrix Reasoning). Higher NT-proBNP was further associated with steeper decline 
in working memory (Letter-Number Sequencing) and in executive function measured 
by verbal fluency - domains which it had only marginally been linked to in analyses 
of year 4 level of cognitive function (Table 6.4) and of estimated lifetime decline 




Compared with the findings for estimated lifetime cognitive change (Table 6.8; 
Table 6.9), the strength of associations was increased particularly for NT-proBNP 
and cIMT. For instance, each standard deviation increase in baseline cIMT was 
associated with a 0.15 lower follow-up g with age, sex and baseline g held constant. 
All associations survived multivariable adjustment for vascular risk factors and were 
largely unaffected by adjustment for MHVS or, for analyses of g, by additional 
adjustment for SIMD or for stroke (Table 6.11) This suggests that individuals with 
greater atherosclerotic burden at baseline experienced a steeper subsequent cognitive 
decline independent of potential confounding by a prior history of stroke, by 
individual differences in peak pre-morbid ability or by socioeconomic status. 
 
Table 6.11: Linear regression analyses of associations between subclinical 
macrovascular disease and four-year cognitive change (g and individual 
cognitive tests) 













     
Multi-adjusted
b -0.06 (0.028) 0.07 (0.021) -0.05 (0.08) 
    
+MHVS
c -0.06 (0.030) 0.06 (0.027) -0.06 (0.040) 
Faces 








    
Multi-adjusted
b -0.04 (0.23) 0.03 (0.25) -0.08 (0.011) 
    
+MHVS
c -0.03 (0.27) 0.03 (0.35) -0.08 (0.006) 
Letter Number Sequencing 








      
Multi-adjusted
b
  -0.07 (0.027) 0.04 (0.23) -0.01 (0.83) 
   +MHVS
c -0.06 (0.06) 0.02 (0.46) -0.01 (0.69) 
Trail-Making  








   Multi-adjusted
b 0.03 (0.23) -0.06 (0.037) 0.04 (0.14) 
   +MHVS
c 0.03 (0.32) -0.05 (0.06) 0.05 (0.10) 
Verbal Fluency  








    Multi-adjusted
b -0.07 (0.001) 0.03 (0.16) -0.01 (0.78) 
    +MHVS
c -0.07 (0.001) 0.02 (0.28) -0.01 (0.72) 
Digit Symbol Coding 








   Multi-adjusted
b -0.04 (0.10) 0.05 (0.038) -0.07 (0.006) 
  +MHVS
c -0.04 (0.14) 0.05 (0.043) -0.07 (0.005) 
Matrix Reasoning     










    Multi-adjusted
b -0.01 (0.79) 0.01 (0.81) -0.08 (0.005) 
   +MHVS
c -0.01 (0.79) 0.00 (0.94) -0.09 (0.002) 
g 








   Multi-adjusted
b -0.10 (0.005) 0.10 (0.005) -0.12 (0.001) 
   +MHVS
c -0.10 (0.008) 0.09 (0.018) -0.13 (0.001) 
   +SIMD
d
 -0.09 (0.016) 0.07 (0.046) -0.13 (0.001) 
   +stroke
e
 -0.08 (0.022) 0.06 (0.06) -0.12 (0.001) 
Values are standardised β coefficients (p-values). Outcome variables are year 4 follow-up 
cognitive test scores. Data for individual cognitive tests are non-imputed; for g are imputed. 
Trail-Making Test-B is log-transformed. NT-proBNP, N-terminal pro-brain natriuretic peptide; 
Carotid IMT, carotid intima-media thickness;  Trail-Making, Trail-Making Test-B; Verbal 
Fluency, Borkowski Verbal Fluency Test; MHVS, Mill-Hill Vocabulary Scale.  
a
adjusted for age, sex, baseline scores.  
b
adjusted models adjusted for age, sex, baseline scores, total cholesterol, smoking 
(current/ex/never), systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit. 
c
adjusted for age, sex, baseline scores, total cholesterol, smoking (current/ex/never), systolic 
blood pressure at clinic visit, diastolic blood pressure at clinic visit, baseline MHVS.  
d
adjusted for age, sex, baseline g, total cholesterol, smoking (current/ex/never), systolic blood 
pressure at clinic visit, diastolic blood pressure at clinic visit, baseline MHVS, SIMD (quintiles) 
e
adjusted for age, sex, baseline g, total cholesterol, smoking (current/ex/never), systolic blood 
pressure at clinic visit, diastolic blood pressure at clinic visit, baseline MHVS, SIMD (quintiles), 
stroke 




To summarise, effect sizes were relatively small throughout the statistically 
significant findings presented in this chapter. A lower peak pre-morbid ability in 
young adulthood (which was estimated using a test of vocabulary) was associated 
with an increased risk of symptomatic and subclinical macrovascular disease at the 
baseline assessment of the ET2DS, although individual differences in socioeconomic 
status appeared to play a confounding role in this association.  
 
All of the baseline macrovascular predictors (except TIA) were associated with a 
lower level of cognitive function at year 4, with significant findings most frequently 
observed for measures of processing speed and the memory domain.  
 
None of the associations between symptomatic disease manifesting distant from the 
brain and cognitive function at year 4 survived the adjustment for an estimate of peak 
pre-morbid ability. These predictors were also overall unrelated to late-life cognitive 
trajectories. In contrast, a history of stroke stood out as associated with steeper 
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estimated lifetime decline independently of socioeconomic status. Yet, the finding of 
stroke associations with a steeper four-year decline appeared to be partly driven by 
estimated peak pre-morbid ability and by socioeconomic status. It therefore appears 
that the cerebrovascular accident may have relatively more severely affected 
cognitive function between pre-stroke to post-stroke estimations/assessments 
irrespective of the participant’s socioeconomic status, with a relatively weaker role in 
the determination of post-stroke cognitive change. It may be the case that participants 
with a relatively lower peak pre-morbid ability in young adulthood and those with a 
relatively lower socioeconomic status were at increased risk of later stroke and also 
experienced an accelerated late-life cognitive decline relative to the remaining 
sample. 
 
Although the comparison of effect sizes between the symptomatic (categorical) and 
subclinical (continuous) disease variables is not informative, the overall patterns of 
findings may be compared between the two groups of predictors. Contrasting the 
results for stroke, associations of the three subclinical markers of macrovascular 
disease were, relatively independently of socioeconomic status, overall stronger for 
analyses of four-year cognitive change than of estimated lifetime change. Moreover, 
only the latter association was confounded by stroke, further demonstrating that the 
finding of associations of the subclinical disease markers with four-year cognitive 
change is relatively stronger and more informative with respect to an individual 
patient’s risk of cognitive impairment. A greater atherosclerotic burden of the body 
at baseline preceded an accelerated cognitive decline and did so independent of all 








Chapter 7: Results III: Severe hypoglycaemia and 
cognition 
7.1 Overview and statistical methods 
A number of investigations are presented in this chapter: 
1. The groups reporting severe hypoglycaemia (SH) at baseline or at year 4 and 
the respective remaining populations are compared in terms of demographics 
and clinical characteristics. 
2. Results from the prospective 6-month survey of SH administered following 
the year 1 clinic are compared with the self-report of incident SH occurring 
between baseline and year 4 with the aim to evaluate the overall validity of 
the self-report measure in the ET2DS. 
3. Hypoglycaemia associations with cognition function are investigated with SH 
treated both as a potential risk factor for poorer cognitive outcome, and as a 
potential consequence of poorer prior cognitive ability. In order to determine 
the independence of the findings from these analyses from potential 
influences by subjects with dementia diagnosis, the analyses of SH as a 
potential consequence of poorer cognitive ability and as a risk factor for 
poorer cognitive outcome (which was restricted to analyses of the four-year 
change in cognitive function – the main outcome of interest), were repeated 
with exclusion of dementia cases. Results from these analyses are shown in 
Appendix D; none of the findings reported in this chapter were altered in 









7.2 Risk factor profiles in subjects reporting hypoglycaemia 
7.2.1 Risk factor associations with a lifetime history of severe 
hypoglycaemia 
Individuals with a lifetime history of SH reported at baseline had longer disease 
duration, and were more likely to be female, on insulin treatment and to have lower 
blood pressure and poorer glycaemic control (Table 7.1). They also had increased 
prevalence of macro- and microvascular disease at baseline. Amongst the 
macrovascular disease variables, prevalence particularly of coronary heart disease 
appeared to be increased in the group with a baseline history of SH. Mean age, mean 
cholesterol, prevalence of symptomatic peripheral arterial disease and smoking 
history appeared to be equivalent in both groups. There was lower MMSE in 
participants with a baseline history of SH (geometric means 28.3 ± 1.1 versus 27.9 ± 
1.1; p=0.023). History of SH was unrelated to the risk of dementia diagnosis by year 




















Table 7.1: Baseline risk factors in individuals with a lifetime history of severe 
hypoglycaemia reported at baseline  












Age (years) 67.9 ± 4.2 67.9 ± 4.4 0.98 
Male sex (%) 491 (52.9) 46 (41.1) 0.018 
Duration of diabetes 
(years) 
6 (3 – 10) 10 (6 – 15) <0.001 
Current treatment 
    Insulin +/-tablets    
    Tablets alone  










HbA1c (%) 7.36 ± 1.06 7.66 ± 1.31 0.007 
Systolic bp (mmHg) 133.9 ± 16.3 128.8 ± 17.23 0.002 
Diastolic bp (mmHg) 69.5 ± 8.9  65.8 ± 9.4 <0.001 
Macrovascular disease  
     Myocardial infarction 
     Angina  
     Stroke 
     TIA 
     Claudication 
























4.32 ± 0.90 4.16 ± 0.84 0.09 
HDL cholesterol (mmol/L) 1.29 ± 0.36 1.29 ± 0.38 0.97 
Smoking 
   Current 
   Ex-smoker 











   No 
   Mild 










Values are means ± SD, medians (interquartile range) or n (%). Log-transformed values were 
used for analyses of duration of diabetes. TIA, transient ischaemic attack; ‘any MVD’, any 
symptomatic macrovascular disease; DR, diabetic retinopathy; HDL, high-density lipoprotein; 







7.2.2 Risk factors associations with incident severe hypoglycaemia 
The baseline characteristics associated with incident SH were found to be very 
similar to those identified to be associated with a baseline history of SH (Table 7.2), 
which may be attributed to large overlaps in participants between the two groups (27 
of the 85 participants in the incident SH group had also had a lifetime history of SH 
at baseline). Subjects reporting incident SH tended to be female, had longer duration 
of diabetes, were likely to be on insulin treatment, had poorer glycaemic control, 
lower blood pressure and increased prevalence of TIA at baseline. Contrasting the 
findings for a baseline history of SH, incident SH was unrelated to the remaining 
macrovascular disease categories or to microvascular disease at baseline. Patients 
with incident SH also tended be younger and were likely to be smoking at baseline, 
despite age and smoking not being associated with a baseline history of SH (Table 
7.1). Baseline MMSE scores were similar for the incident SH group and the 





















Table 7.2: Baseline risk factors in individuals with incident severe 
hypoglycaemia  










Age (years) 67.8 ± 4.2 66.7 ± 4.1 0.022 
Male sex (%) 393 (53.8) 32 (37.6) 0.005 
Duration of diabetes 
(years) 
6 (3 – 10) 10 (5 – 15) <0.001 
Current treatment 
    Insulin +/-tablets    
    Tablets alone  










HbA1c (%) 7.32 ± 1.06 7.86 ±1.22 <0.001 
Systolic bp (mmHg) 132.8 ± 15.8 129.7 ± 15.4 0.09 
Diastolic bp (mmHg) 69.2 ± 9.2 66.8 ± 6.2 0.002 
Macrovascular disease  
     Myocardial infarction 
     Angina  
     Stroke 
     TIA 
     Claudication 
























4.32 ± 0.90 4.34 ± 0.80 0.89 
HDL cholesterol (mmol/L) 1.29 ± 0.36 1.26 ± 0.35 0.35 
Smoking 
   Current 
   Ex-smoker 











   No 
   Mild 










Values are means ± SD, medians (interquartile range) or n (%). Duration of diabetes was log-
transformed. TIA, transient ischaemic attack; ‘any MVD’, any symptomatic macrovascular 










7.3    Validation of self-reported hypoglycaemia in sub-study 
As described in Chapter 5 (Results I), 45 episodes were reported by 30 subjects 
during the 6-month survey of SH carried out immediately after the year 1 clinic. 
Twenty-three of the 30 individuals with SH in the 6-month survey returned for the 
year 4 follow-up, and 17 (74%) there reported incident SH in the 4 years since 
baseline. Six individuals (26%) failed to recall that they had experienced SH since 
baseline, overall suggesting a reasonable level of accuracy in the recall of 
hypoglycaemic episodes. 
7.4 Cognitive function as a risk factor for hypoglycaemia 
To investigate the role of a lower cognitive function as a potential risk factor for 
hypoglycaemia, analyses of covariance (ANCOVAs) compared baseline MHVS 
(which is used here to estimate peak pre-morbid cognitive ability) and baseline 
global ability measured by g between the group with ≥1 episodes of incident SH and 
subjects who remained free of incident SH during follow-up. The odds ratios for 
incident SH of the respective lowest (versus the remaining two) tertiles of MHVS 
and baseline g were calculated. 
7.4.1 Estimated peak pre-morbid ability and risk of hypoglycaemia 
When treated as a continuous variable, baseline MHVS was not significantly related 
to a baseline history of SH (age- and sex-adjusted means in ‘SH’ group 30.26, 95% 
CI 29.28, 31.24 versus 31.06, 95% CI 30.72, 31.40 in ‘no SH’ group; p=0.13). 
However, individuals in the lowest tertile of the MVHS distribution (versus the 
remaining two tertiles) had significantly increased likelihood of having experienced 
SH prior to baseline (age- and sex-adjusted OR 1.55; 95% CI 1.04, 2.32, p=0.033).  
 
Individuals who went on to experience incident SH between baseline and year 4, and 
the remaining sample also had similar baseline MHVS scores (age- and sex-adjusted 
mean 31.01, 95% CI 29.92, 32.10 versus 31.61, 95% CI 31.24, 31.98, p=0.30). The 
individuals in the lowest tertile of the MHVS distribution were not at increased risk 
of incident SH when compared with the remaining tertiles (age- and sex-adjusted OR 
1.13, 95% CI 0.69, 1.83, p=0.63). These results were largely unchanged when 
analyses of baseline MHVS and incident hypoglycaemia were restricted to first-ever 
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incident SH (adjusted mean MHVS in ‘SH’ group 30.58, 95% CI 29.20, 31.91 versus 
31.69, 95% CI 31.31, 32.08 in ‘no SH’ group, p=0.11; age- and sex-adjusted OR 
1.30, 95% CI 0.72, 2.33, p=0.39).  
7.4.2 Baseline cognitive function and risk of hypoglycaemia 
The group with incident SH had significantly lower global cognitive ability at 
baseline compared with the individuals free of incident SH (age- and sex-adjusted 
mean g -0.08, 95% CI -0.27, 0.12 versus 0.17, 95% CI 0.10, 0.24, p=0.019). The 
lowest tertile of baseline g was at increased risk of incident SH compared with the 
remaining tertiles (age- and sex-adjusted OR 2.04, 95% CI 1.25, 3.31, p=0.004). 
These findings remained statistically significant and even appeared to strengthen 
when analyses were restricted to risk of first-ever incident SH (age- and sex-adjusted 
mean g -0.08, 95% CI -0.33, 0.16 versus 0.18, 95% CI 0.12, 0.25, p=0.038; age- and 
sex-adjusted OR 2.46, 95% CI 1.37, 4.39, p=0.002), showing that the increased risk 
of hypoglycaemia in individuals with lower late-life ability was not driven by 
potential cognitive deficits caused by previous episodes.  
7.5 Hypoglycaemia as a risk factor for poorer cognitive 
function 
In the analyses on hypoglycaemia as a risk factor, a potential dose-response 
relationship between exposure to SH and cognitive outcome (level of cognitive 
function at year 4, estimated lifetime cognitive change, and four-year cognitive 
change) was initially explored by plotting each cognitive outcome against the four 
groups representing the frequency of hypoglycaemia (0, 1-2, 3-4 or ≥5 episodes prior 
to baseline or during follow-up). In subsequent ANCOVAs associating SH with each 
cognitive outcome, age and sex were controlled for in a first step, before 
conventional vascular and metabolic risk factors, macrovascular disease and 
microvascular disease were entered into the models with the aim to evaluate the 
independence of findings from these potential confounders. Unadjusted mean 
differences in cognitive test performance for the groups with and those without SH 
are shown in Appendix F.  
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7.5.1 Hypoglycaemia and cognitive function at year 4 
Lifetime history of severe hypoglycaemia and level of cognitive function at 
year 4 
Follow-up g was plotted against the four categories representing frequency of a 
lifetime history of hypoglycaemia reported at baseline (Figure 7.1a). Due to low 
participant numbers, confidence intervals were relatively large for the three groups 
reporting hypoglycaemia, and an age- and sex-adjusted ANCOVA showed that the 




Figure 7.1: Follow-up g according to lifetime number of episodes of severe 
hypoglycaemia (SH), categorised to 4 groups (a) and 2 groups (b) (error bars 
represent 95% confidence intervals) 
 
 
With the aim of increasing statistical power, the groups with ≥1 episodes were 
collapsed (Figure 7.1b) and compared with hypoglycaemia-free individuals. The 
group without a history of SH outperformed the group with a baseline history of SH 
on g and on tests of reasoning (Matrix Reasoning), executive functioning (Trail-
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Making Test-B) and processing speed (Digit Symbol Coding) (Table 7.3), including 
reaction time (Table 7.4). In age and sex-adjusted analyses, the significant group 
differences in cognitive test scores were  of small to medium effect size (Cohen’s |d| 
= 0.24 to 0.39 for individual cognitive tests significantly associated with SH) 
(Cohen, 1992). Effect sizes were relatively largest for executive function, with SH 
explaining 1.4% of variance in Trail-Making Test-B performance. For the group with 
a history of SH, mean performance on the test was at around the 66
th
 percentile of the 
group free of a history of SH.  A history of SH accounted for 0.8% of variance in g; 
mean g for this group was at around the 62
nd
 percentile of subjects free of a history of 
SH.  
 
For g and Digit Symbol Coding, multivariable adjustment led to a p-value which was 
just short of statistical significance and for Matrix Reasoning the strength of the 
association was reduced but remained significant. For Trail-Making Test-B 
performance, the effect size was only marginally reduced and for reaction time tests 
even slightly increased in this modelling step. Thus, associations of hypoglycaemia 
and cognitive function with other clinical covariates, including micro- and 
macrovascular disease and conventional vascular and metabolic risk factors, did not 
appear to constitute major contributors to the observation of a lower cognitive 
function, particularly a lower processing speed measured by reaction time and lower 
executive function measured by the Trail-Making Test-B, in subjects with a history 







Table 7.3: Lifetime history of severe hypoglycaemia and cognitive function at year 4 
 No severe hypoglycaemia 
(n=739) 
















11.77 (11.40 – 12.13) 
9.01 (8.80 – 9.22) 
37.22 (36.29 – 38.14) 
50.67 (49.67 – 51.66) 
109.07 (105.95 – 112.28) 
69.35 (68.76 – 69.94) 
27.28 (26.70 – 27.87) 
0.04 (-0.03 – 0.11) 
 
10.14 (8.98 – 11.31) 
8.42 (7.74 – 9.09) 
34.64 (31.72 – 37.56) 
46.30 (43.19 – 49.41) 
128.64 (117.21 – 141.03) 
68.70 (66.85 – 70.56) 
27.71 (25.86 – 29.57) 






























11.81 (11.44 – 12.19) 
9.03 (8.82 – 9.24) 
37.45 (36.52 – 38.38) 
50.65 (49.64 – 51.65) 
108.42 (105.21 – 111.61) 
69.43 (68.83 – 70.04) 
27.41 (26.81 – 28.01) 
0.06 (-0.01 – 0.13) 
 
10.47 (9.25 – 11.70) 
8.50 (7.79 – 9.20) 
35.52 (32.48 – 38.56) 
47.71 (44.48 – 50.95) 
125.09 (113.52 – 137.69) 
69.38 (67.41 – 71.35) 
28.40 (26.47 – 30.33) 



















Values are adjusted means (95% CI). N = 778 to 809 for Model 1; N = 743 to 769 for Model 2. Data for g have been imputed, for remaining 
cognitive tests are non-imputed. Trail-Making Test-B is log-transformed; means reported for this test are geometric means. Letter-Number, 
Letter Number Sequencing, Verbal Fluency, Borkowski Verbal Fluency Test, Trail-Making, Trail-Making Test-B. 
a
adjusted for age, sex, HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, 
smoking (ex/current/never), HbA1c at clinic visit, transient ischaemic attack, stroke, myocardial infarction, angina, retinopathy. 
Model 1: Cohen’s  d = 0.31 for g; d = 0.31 for Digit Symbol Coding; d = 0.32 for Matrix Reasoning; d = -0.39 for Trail-Making Test-B. 










Table 7.4: Lifetime history of severe hypoglycaemia and reaction time at year 4 
 No severe hypoglycaemia 
(n=739) 
Severe hypoglycaemia 





Model 1: age, sex 
   SRT mean 
   CRT mean 
 
314.19 (309.51 – 318.62) 
629.53 (620.43 – 638.64) 
 
336.30 (320.54 – 352.48) 









    
SRT mean 
   CRT mean 
 
313.88 (309.20 – 318.62) 
628.72 (619.41 – 638.03) 
 
337.65 (321.18 – 354.96) 







Values are adjusted means (95% CI). N = 737 and 782 for Model 1; N = 702 and 745 for Model 2. SRT mean is log-transformed; means 
reported for this test are geometric means. SRT and CRT are measured in milliseconds. SRT, simple reaction time; CRT, choice reaction 
time. 
a
adjusted for age, sex, HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, 
smoking (ex/current/never), HbA1c at clinic visit, transient ischaemic attack, stroke, myocardial infarction, angina, retinopathy.  
Model 1: Cohen’s d = -0.24 for Choice Reaction Time; d = -0.31 for Simple Reaction Time. 








Incident severe hypoglycaemia and level of cognitive function at year 4 
In an age- and sex-adjusted ANCOVA, the frequency of incident SH was found to be 
significantly associated with follow-up g (F (3, 801) = 5.44; p=0.001), but the 
association, which was again limited by large confidence intervals, did not appear to 
be linear (Figure 7.2a).  
 
 
Figure 7.2: Follow-up g according to number of episodes of incident severe 
hypoglycaemia (SH), categorised to 4 groups (a) and 2 groups (b) (error bars 




With all participants with ≥1 episodes of incident SH grouped together in order to 
retain statistical power (Figure 7.2b), incident SH between baseline and year 4 was 
significantly and (compared with findings for a baseline history of SH) relatively 
strongly associated with lower performance on seven of the nine individual cognitive 
tests (all except Borkowski Verbal Fluency Test and Logical Memory), and with 
lower g (Table 7.5; Table 7.6). Effect sizes for tests significantly associated with 
incident SH were of small to medium effect sizes (Cohen’s |d| = 0.28 to 0.39) 
(Cohen, 1992), with relatively strongest findings for g. Hypoglycaemia accounted for 





percentile of g in subjects free of incident SH. Effect sizes were somewhat attenuated 
when vascular risk factors, micro- and macrovascular disease were controlled for, but 
did not lose statistical significance, demonstrating that associations of incident 
hypoglycaemia with these potential confounders did appear to strongly contribute to 
the group differences in the level of late-life cognitive function. As shown in 
Appendix E, effect sizes and significance levels of the findings presented in this 
section were also largely unchanged when analyses were restricted to first-ever 
incident SH. The associations of incident SH and late-life cognitive function 
presented in this section therefore do not appear to be driven by those 27 subjects in 







Table 7.5: Incident severe hypoglycaemia and cognitive function at year 4 
 No severe 
hypoglycaemia  
(n=730) 
Severe hypoglycaemia  




Model 1: age, sex 
   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
11.82 (11.45 – 12.19) 
9.07 (8.86 – 9.28) 
37.22 (36.30 – 38.15) 
50.84 (49.85 – 51.83) 
108.31 (105.21 – 111.50) 
69.61 (69.02 – 70.20) 
27.43 (26.84 – 28.02) 
0.07 (0.00 – 0.13) 
 
10.02 (8.92 – 11.13) 
8.19 (7.55 – 8.83) 
35.36 (32.60 – 38.11) 
46.74 (43.78 – 49.71) 
126.34 (115.82 – 137.83) 
67.08 (65.33- 68.84) 
26.77 (25.00 – 28.54) 






















   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
11.83 (11.46 – 12.21) 
9.08 (8.86 – 9.29) 
37.42 (36.49 – 38.35) 
50.84 (49.84 – 51.83) 
107.99 (104.90 – 111.16) 
69.71 (69.10 – 70.31) 
26.63 (27.03 – 28.23) 
0.08 (0.01 – 0.15) 
 
10.55 (9.39 – 11.70) 
8.31 (7.65 – 8.97) 
36.70 (33.85 – 39.54) 
47.76 (44.72 – 50.81) 
121.63 (111.16 - 133.09) 
67.63 (65.78 – 69.47) 
26.75 (24.92 – 28.59) 



















Values are adjusted means (95% CI). N = 776 to 808 for Model 1; N = 742 to 769 for Model 2. Data on g are imputed, for remaining 
cognitive tests are non-imputed. Trail-Making Test-B is log-transformed; means reported for this test are geometric means. Letter-Number, 
Letter Number Sequencing, Verbal Fluency, Borkowski Verbal Fluency Test, Trail-Making, Trail-Making Test-B.  
a
adjusted for age, sex, HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, 
smoking (ex/current/never), HbA1c at clinic visit, transient ischaemic attack, stroke, myocardial infarction, angina, retinopathy. 
Model 1: Cohen’s d = 0.29 for Faces; d = 0.29 for Digit Symbol Coding; d = 0.32 for Letter-Number Sequencing; d = -0.36 for Trail-Making 
Test-B; d = 0.39 for g.  
Model 2: Cohen’s d = 0.22 for Digit Symbol Coding; d = 0.24 for Faces; d = 0.28 for Letter-Number Sequencing; d = -0.28 for Trail-Making 






Table 7.6: Incident severe hypoglycaemia and reaction time at year 4 
 No severe hypoglycaemia 
(n=730) 
Severe hypoglycaemia  





Model 1: age, sex 
   SRT mean 
   CRT mean 
 
314.19 (309.51 – 318.94) 
630.41 (621.22 – 639.59) 
 
333.29 (318.62 – 348.63) 









    
SRT mean 
   CRT mean 
 
315.58 (309.51 – 318.93) 
630.49 (621.10 – 639.88) 
 
330.63 (315.44 – 346.19) 







Values are adjusted means (95% CI). N = 736 and 781 for Model 1; N = 701 and 744 for Model 2. SRT mean is log-transformed; means 
reported for this test are geometric means. SRT and CRT are measured in milliseconds. SRT, simple reaction time; CRT, choice reaction 
time. 
a
adjusted for age, sex, HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, 
smoking (ex/current/never), HbA1c at clinic visit, transient ischaemic attack, stroke, myocardial infarction, angina, retinopathy. 
Model 1: Cohen’s d = 0.28 for Simple Reaction Time. 













7.5.2 Hypoglycaemia and estimated lifetime cognitive change 
Lifetime history of severe hypoglycaemia and estimated lifetime cognitive 
change 
The frequency of lifetime SH was overall significantly associated with the estimated 
change in cognitive function since peak pre-morbid ability as determined by 
adjustment of follow-up g for age, sex and baseline MHVS (F (3, 792) = 3.42; 
p=0.017), but again the finding suggested a non-linear relationship and was limited 
by large confidence intervals of the hypoglycaemia groups (Figure 7.3a).  
 
 
Figure 7.3: Follow-up g adjusted for baseline scores on the Mill-Hill 
Vocabulary Scale (MHVS) according to lifetime number of episodes of severe 
hypoglycaemia (SH), categorised to 4 groups (a) and 2 groups (b) (error bars 





Analyses comparing participants free of a lifetime history of SH with individuals 
with ≥1 episode (Figure 7.3b) showed significant associations between a lifetime 
history of SH and steeper estimated lifetime cognitive decline, which was 
statistically significant for the domains of reasoning (Matrix Reasoning), 
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processing speed (Digit Symbol Coding; Choice Reaction Time; Simple Reaction 
Time), executive function (Trail-Making Test-B) and global ability measured by 
g (Table 7.7; Table 7.8). The associations were of small to medium effect size, 
with Cohen’s |d| ranging between 0.26 and 0.37. Group differences were 
relatively largest for the Trail-Making Test-B of executive function. A history of 
SH accounted for 1.5% of estimated lifetime change in performance on this test 
and mean performance by the group with a history of SH was at around the 65
th
 
percentile of the Trail-Making distribution for the subjects free of a history of 
SH. These findings were largely independent of micro- and macrovascular 
disease or of vascular and metabolic risk factors). The group difference in g, for 
instance, remained relatively stable in terms of effect size (in age- and sex-
adjusted model, Cohen’s d = 0.28; in fully adjusted model d = 0.27); for the tests 
of reaction time effect sizes even slightly increased in this modelling step. Thus, 
individuals who were exposed to SH tended to experience a steeper cognitive 
decline between pre-hypoglycaemia peak pre-morbid ability and post-
hypoglycaemia late-life cognitive function relatively independent of potential 





Table 7.7: Lifetime history of severe hypoglycaemia and year 4 cognitive test scores adjusted for baseline MHVS   
 No severe hypoglycaemia 
(n=739) 
Severe hypoglycaemia  




Model 1: age, sex, 
baseline MHVS 
   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
 
11.72 (11.40 – 12.05) 
9.01 (8.82 – 9.21) 
37.18 (36.33 – 38.03) 
50.62 (49.70 – 51.54) 
109.07 (106.17 – 112.06) 
69.33 (68.76 – 68.89) 
27.28 (26.76 – 27.81) 
0.04 (-0.02 – 0.10) 
 
 
10.41 (9.37 – 11.45) 
8.47 (7.85 – 9.10) 
34.92 (32.23 – 37.60) 
46.63 (43.74 – 49.52) 
127.61 (116.98 – 139.21) 
68.73 (66.94 – 70.52) 
27.89 (26.23 – 29.55) 
























   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
11.80 (11.47 – 12.14) 
9.05 (8.85 – 9.25) 
37.48 (36.61 – 38.35) 
50.67 (49.73 – 51.61) 
108.31 (105.32 – 111.39) 
69.44 (68.86 – 70.03) 
27.45 (26.91 – 27.99) 
0.06 (0.00 – 0.12) 
 
10.41 (9.32 – 11.51) 
8.42 (7.77 – 9.08) 
35.12 (32.30 – 37.94) 
47.45 (44.43 – 50.47) 
126.09 (115.12 – 138.10) 
69.09 (67.18 – 71.00) 
28.20 (26.46 – 29.94) 



















Outcome variables are follow-up cognitive test scores. Values are adjusted means (95% CI). N = 770 to 800 for Model 1; N = 735 to 760 for 
Model 2. Data for g are imputed, for remaining cognitive tests are non-imputed. Trail-Making Test-B is log-transformed; means reported for 
this test are geometric means. Letter-Number, Letter Number Sequencing, Verbal Fluency, Borkowski Verbal Fluency Test, Trail-Making, 
Trail-Making Test-B, MHVS, Mill-Hill Vocabulary Scale. 
a
model 1 + HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, smoking 
(ex/current/never), HbA1c at clinic visit, transient ischaemic attack, stroke, myocardial infarction, angina, retinopathy. 
Model 1: Cohen’s d = 0.26 for Matrix Reasoning; d = 0.28 for g; d = 0.28 for Digit Symbol Coding; d = -0.37 for Trail-Making Test-B.  








Table 7.8: Lifetime history of severe hypoglycaemia and reaction time at year 4 adjusted for MHVS 
 No severe hypoglycaemia 
(n=739) 
Severe hypoglycaemia 





Model 1: age, sex, 
baseline MHVS 
   SRT mean 
   CRT mean 
 
 
314.51 (309.82 – 318.94) 
629.55 (620.13 – 638.49) 
 
 
336.30 (320.86 – 352.83) 











    
SRT mean 
   CRT mean 
 
313.88 (309.20 – 318.62) 
628.49 (619.33 – 637.65) 
 
339.68 (323.11 – 356.74) 







Values are adjusted means (95% CI). N = 729 and 774 for Model 1; N = 694 and 737 for Model 2. SRT mean is log-transformed; means 
reported for this test are geometric means. SRT and CRT are measured in milliseconds. SRT, simple reaction time; CRT, choice reaction 
time; MHVS, Mill-Hill Vocabulary Scale 
a
adjusted for age, sex, MHVS, HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic 
visit, smoking (ex/current/never), HbA1c at clinic visit, transient ischaemic attack, stroke, myocardial infarction, angina, retinopathy. 
Model 1: Cohen’s d = -0.25 for Choice Reaction Time; d = -0.30 for Simple Reaction Time. 




Incident severe hypoglycaemia and estimated lifetime cognitive change 
An ANCOVA with adjustment for age and sex revealed that the frequency of 
incident SH was significantly related to estimated lifetime cognitive change (F (3, 
791) = 4.48; p=0.004), but again the pattern of results appears inconsistent, with 
large confidence intervals (Figure 7.4a).   
 
Figure 7.4: Follow-up g adjusted for baseline scores on the Mill-Hill 
Vocabulary Scale (MHVS) according to number of episodes of incident severe 
hypoglycaemia (SH), categorised to 4 groups (a) and 2 groups (b) (error bars 





Consistent with the observation in Figure 7.4b, analyses comparing subjects free 
of incident SH with those who experienced ≥1 episode between baseline and year 
4 revealed that the incident SH group tended to have experienced steeper 
estimated lifetime decline in reasoning (Matrix Reasoning), processing speed 
(Digit Symbol Coding; Simple Reaction Time), executive function (Trail-Making 
Test-B), nonverbal memory (Faces) and global ability measured by g (Table 7.9; 
Table 7.10). Amongst all analyses presented in this chapter, this was also the 
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only one to reveal statistically significant associations for the Letter-Number 
Sequencing Test of working memory. Effect sizes for statistically significant 
associations in age- and sex-adjusted analyses were of relatively small effect size 
(Cohen’s |d| = 0.20 to 0.32). Again, associations were relatively independent 
from individual differences in micro- and macrovascular disease or vascular and 
metabolic risk factors, since associations of incident SH with estimated lifetime 
decline on g and on all cognitive tests with significant associations in the initial 
model, except Digit Symbol Coding, survived multivariable adjustment with 
relative preservation of effect sizes. The findings again were largely similar when 
analyses were restricted to first-ever incident SH (Appendix E), showing that 
subjects in this group who also had a baseline history of SH did not drive the 





Table 7.9: Incident severe hypoglycaemia and year 4 cognitive test scores adjusted for baseline MHVS 
 No severe hypoglycaemia 
(n=730) 
Severe hypoglycaemia  





Model 1: age, sex, 
baseline MHVS 
   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
 
11.78 (11.45 – 12.11) 
9.06 (8.67 – 9.25) 
37.14 (36.29 – 37.99) 
50.76 (49.84 – 51.69) 
108.53 (105.64 – 111.50) 
69.58 (69.01 – 70.14) 
27.38 (26.85 – 27.91) 
0.06 (0.00 – 0.12) 
 
 
10.23 (9.25 – 11.22) 
8.33 (7.75 – 8.92) 
35.97 (33.43 – 38.51) 
47.41 (44.65 – 50.16) 
124.21 (114.43 – 134.83) 
67.24 (65.55 – 68.94) 
27.36 (25.77 – 28.95) 
























   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory  
   ‘g’ 
 
11.81 (11.47 – 12.15) 
9.08 (8.88 – 9.28) 
37.36 (36.50 – 38.23) 
50.80 (49.86 – 51.74) 
108.09 (105.11 – 111.16) 
69.69 (69.10 – 70.27) 
27.61 (27.07 – 28.15) 
0.07 (0.02 – 0.13) 
 
10.66 (9.62 – 11.70) 
8.38 (7.77 – 9.00) 
37.11 (34.46 – 39.76) 
48.09 (45.24 – 50.95) 
120.54 (110.61 – 131.24) 
67.68 (65.89 – 69.48) 
27.08 (25.42 – 28.74) 



















Outcome variables are follow-up cognitive test scores. Values are adjusted means (95% CI). N = 768 to 798 for Model 1; N = 734 to 760 
for Model 2. Data for g are imputed, for remaining cognitive tests are non-imputed. Trail-Making Test-B is log-transformed; means 
reported for this test are geometric means. Letter-Number, Letter Number Sequencing; Verbal Fluency, Borkowski Verbal Fluency Test; 
Trail-Making, Trail-Making Test-B; MHVS, Mill-Hill Vocabulary Scale. 
a
model 1 +HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, smoking 
(ex/current/never), HbA1c at clinic visit, transient ischaemic attack, stroke, myocardial infarction, angina, retinopathy. 
Model 1: Cohen’s d = 0.20 for Faces; d = 0.24 for Digit Symbol Coding; d = 0.27 for Letter-Number Sequencing; d = 0.31 for Matrix 
Reasoning; d = 0.31 for g; d = -0.32 for Trail-Making Test-B. Model 2: Cohen’s d = 0.23 for Faces; d = 0.23 for Matrix Reasoning; d = 








Table 7.10: Incident severe hypoglycaemia and reaction time at year 4 adjusted for MHVS 
 No severe hypoglycaemia 
(n=730) 
Severe hypoglycaemia  





Model 1: age, sex, 
baseline MHVS 
   SRT mean 
   CRT mean 
 
 
314.51 (310.13 – 319.29) 
630.72 (629.35 – 639.74) 
 
 
331.96 (317.67 – 346.89) 











    
SRT mean 
   CRT mean 
 
314.51 (309.82 – 319.26) 
630.70 (621.45 – 639.96) 
 
329.63 (314.82 – 345.16) 







Values are adjusted means (95% CI). N = 728 and 773 for Model 1; N = 639 and 736 for Model 2. SRT is log-transformed; means reported 
for this test are geometric means. SRT and CRT are measured in milliseconds. SRT, simple reaction time; CRT, choice reaction time; 
MHVS, Mill-Hill Vocabulary Scale. 
a
adjusted for age, sex, MHVS, HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic 
visit, smoking (ex/current/never), HbA1c at clinic visit, transient ischaemic attack, stroke, myocardial infarction, angina, retinopathy. 







7.5.3 Hypoglycaemia and four-year cognitive change
Lifetime history of severe hypoglycaemia and four-year cognitive change 
The frequency of a lifetime history of SH reported at baseline was found to be 
overall unrelated to the change in g between baseline and year 4 (age- and sex-
adjusted F (3, 801) = 1.91; p=0.12; Figure 7.5a).  
 
 
Figure 7.5: Four-year cognitive change according to lifetime number of 
episodes of severe hypoglycaemia (SH), categorised to 4 groups (a) and 2 groups 


















The results become clearer when statistical power is increased by collapsing the 
groups with ≥1 episodes (Figure 5b). Overall, this group tended to experience 
steeper decline in global ability measured by g, in reasoning (Matrix Reasoning) 
and in executive function measured by the Trail-Making Test-B over the course 
of the study (Table 7.11). Effect sizes were small (Cohen’s |d| = 0.20 for Trail-
Making Test-B; 0.28 for g; 0.32 for Matrix Reasoning). Hypoglycaemia 
accounted for 0.7% of variance in four-year change in g, and mean g in the group 
with a history of SH was at around the 61
st
 percentile of the distribution of g of 
subjects free of a history of SH. The findings for g and for Matrix Reasoning 
were relatively independent from potential confounding by clinical covariates or 
by potential effects of peak pre-morbid ability, which was controlled for in a final 
step due to a potential for associations both with the risk of hypoglycaemia and 
with late-life cognitive decline. In fully adjusted models, Cohen’s d was 0.26 for 
g and 0.30 for Matrix Reasoning, showing that subjects with a history of SH on 
average scored at around the 60
th
 percentile of the distribution of four-year 
decline in g and around the 62
nd
 percentile of the distribution of four-year decline 






Table 7.11: Lifetime history of severe hypoglycaemia and four-year cognitive change  
 No severe hypoglycaemia 
(n=739) 
Severe hypoglycaemia  




Model 1: age, sex, 
baseline score 
   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory  
   ‘g’ 
 
 
11.78 (11.50 – 12.06) 
8.99 (8.81 – 9.17) 
37.09 (36.55 – 37.63) 
50.44 (49.76 – 51.11) 
109.73 (107.45 – 112.17) 
69.36 (68.88 – 69.84) 
27.40 (26.94 – 27.86) 
0.03 (-0.04 – 0.10) 
 
 
10.19 (9.30 – 11.08) 
8.72 (8.13 – 9.30) 
36.20 (34.50 – 37.89) 
48.54 (46.41 – 50.70) 
119.34 (111.39 – 127.74) 
69.39 (66.88 – 69.91) 
27.30 (25.85 – 28.74) 
























   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency  
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
11.85 (11.57 – 12.14) 
9.02 (8.84 – 9.21) 
37.38 (36.83 – 37.93) 
50.51 (49.81 – 51.20) 
109.07 (106.70 – 111.05) 
69.48 (68.99 – 69.97) 
27.54 (27.07 – 28.00) 
0.03 (-0.04 – 0.11) 
 
10.31 (9.37 – 11.26) 
8.70 (8.09 – 9.31) 
36.49 (34.69 – 38.29) 
49.06 (46.82 – 51.30) 
116.51 (108.42 – 125.21) 
68.73 (67.12 – 70.33) 
27.93 (26.42 – 29.44) 






















   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
11.83 (11.55 – 12.11) 
9.04 (8.87 – 9.22) 
37.37 (36.82 – 37.92) 
50.51 (49.82 – 51.20) 
108.96 (106.59 – 111.39) 
69.48 (68.99 – 69.96) 
27.55 (27.10 – 28.00) 
0.04 (-0.04 – 0.11) 
 
10.32 (9.40 – 11.23) 
8.61 (8.02 – 9.20) 
36.38 (34.59 – 38.18) 
48.97 (46.75 – 51.20) 
117.21 (109.07 – 125.96) 
68.63 (67.03 – 70.23) 
27.93 (26.47 – 29.39) 





















Outcome variables are follow-up cognitive test scores. Values are adjusted means (95% CI). N = 770 to 807 for Model 1; N = 736 to 768 for 
Model 2; N = 730 to 760 for Model 3. Data for g are imputed, for remaining cognitive tests are non-imputed. Trail-Making Test-B is log-
transformed; means reported for this test are geometric means. Letter-Number, Letter Number Sequencing; Verbal Fluency, Borkowski 
Verbal Fluency Test; Trail-Making, Trail-Making Test-B; MHVS, Mill-Hill Vocabulary Scale. 
a
model 1 + HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, smoking 
(ex/current/never), HbA1c at clinic visit, transient ischaemic attack, stroke, myocardial infarction, angina, retinopathy. 
b
model 2 + baseline MHVS 
Model 1: Cohen’s d = -0.20 for Trail-Making Test-B; d = 0.28 for g; d = 0.32 for Matrix Reasoning. 
Model 2: Cohen’s d = 0.28 for g; d = 0.30 for Matrix Reasoning. 




Incident severe hypoglycaemia and four-year cognitive change 
The frequency of incident SH during follow-up was found to be associated with 
concurrent cognitive change (age- and sex-adjusted F (3, 800) = 4.60; p=0.003). The 
finding was restricted by large confidence intervals (Figure 7.6a), and so groups with 
≥1 episode of incident SH were collapsed (Figure 7.6b).  
 
 
Figure 7.6: Four-year cognitive change according to number of episodes of 
incident severe hypoglycaemia (SH), categorised to 4 groups (a) and 2 groups 



















The group with incident SH experienced steeper four-year cognitive decline 
compared with participants who remained free of SH (Table 7.12). Effect sizes 
were similarly small to those found for a lifetime history of SH (Table 7.11), with 
Cohen’s |d| ranging from 0.19 for decline in Digit Symbol Coding to 0.29 for 
decline in g. Compared with the findings for year 4 level of ability and estimated 
lifetime cognitive change, effect sizes were also overall weaker. Incident 
hypoglycaemia accounted for 0.9% of variance in four-year decline in g, and the 
group with incident SH on average scored at around the 61
st
 percentile of the 
remaining sample’s distribution of four-year decline in g. Findings somewhat 
attenuated but for Matrix Reasoning, Faces and for g remained statistically 
significant when potential clinical covariates were controlled for. Individual 
differences in estimated peak pre-morbid ability did not appear to play a role in 
the associations of incident hypoglycaemia and cognitive decline; for Matrix 
Reasoning and g the addition of MHVS to the model even increased effect sizes 
when compared with the previous modelling step (Cohen’s |d| = 0.24 and 0.25, 
respectively in fully adjusted models). Again, findings were largely unchanged 
when analyses presented in this section were restricted to first-ever incident SH 











Table 7.12: Incident severe hypoglycaemia and four-year cognitive change  
 No severe hypoglycaemia 
(n=730) 
Severe hypoglycaemia  





Model 1: age, sex, 
baseline score 
   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
 
11.78 (11.49 – 12.06) 
9.04 (8.86 – 9.22) 
37.20 (36.66 – 37.74) 
50.69 (50.01 – 51.37) 
108.96 (106.59 – 111.27) 
69.55 (69.08 – 70.03) 
27.45 (26.98 – 27.91) 
0.04 (-0.03 – 0.12) 
 
 
10.58 (9.72 – 11.44) 
8.56 (8.01 – 9.12) 
35.78 (34.17 – 37.93) 
48.06 (46.03 – 50.10) 
119.10 (111.61 – 127.10) 
37.38 (65.94 – 68.82) 
27.25 (25.85 – 28.65) 
























   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
11.82 (11.53 – 12.11) 
9.05 (8.87 – 9.24) 
37.47 (36.20 – 38.03) 
50.74 (50.05 – 51.43) 
108.42 (106.06 – 110.83) 
69.66 (69.17 – 70.15) 
27.62 (27.15 – 28.10) 
0.04 (-0.04 – 0.11) 
 
10.85 (9.94 – 11.75) 
8.63 (8.06 – 9.20) 
36.46 (34.76 – 38.16) 
48.61 (46.49 – 50.73) 
115.93 (108.31 – 124.09) 
67.87 (66.36 – 69.39) 
27.47 (26.02 – 28.92) 






















   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
 
11.80 (11.52 – 12.08) 
9.07 (8.89 – 9.24) 
37.47 (36.91 – 38.02) 
50.74 (50.04 – 51.43) 
108.31 (105.95 – 110.72) 
69.64 (69.16 – 70.13) 
 
10.86 (9.97 – 11.74) 
8.64 (8.08 – 9.19) 
36.35 (34.66 – 38.05) 
48.65 (46.55 – 50.75) 
115.93 (108.31 – 123.97) 

















   Logical Memory 
   ‘g’ 
27.64 (27.18 – 28.09) 
0.04 (-0.03 – 0.12) 
27.48 (26.09 – 28.88) 





Outcome variables are follow-up cognitive test scores. Values are adjusted means (95% CI). N = 768 to 806 for Model 1; N = 735 to 768 
for Model 2; N = 729 to 760 for Model 3. Data for g are imputed, for remaining cognitive tests are non-imputed. Trail-Making Test-B is 
log-transformed; means reported for this test are geometric means. Letter-Number, Letter Number Sequencing; Verbal Fluency, Borkowski 
Verbal Fluency Test; Trail-Making Test-B; MHVS, Mill-Hill Vocabulary Scale. 
a
model 1 + HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, smoking 
(ex/current/never), HbA1c at clinic visit, transient ischaemic attack, stroke, myocardial infarction, angina, retinopathy. 
b
model 2 + baseline MHVS. 
Model 1: Cohen’s d = 0.19 for Digit Symbol Coding; d = -0.21 for Trail-Making Test-B; d = 0.24 for Matrix Reasoning; d = 0.25 for 
Faces; d = 0.29 for g. 
Model 2: Cohen’s d = 0.20 for Matrix Reasoning; d = 0.20 for Faces; d = 0.22 for g. 
Model 3: Cohen’s d = 0.19 for Faces; d = 0.24 for Matrix Reasoning; d = 0.25 for g. 
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7.5 Summary  
Overall, the present analyses demonstrate a bidirectional relationship of 
hypoglycaemia with cognitive function. Subjects with a baseline history of severe 
hypoglycaemia had a 55% increased likelihood of having had a relatively low 
cognitive ability in young adulthood as estimated by the MHVS. A reduced late-life 
cognitive ability (although not a reduced estimated ability in young adulthood) also 
predisposed participants to an over two-fold increased risk of first-ever severe 
hypoglycaemia during the follow-up of the ET2DS. Additionally, a temporally 
relatively distant (lifetime history of SH) as well as a more recent (incident SH) 
experience of hypoglycaemia appeared to be linked to a lower level of late-life 
cognitive function in later life in associations of small to medium effect sizes. In 
addition to global ability measured by g, the cognitive domains most consistently 
associated with hypoglycaemia were non-verbal memory (Faces), executive function 
(Trail-Making Test-B), processing speed (Digit Symbol Coding; Choice Reaction 
Time; Simple Reaction Time) and non-verbal reasoning (Matrix Reasoning). On first 
inspection, somewhat larger effect sizes and a higher number of statistically 
significant cross-sectional associations with individual cognitive tests for analyses of 
a recent than of a more distant history of hypoglycaemia (which was particularly 
evident for the memory domain) could be seen to suggest that (should the present 
findings represent causality) hypoglycaemia affects cognitive function more severely 
in the short- than in the long-term. This would imply a potential for cognitive 
function to ‘recover’ following a hypoglycaemic episode.   
 
However, the findings from subsequent analyses speak against this interpretation. 
The experience of hypoglycaemia either prior to or during the study period was 
linked to a steeper decline between estimated peak (pre-hypoglycaemia) cognitive 
function and (post-hypoglycaemia) assessment in later life, as well as to a steeper 
late-life cognitive decline, and the strength of associations were relatively 
independent of the amount of time that had passed between the hypoglycaemic 




Finally, the finding of relatively weaker associations for the rates of four-year decline 
than for estimated lifetime decline appear to mirror those reported for stroke in 
Chapter 6 (Results II) and show that the initial effects of hypoglycaemia on cognitive 
function appeared to be more severe than its effects on subsequent post-



























Chapter 8: Results IV: Risk factors and cognition 
8.1 Overview 
Because participants of the ET2DS underwent extensive clinical characterisation, its 
data allows the concurrent analysis of a wider range of risk factors and their 
relationship with cognitive outcome. The aim of the first part of this chapter, which 
presents results from exploratory analyses, is to assess the relative importance of a 
range of risk factors in the determination of cognitive function and cognitive decline.  
 
Initially, the risk factors to be used in the multivariate analyses of this chapter will be 
described, before bivariate associations amongst them are presented with the aim to 
set the background for the exploratory multivariable analyses associating risk factors 
with cognitive function and cognitive decline.  
 
Due to some evidence which suggests that a number of risk factors may reflect the 
same underlying damage to the body (e.g., (T. Seeman et al., 2010)), the second part 
of the chapter will then evaluate the usefulness of a summary measure of ‘allostatic 
load’, which is derived from several risk factor measurements, and its relationship 
with later-life cognitive function and cognitive decline in the ET2DS.  
8.2 Variables used in this chapter 
A majority of the available baseline/ year 1 risk factor variables described in Chapter 
5 (Results I) was used in the exploratory multivariable analyses presented in this 
chapter. Compared with Chapters 6 and 7 (Results II and III), some changes were 
applied to the risk factor variables in order to reduce the total number of risk factor 
variables (a, b, c), to maximise their validity (d, e, f) or to allow point-biserial or 
Pearson correlations (g, h). To summarise:  
 
a) A binary coronary heart disease (CHD) variable was created to reflect the 
presence of MI and/or angina.  
b) Intermittent claudication and/or ABI≤0.90 were summarised as a binary 
‘peripheral atherosclerosis (PA) variable.  
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c) Stroke was chosen as the only measure of cerebrovascular disease, as the 
validity of TIA may be questionable on the basis of possible misattribution of 
other age-related diseases to TIA. 
d) Historical data on HbA1c and blood pressure obtained from the Lothian 
Diabetes Register replaced the variables measured at the clinic. Historical 
data may be more robust to confounding from factors associated with the 
clinic visit (e.g., heightened anxiety which may temporarily increase blood 
pressure), is less affected by intra-individual fluctuations and reflects the 
long-term exposure to the respective risk factor. Pearson correlations showed 
that the historical HbA1c variable correlated strongly and positively with 
HbA1c at the clinic visit (r=0.70; p<0.001) and moderately with plasma 
glucose at the clinic visit (r=0.38; p<0.001). Historical systolic blood pressure 
also correlated positively with systolic blood pressure measured at the clinic 
(r=0.49; p<0.001). 
e) An LDL:HDL ratio was derived from the HDL and LDL variables. The ratio 
reflects the protective and detrimental contributions of each more 
appropriately and consequently has stronger predictive value for risk of 
cardiovascular disease when compared with non-ratio measures of cholesterol 
(e.g., HDL cholesterol) (Millán et al., 2006). As expected, LDL:HDL 
correlated positively with total cholesterol (r=0.43; p<0.001) and negatively 
with HDL cholesterol (r=-0.66; p<0.001). 
f) A retrospective ‘packyears’ variable replaced the categorical smoking 
variable (never/ex/current). Packyears could be assumed to be a more 
accurate reflection of the lifetime exposure to the vascular burden and 
toxicity associated with smoking, because it takes into account a person’s 
complete smoking history and appears to have acceptable validity as 
determined by comparison with prospectively ascertained data on packyears 
(Bernaards, Twisk, Snel, Van Mechelen, & Kemper, 2001). Due to its 
continuous nature, the variable may also have increased statistical power over 
the categorical smoking variable. The distributions of packyears according to 





Table 8.1: Means packyears according to smoking group 
 Mean ± SD  
Never smoked (n=414) 0 ± 0 
Ex-smoker (n=472) 25.70 ± 5.93 
Current smoker (n=133) 35.91 ± 3.44 
Packyears were square-root transformed. 
Means and standard deviations were back-transformed. 
SD, standard deviation. 
 
g) In the bivariate associations presented in section 8.3, diabetic retinopathy 
(DR) was represented as a binary variable (any DR versus no DR). The 
original three-level categorical variable (moderate/severe DR versus mild DR 
versus no DR) was then used in the multivariable analyses of section 8.4.  
h) In the correlations of risk factors presented in section 8.3, units of alcohol 
consumption in the previous year was used as a continuous variable, but in 
the multivariable analyses presented in section 8.4 was then analysed in terms 
of quintiles with the first quintile as abstainers. This is thought to be the most 
accurate reflection of the distribution of alcohol consumption in the sample 
and avoids the use of arbitrary thresholds, such as government guidelines 
(Conaglen, 2009).  
Overall, the following 15 risk factors were included in the multivariable analyses 
presented in section 8.4: peripheral atherosclerosis (PA; presence of claudication 
and/or ABI≤0.90), coronary heart disease (CHD; angina and/or MI), stroke, cIMT, 
NT-proBNP, diabetic retinopathy (DR), packyears, alcohol consumption (quintiles), 
waist-hip ratio, LDL:HDL, historical systolic blood pressure, historical HbA1c, 
inflammation factor, cortisol and baseline history of severe hypoglycaemia (SH). All 
except cIMT were measured at baseline; cIMT was measured at year 1. Incident SH 
was not considered in these analyses, because the focus was on the predictive ability 
of baseline/ year 1 risk factors, and because the correlation of baseline history of SH 
with incident SH would have led to difficulty in the modelling process (i.e., it is 
likely that even if both a history of SH and incident SH had made contributions to 
cognitive outcome, only one of the measures would be identified as a significant 




8.3 Inter-correlations amongst risk factors 
The bivariate associations amongst the risk factors are shown in Table 8.2. To 
summarise: 
 Individuals with higher inflammation tended to have poorer risk factor 
profiles throughout, with exception of non-significant associations with 
cIMT, retinopathy and waist-hip ratio.    
 Many of the factors reflecting lifestyle (packyears, waist-hip ratio, 
LDL:HDL, alcohol) were interrelated; results were more inconsistent for 
blood pressure. 
 People with higher depressive symptoms tended to have higher inflammation, 
atherosclerosis, higher likelihood of a history of severe hypoglycaemia, and 
poorer lifestyle, although depressive symptoms correlated negatively with 
alcohol consumption. 
 Findings for CHD and stroke largely overlapped. In addition to inflammation, 
both were associated with higher waist-hip ratio, higher LDL:HDL and 
higher packyears, as well as with peripheral arterial disease, retinopathy and 
cardiac stress evident in raised NT-proBNP 
 Higher alcohol consumption was negatively related to a majority of disease 
variables, but was linked to higher cIMT. Considering that this data is cross-
sectional, the finding could either suggest protective effects of alcohol on 
disease processes or could show that people who are affected by disease stop 
drinking alcohol.  
 Participants with a history of severe hypoglycaemia were likely to suffer from 
microvascular disease, tended to experience increased cardiac stress (NT-
proBNP) and had lower blood pressure, higher inflammation and higher 
HbA1c.  
 Cortisol stood out as relatively unrelated to all of the remaining risk factors, 
although individuals with higher cortisol tended to have raised inflammation 







Table 8.2: Univariate associations amongst risk factors 










PA*  cIMT NT-
proBNP 


































































































































































































































































































































































































CRP                 -- 0.43 
(<0.001) 
0.81**  
IL-6                  -- 0.76**  
310 
 
Analyses between continuous variables and between one continuous are two-tailed Pearson correlations. All risk factors except cIMT were measured at 
baseline; cIMT was measured at year 1. Analyses between one continuous and one categorical variable are point-biserial correlations. Analyses between 
two categorical variables are logistic regression analyses. Values are correlation coefficients (p-values).  
All variables except cIMT measured at baseline; cIMT was measured at year 1. NT-proBNP, alcohol, TNF α, IL-6 and CRP are log-transformed. Packyears 
are square root-transformed. *binary categorical variables. **values are factor loadings. ***values are odds ratios. HADS-D, depression subscale of the 
Hospital Anxiety and Depression Questionnaire; CHD, coronary heart disease (myocardial infarction and/or angina); PA, peripheral atherosclerosis 
(intermittent claudication and/or ABI ≤0.90), bp, blood pressure; WHR, waist-hip-ratio; SH, baseline history of severe hypoglycaemia; fibrin., fibrinogen; 
IL-6, interleukin-6; TNF-α, tumor necrosis factor α; CRP, c-reactive protein; LDL:HDL, low-density lipoprotein: high-density lipoprotein ratio; NT-
proBNP, N-terminal pro-brain natriuretic peptide; DR, diabetic retinopathy; cIMT, carotid intima-media thickness; ‘inflammation’ is the inflammation 
‘factor’ extracted from TNF- α, IL-6, CRP and fibrinogen. PA, DR, CHD and SH are binary variables.
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8.4 Multivariable association of a range of risk factors with 
cognitive outcome  
8.4.1 Stepwise linear regression method 
The relationship of all of the risk factors with late-life cognitive outcome (follow-up 
g, estimated lifetime change g, four-year change in g) was investigated using a 
combination of hierarchical and stepwise regression procedures. In the first block of 
the regression model, the covariates to be controlled for were entered. The stepwise 
procedure was then applied to the second block of the analysis.  
 
In a stepwise procedure, all ‘predictors’ under investigation are entered one at a time 
and the one predictor most strongly related to the specific outcome is revealed. All 
further predictors are then entered one at a time, and those with statistical 
significance above a pre-specified criterion are retained. As predictors became non-
significant upon inclusion of another predictor, these are removed from the model. 
This automated process is terminated once no further significant predictors are 
found. The stepwise procedure is therefore a combination of the ‘forward selection’ 
(where predictors are added into the model one at a time with retention of significant 
predictors) and the ‘backward elimination’ approach (where the model starts out with 
all predictors and subsequently removes predictors one at a time where significance 
is below a given threshold) (Livingston, Cao, & Dimick, 2010). The stepwise 
procedure is advantageous in the analysis of a large number of predictors, because it 
reveals the contribution of each to the outcome in terms of the proportion of variance 
in the outcome measure accounted for. It further allows the identification of an 
‘optimal’ model explaining the data.  
 
The approach has also met with criticism in the literature, however. It has been noted 
that the selection of predictors in the stepwise procedure is flawed, because the 
procedure may underestimate standard errors and p-values and may result in 
‘optimistic’, i.e. overestimated, beta coefficients (Pace, 2008; Wang, Zhang, & 
Bakhai, 2004). Consequently, stepwise regression has a high probability of ‘model 
overfitting’ due to the identification of spurious associations between predictors and 
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outcome (Livingston et al., 2010). In one stepwise linear regression simulation, this 
occurred in one out of 20 predictors (Genell, Nemes, Steineck, & Dickman, 2010); 
another study on logistic stepwise regression found it to be the case in between 38% 
and 80% of simulations depending on sample size (Pace, 2008). This risk of error 
may be even higher when a redundant predictor is correlated with a true predictor 
(Genell et al., 2010). Consequently, there is an overall uncertainty on the 
contribution of the predictors, so that findings from a stepwise regression procedure 
on one population may not generalise to others, particularly when the data set is 
small. Despite these problems, researchers tend to implicitly interpret what they 
identify as the ‘optimal’ model as correct (D. Wang et al., 2004).  
 
Yet, given that the stepwise regression approach is relatively common in the field of 
medical statistics (D. Wang et al., 2004), as well as in the literature investigating a 
number of potential predictors of cognitive outcome (Starr, Deary, Inch, Cross, & 
MacLennan, 1997; Stewart, Deary, Fowkes, & Price, 2006) or other health outcomes 
(Gale, Deary, Cooper, & Batty, 2012), and considering that the ET2DS has a 
relatively large sample size, stepwise regression is deemed suitable for the purpose of 
this chapter. The ‘throw-in-everything’ analyses presented here are intended as 
exploratory and all interpretations will be made with the consideration that the final 
model may not be an entirely accurate reflection of the underlying associations and 
generalisable to other populations. The findings should be seen as an initial 
contribution to the literature, which requires replication and validation in other, 
similarly large samples.  
8.4.2 Multivariable association of risk factors with cognitive function 
at year 4 
In a linear regression model of the relationship between all individual risk factors and 
follow-up g, age and sex were controlled for in a first block irrespective of whether 
or not their contributions to the model were statistically significant (Table 8.3). In the 
next, stepwise block, all of the aforementioned 15 risk factors (also listed in the 
footnote of Table 8.3) were entered in an automated fashion one at a time and 
retained in the model in cases of p<0.05. In cases where significance levels decreased 
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following addition of other predictors in subsequent steps, previous predictors were 
removed from the model at p>0.10. Analyses were restricted to g rather than 
individual cognitive tests in order to limit the total number of analyses and because 
the relative predictive ability of risk factors with respect to the level of or changes in 
global ability are deemed most informative. Duration of diabetes and treatment mode 
were not controlled for with the aim to avoid over-adjustment. The final ‘optimal’ 
model of follow-up g is shown in Table 8.3.  
 
Higher inflammation at baseline was the predictor which accounted for the largest 
proportion of variance in follow-up g with age and sex controlled for (3.7%). Higher 
packyears and higher waist-hip ratio also contributed significantly to the final model, 
although lower alcohol consumption was identified as a significant predictor of lower 
g. Contrasting the significant findings in the multivariate analyses presented in 
Chapters 6 and 7 (Results II and III), a baseline history of severe hypoglycaemia was 
not retained, and stroke was the only measure of macrovasuclar disease in the final 
model. It accounted for 0.7% of variance in g with all of the remaining predictors in 
the model held constant.  
 
In order to establish the independence of these findings from potential confounding 
by depressed mood, the analysis was repeated with adjustment for baseline HADS-D 
in the block which also controlled for age and sex. The contributions of individual 
risk factors to g were close to identical to the age- and sex-adjusted model,  although 
the total R
2

































Age* -0.27 0.01 <0.001 0.091 
Sex* 0.08 0.08 0.089 
+inflammation factor -0.14 0.04 <0.001 0.037 
+alcohol 0.19 0.03 <0.001 0.027 
+packyears -0.13 0.01 <0.001 0.021 
+waist-hip ratio -0.14 0.55 <0.001 0.016 
+stroke -0.08 0.16 0.018 0.007 
Total R
2
    0.199 
 
Model 2 
Age* -0.27 0.01 <0.001  
0.122 Sex* 0.09 0.09 0.038 
HADS-D* -0.10 0.06 0.004 
+inflammation factor -0.13 0.04 <0.001 0.028 
+alcohol 0.19 0.03 <0.001 0.025 
+packyears -0.12 0.01 0.001 0.016 
+waist-hip ratio -0.13 0.56 0.002 0.012 
+stroke -0.07 0.16 0.036 0.005 
Total R
2
    0.209 
N=672 for both models. G has been imputed. 
a




change following addition of predictor into the respective previous model. 
*
entered in a first 
block. Log-transformed values were used for NT-proBNP; square root transformed values were 
used for packyears.  
Variables entered in stepwise procedure: PA (presence of claudication and/or ABI≤0.90), CHD 
(angina and/or MI), stroke, cIMT, NT-proBNP, DR, packyears, alcohol consumption (quintiles), 
waist-hip ratio, LDL:HDL, systolic blood pressure, HbA1c, inflammation factor, cortisol, 
baseline history of SH.   
CHD, coronary heart disease; PA, peripheral atherosclerosis; LDL:HDL, low-density lipoprotein 
to high-density lipoprotein ratio; ABI, ankle brachial pressure index; DR, diabetic retinopathy; 
SH, severe hypoglycaemia; HADS-D, Depression Subscale of the Hospital Anxiety and 











8.4.3 Multivariable association of risk factors with estimated lifetime 
change in cognitive function 
Analyses of estimated lifetime change in g were performed using a stepwise linear 
regression procedure of follow-up g, which followed the adjustment for age, sex and 
baseline MHVS in a first block. This step determined that MHVS alone accounted 
for 27.6% of variance in follow-up g. The same 15 individual risk factors were again 
entered one at a time in an automated procedure and retained in the model if their 
association with was p<0.05. If subsequent addition of other predictors rendered 
associations of previously entered predictors non-significant at p>0.10, these were 
removed from the model. The final, optimal model identified in these analyses is 
shown in Table 8.4.  
 
Although overall effect sizes were reduced, the significant contributors to the model 
of estimated lifetime change in g were largely similar to the model of follow-up g. 
The risk factors identified to contribute to the estimated lifetime change in g were 
inflammation, stroke, alcohol and packyears. Additionally, waist-hip ratio was no 
longer retained in the model and instead HbA1c was identified as a significant 
predictor. This could potentially be due to the correlation of HbA1c with waist-hip 
ratio (r=0.11; Table 8.2).  
 
Again, inflammation had the relatively largest contribution. Higher late-life 
inflammation was associated with a steeper estimated lifetime cognitive decline, and 
accounted for 1.8% of the variance in this outcome with age and sex controlled for. 
A baseline history of stroke was also associated with significant decrements between 
estimated peak pre-morbid ability and post-stroke ability in later life, accounting for 
0.6% of the variance. Again, higher packyears and lower alcohol consumptions were 
also significant predictors. Each accounted for 0.5% of additional variance following 
their respective addition to the model. HbA1c accounted for 1% of additional 





Again, neither a baseline history of severe hypoglycaemia nor macrovascular disease 
(except stroke) was retained in the model. Additional adjustment for HADS-D only 
marginally attenuated the contributions by significant predictors to the initial model 
(Model 2; Table 8.4).  
 
 













Age* -0.30 0.01 <0.001 0.117 
Sex* 0.17 0.07 <0.001 
+inflammation factor -0.11 0.03 0.001 0.018 
+HbA1c -0.09 0.03 0.004 0.010 
+stroke -0.07 0.14 0.018 0.006 
+packyears -0.09 0.01 0.006 0.005 
+alcohol 0.08 0.02 0.016 0.005 
Total R
2
    0.161 
 
Model 2 
Age* -0.30 0.01 <0.001  
0.128 Sex* 0.18 0.07 <0.001 
HADS-D* -0.06 0.05 0.042 
+inflammation factor -0.10 0.03 0.001 0.015 
+HbA1c -0.08 0.03 0.007 0.008 
+stroke -0.07 0.14 0.031 0.005 
+packyears -0.08 0.01 0.013 0.004 
+alcohol 0.08 0.02 0.017 0.005 
Total R
2
    0.165 
N=665 for both models. Baseline MHVS was entered in a first block (R
2
 change = 0.276; this is 
not included in total R
2
 shown in Table), so that the outcome is follow-up g adjusted for baseline 
MHVS. 
a




change following addition of predictor into the 
respective previous model.*entered in a second block. G has been imputed. Log-transformed 
values were used for NT-proBNP; square root transformed values were used for packyears. 
Variables entered in stepwise procedure: PA (presence of claudication and/or ABI≤0.90), CHD 
(angina and/or MI), stroke, cIMT, NT-proBNP, DR, packyears, alcohol consumption (quintiles), 
waist-hip ratio, LDL:HDL, systolic blood pressure, HbA1c, inflammation factor, cortisol; 
baseline history of SH. 
CHD, coronary heart disease; PA, peripheral atherosclerosis; LDL:HDL, low-density lipoprotein 
to high-density lipoprotein ratio; ABI, ankle brachial pressure index; DR, diabetic retinopathy; 





8.4.4 Multivariable association of risk factors with four-year 
cognitive change 
The contributions of the range of risk factors to four-year change in cognitive 
function were also explored. With regression scores of follow-up g adjusted for 
baseline g as the outcome, age and sex were controlled for in a first block. In the 
stepwise part of the analysis, the 15 risk factors were entered one at a time in an 
automated procedure. These were retained if p<0.05 and removed if the level of 
significance dropped to p>0.10 following the addition of subsequent predictors. 
Results of the final model are shown in Table 8.5. As was also found for the level of 
cognitive function and for estimated lifetime cognitive change, inflammation and 
packyears were identified as significant predictors of the four-year change in g. 
HbA1c was also included, mirroring its significant contribution to the final model of 
estimated lifetime cognitive change. NT-proBNP and cIMT, neither of which had 
been included in the models of level of cognitive function and estimated lifetime 
cognitive change, were novel additions to the model.  
 
Inflammation again was identified as the strongest predictor of four-year decline in g, 
and accounted for 2.2% of variance. Higher cIMT and higher NT-proBNP accounted 
for 1.6% and 0.6% if variance in four-year decline in g over and above the respective 
previously entered predictors. Higher HbA1c accounted for 1% of variance. Each 
standard deviation increase in HbA1c was associated with a 0.10 standard deviation 
decrease in follow-up g with baseline g and all of the remaining predictors held 
constant, demonstrating a relatively small effect size. In order to ascertain the 
independence of these findings from depressed mood, the analysis was repeated with 
HADS-D entered in a first block along with age and sex. Again, the findings were 
almost unchanged (Model 2; Table 8.5). Adjustment for MHVS along with age and 
sex in a first block aimed to explore the independence of the findings from individual 
differences in peak pre-morbid abilities, and slightly reduced the effect sizes of the 
final regression model of four-year change in g (Model 3; Table 8.5). In this step, the 
association of NT-proBNP became just short of statistical significance (p=0.055) and 
so this predictor was not retained in the final model. The variance explained by the 
remaining risk factors was largely unchanged, although it reduced notably, for 
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inflammation, for instance, from 2.2% in age- and sex-adjusted analyses to 1.9% in 
analyses adjusted for age, sex and MHVS. 
















Age* -0.10 0.01 0.015 0.022 
Sex* 0.05 0.08 0.243 
+inflammation -0.10 0.04 0.016 0.022 
+cIMT -0.12 0.22 0.003 0.016 
+packyears -0.11 0.01 0.007 0.011 
+HbA1c -0.10 0.04 0.007 0.010 
+NT-proBNP -0.08 0.03 0.037 0.006 
Total R
2
    0.086 
 
Model 2 
Age* -0.09 0.01 0.016 0.024 
Sex* 0.05 0.08 0.261 
HADS-D* 0.02 0.06 0.690 
+inflammation -0.10 0.04 0.015 0.020 
+cIMT -0.12 0.22 0.003 0.016 
+packyears  -0.11 0.01 0.006 0.011 
+HbA1c -0.10 0.04 0.007 0.010 
+NT-proBNP -0.09 0.03 0.034 0.006 
Total R
2
    0.086 
 
Model 3 
Age* -0.12 0.01 0.001 0.051 
Sex* 0.05 0.08 0.184 
MHVS* 0.15 0.01 <0.001 
+cIMT -0.13 0.22 0.001 0.014 
+inflammation -0.10 0.04 0.011 0.019 
+HbA1c -0.10 0.04 0.008 0.010 
+packyears -0.09 0.01 0.019 0.008 
+NT-proBNP -- -- -- -- 
Total R
2
    0.102 
N=671 for Model 1 and Model 2. N=665 for Model 3. Outcome variable is follow-up g 
adjusted for baseline g. G has been imputed.
 a




change following addition of predictor into the respective previous model.   
*entered in a first block. Log-transformed values were used for NT-proBNP; square root 
transformed values were used for packyears. Variables entered in stepwise procedure: 
PAD (presence of claudication and/or ABI≤0.90), CHD (angina and/or MI), stroke, cIMT, 
NT-proBNP, DR, packyears, alcohol consumption (quintiles), waist-hip ratio, LDL:HDL, 
systolic blood pressure, HbA1c, inflammation factor, cortisol, baseline history of SH. 
CHD, coronary heart disease; PAD, peripheral arterial disease; LDL:HDL, low-density 
lipoprotein to high-density lipoprotein ratio; ABI, ankle brachial pressure index; DR, 
diabetic retinopathy; SH, severe hypoglycaemia. 
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8.4.5 Summary of the findings from multivariable analyses 
In the stepwise regression analysis of 15 risk factor variables measured in the 
ET2DS, inflammation, smoking, alcohol intake, glycaemic control, abdominal 
obesity, stroke, cIMT and NT-proBNP were all identified as those with the strongest 
associations with cognitive outcome, as is illustrated in Figure 8.1. In all three final 
‘optimal’ models of follow-up g, estimated lifetime decline in g and late-life decline 
in g, inflammation was the strongest contributor. Higher packyears, a higher waist-
hip ratio and poorer glycaemic control were also linked to poorer cognitive outcome. 
Packyears was included in all three final models, HbA1c was included in the models 
of estimated lifetime and late-life cognitive change only, and the contribution of 
waist-hip ratio was limited to the cross-sectional analysis of the level of cognitive 
function at year 4. Higher alcohol consumption was associated with better level of 
late-life cognitive function and a shallower estimated lifetime cognitive decline, but 
was not associated with the four-year cognitive change in older age. Of note, age was 
identified as the single most important factor predicting late-life cognitive function, 
estimated lifetime cognitive change and late-life cognitive change. All results from 
the stepwise regression procedures were largely similar when participants with 








Figure 8.1: Venn diagram of significant predictors of cognitive outcome 
identified in the stepwise regression procedures.  Note that these findings are 
strongly dependent on the variables entered into the modelling process as well 
as their inter-relationships, and so may not be definitive and replicable in 
another cohort. Font size is used to indicate relative effect sizes of associations. 
Percentages in brackets indicate total proportion of variance in respective 
model accounted for by the respective five risk factors, age and sex.  
 
Neither the symptomatic macrovascular disease variables nor severe hypoglycaemia 
were significant contributors in the final model of four-year cognitive decline. For 
hypoglycaemia, this contrasts the findings described in Chapter 8 (Results III). For 
the macrovascular disease variables this is consistent with the findings in Chapter 7 
(Results II), which implicated stroke as a predictor of steeper estimated lifetime 
cognitive change with a lesser role in the post-stroke cognitive change measured 
between baseline and year 4. In support of the findings of Chapter 7 (Results II), the 
subclinical markers NT-proBNP and cIMT were both identified as significant 
contributors in the final model of late-life cognitive decline. Although a lower ABI 
had been significantly associated with a steeper four-year cognitive decline in 
Chapter 7 (Results II), ‘peripheral atherosclerosis’, which captured subjects with 
subclinical (ABI ≤0.90) and/or symptomatic peripheral arterial disease (intermittent 
claudication), was not retained in the final regression model of four-year change in g, 
but this could potentially be due to reduced statistical power due to the categorical 
nature of the variable.  
321 
 
Chapter 9: Discussion 
9.1 Overview 
Using two waves of data from the Edinburgh Type 2 Diabetes Study (ET2DS), this 
thesis set out to investigate associations of macrovascular disease and severe 
hypoglycaemia with late-life cognitive decline short of frank dementia in older 
people with type 2 diabetes, with an attempt to explore potential underlying 
mechanisms through statistical adjustment for a wide list of potential confounders. 
Additionally, a statistical model was used to assess the relative contribution of a 
much wider range of potential risk factors to late-life cognitive decline, in a 
multivariable analysis fairly unique to the literature on human cognitive decline. In 
the present chapter, the main findings are discussed in the context of previous 
literature, before potential directions for future research, including investigations into 
possible targets for intervention, are described.  
9.2 Main findings 
In men and women aged 60-75 years with type 2 diabetes participating in the 
community-based Edinburgh Type 2 Diabetes Study (ET2DS), global cognitive 
function measured by g as well as ability in a number of age-sensitive cognitive 
domains declined over a four-year follow-up period. Individuals with a lower peak 
pre-morbid ability in young adulthood (estimated by a baseline test of vocabulary, 
MHVS) were more likely to have symptomatic macrovascular disease, evidence of 
subclinical macrovascular disease and to have experienced at least one episode of 
severe hypoglycaemia in later life (all assessed at baseline in the ET2DS). For severe 
hypoglycaemia, individuals with poorer global cognitive function at baseline were 
also at two-fold increased risk of having a first-ever severe hypoglycaemic episode 
over the subsequent four years.   
 
The main outcome of interest for this thesis was the association of metabolic and 
vascular risk factors with subsequent, late-life cognitive decline. In this respect, 
stroke, subclinical macrovascular disease (measured by ankle-brachial index, ABI, 
circulating NT-proBNP or carotid intima-media thickness, cIMT), as well as a 
history of severe hypoglycaemia were all associated with a steeper decline in 
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cognitive function since estimated peak pre-morbid ability and with a steeper four-
year cognitive decline between baseline and four-year follow-up. For severe 
hypoglycaemia, incident hypoglycaemia episodes during the study period were also 
associated with steeper four-year cognitive decline. However, overall effect sizes of 
statistically significant findings were relatively small. This is likely to be due to a 
range of factors influencing and/or correlating with four-year cognitive decline. 
Consequently, individual measured risk factors then account for miniscule 
proportions of variance, as further discussed below in the section on findings from 
multivariable models. For instance, a history of hypoglycaemia reported at baseline 
and incident severe hypoglycaemia accounted for only 0.07% and 0.09% of variance 
in four-year decline in global ability measured by g, respectively. Similarly small 
effect sizes were also found for findings on macrovascular disease associations with 
cognitive decline. For stroke and for severe hypoglycaemia, associations were 
relatively more apparent for estimated lifetime cognitive decline, whereas for cIMT, 
NT-proBNP and ABI associations were more apparent for four-year cognitive 
decline, and only in these analyses were relatively independent of estimated peak 
pre-morbid cognitive function, socioeconomic status and stroke. In contrast, 
associations of these subclinical markers of macrovascular disease with level of late-
life cognitive function and with estimated lifetime cognitive change appeared to 
stand under the confounding or mediation by these factors.   
 
The exploratory analyses presented in the second part of the thesis assessed a total of 
15 baseline metabolic and vascular risk factors in their relative contribution to a 
statistical model for late-life cognitive decline. The inflammation ‘factor’, extracted 
from circulating levels of four inflammatory markers, and packyears, reflecting the 
lifetime exposure to smoking, were identified as significant predictors in the 
‘optimal’ models of global cognitive ability at year 4, of estimated lifetime change in 
cognitive function, and of four-year change in global ability. Inflammation was 
identified as the strongest predictor, and accounted for 3.7% of variance in follow-up 
cognitive function and for 2.2% in four-year cognitive decline with age and sex 
controlled for. Significant contributions of waist-hip ratio to the statistical models 
were restricted to the level of cognitive function at year 4, and contributions of stroke 
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and alcohol consumption were limited to level of cognitive function at year 4 and 
estimated lifetime change in cognitive function. Long-term hyperglycaemia as 
measured by HbA1c contributed to the models of estimated lifetime cognitive change 
and of four-year cognitive change only. In the ‘optimal’ model of the latter, NT-
proBNP and cIMT also contributed as significant predictors. For all risk factors 
(except alcohol which appeared to be protective), higher severity of disease or more 
detrimental lifestyle factors were associated with poorer cognitive outcome.  
9.3 Study strengths 
Due to its prospective study design, the ET2DS allowed the investigation of the 
relationship between baseline risk factors and subsequent cognitive change. The 
relatively large sample size of the study led to relatively high power of statistical 
analyses to detect actual associations present in the data, which depends strongly on 
the number of observations. 
 
The sample recruited for the ET2DS was largely representative of all invited 
participants (Marioni et al., 2010). In contrast to other cohort studies often recruiting 
from a single city, recruitment was made from the population living in the city of 
Edinburgh and in rural areas in the Lothian area. The study population included 
participants from the full spectrum of community-living people with type 2 diabetes, 
with treatment modalities ranging from diet-controlled to insulin-treated. Overall, the 
study therefore should have acceptably high external validity, i.e. should be 
generalisable to the target population of all older people with type 2 diabetes living 
in Scotland (Szklo, 1998). Given the diabetic status of its participants, the retention 
rate of 78% between baseline and year 4, which is comparable to that of other 
prospective cohort studies (Kramer, von Muhlen, & Barrett-Connor, 2010; L. Wang 
et al., 2004) was very good. A large battery of well-validated cognitive tests free of 
floor and ceiling effects assessed performance on a range of cognitive domains. 
Influences by current mild hypoglycaemia on cognitive test performance were 
prevented by ensuring that blood glucose levels were well within the 





Participants were extensively characterised in terms of demographic and clinical risk 
factors, as well as cognitive testing, and hospital data were consulted to confirm 
diagnoses of clinical conditions including dementia and symptomatic macrovascular 
disease. All research staff were appropriately trained in their respective assessments, 
and cognitive test administration was validated prior to clinic begin by an external 
research associate. Standard operating procedures were followed to reduce observer 
bias. This detailed and accurate assessment of a wide range of potential confounding 
variables enabled high quality multivariable analyses to be undertaken.   
 
In contrast to much of the previous literature, the ET2DS aimed to capture the entire 
range of age-related cognitive decline rather than focusing on the end-point of 
dementia, and, with only 19 participants identified as suffering from dementia by 
year 4, the study was relatively successful in this venture. Repetition of the main 
analyses with exclusion of dementia cases did not alter the statistical significance or 
effect size of findings, showing that dementia did not drive the risk factor 
associations with cognitive decline reported in this thesis.  
 
Missing observations negatively impact on a study’s statistical power to detect 
associations in the data. This may become problematic particularly in analyses 
involving a number of variables, such as the principal component analysis used to 
extract the general cognitive ability factor g, where analyses are then affected by an 
increased risk of Type II statistical error, i.e. the acceptance of a false null 
hypothesis. In the ET2DS, the loss of statistical power due to missing cognitive test 
data was strategically avoided through the use of standard operating procedures and 
an effort of testers to motivate participants. This resulted in relatively little data 
missing for cognitive tests at baseline (<2% for each test) and at year 4 (<5% for 
each test). Additionally, for the seven tests of fluid-type cognitive ability, missing 
data for participants with missing data on one, two or three tests was imputed prior to 
the calculation of g. The approach reduced the proportion of missing data on these 
tests to below 0.5% at baseline and to below 1% for the tests at year 4, and will have 
aided the successful detection of exposure-outcome associations in analyses of g. 
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9.4 Study limitations 
9.4.1 Limitation of study design, risk factor variables and statistical 
analyses 
Some limitations to the study design and the methodology of analyses presented in 
this thesis must be addressed. Prospective cohort studies are commonly vulnerable to 
a distortion of findings due to exclusion of individuals who are affected by the 
outcome of interest prior to study begin (left truncation), a failure to establish the 
outcome of interest by the end of the study (right censoring) and the inclusion of 
subjects who were affected by the outcome prior to study begin (left censoring). Left 
truncation leads to an underestimation of associations between predictors and 
outcome, for instance (Applebaum, Malloy, & Eisen, 2011; Cain et al., 2011). 
However, given the advanced age of subjects, who were recruited at an age at which 
cognitive declines tend to develop, as well as the continuous nature of the outcome of 
interest, these issues are unlikely to apply to the ET2DS. The study provided a 
‘snapshot’ of age-related cognitive declines rather than focusing on incidence of a 
categorically assessed measure of cognitive function, such as the incidence of 
dementia.  
 
Yet, the two-wave design of the study offering this ‘snapshot’ restricts the 
interpretation of cognitive ‘change’ of participants. Whereas a study with two waves 
may be successful in the estimation of the mean change of a sample between two 
time points, it may be less able to accurately capture person-specific changes in 
cognitive function, because the individual time paths for each participant are poorly 
defined (Rogosa, Brandt, & Zimowski, 1982; Wilson et al., 2002). This is due to 
inevitable influences of measurement error (further described in Section 9.4.2) on 
scores at each time point, which constitutes a kind of ‘noise’ masking the ‘signal’ 
under investigation, i.e. the longitudinal change in cognitive ability (Salthouse & 
Nesselroade, 2011). Studies with multi-wave designs (those with cognitive test data 
collected at three or more waves) are preferable to studies with two-wave designs, 
because measurement error is compensated for to an extent by repeated measurement 
of cognitive function. Yet, one group of researchers noted that “certainly, two waves 
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of data are better than one” (Rogosa et al., 1982, p. 729), and the current findings 
may be seen as a first step towards the investigation of risk factor associations with 
cognitive decline in the ET2DS. Future waves of the study could now be used to 
confirm or refute the findings presented in this thesis.  
 
Due to its observational study design, the present analyses were unable to evaluate 
the potential for causality in the reported associations, however, because none of the 
exposure variables were manipulated. As well as causal relationships, all associations 
of risk factors with cognitive decline reported in this thesis could therefore reflect 
associations of both with other, measured or unmeasured factors. The multivariable 
adjustment at least for a number of measured potential confounders aimed to explore 
this issue. The present findings, most of which survived multivariable adjustment, 
now merit further investigation, for instance in randomised controlled trials where 
possible, in order to identify potential causality underlying any associations.  
 
Another limitation, which is similarly difficult to avoid, is the selective attrition 
between baseline and year 4, which may have systematically affected findings. Thus, 
year 4 data was ‘missing at random’ (but not ‘missing completely at random’), 
meaning that for each subject, data observed at baseline (including lower cognitive 
test scores), influenced the probability of missing data at follow-up (Dufouil, Brayne, 
& Clayton, 2004). This type of attrition will have selected the ‘attenders’ of the year 
4 follow-up for high ability and will have led to an underestimation of cognitive 
declines during the study period. This was previously demonstrated in a cohort study 
reporting a substantial increase in ten-year cognitive declines following adjustment 
for drop-out (Chatfield, Matthews, Brayne, & Study, 2007).  
 
The interpretation of findings is also limited by the specific risk factor variables used 
in this thesis. In contrast to cognitive test data, risk factor data were not imputed, and 
so any missing data on these parameters led to a disproportionate reduction in 
statistical power in analyses involving a number of risk factors. Specifically, this 
applied to the stepwise regression analyses associating 15 risk factors with cognitive 
outcome, which ‘lost’ around one fifth of the sample due to various missing risk 
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factor data. Although the present analysis appears to have been unique in the use of 
an inflammation ‘factor’ (a single previous study had calculated a z-score from CRP 
and TNF-α; (Arfanakis et al., 2013)), findings are uninformative with respect to the 
contribution of individual markers. The use of the ‘packyears’ variable also did not 
allow an evaluation of associations of having ever smoked versus currently smoking 
with the risk of cognitive decline (Anstey, von Sanden, Salim, & O'Kearney, 2007). 
Alcohol intake was investigated in a linear fashion, despite the fact that the 
relationship of this risk factor with cognitive function appears to be complex and 
may be more appropriately represented by an inverted U-shaped function. 
Contrasting potential beneficial effects of moderate drinking compared with 
abstaining (Peters, Peters, Warner, Beckett, & Bulpitt, 2008), excessive drinking 
appears to have detrimental effects on cognition (Edelstein, Kritz-Silverstein, & 
Barrett-Connor, 1998; Hudetz & Warltier, 2007; Smith & Atkinson, 1995). However, 
strong contributions by excessive drinkers to findings, which could mask beneficial 
effects of moderate drinking in linear analyses, appear unlikely. All participants of 
the ET2DS were older and were suffering from diabetes, and only 5.6% reported 
ever having been told by a doctor that they had an alcohol problem.  
 
Finally, with as many as 750 individual analyses reported in Chapter 6 (Results II) 
alone, the analyses presented in this thesis total thousands. One possibility to deal 
with the resulting high risk of Type I statistical error is to apply Bonferroni 
adjustment to p-values. As described in the Method chapter, this type of adjustment 
is often deemed too conservative (Perneger, 1998), including in this instance. The 
Bonferroni-adjusted p-value indicating statistical significance would be p<0.00007 
for Chapter 6 alone, and (presumably) few or none of the analyses would survive this 
adjustment. However, the overall pattern of results suggests that a majority of 
findings with p<0.05 reflect more than chance results, so that the findings presented 
here likely to be relatively accurate reflections of risk factor associations with 
cognitive decline. None of the findings are interpreted as ‘correct’ and all merit 




9.4.2 Limitations of cognitive measurements 
Cognitive test scores are generally influenced by error from a variety of sources, 
including test-specific measurement error. The MHVS, for instance, relies on literacy 
skills. The use of this test in particular was additionally restricted, because it 
represented a mere estimate of peak pre-morbid ability. With recruitment not made 
until later life, data on the actual level of cognitive function in early life was not 
available for the participants of the ET2DS. However, the MHVS has previously 
been shown to correlate strongly with more commonly used, well-recognised 
estimates of pre-morbid ability, such as the National Adult Reading Test (NART) 
(O'Carroll & Gilleard, 1986), and so its use was deemed acceptable for the purpose 
of the present analyses.  
 
With exception of the reaction time test at year 4, each cognitive test was 
administered in a single trial at each wave. Because intra-individual variability 
appears to increase with age (Dykiert, Der, Starr, & Deary, 2012; West, Murphy, 
Armilio, Craik, & Stuss, 2002) and more severely in low-ability individuals (Rabbitt, 
Osman, Moore, & Stollery, 2001), it may have systematically affected test scores. 
Test scores may further be influenced by intra- and inter-tester variability in the 
ability to motivate participants and in the precision of test administration. For the 
MMSE, for instance, a previous study found that MMSE scores for identical subjects 
were dependent on testers (Fabrigoule, Lechevallier, Crasborn, Dartigues, & 
Orgogozo, 2003). No adjustments were made for blood glucose levels at the time of 
testing despite potential impacts of diurnal fluctuations in glycaemic control on 
cognitive test performance (McCall, 2005), potentially further contributing to 
measurement error affecting cognitive tests.  
 
At their second visit to the research clinic, patients were also familiar with the clinic 
environment, the research staff and the experience, and in addition to an implicit 
learning of the testing material will have had the opportunity to develop strategies to 
improve performance. Such practice effects, which appear to eradicate only around 
seven years after initial exposure to the test material (Salthouse, Schroeder, & Ferrer, 
2004), further (in addition to selective attrition) are likely to have added to an 
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underestimation of the cognitive decline during the study period. For the tests of 
verbal and non-verbal memory (Faces, Logical Memory), practice effects may help 
to explain the significant improvements in scores between baseline and year 4.  
 
Yet, with a previous report of significant improvements in cognitive test scores on as 
many as four of nine cognitive tests over similar length of follow-up (Fontbonne, 
Berr, Ducimetière, & Alpérovitch, 2001) (compared with two of seven cognitive 
tests in the ET2DS), it may be assumed that the underestimation of cognitive 
declines here were relatively limited. Additionally, the measurement error affecting 
the seven cognitive tests of fluid ability were partly compensated for by the 
calculation of a general ability factor g, and systematic influences by inter- and intra-
tester variability in test administration and scoring appear unlikely given that 
standard operating procedures were followed and staff were appropriately trained in 
the administration of the cognitive test battery.  
 
Overall, the ET2DS was affected by a number of limitations. Many, including 
potential influences by selective attrition, practice effects and an inability to reveal 
causality behind any associations, are inherent to all prospective cohort studies. The 
use of two-wave data further restricted the analysis of cognitive change due to 
measurement error affecting scores at each time point. However, all possible steps 
were taken to shield the analyses presented in this thesis from such influences.  
9.5 Comparison of findings with previous studies, issue of 
confounding and potential mechanisms  
In this section, the main findings presented in this thesis are described with reference 
to the previous literature. For the analyses of specific risk factors (macrovascular 
disease; severe hypoglycaemia), the roles of potential confounding factors and/or 
potential underlying mechanisms are evaluated.  
9.5.1 Macrovacular disease and cognition  
The findings from analyses of the relationship of macrovascular disease with 
cognitive function and cognitive decline during the course of the study are 
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interpreted separately for risk factors representing symptomatic and those 
representing potentially subclinical levels of disease.  
Symptomatic macrovascular disease and cognition  
In contrast to the previous, limited literature on the relationship between coronary 
artery disease and cognitive ability in people with type 2 diabetes (Bruce, Davis, 
Casey, Starkstein, Clarnette, Foster, et al., 2008; Cukierman-Yaffe et al., 2009; de 
Galan et al., 2009), angina and prior myocardial infarction (MI) were both associated 
with a lower level of late-life cognitive function.  However,  these finding appeared 
to be confounded by pre-morbid ability and lower pre-morbid ability itself appeared 
to predispose patients to late-life macrovascular disease as well as to lower ability in 
later life - it has been suggested that similar findings in previous studies may be due 
to poorer lifestyle, lower system integrity or reduced disease and injury prevention in 
lower-ability individuals (Batty, Deary, & Gottfredson, 2007). The present 
prospective analyses have extended current literature on type 2 diabetes, previously 
restricted to comparisons of the prevalence of CHD between cognitive ‘decliners’ 
and ‘non-decliners’ (Bruce, Davis, Casey, Starkstein, Clarnette, Almeida, et al., 
2008; Reijmer et al., 2011), by showing that CHD was relatively unrelated to the 
subsequent rate of potentially more subtle cognitive decline. Together with the 
consistently non-significant findings for PAD, the results suggest that symptoms of 
macrovascular disease manifesting in areas other than the brain may not be useful 
risk markers for cognitive decline in people with type 2 diabetes. 
 
Previous studies on cerebrovascular disease and cognition have mainly used data on 
stroke or infarction on brain imaging. In the ET2DS, stroke and transient ischaemic 
attack (TIA) were ascertained, but significant findings were restricted to stroke. This 
disparity is unexpected considering identical aetiology for stroke and TIA, but may 
be attributed to a relatively low number of participants in the TIA group (a relatively 
large proportion of attacks remain undiagnosed (Kessler & Thomas, 2009)) or to a 
common misdiagnosis (Prabhakaran, Silver, Warrior, McClenathan, & Lee, 2008). 
Stroke is already a well-established risk factor associated with cognitive dysfunction 
and impairment (Pendlebury & Rothwell, 2009), although the relationship with 
milder forms of impairment and cognitive decline in exclusively diabetic populations 
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had previously not been extensively investigated. Consistent with some of the rare 
previous studies of people with type 2 diabetes applying detailed cognitive testing 
(Manschot et al., 2007; Manschot et al., 2006; Umemura et al., 2011), the level of 
processing speed, in addition to executive function and global ability measured by g, 
was most severely compromised in participants with a history of stroke. All 
associations survived adjustment for MHVS and were also independent of 
socioeconomic status measured by Scottish Index of Multiple Deprivation (SIMD) 
quintiles. This may demonstrate a fall in cognitive function at the time of the event, 
which did not completely recover to a pre-stroke level even over the course of at 
least four years. The overall weakness of effect sizes were perhaps surprising, 
however, when considering that the cerebrovascular accident(s) occurred in the 
brain, i.e. the ‘substrate’ of cognition, but may demonstrate a potential for the brain 
to recover parts of its function following stroke.  
 
Conventional vascular risk factors, including blood pressure and smoking history, 
did not appear to drive the relationship between stroke and steeper estimated lifetime 
cognitive decline. Instead, the mechanisms by which the event affected cognitive 
function are likely to be direct. Stroke causes infarction in the area surrounding the 
occluded artery and the blood flow in this tissue is reduced to around 20% of 
previous flow (Sims & Muyderman, 2010). In addition to the resulting neuronal loss, 
infarcts increase oxidative stress (identified as a major cause of ageing (Kirkwood, 
2005)) and initiate inflammatory responses (Barreto, White, Ouyang, Xu, & Giffard, 
2011). In both humans and in animal models, stroke has also been linked to an 
increase in beta amyloid generation (Lee et al., 2005; Zhang et al., 2010), although, 
as aforementioned these potential immediate effects of stroke on cognition may have 
experienced improvement between the event and the cognitive assessment at the 
clinic, for instance through implicit compensation of deficits. Mediation of the 
decline between (estimated) pre- and post-stroke ability by vascular depression, 
which may be caused by vascular damage to frontal-subcortical circuits (Newberg, 
Davydow, & Lee, 2006) and manifests in symptoms similar to vascular dementia 
(Alexopoulos et al., 1997), appears unlikely given that the findings for stroke in the 
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multivariable analysis of Chapter 8 (Results IV) survived post-hoc adjustment for 
depressive symptoms (HADS-D).  
 
Contrary to two previous investigations in older adults with type 2 diabetes (Bruce, 
Davis, Casey, Starkstein, Clarnette, Almeida, et al., 2008; Reijmer et al., 2011), but 
consistent with one that had applied less detailed cognitive testing (Wu et al., 2003) 
and with evidence from the general population (Haan, Shemanski, Jagust, Manolio, 
& Kuller, 1999; Kalmijn, Feskens, Launer, & Kromhout, 1996; Vermeer et al., 
2003), a baseline history of stroke was associated with a steeper rate of late-life 
cognitive decline. Yet, these prospective associations were even weaker and less 
statistically significant compared with the analyses of estimated lifetime decline. 
Adjustment for MHVS (which predisposed participants to an increased risk of stroke 
as well as to a steeper late-life cognitive decline, consistent with at least some of the 
overall mixed evidence from the general population (Bourne, Fox, Deary, & 
Whalley, 2007; Gow et al., 2012)) led to statistical non-significance for g, and 
additional adjustment for SIMD further attenuated the finding. Overall, the evidence 
therefore suggests that the event weakly but negatively impacted on cognitive 
function, but played a lesser role in the determination of post-stroke cognitive 
trajectories.  
Subclinical markers of macrovascular disease and cognition  
The present investigation of NT-proBNP, cIMT and ABI was unique in two ways. It 
was the first prospective study of ABI and cIMT and cognitive decline measured 
prospectively by detailed neuropsychological tests in a population with type 2 
diabetes, and was also the first to investigate NT-proBNP in any cognitive context in 
people with type 2 diabetes.  
 
For NT-proBNP, cIMT and ABI, associations with lower level of ability were most 
consistently found for global ability measured by g, for various measures of the 
memory domain and for processing speed (associations with the latter as measured 
by reaction time were particularly strong for cIMT), but these findings appeared to 
be driven by socioeconomic status as well as by stroke. It may be the case that 
individuals with greater late-life atherosclerosis were likely to have come from a 
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relatively lower socioeconomic background, to have had a history of stroke and 
(potentially due to these factors) were also likely to have a relatively lower late-life 
cognitive ability. Some previous studies have neglected the necessity of considering 
peak pre-morbid ability or its proxies in cross-sectional analyses of subclinical 
macrovascular disease (e.g., (Bruce, Davis, Casey, Starkstein, Clarnette, Foster, et 
al., 2008)). The present analyses have shown that the cross-sectional findings in the 
ET2DS were not driven by potential confounding by peak pre-morbid ability.  
Adjustment for estimated peak pre-morbid ability additionally allowed the analysis 
of risk factor associations with estimated lifetime change in cognitive function 
between young adulthood and later life. In associations of the subclinical markers of 
macrovascular disease (except those of cIMT) with this outcome, socioeconomic 
status and stroke appeared to play a confounding or mediating role. It is plausible, for 
instance, that a lower socioeconomic status may have predisposed people to an 
increased risk of late-life atherosclerosis of the heart and the periphery, an increased 
risk of stroke as well as to a steeper cognitive decline between peak pre-morbid 
ability and later life, although the data presented in this thesis does not allow 
conclusion as to specific underlying causal pathways. Atherosclerosis of the carotid 
artery (cIMT) appeared to play a role which was independent of socioeconomic 
status or of stroke, showing that this marker may be particularly valuable in the risk 
assessment of a patient’s (estimated) lifetime cognitive change.  
 
The previous prospective literature on NT-proBNP, cIMT or ABI and cognitive 
decline short of dementia had been severely restricted by flawed study designs, 
including extremely short follow-up periods (Bruce, Davis, Casey, Starkstein, 
Clarnette, Almeida, et al., 2008; McDonagh et al., 2010), the use of screening 
instruments (Kerola et al., 2010) potentially unsuitable for the detection of subtle 
cognitive declines (Tombaugh & McIntyre, 1992), the cognitive categorisation of 
participants and subsequent loss of statistical power (Bruce, Davis, Casey, Starkstein, 
Clarnette, Almeida, et al., 2008), or the focus on people with type 1 diabetes 
(Jacobson et al., 2011) despite their relatively young age,  therefore neglecting the 
‘crucial period’ of brain development in later life (Biessels, Deary, & Ryan, 2008). 
For ABI, inclusion of individuals with abnormally high measurements is also 
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common in the literature despite the fact that due to high ABI reflecting stiffened 
arteries, their inclusion may weaken any linear analyses. This becomes apparent in a 
strengthening of findings on ABI-cognition links following the exclusion of high-
ABI individuals (Feinkohl et al., 2013; Laurin, Masaki, White, & Launer, 2007).  
 
With these potential flaws in previous studies addressed, the findings presented in 
this thesis have now demonstrated that higher circulating natriuretic peptides, higher 
cIMT and lower ABI at baseline are all relatively weakly but significantly associated 
with a steeper late-life cognitive decline in people with type 2 diabetes. Contrasting 
the evidence for symptomatic macrovascular disease, the associations of cognitive 
decline appeared slightly stronger for four-year cognitive decline compared with 
associations of these vascular markers with estimated lifetime cognitive decline. This 
pattern of results is of interest, because in terms of identifying elderly subjects at risk 
of subsequent cognitive decline, information on a patient’s future decline may be 
more valuable compared with information which incorporates past decline.  
The prospective observations were independent of potential confounding by 
estimated peak pre-morbid ability or of socioeconomic status.  
 
Similar to some of the previous literature, which had considered the potential 
confounding role of stroke in associations of subclinical macrovascular disease with 
cognitive function or decline (Daniels et al., 2011; Kerola et al., 2010; Saleh, 2010), 
associations with estimated lifetime and late-life decline also either survived 
additional adjustment for stroke or fell just short of statistical significance. This 
demonstrates the usefulness of measuring late-life markers of atherosclerosis which 
may not have reached symptomatic levels. These markers appear to offer some, 
albeit relatively limited, information on the risk of future cognitive decline over and 
above the evaluation of a patient’s potential history of stroke and stroke-associated 
neuronal damage, their pre-morbid ability or of their socioeconomic background. 
Their relationship with cognitive function was also not confounded by their 
associations with vascular risk factors, including smoking and hypertension, which 




   
Instead, the mechanisms relating NT-proBNP, ABI and cIMT to cognitive decline 
are likely to involve correlations of atherosclerosis in the periphery, the carotid artery 
and of the heart with atherosclerosis in the cerebral vasculature, including the risk of 
incident symptomatic or asymptomatic cerebral infarction (which was not considered 
in the present analyses). This explanation is supported by relatively largest effect 
sizes for cIMT, which is measured in relatively closest proximity to the brain, than 
for ABI or NT-proBNP. Additionally, all three markers were associated with slower 
processing speed (mirroring previous evidence, (Johnson, Price, Rafnsson, Deary, & 
Fowkes, 2010; Kindermann et al., 2012; Komulainen et al., 2007), which appears to 
be a typical early sign of dementia of the vascular type in particular (Kalaria & 
Erkinjuntti, 2006). Their roles as proxies of cerebral vascular pathology are also 
demonstrated in reports from brain imaging studies associating ABI (Bouchi et al., 
2012), NT-proBNP (Nilsson, Gustafson, & Hultberg, 2012; Tabara et al., 2013) and 
cIMT (De Leeuw et al., 2000; Saleh, 2010; Takahashi et al., 2006) with symptomatic 
cerebrovascular disease, white matter heterogeneity, white matter lesions or 
leukoaraiosis. 
 
Further potential mechanisms are marker-specific. Localised atherosclerosis of the 
carotid artery involves an increased risk of the formation of atherosclerotic plaques, 
which may become a source of thromboemboli resulting in cerebral infarction 
(Hollander et al., 2002). Raised circulating levels of natriuretic peptides are typical of 
congestive heart failure (CHF), which is associated with an increased risk of the 
development of cardiac mural emboli resulting in cerebral infarction (Bennett & 
Sauvé, 2003) and with cerebral hypoperfusion due to poor cardiac output (Bennett, 
Sauvé, & Shaw, 2005). Some evidence also points to direct effects of the peptide on 
endothelial dysfunction (Chong et al., 2004; van der Zander, Houben, Kroon, & de 
Leeuw, 1999). Although natriuretic peptides appear to be unable to pass the blood-
brain barrier (Ermisch, Rühle, Kretzschmar, & Baethmann, 1991), it may be 
plausible that the blood-brain barrier is vulnerable to their passage when BBB 
function is compromised, as is the case in diabetes (Hawkins, Lundeen, Norwood, 
Brooks, & Egleton, 2007). This suggestion is highly speculative and the present 
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observational study of course does not allow evaluations of any of the 
aforementioned potential pathophysiological mechanisms.  
Integration of findings for symptomatic and subclinical macrovascular 
disease, and implications  
Overall, the present results provide additional evidence that the impact of vascular 
disease on cognition may not be restricted to localised cerebral small vessel disease 
or altered blood flow and ischaemic damage as a consequence of stroke, and that 
cognitive decline could reflect systemic atherosclerotic changes. NT-proBNP, ABI 
and cIMT appear to function as biomarkers of risk of late-life cognitive decline, 
despite their strong associations with subclinical macrovascular disease in different 
areas of the vasculature and may offer some valuable information over and above 
traditional vascular risk factors. Stroke-associated declines in cognitive function 
were relatively limited considering the role of the brain as the ‘substrate’ for 
cognition, and were largely restricted to declines between (estimated) pre-stroke 
ability and post-stroke ability in later life. Associations of stroke with four-year 
cognitive decline was relatively weaker; none of the remaining measures of 
symptomatic macrovascular disease (MI, angina, PAD) were related to this outcome. 
Consequently, determination of subclinical macrovascular disease using continuous 
measures may be preferable over symptomatic categorically assessed macrovascular 
disease for the early identification of individuals at risk of late life cognitive decline. 
With the proximity of the carotid artery to the brain, cIMT could be hypothesised to 
represent the most accurate, non-invasive marker of asymptomatic cerebral vascular 
damage. In people with stroke, the monitoring of cognitive development may only be 
necessary in the short-term and in consideration of pre-stroke ability (estimated for 
instance by MHVS, occupation or relative report) to ascertain the damage caused by 
the event. However, it must be recognised that the categorical nature of ‘events’ data 
compared with the continuous distribution of the subclinical measures is likely to 




9.5.2 Severe hypoglycaemia and cognition 
Considering that all analyses of severe hypoglycaemia (SH) in the ET2DS were 
based on self-report, the validation of this data was paramount to ensure the validity 
of the study’s findings. The 6-month survey of SH embedded in the main study 
aimed to address this issue. Its findings are initially described, before associations of 
SH with cognition are discussed in the context of previous literature. An attempt is 
made to account for any disparities of the present findings with those described in 
previous studies.  
Validation of self-report data in the ET2DS  
The blood glucose measurements reported during the 6-month survey of SH 
indicated that participants successfully identified severe episodes all of which 
appeared to have remained short of coma. The comparison of the retrospective recall 
of SH at year 4 with the prospectively ascertained data in the 6-month survey of SH 
further showed that 74% of the participants accurately recalled the experience of 
severe hypoglycaemia around four years after the episode had occurred. Two 
previous studies which, like the ET2DS, ascertained hypoglycaemia prospectively by 
telephone report and response to bi-monthly questionnaires, found that as many as 
94% of patients with type 2 diabetes (Akram, Pedersen-Bjergaard, Carstensen, 
Borch-Johnson, & Thorsteinsson, 2009) and 90% of patients with type 1 diabetes 
(Pedersen-Bjergaard, Pramming, & Thorsteinsson, 2003) accurately recalled their 
experience of SH. However, recall in these studies will have been facilitated by short 
follow-up of one year which contrasts around three years in the present study.  
Bidirectional relationship of severe hypoglycaemia with cognitive function  
Even moderate hypoglycaemia is known to generate cognitive symptoms (Suh, 
Hamby, & Swanson, 2007), but potential long-term effects of severe episodes on 
brain function were at the centre of this thesis. A number of cross-sectional studies 
(Bruce et al., 2009; Punthakee et al., 2012) and cross-sectional analysis of the 
ET2DS itself (Aung et al., 2012) have previously demonstrated a relationship 
between hypoglycemia and poorer cognitive function in people with type 2 diabetes. 
However, there has been uncertainty about the reasons for this association and the 
direction of any possible causal relationship between hypoglycaemia and cognitive 
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decrements. The following sections discuss the evidence from the present analyses 
and from the previous literature separately for hypoglycaemia as a potential risk 
factor for cognitive decline and as an event which occurs subsequent to poorer initial 
cognitive function.  
Reduced cognitive function predicted incidence of severe hypoglycaemia 
This appears to be the first analysis of the relationship between hypoglycaemia and 
peak pre-morbid ability in young adulthood as estimated by a vocabulary-based test 
in older patients with type 2 diabetes. Similar to a study of people with type 1 
diabetes which estimated peak pre-morbid ability by the National Adult Reading Test 
(NART) (Deary et al., 1993; Deary, Langan, Graham, & Hepburn, 1992), baseline 
MHVS was unrelated to the risk of incident SH during the four years of follow-up in 
the ET2DS. This could be due to limited statistical power to detect associations 
based on the relatively short period of follow-up, which resulted in incident SH 
occurring in only 85 subjects. Compared with analyses of incident SH, statistical 
power was increased in the analyses of a lifetime history of SH reported prior to 
baseline, which affected 112 participants. Here, a lower baseline MHVS (relative to 
the distribution) was statistically significantly related to a 55% increased likelihood 
of having experienced SH prior to baseline, overall suggesting that a lower peak pre-
morbid ability in young adulthood may predispose individuals to an increased risk of 
hypoglycaemia.  
 
Patients with reduced late-life global function (relative to the distribution) were also 
at two-fold increased risk of incident SH during follow-up. This part of the results 
supported a number of previous studies reporting a two- to three-fold increased risk 
of hypoglycaemia during the course of three to twelve years in lower-functioning 
individuals with type 2 diabetes (Bruce et al., 2009; de Galan et al., 2009; Punthakee 
et al., 2012; Yaffe et al., 2013). In the light of the apparent bidirectional relationship 
of cognitive function with hypoglycaemia, which is described below, it is crucial to 
consider the potential for such associations to be driven by recurrent episodes. Prior 
to the present analysis (which found that the two-fold increased risk persisted and 
even slightly increased in effect size), ACCORD-MIND had been the only previous 
instance which investigated associations of cognitive function with the risk of first-
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ever incidence of hypoglycaemia (Punthakee et al., 2012). Basis for the increased 
risk of hypoglycaemia in lower-functioning individuals may be a lower ability to 
adhere to prescribed treatment, to recognise hypoglycaemia, to respond appropriately 
when it occurs or to prevent hypoglycemia through modification of diabetes therapy. 
The evidence from children with type 1 diabetes (McNally, Rohan, Shroff Pendley, 
Delameter, & Drotar, 2010) and from other, older, patient populations (Alosco et al., 
2012) supports links of lower cognitive function with poorer treatment adherence, 
although this does not appear to have been studied in people with type 2 diabetes. 
Severe hypoglycaemia as a risk factor for cognitive decline 
Compared with the evidence of lower cognitive function as a risk factor for 
subsequent hypoglycaemia and of lasting cognitive deficits following hypoglycaemic 
episodes resulting in coma (Chalmers et al., 1991; Iino et al., 2000; Xu et al., 2011), 
to date there has been less epidemiological evidence to support the hypothesis that 
severe hypoglycemia, which usually remains short of coma, may have a direct or 
indirect effect on the brain resulting in cognitive decrements.  
 
In adults with type 1 diabetes, some evidence suggests that people with a history of 
SH may experience an accelerated estimated lifetime decline in cognitive function 
(Deary et al., 1992; Langan, Deary, Hepburn, & Frier, 1991), but the balance of 
cross-sectional (Brands, Biessels, De Haan, Kappelle, & Kessels, 2005) and 
prospective evidence, including from the DCCT/EDIC, has shown that SH may not 
affect cognitive function in this way (Reichard, Pihl, Rosenqvist, & Sule, 1996; The 
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions 
and Complications (DCCT/EDIC) Study Research Group, 2007). However, 
comparison of findings between people with type 2 diabetes, including those 
participating in the ET2DS, and patients with type 1 diabetes may not be appropriate. 
Patients with type 1 diabetes are typically younger and have a lower prevalence of 
co-morbidities (Plotnikoff et al., 2007). Additionally, the DCCT cohort was atypical 
in that the participants had been selected for having high compliance with treatment 
and a low risk of hypoglycemia, such that these findings were restricted by low 
prevalence of both the risk factor (hypoglycemia) and the outcome (age-related 




In type 2 diabetes, the experience of hypoglycemia appears to be a risk factor for 
future dementia (Lin & Sheu, 2013; Whitmer, Karter, Yaffe, Quesenberry, & Selby, 
2009; Yaffe et al., 2013). With dementia at the end-point of the spectrum of 
cognitive decline, associations of hypoglycaemia with subsequent cognitive 
impairment short of dementia are to be expected. The present analysis was the first to 
associate hypoglycaemia with potentially subtle cognitive decline in an observational 
analysis. It has provided the most robust evidence to date that exposure to at least 
one episode of severe hypoglycemia either preceding or concurrent with, change in 
cognition during ageing, is associated with an increase in the rate of estimated 
lifetime cognitive decline since peak pre-morbid ability as well as in the late-life 
cognitive decline short of frank dementia. Effects sizes were overall modest, with SH 
accounting for <1% of variance in four-year decline in g. The mean decline in g of 
the groups with hypoglycaemia was at around the 60
th
 percentiles of the mean 
decline of the respective group free of hypoglycaemia. Relatively stronger 
associations with estimated lifetime than with four-year cognitive decline suggest 
that short-term effects of pre-episode to post-episode declines were more severe 
compared with long-term post-episode cognitive declines. Reasoning, executive 
function, processing speed and non-verbal memory appeared particularly vulnerable. 
The finding for the memory domain is consistent with published evidence for 
associations of hypoglycaemia with dementia (e.g., (Yaffe et al., 2013)), which is 
commonly preceded by memory impairment (Petersen, 2004). Unfortunately, it was 
not possible to investigate potential dose-response relationships due to few 
participants having been exposed to three or more episodes in the ET2DS. 
 
A single previous investigation with observational study design had been performed 
on the topic, and had revealed no statistically significant links between 
hypoglycaemia and the risk of conversion between normal functioning, impairment 
short of dementia and frank dementia during two-year follow-up (there was even a 
non-significant trend for higher prevalence of hypoglycaemia in participants who 
converted compared with those who did not) (Bruce et al., 2009). The focus of the 
ET2DS on cognitive decline in the dementia-free range as well as its greater power 
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to detect associations due to the treatment of cognitive decline as a continuous 
measure and longer follow-up period could potentially account for the disparity 
between the present significant associations and the null findings from this previous 
study.  
 
The present results also contrast with those from the three previous prospective 
analyses (all of which were RCTs) of hypoglycaemia and cognitive decline which is 
short of dementia in people with type 2 diabetes. In ACCORD-MIND and 
ADVANCE patients in intensive treatment groups (with higher incidence of 
hypoglycemia) cognitively declined at similar rates over 40-months and five-years of 
follow-up, respectively, compared with the respective standard treatment groups (de 
Galan et al., 2009; Launer et al., 2011). However, as noted in Chapter 3, both were 
RCTs involving strict glycemic control, with cognitive function as a secondary 
endpoint. Because improving glycemic control may improve cognitive dysfunction 
when glycemic control is suboptimal (Ryan et al., 2006), detrimental effects of 
hypoglycemia were potentially counteracted by the specific therapeutic interventions. 
Future re-analyses of the data from ACCORD-MIND and ADVANCE could apply 
adjustment for baseline and follow-up HbA1c to evaluate this possibility. 
ADVANCE also assessed cognitive decline using a screening instrument for 
dementia, which may be insensitive to subtle cognitive changes (Tombaugh & 
McIntyre, 1992). Annual incidence of hypoglycemic episodes (defined on the basis 
of criteria comparable to severe hypoglycemia in the present study) in ADVANCE 
was low compared with the ET2DS and ACCORD-MIND, because none of its 
participants received insulin treatment. Finally, the null findings by a small RCT on 
the effects of antihypertensive medication are questionable on the basis of their use 
of self-report to measure cognitive function, a short five-month follow-up and the 
inclusion of participants with a wide age range (McGill et al., 2007).  
Neurological damage and persistent processing abnormalities following 
hypoglycaemia 
With the overall inconsistency in the evidence on links between hypoglycaemia and 
cognitive decline short of dementia, studies assessing the neurological evidence may 
prove informative. In this section, the literature on associations of hypoglycaemia 
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with cerebral damage is reviewed, before pathophysiological mechanisms potentially 
underlying any associations of hypoglycaemia with cognitive deficits or neurological 
damage are described.  
Studies of humans 
Two reviews of the literature (Auer, 2004; Ryan, 2009) note that evidence of lasting 
brain damage, such as brain atrophy or lesions (Fujioka et al., 1997; Iino et al., 
2000), is typically restricted to hypoglycaemic episodes which result in coma, with 
null findings reported for instance on associations of SH (not usually involving 
coma) with EEG abnormalities (Brismar, Hyllienmark, Ekberg, & Johansson, 2002) 
or grey matter volumes (Musen et al., 2006).  
 
Yet, it may be too soon to discount the potential for neurological damage caused by 
severe hypoglycaemia without coma. One study of children with type 1 diabetes 
(aged 7 to 17 years) showed that exposure to incident severe hypoglycaemia during 
two years of follow-up was associated with a concurrent reduction of white matter in 
occipital and parietal regions (Perantie et al., 2011). With a similarly ‘crucial period’ 
for cognitive development in later life (Biessels et al., 2008), neurological damage 
due to hypoglycaemia may also be likely with an advanced age of the patient. 
Indeed, in a sample of middle-aged diabetes patients, a control group showed no 
cortical atrophy on MRI, whereas 45% of subjects in the group with a history of at 
least five episodes of hypoglycaemia (which usually remains short of coma) did 
(Perros, Deary, Sellar, Best, & Frier, 1997). The study was relatively small and failed 
to establish associations of SH with cognitive function, but was supported by two 
case reports of middle-aged adults describing EEG abnormalities and cerebral 
atrophy (Schuler, Petersen, Khalaf, & Kerp, 1989), as well as reductions in white and 
grey matter volumes and white matter lesions (Kirchhoff et al., 2013) following 
recurrent episodes of severe hypoglycaemia without coma. Clearly, further brain 







Contrasting the mixed evidence from human studies, animal models typically reveal 
lasting damage to the brain following moderate or severe hypoglycaemia even in 
absence of coma (which is usually detected by a flat EEG). Recurrent severe 
episodes have been shown to permanently impair hippocampal synaptic plasticity 
(Yamada et al., 2004), to cause microglia activation, oxidative injury, cortical 
neuronal death and impairment in spatial learning and memory in rodents (Won et 
al., 2012). Even a single hypoglycaemic event without loss of consciousness has 
been related to cell death in the rodent hippocampus (Ennis, Tran, Seaquist, & Rao, 
2008) and cortex, including correlations of the severity of the episode with degree of 
cell death (Tkacs, Pan, Raghupathi, Dunn-Meynell, & Levin, 2005).  
 
Although animal models offer the ultimate level of experimental control and 
therefore provide useful supplements to the evidence from studies of humans, it 
should be noted that a comparison of humans with animals is severely restricted. In 
absence of coma, hypoglycaemia in humans is unlikely last for hours (as is often the 
case in animal models) and the long-term effects which human studies are concerned 
with span months and years rather than days or weeks. Animal models also usually 
involve developing or adult rodents rather than older animals. The aforementioned 
evidence from animal studies therefore does not allow inference on hypoglycaemia 
effects on the human brain. It does, however, at least suggest the possibility of severe 
and particularly recurrent hypoglycaemia causing lasting (potentially subclinical) 
damage to the brain. 
Potential pathophysiological mechanisms and issue of confounding  
Potential underlying mechanisms by which hypoglycaemia may contribute to brain 
damage and resulting cognitive deficits are likely to involve the starvation of neurons 
of glucose previously demonstrated in vitro (Northam & Lin, 2010). Additionally, 
hypoglycaemia appears to lead to changes in synaptic function and neuronal death 
due to oxidative stress, as well as an inflammatory response involving the release of 
endogenous neurotoxins and the accumulation of excitatory amino acids (Fujioka et 




Of course, the observational study design of the ET2DS does not allow conclusions 
with respect to the contribution of such mechanisms to the present findings. It also 
necessitates the consideration of potential confounding variables. Given that in a 
number of previous studies of people with type 1 or type 2 diabetes, as well as in the 
ETDS, hypoglycaemia was associated with symptoms of depression, increased 
anxiety or lower happiness (Kirchhoff et al., 2013; Shao, Ahmad, Khutoryansky, 
Aagren, & Bouchard, 2013; Strachan, Deary, Ewing, & Frier, 2000; Wredling, 
Theorell, Roll, Lins, & Adamson, 1992), a confounding or mediating role of such 
factors in the present associations of hypoglycaemia with cognitive decline may be 
plausible. Yet, associations of hypoglycaemia with cognitive decline survived post-
hoc adjustment for HADS-D (Feinkohl et al., 2014), showing that the findings 
reported in this thesis were relatively independent of depression.  
 
Confounding by other clinical parameters or by pre-morbid ability is also possible, 
but the adjustment of associations of hypoglycaemia with cognitive decline for 
MHVS, as well as for a range of potential confounders measured at baseline (as 
presented in this thesis) or at year 4 (Feinkohl et al., 2014) did not greatly alter any of 
the findings. Although confounding by factors not considered in this thesis is 
possible, we may be relatively confident that the results presented here are not 
merely reflections of associations of hypoglycaemia with pre-morbid ability or with 
vascular risk factors, micro- or macrovascular disease (including stroke) which could 
themselves either causally influence or act as proxies for late-life cognitive decline.  
Potential implications for clinical management of patients 
The first part of our findings of a two-fold increased risk of hypoglycaemia in lower-
ability individuals implies that in cases where an older patient’s cognitive ability is 
reduced, be it due to early signs of cognitive impairment or lower cognitive reserve, 
the involvement of their carer in the management of treatment may be advisable.  
 
Although the nature of the study design of the ET2DS does not allow an inference of 
causality and the findings were only of small to medium effect size (with relatively 
smaller effect size for associations with late-life cognitive decline compared with 
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estimated lifetime decline), they at least show that a hypoglycaemic event may 
somewhat impact on a patient’s cognitive functions and that their post-event 
cognitive decline may additionally be accelerated compared with patients who 
remain free of severe hypoglycaemia. These observations appear to be independent 
of other clinical covariates. In a clinical setting, a patient’s history of hypoglycaemia 
alone may provide some important information in the ascertainment of their risk of 
future cognitive decline, although effect sizes were much smaller compared with 
findings in the cognition-hypoglycaemia direction. If future studies find the 
association reported here to be causal in nature, it will be necessary to address the 
effect of strict glycaemic control on cognitive function in the clinical management of 
older people with type 2 diabetes. The balance of risks for complications associated 
with hypoglycaemia and hyperglycaemia (including micro- and macrovascular 
disease and cognitive impairment) are perhaps best evaluated on an individual-
patient basis, and under consideration of patients’ current cognitive status. Overall, 
however, I conclude that the education of patients with relatively low cognitive 
function, or their carers, in terms of diabetes and its treatment (to reduce their risk of 
future hypoglycaemia) may be of greater importance than the cognitive monitoring 
of patients who have experienced an episode of SH in the past.  
9.5.3 Risk factor associations with cognition identified in 
multivariable analyses of a wider range of risk factors  
The second part of the analyses presented in this thesis was concerned with the 
comparison of the predictive ability of a wider range of metabolic and vascular risk 
factors with respect to late-life cognitive function and cognitive change in the 
ET2DS. Contrasting with the analyses of macrovascular disease and severe 
hypoglycaemia, no assumptions on potential mechanisms underlying any significant 
contributions of risk factors to the risk of cognitive decline are made on the basis of 




‘Optimal’ model of cognitive decline and comparison with previous 
literature on multiple risk factors 
Despite a recent systematic review reporting that many of a total of 24 potential 
clinical, demographic and behavioural risk factors reviewed were, individually, more 
or less strongly associated with the risk for cognitive decline (Plassman, Williams, 
Burke, Holsinger, & Benjamin, 2010), the present consideration of a wider range of 
risk factors and the focus on their relative usefulness in the estimation of risk appears 
to be fairly unique in the literature. In the stepwise regression analysis of 15 potential 
vascular and metabolic risk factors, inflammation, packyears, HbA1c but only some 
of the markers of subclinical macrovascular disease (NT-proBNP, cIMT) were 
identified as significant predictors of four-year cognitive decline. A number of 
previous studies focusing on single risk factors had previously shown significant 
associations of inflammation (Marioni et al., 2011; Yaffe et al., 2003), smoking 
(Anstey et al., 2007) and hyperglycaemia (Lamport, Lawton, Mansfield, & Dye, 
2009; Launer et al., 2011) with cognitive impairment.  
 
Recently, the concept of allostatic load has attracted attention in the field of cognitive 
ageing. Allostatic load, based on the concept on allostasis – the body’s ability to 
achieve and maintain equilibrium through neuronal, endocrine, cardiovascular 
responses to environmental stressors (Evans & Schamberg, 2009) – is a summary 
measure of risk factors. These may include hormone levels, HbA1c, blood pressure, 
waist-hip ratio, HDL and total cholesterol, cortisol, norepinephrine, epinephrine, 
dehydroepiandrosterone sulphate (DHEA-S) and inflammatory markers 
(Karlamangla, Singer, McEwen, Rowe, & Seeman, 2002; McEwen & Seeman, 1999; 
T. E. Seeman, Singer, Rowe, Horwitz, & McEwen, 1997). For instance, summary 
scores may be calculated for each individual on the basis of scoring within the 
distribution of each risk factor (e.g., in tertiles). Considering the aforementioned 
range of risk factors commonly used to obtain allostatic load summary measures, it is 
unsurprising that allostatic load has been linked to diabetes (Crews, 2007). Allostatic 
load summary measures have also been shown to predicted three-year, four-year and 
seven-year cognitive decline short of dementia in a sample of older adults 
(Karlamangla et al., 2002; T. E. Seeman, McEwen, Rowe, & Singer, 2001; T. E. 
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Seeman et al., 1997), consistent with the evidence described in Chapter 2 on 
individual risk factor associations with cognitive decline. However, the usefulness of 
such a summary measure, which does not offer any information over and above that 
from analyses of individual risk factors, may be limited. After all, the observation 
that a measure of allostatic load predicts cognitive decline is relatively meaningless 
in terms of potential strategies for intervention, given that it does not reflect at all 
which of its component risk factors was in fact driving the association. Compared 
with the alloostatic load approach to the data, the present analysis of a total of 15 risk 
factors and their association with cognitive decline was certainly more informative, 
and may be used to inform future observational as well as intervention studies.  
Effect sizes of the multivariable analyses in the ET2DS were relatively modest, with 
risk factors accounting for between 0.6% (for NT-proBNP, over and above age, sex, 
inflammation, packyears, cIMT and HbA1c) and 2.2% (for inflammation, over and 
above age and sex) of variance in decline in g. The present findings do not allow 
conclusions with respect to causality, but suggest that the (perhaps combined) 
measurement of these factors, rather than the measurement of factors such as 
microvascular disease, symptomatic vascular disease or cholesterol, may be useful in 
the ascertainment of a patient’s risk of cognitive decline. 
 
Some previous studies had investigated smaller groups of selected risk factors in 
stepwise regression analyses similar to the analyses presented in this thesis, but also 
appeared to aim to ascertain the underlying causes of associations of single risk 
factors, such as smoking (Stewart et al., 2006) or hypertension (Starr et al., 1997) 
rather than to compare potential predictive ability amongst risk factors. One rare 
previous study on a wider range of risk factors was recently performed on older 
adults undergoing coronary artery bypass grafting. Education, pre-operative 
medication, pre-operative cognitive decline and a range of clinical risk factors, 
including the presence of hypertension, hyperlipidaemia, PAD, history of 
cerebrovascular disease, cerebral infarct on MRI, three-vessel disease, extracorporeal 
circulation time and ascending aortic atherosclerosis, were all entered in a stepwise 
logistic regression model on the risk of post-operative cognitive dysfunction; pre-
operative declines, ascending aortic atherosclerosis and cerebral infarction were 
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retained as significant predictors (Otomo, Maekawa, Goto, Baba, & Yoshitake, 
2013). Due to the nature of the stepwise modelling process, findings depend strongly 
on the specific variables entered into the model. A comparison of the present 
analyses with the aforementioned study is therefore extremely difficult. At least the 
finding of a contribution by aortic atherosclerosis to the model appears to mirror the 
inclusion of cIMT in the model of four-year cognitive decline presented in this 
thesis.  
Account of the disparity between findings from univariate analyses and 
multivariable approach 
The fact that a baseline history of stroke, of severe hypoglycaemia and baseline 
peripheral atherosclerosis (intermittent claudication and/or ABI≤0.90) were not 
included in the ‘optimal’ model of four-year cognitive decline should not be seen to 
oppose or invalidate the significant findings for these risk factors in Chapter 6 
(Results II) and Chapter 7 (Results III). As reviewed in Chapter 8, it is in the nature 
of the ‘throw-in-everything’ approach of the stepwise modelling procedure to neglect 
the potentially complex inter-relationships amongst the variables entered into the 
analysis. For instance, if one potential predictor is highly correlated with another, it 
is likely that only one will be identified as a significant contributor to the outcome 
under assessment. The fact that both NT-proBNP and cIMT were included in the 
model (despite both reflecting subclinical atherosclerosis) may be attributed to 
relatively weak correlations between the two risk factors (r=0.11). Potential 
mediation of associations by other risk factors is also not considered in the stepwise 
procedure. Although not part of the present research question aimed at comparing the 
predictive ability between risk factors, future studies could now apply formal tests of 
the complex inter-relationships, including mediatory roles, amongst risk factors in 
their associations with cognitive decline, for instance using structural equation 
modelling (SEM). Any of the ten risk factors which were not included in the final 
‘optimal’ model of four-year cognitive decline may in fact be important markers of 
the risk for cognitive decline and, should future studies reveal causal contributions, 




Symptomatic macrovascular disease, for instance, could contribute to cognitive 
decline through mediation by increases in inflammation, given that atherosclerosis 
initiates a pro-inflammatory response at vessel walls (Nash, 2005), but could be 
‘dropped’ from the regression model which then identifies inflammation but not 
macrovascular disease as a significant predictor.  
 
Influences from the nature of the stepwise modelling procedure on results are also 
illustrated by the pattern of findings for waist-hip ratio. The risk factor was not a 
predictor of four-year cognitive change in the multivariable analyses, despite its 
inclusion in the cross-sectional model of late-life cognitive function and previous 
prospective evidence of links of obesity with steeper rates of cognitive decline 
(Abbatecola et al., 2010; Kilander, Nyman, Boberg, & Lithell, 1997; Profenno, 
Porsteinsson, & Faraone, 2010). This failure to identify waist-hip ratio as a 
significant contributor to the model may have been due to correlations with other risk 
factor measurements. Specifically, any associations of waist-hip ratio with cognitive 
decline may have been masked by the significant association of the inflammation 
factor and HbA1c with this outcome in the multivariable model. Fat mass is 
associated with hyperglycaemia and is also an origin of a range of products, 
including inflammatory markers, which could mediate a relationship of abdominal 
obesity with cognitive decline (Sundell, 2005). Waist-hip therefore could therefore 
have been ‘dropped’ from the model despite a potential role in the determination of a 
person’s risk of late-life cognitive decline. In future studies, structural equation 
modelling could be applied to formally test such possible pathways, which in the 
present data appear to be supported by statistically significant associations of a 
higher waist-hip ratio with a steeper estimated lifetime cognitive decline and a 
steeper four-year cognitive decline in the largely unadjusted univariate analyses 
(Appendix D).  
 
In contrast to waist-hip ratio, the nature of the modelling process does not appear to 
have contributed to the failure of alcohol consumption (identified as a marker of a 
higher level of late-life cognitive function and shallower estimated lifetime cognitive 
change in the present and in previous analyses (Fan, O'Donnell, Singh, Pungan, & 
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Perlmutter, 2008; Hogenkamp et al., 2014; Townsend, Devore, Kang, & Grodstein, 
2009)), to be included in the ‘optimal’ model of four-year cognitive change. Instead, 
given that even in the largely unadjusted univariate analyses presented in Appendix 
D, alcohol was unrelated to this specific outcome, late-life level of alcohol 
consumption does not appear to be a useful marker of the risk of future cognitive 
decline.  
Account of relatively small effect sizes in statistically significant findings from 
univariate and multivariable analyses 
 
Although on first inspection, the small effect sizes in multivariable models as well as 
in the analyses of severe hypoglycaemia and macrovascular disease as individual risk 
factors may be discouraging and so require further discussion. Even with a total of 15 
risk factors considered in these analyses, of which five (in addition to age and sex) 
were included in the respective final ‘best fitting’ model of late-life cognitive 
function, estimated lifetime cognitive change and that of four-year cognitive change 
were able to explain only 19.9%, 16.1% and 8.6% of variance in the respective 
outcome. The proportion of variance in the data was even smaller when age was 
excluded from the models. Age, in fact, was identified as the single most important 
risk factor predicting an individual’s cognitive outcome, which in itself is an 
important finding, because data on age are free and easily obtainable. Consequently, 
clinicians should initially consider a patient’s age in the estimation of their specific 
risk of cognitive impairment and presumably already do so routinely on an intuitive 
basis.  
 
The relatively small effect sizes for individual risk factors other than age found in the 
multivariable models, as well as in the analysis of severe hypoglycaemia and of 
macrovascular disease, are likely to simply lie in the nature of research into cognitive 
ageing and are not at all dissimilar to findings from other research studies of the 
field, as reviewed in Chapters 2 and 3. An individual’s pattern of cognitive change is 
after all likely to be dependent on a wide range of demographic, psychosocial and 
clinical risk factors. In the present analyses, a relatively large number but by no 
means cover all of the risk factors were considered. This is because many potential 
risk factors were not measured in the ET2DS (e.g., genetic factors; nutritional habits) 
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or may even yet be unknown to the research field. However, even with relatively 
small effect sizes of associations, the present analyses have identified potentially 
important risk factors for cognitive decline in patients with type 2 diabetes, and so 
may be assumed to have advanced the research field. 
9.6 Conclusions and future directions  
The present analyses have made a contribution to the literature on cognitive 
impairment in type 2 diabetes. In a relatively unique, large-scale epidemiological 
study focusing entirely on older people with type 2 diabetes, a wide range of 
potentially modifiable risk factors, including macrovascular disease and 
hypoglycaemia, were compared in their associations with late-life cognitive decline 
short of dementia.  
 
In the first set of analyses, single risk factors were focused on with consideration of a 
comprehensive list of potential confounders, aimed at the identification and 
exploration of potential underlying mechanisms. A bidirectional relationship between 
severe hypoglycaemia and cognitive function and decline was identified, with lower 
ability at baseline predisposing patients to a two-fold increased risk of incident 
severe hypoglycaemia. Whereas for both stroke and severe hypoglycaemia, 
associations with cognitive decline between pre-event estimated level and post-event 
level compared with their associations with subsequent rates of cognitive decline, the 
opposite pattern was found for the subclinical markers cIMT, NT-proBNP and ABI. 
Independent of a wide range of potential confounders, including stroke and 
socioeconomic status, atherosclerosis of the body, which may remain symptomless, 
correlated with the risk of cognitive decline. We may speculate about potential 
correlations with the damage to the cerebral vasculature as the basis for these 
associations in the present observational data. This implies that patients’ risk of 
cognitive impairment could potentially be reduced through the intensive management 
of vascular risk factors (as has been suggested in a previous study (Petrova, 
Prokopenko, Pronina, & Mozheyko, 2010)). The findings further show that the 
subclinical markers of macrovascular disease could be more useful in the 
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ascertainment of a patient’s risk of future cognitive decline compared with 
symptomatic macrovascular disease. 
 
In the second part of the thesis, the predictive ability for cognitive decline of a total 
of 15 potentially modifiable risk factors was investigated in a multivariable approach 
relatively unique to the literature on cognitive ageing. Findings overall suggest that 
(in addition to subclinical macrovascular disease and severe hypoglycaemia), 
inflammation, smoking and glycaemic control appear to be useful markers for 
patients’ risk of future cognitive decline. The results warrant replication, but 
demonstrate that in an attempt to identify patients with type 2 diabetes at risk of 
cognitive impairment, a routine, combined ascertainment of subclinical 
macrovascular disease, inflammation, glycaemic control and history of smoking and 
hypoglycaemia could be advocated. Although amongst the three markers of 
subclinical macrovascular disease, cIMT appeared to be most strongly related to late-
life cognitive decline, systemic atherosclerosis could perhaps be best routinely 
ascertained by ABI, given the relative ease and low cost of measurement compared 
with NT-proBNP (measured in plasma) and cIMT (measured by ultrasound).  
 
All analyses presented in this thesis merit replication in the observational analysis of 
other, large-scale cohorts of older adults with type 2 diabetes. Further 
epidemiological studies following case-control designs could also compare risk 
factor associations with cognitive decline between people with type 2 diabetes and 
non-diabetic older adults. This would help to determine whether or not the findings 
from the ET2DS are specific to people affected by diabetes, and would provide 
evidence on the role of the risk factors identified to correlated with cognitive decline 
in patients with type 2 diabetes in the increased risk of cognitive impairment relative 
to non-diabetic older adults. 
 
Randomised controlled trials - the ‘gold-standard’ in epidemiological research - may 
be used in the investigation of some but by no means all individual risk factors and 
their relationship with the rate of cognitive decline, because only some may be 
modified through treatment. This may apply, for instance, to patients’ vascular risk 
353 
 
or inflammation, which are modifiable through lifestyle intervention as well as 
pharmaceutical treatment. The key advantage of randomised controlled trials is an 
ability to infer causality from associations- the key problem of cohort studies such as 
the ET2DS. However, trials are costly and have sample sizes which are usually much 
smaller than those of cohort-studies. Due to the requirement of participants to adhere 
to their respective treatment arm, motivation to participate may lead to samples 
which are not typical of the target population. Attrition of participants following 
baseline assessment may also be higher compared with observational cohort studies. 
Finally, follow-up of randomised controlled trials are also usually shorter than those 
of observational cohort studies, which may have durations of an entire lifetime (e.g., 
Lothian Birth Cohort of 1921, Gow et al., 2008), and so may not provide evidence on 
long-term effects.  
 
The use of randomised controlled settings for the investigation of risk factor 
associations with cognitive decline may also be unfeasible for many risk factors. For 
instance, genetic factors may not be altered (although this fact provides an 
opportunity in itself to investigate risk factor associations with cognition, using the 
Mendelian randomisation approach). Socioeconomic status, which may be a likely 
starting point of the path towards late-life disease as well as cognitive impairment, is 
also extremely difficult to manipulate. This is reflected in the observation that an 
individual’s relative position in society tends to remain relatively stable between 
birth and older age. Although targeted programs and public health policy may help to 
work against negative effects of a low socioeconomic status on health, these are 
close to impossible to conduct in randomized controlled settings. Lifestyle 
interventions targeting body weight or smoking, too, may be likely to be 
unsuccessful relative to pharmaceutical interventions which require only the taking 
of medication once or twice per day.  
 
Although glycaemic control may be modified pharmaceutically, the use of 
randomised controlled trials may also be inappropriate for the analysis of 
hypoglycaemia and cognitive decline due to potentially opposing effects of 
hypoglycaemia and improved glycaemic control on cognitive function. Animal 
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models, however, allow the experimental induction of hypoglycaemia without a 
change in long-term glycaemic control and so may continue to prove useful in the 
investigation on hypoglycaemia effects on the brain. Such studies perhaps could be 
modified to reflect hypoglycaemia occurring in humans more closely than is 
currently the case, for instance by using older and diabetic animals and by exposing 
animals to relatively briefer episodes of hypoglycaemia.  
 
The ET2DS itself offers further opportunities for analysis. For the purpose of this 
thesis, only risk factor data collected at baseline (except severe hypoglycaemia, 
which was ascertained at baseline and at year 4) were used. A re-analysis of the 
study with consideration of the year 4 data on subclinical macrovascular disease and 
incidence of symptomatic macrovascular disease during the study period could now 
assess the relationship of a progression of macrovascular disease with the concurrent 
change in cognitive function in the sample. 
 
With respect to research of cognitive ageing in general, future studies should aim to 
apply a multi-wave design, including a serial measurement of cognitive function. 
This would increase the validity of investigations of longitudinal cognitive change. 
Studies of birth cohorts ascertaining cognitive ability in childhood or young 
adulthood may be particularly useful. Based on measured rather than estimated data 
(as used by the ET2DS), such studies enable an analysis of actual lifecourse changes 
in cognitive function. As a drawback, however, these (unless sample size is very 
large so that a diabetic sub-sample could be analysed) do not allow an analysis of a 
sample consisting exclusively of patients with type 2 diabetes.  
 
The present thesis has demonstrated the usefulness of employing a variety of 
statistical analyses in cognitive ageing research. The focus on single risk factors with 
adjustment for potential confounders should continue being used in the attempt to 
explore potential underlying pathophysiological mechanisms linking individual risk 
factors with late-life cognitive decline in observational settings. Additionally, future 
studies should consider a wider range of risk factors in an attempt to identify those 




With the problems surrounding the use of stepwise regression procedures in the 
analysis of a wider range of risk factors particularly in the light of complex inter-
relationships amongst risk factors, the use of structural equation modelling, including 
latent growth curve modelling if multi-wave data on cognitive function is available, 
could prove useful. Latent growth curve modelling is based on previous knowledge 
of risk factor associations with cognitive decline and allows the testing of specific 
hypotheses on relationships, including mediation, amongst risk factors and on their 
relationships with cognitive change. The approach has recently been applied to the 
study of contributions by smaller groups of risk factors for cognitive ageing (Gow et 
al., 2011; Gow et al., 2008). Future studies could now extend this to an investigation 
of a wider array of risk factors. Such analyses would supplement the present 
comparison of the relative predictive ability amongst risk factors with respect to the 
risk of cognitive decline and, once followed up by randomised controlled trials where 
possible, would ultimately help to identify the driving force(s) underlying the 
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Appendix A: Dementia in the ET2DS 
 
Table A.1: Data searched to identify participants with dementia 
following completion of the year 4 clinic  
Source N searched 
If patient died prior to follow-up, date of death All 
Report of dementia in communication with patient or 
relatives 
If applicable 
Mini-Mental-State Examination (MMSE) score 
below 24 at baseline 
All 
Missing MMSE score at baseline  All 
ISD hospital discharge code for dementia* between 
1981 and 2006 
All 
Baseline self-reported use of medication for 
dementia** in baseline questionnaire 
All 
MMSE<24 at follow-up All 
Missing MMSE score at follow-up  All 
ISD hospital discharge code for dementia* between 
baseline ISD request (2006) and June 2011 
All 
Self-reported use of medication for dementia** in 
follow-up questionnaire 
All 
If died between baseline and follow-up, death code 
for dementia* 
All 
Psychiatrist diagnosis of dementia obtained from 
psychiatry/hospital notes (database at Royal 
Edinburgh Hospital, ‘PiMS’) 
All 
GP cognitive questionnaire sent out Subjects with MMSE<24 
baseline/follow-up and/or 
MMSE missing at 
baseline/follow-up and/or 
participants with ISD 
dementia code but no other 
criteria fulfilled, and all non-
attenders 
GP responded to questionnaire  
GP reports that patient suffers from dementia  
Year of diagnosis if available 
GP reports that patient is on dementia medication** 
Comments by GP on cognitive questionnaire/ in 
personal communication 
* ICD codes: F00, F01, F02, F03, G30 (codes beginning with FXX or GXX were 
additionally checked to ensure these were unrelated to dementia). **Donepezil (Aricept), 
Rivastigmine (Exelon), Galantamine (Reminyl), Memantine (Ebixa)  










Table A.2: Summary of information on possible dementia diagnosis 

























0001C           yes                   
0017F dementia                   yes         
0037C   yes                           
0049F       yes                       
0050F                       VaD 2010 yes   
0060F     yes                         
0061E   yes                           
0065E             yes                 
0077D     yes     yes                   
0079F   yes                           
0084B   yes                           
0113B           yes                   
0152A           yes                   
0197D           yes                   









                          old age psych: 
cognitive problems 
due to low mood 
0260E                             GP phoned summer 
2011; in process of 
diagnosis; unable to 
contact GP since 
0268F FTD yes       yes   yes               





                            
0320C   yes           yes   yes           
0322F dementia       yes           yes "senile 
dementia" 
2009 yes   
0342C   yes         yes                 
0392B   yes                           
0397E   yes                           
0423C           yes                   
0429E                       VaD 2008     
0437C   yes       yes                   
0439E VaD             yes               
0479D   yes                           
0487D           yes                   
0503D             yes                 
0504A             yes                 
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0506E             yes               old age psych: does 
not have dementia 
0520E   yes           yes     yes         
0537C   yes                           
0588C   yes                           
0607E   yes                           
0615F                     yes VaD 2010     
0634E   yes                   VaD 2008     
0663A   yes       yes                   
0670A     yes                         
0675E           yes                   
0692C   yes   yes   yes   yes       VaD 2004     
0715B           yes           mixed AD and 
VaD 
2011     
0718F   yes                           
0795D   yes                           
0815F   yes                           
0824F   yes       yes           mixed AD and 
VaD 
2011 yes   
0838C dementia             yes       VaD 2008 yes   
0846F           yes                   
0850F                     yes         
0856F           yes                   
0865A                       "dementia" 2010     
0868F           yes                   
0961B   yes       yes                 MCI diagnosis 
0970C           yes                   
0973F   yes                           
1013A dementia                   yes VaD   yes   
1116A             yes                 
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1131F             yes               MCI diagnosis 
1133B                     yes         
1155C dementia             yes               
1162E   yes                           
1166F     yes                         
1184C             yes                 
1201F   yes                           
1212D   yes                           
1230F   yes                           
Data only reported for subjects who meet at least one of the criteria for dementia and/or failed to attend the year 4 clinic.  
‘Old age psych’, old age psychiatrist; GP, general practitioner; MCI, mild cognitive impairment; FTD, fronto-temporal dementia; VaD, vascular 
dementia; AD, Alzheimer’s Disease; ‘meds’ or ‘GP meds’, self-report/ GP report of Donepezil (Aricept), Rivastigmine (Exelon), Galantamine 
(Reminyl), Memantine (Ebixa) ; ISD, ICD codes: F00, F01, F02, F03, G30 (codes beginning with FXX or GXX were additionally checked to ensure 
these were unrelated to dementia); ‘death code’, ICD codes: F00, F01, F02, F03, G30 (codes beginning with FXX or GXX were additionally checked 




Table A.3: Participants with dementia by year 4 (N = 19) 




































Table A.3: Baseline risk factors according to dementia group 
















Age 71.13 3.40 67.85 4.20 0.001 
Male sex 11 57.9 536 51.2 0.56 
Education 
   University degree 
   Professional qualification 
   Secondary school 






















Scottish Index of Multiple 
Deprivation (SIMD) rank 
   1
st
 quintile 
   2
nd
 quintile 
   3
rd
 quintile 
   4
th
 quintile 
































HADS-D 5 3 - 11 5 3 - 8 0.005 
Duration of diabetes (years) 5 3 - 17 6 3 - 11 0.63 
Current treatment 
    Insulin +/-tablets    
    Tablets alone  




















) 27.58 4.15 31.50 5.69 0.003 
Waist-hip ratio 0.96 0.08 0.97 0.08 0.93 
% body fat 35.36 6.91 38.13 7.55 0.12 
Total cholesterol (nmol/L) 4.52 1.28 4.31 0.90 0.50 
HDL cholesterol (nmol/L) 1.31 0.33 1.29 0.36 0.81 
LDL:HDL ratio 3.55 1.10 3.53 1.08 0.94 
Systolic bp at clinic visit 136 19 133 16 0.47 
Diastolic bp at clinic visit 67 7 69 9 0.41 
Historical systolic bp 137 9 138 10 0.66 
Ankle brachial index 0.92 0.19 0.96 0.17 0.32 
Packyears 9 0 - 30 7 0 - 32 0.59 
Alcohol (units/year) groups 
    0 
    1 
    2 
    3 


























Cortisol 721.02 212.29 722.21 196.14 0.98 
CRP 1.62  0.48 – 3.10 1.86 0.88 – 4.40 0.08 
IL-6 3.05 2.27 – 4.85 2.87  1.94 – 4.47 0.47 
Fibrinogen 3.48 0.55 3.65 0.75 0.32 
TNF-α 1.15  0.46 – 1.44 1.07 0.69 – 1.63 0.26 
Inflammation factor -0.22 0.90 0.00 1.00 0.34 
Retinopathy 
   no 
















   moderate/ 
   severe 
0 
 
0.0 47 4.6 
Symptomatic MVD 
     MI 
     Angina  
     Stroke 
     TIA 


























NT-proBNP  107.5 60 - 237 74.5 37 - 169 0.27 
Carotid IMT 1.00 0.08 0.99 0.17 0.83 
Historical HbA1c (%) 7.26  1.30 7.40 0.89 0.49 
HbA1c at clinic visit (%) 7.43 2.19 7.40 1.09 0.95 










CI, confidence interval. Log-transformed values were used for analyses of duration of diabetes, 
HADS-D, NT-proBNP, CRP, TNF-α and IL-6. Packyears has been square root transformed. These 
variables are displayed as medians and 95% CI.  
N=13 to 19 in ‘dementia’ group; N = 904 to 1047 in ‘no dementia’ group. 
MVD, macrovacular disease; carotid IMT, carotid intima-media thickness; NT-proBNP, N-terminal 
pro-brain natriuretic peptide; ABI, ankle brachial pressure index; MI, myocardial infarction; TIA, 
transient ischaemic attack; PAD, peripheral arterial disease; CRP, c-reactive protein; IL-6, interleukin-
6; TNF-α, tumor necrosis factor alpha; bp, blood pressure; HADS-D, Depression subscale of the 










Appendix B: Distribution of variables  
Distributions of risk factors at baseline 
 
Figure B.1: Distribution of age 
 
Figure B.2: Distribution of NT-proBNP 
 





Figure B.4: Distribution of HADS-D score 
 
 
Figure B.5: Distribution of HADS-A score 
 





Figure B.7: Distribution of diastolic blood pressure at clinic visit 
 
Figure B.8: Distribution of historical systolic blood pressure 
 
 




Figure B.10: Distribution of total cholesterol 
 
Figure B.11: Distribution of HDL cholesterol 
 




Figure B.13: Distribution of fasting plasma glucose at clinic visit 
 
Figure B.14: Distribution of HbA1c at clinic visit 
 




Figure B.16: Distribution of body fat (%) 
 
Figure B.17: Distribution of waist-to-hip ratio 
 





Figure B.19: Distribution of c-reactive protein  
 
Figure B.20: Distribution of fibrinogen 
 
 




Figure B.22: Distribution of TNF-α 
 
Figure B.23: Distribution of inflammation ‘factor’ 
 
 




Figure B.25: Distribution of packyears 
 
 
Figure B.26: Distribution of alcohol intake in year prior to baseline clinic 
 
 




Distributions of selected baseline risk factor variables following 
transformation 
 
Figure B.28: Distribution of HADS-D score (plus 1) following log-
transformation 
 
Figure B.29: Distribution of HADS-A score (plus 1) following log-
transformation 
 






Figure B.31: Distribution of plasma glucose following log-tranformation 
 
 
 Figure B.32: Distribution of interleukin-6 following log-transformation 
 





Figure B.34: Distribution of c-reactive protein following log-transformation 
 
 








Distributions of cognitive test scores at baseline 
 
Figure B.37:  Baseline distribution of Mill Hill Vocabulary Scale 
 
Figure B.38:  Baseline distribution of Matrix Reasoning 
 





Figure B.40:  Baseline distribution of Borkowski Verbal Fluency Test 
 
Figure B.41:  Baseline distribution of Letter Number Sequencing 
 
 






Figure B.43:  Baseline distribution of total Logical Memory (immediate and 
delayed) 
 




Figure B.45:  Baseline distribution of Mini Mental State Examination 
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Figure B.46: Distribution of baseline Trail-Making Test-B following log-
transformation 
 








Figure B.48:  Follow-up distribution of Mini Mental State Examination 
 









Figure B.51:  Follow-up distribution of Digit Symbol Coding 
 
Figure B.52:  Follow-up distribution of Borkowski Verbal Fluency 
 







Figure B.54: Follow-up distribution of total Logical Memory (immediate and 
delayed) 
 
Figure B.55:  Follow-up distribution of total Faces (immediate and delayed)  
 






Figure B.57:  Follow-up distribution of mean Simple Reaction Time 
(milliseconds)  
 
Figure B.58: Number of correct trials in Choice Reaction Time task 
 
 





Figure B.60: Standard deviation in Simple Reaction Time (milliseconds) 
 
Distribution of selected year 4 cognitive variables following 
transformation 
 





Figure B.62: Number of correct trials in Choice Reaction Time Task following 
log-transformation 
 








Appendix C: Cognitive change between baseline and 
year 4 using imputed data for individual cognitive tests 
 
Table C.1: Cognitive change between baseline and year 4 for attenders, using 
imputed data 
  Baseline  Year 4    









Logical Memory 824 25.85 ± 7.97 27.27 ± 8.26 <0.001 
Faces 824 66.41 ± 7.63 69.25 ± 8.38 <0.001 
Matrix Reasoning 825 13.36 ± 5.24 11.55 ± 5.22 <0.001 
Digit Symbol Coding 823 50.52 ± 14.30 50.01 ± 14.12 0.150 
Trail-Making (s) 823 101 (79 – 133) 107 (83 – 144) <0.001 
Letter-Number Sequencing 823 9.93 ± 2.66 8.86 ± 2.89 <0.001 
Verbal Fluency 825 37.83 ± 12.53 36.83 ± 12.75 <0.001 
Trail-Making, Trail-Making-Test B; Verbal Fluency, Borkowski Verbal Fluency Test; s, seconds. 






























Appendix D: Univariate associations of risk factors with 
cognitive function 
Risk factors and estimated pre-morbid cognitive ability 
 
Table D.1: Univariate association of risk factors with baseline MHVS 
 MHVS 
Any symptomatic MVD -0.14 (<0.001) 
Transient ischaemic attack -0.01 (0.85) 
Stroke -0.06 (0.042) 
Myocardial infarction -0.06 (0.053) 
Angina -0.11 (<0.001) 
Peripheral arterial disease -0.01 (0.80) 
Waist-hip ratio -0.16 (<0.001) 
Total cholesterol 0.05 (0.16) 
HDL cholesterol 0.09 (0.004) 
LDL:HDL -0.04 (0.20) 
Systolic bp at clinic visit 0.00 (0.95) 
Diastolic bp at clinic visit  0.07 (0.07) 
Historical systolic bp 0.03 (0.41) 
Packyears  -0.07 (0.026) 
Alcohol units/year 0.16 (<0.001) 
ABI 0.09 (0.006) 
Carotid IMT 0.02 (0.55) 
NT-proBNP -0.06 (0.06) 
Inflammation factor 0.06 (0.06) 
HbA1c at clinic visit -0.06 (0.053) 
Historical HbA1c -0.03 (0.32) 
Cortisol 0.04 (0.20) 
Diabetic retinopathy  0.01 (0.73) 
Severe hypoglycaemia -0.05 (0.13) 
Duration of diabetes -0.02 (0.50) 
HADS-D -0.12 (<0.001) 
Analyses were linear regression analyses adjusted for age and sex. β values are 
standardised regression  correlation coefficients (p-values). Log-transformed 
variables were used for NT-proBNP, HADS-D, alcohol untis/year and duration 
of diabetes. Square root transformed values were used for packyears. Alcohol 
units/year is based on quintiles. 
N = 909 to 1049.  
Peripheral arterial disease measured by presence of intermittent claudication; 
carotid IMT, carotid intima-media thickness; ABI, ankle-brachial pressure index; 
MVD, macrovascular disease; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; NT-proBNP, N-terminal pro-brain natriuretic peptide; bp, blood 







Risk factors and cognitive function at year 4 
Table D.2: Univariate association of risk factors with cognitive function at year 4 










Any symptomatic MVD -0.17 (<0.001) -0.12 (0.001) -0.11 (0.002) -0.11 (0.002) 0.11 (0.001) -0.15 (<0.001) -0.11 (0.002) -0.11 (0.002) 
Transient ischaemic attack -0.04 (0.29) 0.01 (0.75) -0.04 (0.25) -0.11 (0.002) 0.01 (0.68) -0.02 (0.59) -0.03 (0.38) 0.01 (0.75) 
Stroke -0.16 (<0.001) -0.07 (0.040) -0.06 (0.11) -0.06 (0.06) 0.14 (<0.001) -0.15 (<0.001) -0.07 (0.051) -0.11 (0.002) 
Myocardial infarction 0.09 (0.013) -0.02 (0.50) -0.04 (0.27) -0.10 (0.005) 0.07 (0.06) -0.09 (0.013) -0.07 (0.06) -0.02 (0.50) 
Angina -0.11 (0.002) -0.09 (0.010) -0.05 (0.17) -0.07 (0.041) 0.07 (0.053) -0.13 (<0.001) -0.08 (0.020) -0.04 (0.27) 
Peripheral arterial disease -0.06 (0.10) -0.05 (0.18) -0.06 (0.07) 0.00 (0.97) 0.05 (0.13) -0.01 (0.70) -0.06 (0.11) -0.04 (0.21) 
Waist-hip ratio -0.20 (<0.001) -0.06 (0.15) -0.06 (0.14) -0.13 (0.001) 0.18 (<0.001) -0.21 (<0.001) -0.15 (<0.001) -0.14 (0.001) 
Total cholesterol 0.00 (0.92) -0.05 (0.19) 0.03 (0.46) 0.02 (0.49) 0.00 (0.96) -0.02 (0.51) 0.03 (0.47) -0.03 (0.42) 
HDL cholesterol 0.09 (0.014) 0.06 (0.12) 0.07 (0.036) 0.07 (0.049) -0.05 (0.18) 0.03 (0.40) 0.08 (0.036) 0.09 (0.015) 
LDL:HDL -0.08 (0.022) -0.08 (0.18) -0.02 (0.48) -0.06 (0.10) 0.04 (0.24) -0.06 (0.12) -0.04 (0.28) -0.10 (0.006) 
Systolic bp at clinic visit -0.06 (0.10) -0.03 (0.43) -0.03 (0.33) -0.04 (0.21) 0.03 (0.40) -0.01 (0.82) -0.08 (0.018) -0.07 (0.035) 
Diastolic bp at clinic visit 0.01 (0.79) 0.00 (0.99) 0.00 (0.98) 0.02 (0.66) -0.01 (0.75) 0.03 (0.48) -0.02 (0.58) 0.00 (0.97) 
Historical systolic bp 0.02 (0.48) 0.03 (0.46) -0.02 (0.57) 0.00 (0.90) -0.02 (0.63) 0.03 (0.47) 0.03 (0.43) 0.01 (0.74) 
Packyears  -0.15 (<0.001) -0.05 (0.19) -0.14 (<0.001) -0.12 (0.001) 0.11 (0.003) -0.17 (<0.001) -0.07 (0.048) -0.05 (0.17) 
Alcohol units/year 0.18 (<0.001) 0.13 (0.001) 0.10 (0.007) 0.13 (0.001) -0.11 (0.003) 0.09 (0.019) 0.13 (0.001) 0.17 (<0.001) 
ABI 0.12 (0.001) 0.11 (0.003) 0.07 (0.041) 0.06 (0.09) -0.10 (0.004) 0.13 (<0.001) 0.05 (0.14) 0.02 (0.51) 
Carotid IMT -0.09 (0.014) -0.05 (0.16) -0.09 (0.014) -0.09 (0.010) 0.06 (0.09) -0.05 (0.19) -0.01 (0.88) -0.04 (0.28) 
NT-proBNP -0.10 (0.005) -0.09 (0.014) -0.07 (0.06) -0.04 (0.21) 0.07 (0.06) -0.07 (0.038) -0.07 (0.048) -0.06 (0.08) 
Inflammation factor -0.20 (<0.001) -0.08 (0.026) -0.11 (0.002) -0.12 (0.001) 0.15 (<0.001) -0.17 (<0.001) -0.16 (<0.001) -0.11 (0.003) 
HbA1c at clinic visit -0.12 (0.001) -0.01 (0.70) -0.08 (0.022) -0.08 (0.022) 0.09 (0.013) -0.09 (0.012) -0.08 (0.019) -0.15 (<0.001) 
Historical HbA1c -0.12 (0.001) 0.02 (0.50) -0.10 (0.002) -0.06 (0.06) 0.11 (0.001) -0.09 (0.013) -0.07 (0.051) -0.13 (<0.001) 
Cortisol 0.00 (0.98) -0.03 (0.42) -0.02 (0.62) 0.02 (0.56) 0.01 (0.76) 0.03 (0.36) -0.01 (0.83) -0.01 (0.74) 
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Diabetic retinopathy -0.05 (0.17) -0.04 (0.27) -0.02 (0.54) -0.01 (0.71) 0.05 (0.19) -0.03 (0.36) -0.03 (0.48) -0.04 (0.24) 
Severe hypoglycaemia -0.09 (0.009) 0.02 (0.66) -0.02 (0.52) -0.09 (0.009) 0.11 (0.001) -0.09 (0.009) -0.06 (0.10) -0.06 (0.10) 
Duration of diabetes -0.09 (0.006) -0.02 (0.52) -0.09 (0.008) -0.06 (0.09) 0.07 (0.045) -0.08 (0.020) -0.06 (0.12) -0.09 (0.010) 
HADS-D -0.20 (<0.001) -0.10 (0.004) -0.06 (0.07) -0.12 (0.001) 0.17 (<0.001) -0.19 (<0.001) -0.17 (<0.001) -0.14 (<0.001) 
Analyses were linear regression analyses adjusted for age and sex. β values are standardised regression  correlation coefficients (p-values). Data for g have been 
imputed, for individual cognitive tests are non-imputed. Log-transformed variables were used for Trail-Making, HADS-D, NT-proBNP and duration of diabetes. 
Square root transformed values were used for packyears. Alcohol units/year is based on quintiles. N = 739 to 824. Peripheral arterial disease measured by presence 
of intermittent claudication; MVD, macrovascular disease; carotid IMT, carotid intima-media thickness; ABI, ankle-brachial pressure index; MVD, macrovascular 
disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-brain natriuretic peptide; bp, blood pressure; HADS-D, 






















Table D.3: Univariate association of risk factors with reaction time at year 4 




Any symptomatic MVD 0.06 (0.11) 0.06 (0.09) 
Transient ischaemic attack 0.01 (0.80) 0.00 (0.94) 
Stroke 0.09 (0.011) 0.05 (0.19) 
Myocardial infarction -0.03 (0.48) -0.02 (0.55) 
Angina 0.04 (0.23) 0.07 (0.08) 
Peripheral arterial disease -0.01 (0.88) 0.08 (0.020) 
Waist-hip ratio 0.13 (0.001) 0.18 (<0.001) 
Total cholesterol -0.03 (0.46) -0.04 (0.34) 
HDL cholesterol -0.05 (0.16) -0.06 (0.15) 
LDL:HDL 0.03 (0.48) 0.04 (0.23) 
Systolic bp at clinic visit 0.07 (0.050) 0.09 (0.010) 
Diastolic bp at clinic visit -0.03 (0.45) -0.04 (0.33) 
Historical systolic bp 0.02 (0.56) 0.05 (0.21) 
Packyears  0.02 (0.69) 0.08 (0.050) 
Alcohol units/year -0.02 (0.70) -0.01 (0.82) 
ABI -0.06 (0.11) -0.08 (0.034) 
Carotid IMT 0.10 (0.005) 0.12 (0.002) 
NT-proBNP 0.00 (0.92) 0.04 (0.31) 
Inflammation factor 0.08 (0.026) 0.08 (0.025) 
HbA1c at clinic visit 0.04 (0.22) 0.04 (0.26) 
Historical HbA1c 0.08 (0.020) 0.06 (0.09) 
Cortisol -0.05 (0.16) -0.03 (0.46) 
Diabetic retinopathy -0.01 (0.70) 0.01 (0.73) 
Severe hypoglycaemia 0.10 (0.007) 0.08 (0.031) 
Duration of diabetes 0.04 (0.31) 0.03 (0.36) 
HADS-D 0.02 (0.50) 0.08 (0.020) 
Analyses were linear regression analyses adjusted for age and sex. β values are 
standardised regression  correlation coefficients (p-values). Log-transformed variables 
were used for SRT mean, HADS-D, NT-proBNP and duration of diabetes . Square root 
transformed values were used for packyears. Alcohol units/year is based on quintiles. 
N = 744 to 797 for SRT and 739 to 748 for CRT. Peripheral arterial disease measured by 
presence of intermittent claudication; MVD, macrovascular disease; carotid IMT, carotid 
intima-media thickness; ABI, ankle-brachial pressure index; MVD, macrovascular 
disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-
terminal pro-brain natriuretic peptide; bp, blood pressure; HADS-D, Depression subscale 
of the Hospital Anxiety and Depression Scale. SRT, simple reaction time; CRT, choice 





Risk factors and estimated lifetime cognitive change 
Table D.4: Univariate associations of risk factors with cognitive function at year 4 adjusted for MHVS  










Any symptomatic MVD -0.06 (0.030) -0.03 (0.31) -0.05 (0.12) -0.02 (0.51) 0.05 (0.17) -0.08 (0.017) -0.03 (0.42) -0.03 (0.33) 
Transient ischaemic attack -0.02 (0.58) 0.03 (0.29) -0.04 (0.28) -0.08 (0.009) 0.00 (0.98) 0.00 (0.97) -0.01 (0.74) 0.02 (0.64) 
Stroke -0.12 (<0.001) -0.04 (0.17) -0.04 (0.28) -0.03 (0.30) 0.12 (<0.001) -0.13 (<0.001) -0.05 (0.14) -0.08 (0.012) 
Myocardial infarction -0.05 (0.11) 0.00 (0.95) -0.02 (0.58) -0.08 (0.015) 0.04 (0.27) -0.05 (0.11) -0.04 (0.18) 0.01 (0.81) 
Angina -0.01 (0.73) -0.02 (0.65) 0.00 (0.95) 0.01 (0.80) 0.00 (0.97) -0.07 (0.034) 0.01 (0.80) 0.03 (0.35) 
Peripheral arterial disease -0.03 (0.26) -0.03 (0.33) -0.06 (0.08) 0.01 (0.66) 0.03 (0.29) 0.00 (0.89) -0.03 (0.42) -0.03 (0.36) 
Waist-hip ratio -0.11 (0.001) 0.02 (0.61) -0.01 (0.82) -0.06 (0.07) 0.13 (0.001) -0.15 (<0.001) -0.09 (0.022) -0.07 (0.08) 
Total cholesterol -0.01 (0.71) -0.05 (0.11) 0.02 (0.63) 0.01 (0.72) 0.00 (0.95) -0.03 (0.36) 0.03 (0.38) -0.04 (0.28) 
HDL cholesterol 0.03 (0.24) 0.01 (0.79) 0.04 (0.20) 0.03 (0.42) -0.02 (0.57) 0.00 (0.93) 0.04 (0.27) 0.05 (0.17) 
LDL:HDL -0.05 (0.08) -0.06 (0.07) -0.01 (0.77) -0.04 (0.22) 0.03 (0.45) -0.04 (0.24) -0.01 (0.67) -0.08 (0.026) 
Systolic bp at clinic visit -0.05 (0.11) -0.02 (0.53) -0.03 (0.38) -0.04 (0.23) 0.02 (0.47) 0.00 (0.99) -0.07 (0.025) -0.07 (0.027) 
Diastolic bp at clinic visit -0.03 (0.35) -0.03 (0.39) -0.02 (0.65) -0.02 (0.64) 0.02 (0.65) 0.00 (0.99) -0.04 (0.20) -0.03 (0.36) 
Historical Systolic bp 0.01 (0.76) 0.02 (0.64) -0.03 (0.42) -0.02 (0.62) -0.01 (0.79) 0.01 (0.70) 0.02 (0.58) 0.00 (0.91) 
Packyears  -0.10 (0.001) -0.01 (0.76) -0.11 (0.002) -0.07 (0.028) 0.08 (0.022) -0.15 (<0.001) -0.05 (0.19) -0.02 (0.64) 
Alcohol units/year 0.08 (0.010) 0.05 (0.16) 0.06 (0.11) 0.05 (0.16) -0.05 (0.20) 0.02 (0.58) 0.06 (0.09) 0.10 (0.006) 
ABI 0.08 (0.007) 0.08 (0.017) 0.05 (0.14) 0.02 (0.44) -0.07 (0.030) 0.11 (0.001) 0.02 (0.56) -0.01 (0.81) 
Carotid IMT -0.09 (0.002) -0.06 (0.08) -0.09 (0.008) -0.10 (0.002) 0.07 (0.06) -0.05 (0.13) -0.01 (0.71) -0.05 (0.18) 
NT-proBNP -0.07 (0.012) -0.07 (0.033) -0.05 (0.13) -0.03 (0.38) 0.05 (0.14) -0.05 (0.11) -0.05 (0.12) -0.05 (0.17) 
Inflammation factor -0.14 (<0.001) -0.03 (0.35) -0.08 (0.020) -0.10 (0.001) 0.12 (<0.001) -0.13 (<0.001) -0.11 (0.001) -0.07 (0.049) 
HbA1c at clinic visit -0.08 (0.008) 0.03 (0.39) -0.06 (0.09) -0.05 (0.11) 0.07 (0.042) -0.07 (0.029) -0.05 (0.17) -0.12 (<0.001) 
Historical HbA1c -0.10 (0.001) 0.05 (0.15) -0.10 (0.004) -0.05 (0.10) 0.11 (0.001) -0.08 (0.011) -0.05 (0.11) -0.12 (<0.001) 
Cortisol -0.01 (0.69) -0.04 (0.22) -0.03 (0.43) 0.01 (0.78) 0.02 (0.58) 0.02 (0.54) -0.01 (0.82) -0.03 (0.44) 
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Diabetic retinopathy -0.05 (0.07) -0.04 (0.17) -0.03 (0.46) -0.01 (0.74) 0.05 (0.12) -0.03 (0.29) -0.03 (0.38) -0.04 (0.21) 
Severe hypoglycaemia -0.08 (0.004) 0.02 (0.50) -0.02 (0.53) -0.07 (0.018) 0.11 (0.001) -0.08 (0.010) -0.05 (0.11)  -0.05 (0.12) 
Duration of diabetes -0.08 (0.002) -0.01 (0.69) -0.09 (0.008) -0.05 (0.08) 0.07 (0.041) -0.08 (0.018) -0.05 (0.12) -0.08 (0.010) 
HADS-D -0.14 (<0.001) -0.05 (0.11) -0.03 (0.32) -0.07 (0.023) 0.12 (<0.001) -0.14 (<0.001) -0.12 (<0.001) -0.10 (0.002) 
Analyses were linear regression analyses adjusted for age, sex and baseline MHVS. β values are standardised regression  correlation coefficients (p-values). β values are 
standardised regression  correlation coefficients (p-values). Values of g have been imputed, for individual cognitive tests are non-imputed. Log-transformed variables were 
used for Trail-Making, HADS-D, NT-proBNP, and duration of diabetes. Square root transformed values were used for packyears. Alcohol units/year is based on quintiles. N 
= 733 to 814. Peripheral arterial disease measured by presence of intermittent claudication; MVD, macrovascular disease; carotid IMT, carotid intima-media thickness; ABI, 
ankle-brachial pressure index; MVD, macrovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-brain natriuretic 
peptide; bp, blood pressure; HADS-D, Depression subscale of the Hospital Anxiety and Depression Scale; Trail-Making, Trail-Making Test-B; Verbal Fluency, Borkowski 




Table D.5: Univariate associations of risk factors with reaction time at year 4 






Any symptomatic MVD 0.02 (0.66) 0.02 (0.54) 
Transient ischaemic attack 0.01 (0.76) 0.01 (0.88) 
Stroke 0.08 (0.020) 0.03 (0.35) 
Myocardial infarction -0.03 (0.34) -0.04 (0.33) 
Angina 0.00 (0.95) 0.04 (0.30) 
Peripheral arterial disease -0.01 (0.86) 0.07 (0.07) 
Waist-hip ratio 0.11 (0.006) 0.15 (<0.001) 
Total cholesterol -0.03 (0.42) -0.04 (0.31) 
HDL cholesterol -0.03 (0.36) -0.04 (0.34) 
LDL:HDL 0.01 (0.73) 0.03 (0.38) 
Systolic bp at clinic visit 0.05 (0.12) 0.09 (0.012) 
Diastolic bp at clinic visit -0.02 (0.55) -0.02 (0.53) 
Historical systolic bp 0.02 (0.55) 0.05 (0.15) 
Packyears  0.01 (0.87) 0.05 (0.17) 
Alcohol units/year 0.02 (0.67) 0.01 (0.78) 
ABI -0.05 (0.13) -0.06 (0.13) 
Carotid IMT 0.11 (0.004) 0.12 (0.001) 
NT-proBNP -0.01 (0.72) 0.03 (0.47) 
Inflammation factor 0.06 (0.09) 0.06 (0.08) 
HbA1c at clinic visit 0.00 (0.95) 0.03 (0.43) 
Historical HbA1c 0.06 (0.11) 0.06 (0.11) 
Cortisol -0.05 (0.18) -0.02 (0.53) 
Diabetic retinopathy -0.01 (0.71) 0.01 (0.71) 
Severe hypoglycaemia 0.09 (0.007) 0.08 (0.023) 
Duration of diabetes 0.02 (0.60) 0.03 (0.38) 
HADS-D 0.01 (0.77) 0.07 (0.049) 
Analyses were linear regression analyses adjusted for age, sex and baseline MHVS. β 
values are standardised regression  correlation coefficients (p-values). Log-transformed 
variables were used for SRT mean, HADS-D, NT-proBNP and duration of diabetes. 
Square root transformed values were used for packyears. Alcohol units/year is based on 
quintiles; N = 738 to 788 for SRT and 695 to 740 for CRT.  
Peripheral arterial disease measured by presence of intermittent claudication; MVD, 
macrovascular disease; carotid IMT, carotid intima-media thickness; ABI, ankle-brachial 
pressure index; MVD, macrovascular disease; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; NT-proBNP, N-terminal pro-brain natriuretic peptide; bp, blood 
pressure; HADS-D, Depression subscale of the Hospital Anxiety and Depression Scale; 





Risk factors and four-year cognitive change 
Table D.6: Univariate associations of risk factors with four-year cognitive change 













Any symptomatic MVD -0.09 (0.008) -0.08 (0.002) -0.05 (0.06) -0.03 (0.29) 0.06 (0.018) -0.05 (0.046) -0.07 (0.017) -0.05 (0.019) 
Transient ischaemic attack -0.05 (0.18) 0.01 (0.86) -0.04 (0.21) -0.08 (0.002) 0.01 (0.68) -0.01 (0.68) -0.01 (0.70) 0.00 (0.97) 
Stroke -0.07 (0.036) -0.03 (0.30) -0.02 (0.59) -0.03 (0.20) 0.06 (0.030) -0.06 (0.011) -0.04 (0.25) -0.04 (0.07) 
Myocardial infarction -0.04 (0.29) -0.03 (0.23) 0.00 (0.88) -0.04 (0.10) 0.03 (0.19) -0.02 (0.53) -0.07 (0.031) -0.01 (0.81) 
Angina -0.04 (0.24) -0.06 (0.039) -0.02 (0.41) 0.00 (0.93) 0.04 (0.13) -0.05 (0.022) -0.05 (0.11) -0.03 (0.15) 
Peripheral arterial disease -0.02 (0.57) -0.05 (0.08) -0.05 (0.11) 0.01 (0.70) 0.01 (0.68) 0.02 (0.37) -0.04 (0.23) -0.01 (0.70) 
Waist-hip ratio -0.10 (0.012) -0.02 (0.51) -0.01 (0.81) -0.05 (0.08) 0.06 (0.043) -0.10 (<0.001) -0.10 (0.004) -0.04 (0.07) 
Total cholesterol 0.04 (0.28) -0.02 (0.49) 0.04 (0.22) 0.00 (0.98) -0.03 (0.23) -0.02 (0.51) 0.05 (0.15) -0.02 (0.45) 
HDL cholesterol 0.04 (0.26) 0.04 (0.18) 0.06 (0.037) 0.00 (0.96) -0.04 (0.16) 0.00 (0.95) 0.07 (0.028) -0.01 (0.72) 
LDL:HDL -0.02 (0.49) -0.05 (0.06) -0.01 (0.76) -0.01 (0.65) 0.02 (0.48) -0.02 (0.34) -0.02 (0.49) -0.02 (0.25) 
Systolic bp at clinic visit -0.10 (0.006) -0.04 (0.20) -0.03 (0.27) -0.03 (0.23) 0.01 (0.67) -0.03 (0.23) -0.07 (0.014) -0.05 (0.017) 
Diastolic bp at clinic visit -0.01 (0.86) 0.03 (0.22) -0.02 (0.59) 0.00 (0.96) -0.03 (0.19) 0.02 (0.45) -0.04 (0.16) -0.01 (0.77) 
Historical systolic bp -0.05 (0.19) 0.00 (0.91) -0.03 (0.26) -0.03 (0.19) 0.02 (0.47) 0.02 (0.49) 0.01 (0.80) -0.02 (0.33) 
Packyears  -0.15 (<0.001) -0.05 (0.07) -0.09 (0.003) -0.06 (0.03) 0.05 (0.052) -0.08 (0.001) -0.07 (0.036) -0.05 (0.024) 
Alcohol (units/year) 0.02 (0.60) 0.05 (0.11) 0.05 (0.11) 0.04 (0.21) -0.05 (0.07) 0.01 (0.82) 0.04 (0.25) 0.03 (0.19) 
ABI 0.12 (<0.001) 0.08 (0.006) 0.04 (0.12) 0.02 (0.54) -0.06 (0.012) 0.07 (0.004) 0.05 (0.13) 0.03 (0.12) 
Carotid IMT -0.15 (<0.001) -0.06 (0.030) -0.08 (0.007) -0.08 (0.003) 0.05 (0.08) -0.08 (0.002) -0.02 (0.46) -0.02 (0.50) 
NT-proBNP -0.12 (0.001) -0.07 (0.013) -0.04 (0.15) -0.01 (0.65) 0.04 (0.11) -0.05 (0.053) -0.08 (0.014) -0.07 (0.001) 
Inflammation factor -0.17 (<0.001) -0.07 (0.018) -0.06 (0.030) -0.07 (0.006) 0.07 (0.012) -0.11 (<0.001) -0.14 (<0.001) -0.06 (0.009) 
HbA1c at clinic visit -0.08 (0.025) -0.01 (0.81) -0.05 (0.10) -0.06 (0.034) 0.05 (0.06) -0.05 (0.042) -0.05 (0.09) -0.06 (0.008) 
Historical HbA1c -0.11 (0.001) -0.01 (0.87) -0.60 (0.030) -0.06 (0.034) 0.07 (0.006) -0.04 (0.12) -0.06 (0.036) -0.07 (0.001) 
Cortisol 0.03 (0.44) -0.06 (0.025) 0.01 (0.83) 0.03 (0.23) 0.00 (0.91) 0.06 (0.013) 0.01 (0.65) -0.04 (0.07) 
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Diabetic retinopathy -0.03 (0.34) -0.05 (0.08) 0.00 (0.98) -0.04 (0.11) 0.04 (0.16) 0.02 (0.46) -0.02 (0.49) 0.00 (0.94) 
Severe hypoglycaemia -0.08 (0.020) 0.00 (0.90) -0.03 (0.23) -0.09 (0.001) 0.06 (0.024) -0.04 (0.10) -0.03 (0.37) -0.02 (0.33) 
Duration of diabetes -0.04 (0.21) -0.04 (0.19) -0.03 (0.37) -0.06 (0.020) 0.04 (0.15) -0.02 (0.53) -0.04 (0.24) -0.03 (017) 
HADS-D -0.08 (0.018) -0.04 (0.11) -0.04 (0.14) -0.04 (0.14) 0.05 (0.034) -0.07 (0.005) -0.11 (<0.001) -0.04 (0.033) 
Analyses were linear regression analyses adjusted for age, sex and baseline score. β values are standardised regression  correlation coefficients (p-values). Data for g have 
been imputed, for individual cognitive tests are non-imputed. 
Log-transformed variables were used for TMT-B, HADS-D, NT-proBNP, alcohol units/year and duration of diabetes. Square root transformed values were used for 
packyears. Alcohol units/year is based on quintiles. N = 757 to 822. Peripheral arterial disease measured by presence of intermittent claudication; MVD, macrovascular 
disease; carotid IMT, carotid intima-media thickness; ABI, ankle-brachial pressure index; MVD, macrovascular disease; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; NT-proBNP, N-terminal pro-brain natriuretic peptide; bp, blood pressure; HADS-D, Depression subscale of the Hospital Anxiety and Depression Scale; Trail-








Appendix E: Repetition of selected analyses  
Univariate analyses of risk factors and four-year cognitive change using raw change scores 
Table E.8: Univariate associations of risk factors with four-year cognitive change scores 













Any symptomatic MVD 0.02 (0.53) 0.07 (0.054) 0.03 (0.46) -0.02 (0.54) -0.06 (0.13) 0.01 (0.79) 0.04 (0.25) 0.06 (0.10) 
Transient ischaemic 
attack 
0.04 (0.29) 0.00 (0.94) 0.04 (0.28) 0.08 (0.017) 0.00 (0.92) 0.01 (0.81) 0.00 (0.91) 0.01 (0.89) 
Stroke 0.01 (0.83) 0.00 (0.97) -0.10 (0.80) 0.02 (0.65) -0.04 (0.27) 0.03 (0.34) 0.01 (0.85) 0.04 (0.30) 
Myocardial infarction 0.00 (0.99) 0.04 (0.26) 0.03 (0.36) 0.02 (0.63) -0.01 (0.74) -0.02 (0.62) 0.06 (0.09) 0.00 (0.96) 
Angina -0.01 (0.89) 0.04 (0.25) 0.01 (0.75) -0.04 (0.21) -0.04 (0.26) 0.03 (0.38) 0.02 (0.55) 0.05 (0.20) 
Peripheral arterial 
disease 
-0.01 (0.90) 0.06 (0.12) 0.04 (0.24) -0.02 (0.53) 0.00 (0.96) -0.05 (0.18) 0.02 (0.57) 0.00 (0.99) 
Waist-hip ratio 0.02 (0.66) 0.00 (0.98) -0.02 (0.56) 0.02 (0.70) -0.03 (0.51) 0.07 (0.09) 0.07 (0.08) 0.04 (0.33) 
Total cholesterol -0.05 (0.18) 0.01 (0.86) -0.05 (0.19) 0.02 (0.61) 0.03 (0.39) 0.02 (0.61) -0.06 (0.09) 0.02 (0.53) 
HDL cholesterol 0.00 (0.91) -0.03 (0.38) -0.06 (0.10) 0.05 (0.21) 0.04 (0.27) 0.02 (0.61) -0.07 (0.08) 0.05 (0.21) 
LDL:HDL -0.01 (0.73) 0.04 (0.29) 0.00 (0.99) -0.02 (0.65) -0.02 (0.58) 0.01 (0.69) 0.01 (0.88) 0.01 (0.69) 
Systolic bp at clinic visit 0.08 (0.018) 0.04 (0.23) 0.04 (0.31) 0.03 (0.38) 0.00 (0.90) 0.05 (0.16) 0.07 (0.048) 0.07 (0.042) 
Diastolic bp at clinic visit 0.01 (0.72) -0.06 (0.11) 0.03 (0.41) 0.01 (0.71) 0.04 (0.23) -0.02 (0.55) 0.07 (0.07) 0.01 (0.73) 
Historical systolic bp 0.07 (0.06) 0.00 (0.92) 0.05 (0.19) 0.06 (0.09) -0.02 (0.51) -0.02 (0.61) 0.01 (0.84) 0.04 (0.21) 
Packyears  0.10 (0.009) 0.05 (0.15) 0.07 (0.07) 0.04 (0.35) -0.07 (0.07) 0.08 (0.031) 0.07 (0.06) 0.08 (0.036) 
Alcohol units/year 0.07 (0.09) 0.00 (0.94) -0.02 (0.58) 0.02 (0.66) 0.05 (0.25) 0.04 (0.34) 0.03 (0.49) 0.00 (0.95) 
ABI -0.09 (0.013) -0.04 (0.23) -0.05 (0.15) 0.02 (0.50) 0.07 (0.06) -0.05 (0.20) -0.06 (0.09) -0.04 (0.23) 
Carotid IMT 0.13 (0.001) 0.07 (0.053) 0.09 (0.020) 0.09 (0.015) -0.07 (0.07) 0.13 (0.001) 0.04 (0.29) 0.02 (0.68) 
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NT-proBNP 0.09 (0.014) 0.06 (0.08) 0.03 (0.38) -0.01 (0.80) -0.04 (0.27) 0.05 (0.17) 0.08 (0.034) 0.12 (0.001) 
Inflammation factor 0.10 (0.006) 0.06 (0.09) 0.04 (0.28) 0.04 (0.26) -0.06 (0.08) 0.11 (0.002) 0.13 (0.001) 0.07 (0.042) 
HbA1c at clinic visit 0.03 (0.35) 0.00 (0.99) 0.03 (0.37) 0.05 (0.15) -0.08 (0.037) 0.05 (0.20) 0.03 (0.47) 0.06 (0.09) 
Historical HbA1c 0.07 (0.038) 0.02 (0.56) 0.04 (0.24) 0.06 (0.10) -0.09 (0.011) 0.03 (0.49) 0.06 (0.09) 0.09 (0.014) 
Cortisol -0.03 (0.40) 0.09 (0.009) -0.02 (0.52) -0.05 (0.20) -0.01 (0.71) -0.10 (0.007) -0.03 (0.44) 0.07 (0.049) 
Diabetic retinopathy  0.00 (0.94) 0.06 (0.11) -0.01 (0.70) 0.07 (0.052) -0.03 (0.36) -0.05 (0.16) 0.02 (0.62) -0.02 (0.61) 
Severe hypoglycaemia 0.05 (0.15) 0.01 (0.74) 0.04 (0.21) 0.11 (0.003) -0.07 (0.037) 0.03 (0.44) 0.00 (0.96) 0.02 (0.57) 
Duration of diabetes 0.00 (0.91) 0.05 (0.14) -0.01 (0.69) 0.07 (0.036) -0.04 (0.30) -0.02 (0.68) 0.02 (0.51) 0.02 (0.50) 
HADS-D 0.00 (0.93) 0.09 (0.028) 0.06 (0.13) 0.06 (0.13) -0.09 (0.021) 0.13 (0.001) 0.13 (0.001) 0.12 (0.002) 
β values are standardised regression  correlation coefficients (p-values)  
Due to a normal distribution of the change variable, untransformed data was used for TMT-B. Data for g have been imputed, for individual cognitive tests are non-
imputed. Log-transformed variables were used for Trail-Making, NT-proBNP, HADS-D and duration of diabetes. Alcohol units/year is based on quintiles. 
Packyears is square root transformed. N = 734 to 819. 
Analyses are of raw change scores and adjusted for age and sex. Positive values represent decline in scores between baseline and year 4; negative values represent 
increased scores between baseline and year 4. For the calculation of change in g, baseline g and follow-up g were standardised on the same population (as described 
for the adjustment method in Section 4.5.3). Prior to calculation of the change score for g, follow-up g was multiplied by the ratio of variances and the mean 
difference between baseline and follow-up g. This ensured that both baseline and follow-up g were measured on the same scale and that latent means and variances 
were identical. Peripheral arterial disease measured by presence of intermittent claudication; MVD, macrovascular disease; carotid IMT, carotid intima-media 

















Analyses of incident SH associations with cognitive function and 
cognitive decline with restriction to first-ever incident SH 
For the purpose of excluding subjects who had both a baseline history of SH and 
incident SH from analyses, patients with incident SH as well as a baseline history of 
SH were recoded as ‘missing’ in the analyses reported in this section.  
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Table E.9: First-ever incident severe hypoglycaemia and cognitive function at year 4 
 No severe 
hypoglycaemia  
(n=730) 
Severe hypoglycaemia  





Model 1: age, sex 
   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
11.95 (11.56 – 12.33) 
9.11 (8.89 - 9.33)  
37.54 (36.8 – 38.50) 
51.05 (50.02 – 52.08) 
107.40 (04.17 – 10.50) 
69.59 (68.98 – 70.20) 
27.40 (26.78 – 8.01) 
0.09 (0.01 – 0.16) 
 
10.16 (8.80 – 11.52) 
8.07 (7.28 – 8.85) 
34.35 (30.98 – 37.73) 
46.91 (43.23 – 50.59) 
26.22 (3.64 – 40.33) 
66.78 (64.64 – 68.91) 
25.86 (23.68 – 8.04) 






















   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
11.96 (11.57 – 12.36) 
9.12 (8.89 – 9.34) 
37.72 (36.74 – 38.69) 
51.05 (50.01 – 52.09) 
107.02 (103.75 – 110.28) 
69.67 (69.04 – 70.29) 
27.59 (26.96 – 28.22) 
0.10 (0.02 – 0.17) 
 
10.76 (9.30 – 2.21) 
8.20 (7.38 – 9.02) 
35.91 (32.33 – 39.49) 
47.94 (44.08 – 51.80) 
120.78 (107.99 – 134.96) 
67.36 (65.06 – 69.66) 
25.38 (23.08 – 27.60) 



















Values are adjusted means (95% CI). N = 701 to 727 for Model 1; N = 692 to 769 for Model 2. Data on g are imputed, for remaining cognitive tests 
are non-imputed. Trail-Making is log-transformed. Means for this test are geometric means. Letter-Number, Letter Number Sequencing, Verbal 
Fluency, Borkowski Verbal Fluency Test, Trail-Making, Trail-Making Test-B.  
a
adjusted for age, sex, HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, smoking 










Table E.10: First-ever incident severe hypoglycaemia and reaction time at year 4 
 No severe hypoglycaemia 
(n=730) 
Severe hypoglycaemia  





Model 1: age, sex 
   SRT mean 
   CRT mean 
 
312.62 (307.97 – 37.35) 
628.01 (618.92 – 637.10) 
 
335.29 (317.35 – 354.25) 









    
SRT mean 
   CRT mean 
 
312.31 (307.66 – 317.35) 
627.90 (618.63 – 637.16) 
 
331.96 (313.56 – 351.43) 







Values are adjusted means (95% CI). N = 704 and 667 for Model 1; N = 671 and 634 for Model 2. Means for ln(SRT) are geometric means. SRT 
and CRT are measured in milliseconds. SRT, simple reaction time; CRT, choice reaction time. 
a
adjusted for age, sex, HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, smoking 






















Table E.11: First-ever incident severe hypoglycaemia and year 4 cognitive test scores adjusted for baseline MHVS 
 No severe hypoglycaemia 
(n=730) 
Severe hypoglycaemia  





Model 1: age, sex, 
baseline MHVS 
   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
 
11.88 (11.54 – 12.23) 
9.10 (8.90 – 9.30) 
37.44 (36.55 – 38.33) 
50.95 (49.99 – 51.91) 
107.55 (104.58 – 110.61) 
69.57 (68.98 – 70.16) 
27.34 (26.79 – 27.88) 
0.08 (0.02 – 0.14) 
 
 
10.59 (9.36 – 11.81) 
8.34 (7.62 – 9.05) 
35.43 (32.30 – 38.57) 
48.11 (44.70 – 51.52) 
122.36 (10.72 – 135.37) 
67.07 (65.00 – 69.14) 
26.90 (24.95 – 28.85) 
























   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory  
   ‘g’ 
 
11.90 (11.55 – 12.25) 
9.11 (8.91 – 9.32) 
37.63 (36.73 – 38.53) 
50.96 (49.98 – 51.93) 
107.23 (104.17 – 10.39) 
69.65 (69.05 – 70.26) 
27.55 (26.99 – 28.11) 
0.09 (0.03 – 0.15) 
 
11.19 (9.87 – 12.50) 
8.43 (7.67 – 9.19) 
37.00 (33.66 – 40.32) 
48.98 (45.38 – 52.59) 
117.21 (05.32 – 130.45) 
67.61 (65.37 – 69.86) 
26.24 (24.16 – 28.32) 



















Outcome variables are follow-up cognitive test scores. Values are adjusted means (95% CI). N = 694 to 719 for Model 1; N = 662 to 684 for Model 
2. Data for g are imputed, for remaining cognitive tests are non-imputed. Trail-Making is log-transformed. Means for this test are geometric means. 
Letter-Number, Letter Number Sequencing, Verbal Fluency, Borkowski Verbal Fluency Test, Digit Symbol, Digit Symbol Coding, Trail-Making, 
Trail-Making Test-B, MHVS, Mill-Hill Vocabulary Scale. 
a
model 1 +HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, smoking 








Table E.12: First-ever incident severe hypoglycaemia and reaction time at year 4 adjusted for MHVS 
 No severe hypoglycaemia 
(n=730) 
Severe hypoglycaemia  





Model 1: age, sex, 
baseline MHVS 
   SRT mean 
   CRT mean 
 
 
312.94 (308.28 – 317.67) 
628.24 (619.31 – 637.18) 
 
 
332.95 (35.13 – 351.43) 











    
SRT mean 
   CRT mean 
 
312.94 (308.28 – 317.67) 
628.07 (618.95 – 637.19) 
 
329.31 (311.38 – 348.63) 







Values are adjusted means (95% CI). N = 697 and 660 for Model 1; N = 664 and 627 for Model 2. Means for ln(SRT) are geometric means. SRT 
and CRT are measured in milliseconds. SRT, simple reaction time; CRT, choice reaction time; MHVS, Mill-Hill Vocabulary Scale. 
a
adjusted for age, sex, MHVS, HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, 






















Table E.13: First-ever incident severe hypoglycaemia and four-year cognitive change  
 No severe hypoglycaemia 
(n=730) 
Severe hypoglycaemia  





Model 1: age, sex, 
baseline score 
   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
 
11.89 (11.60 – 12.19) 
9.10 (8.91 – 9.28) 
37.57 (37.02 – 38.13) 
50.96 (50.25 – 51.67) 
107.55 (105.2 – 109.95) 
69.51 (69.01 – 70.00) 
27.41 (26.94 – 27.89) 
0.07 (-0.01 – 0.14) 
 
 
11.01 (9.97 – 12.06) 
8.40 (7.73 – 9.07) 
34.29 (32.34 – 36.24) 
48.10 (45.57 – 50.63) 
121.27 (120.30 – 13.24) 
67.66 (65.90 – 69.41) 
26.83 (25.14 – 28.52) 
























   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
11.94 (11.64 – 12.24) 
9.11 (8.91 – 9.30) 
37.84 (37.27 – 38.41) 
51.00 (50.27 – 51.72) 
107.13 (104.69 – 109.62) 
69.58 (69.08 – 70.09) 
27.58 (27.09 – 28.06) 
0.06 (-0.01 – 0.14) 
 
11.30 (10.18 – 12.43) 
8.50 (7.79 – 9.21) 
34.74 (32.65 – 36.82) 
48.57 (45.88 – 51.26) 
117.45 (107.99 – 127.87) 
68.29 (66.40 – 70.18) 
26.85 (25.05 – 28.64) 






















   Matrix Reasoning 
   Letter-Number 
   Verbal Fluency 
   Digit Symbol Coding 
   Trail-Making 
   Faces 
   Logical Memory 
   ‘g’ 
 
11.89 (11.60 – 12.19) 
9.11 (8.93 – 9.30) 
37.83 (37.27 – 38.40) 
50.97 (50.25 – 51.69) 
107.13 (104.69 – 109.62) 
69.59 (69.08 – 70.09) 
27.58 (27.12 – 28.04) 
0.07 (-0.01 – 0.14) 
 
11.40 (10.30 – 12.50) 
8.60 (7.91 – 9.28) 
34.69 (32.59 – 36.87) 
48.88 (46.21 – 51.54) 
116.40 (106.91 – 126.60) 
68.45 (66.58 – 70.32) 
27.04 (25.32 – 28.75) 





















Outcome variables are follow-up cognitive test scores. Values are adjusted means (95% CI). N = 694 to 726 for Model 1; N = 663 to 691 for 
Model 2; N = 658 to 684 for Model 3. Data for g are imputed, for remaining cognitive tests are non-imputed. Trail-Making is log-transformed. 
Means for this test are geometric means. Letter-Number, Letter Number Sequencing, Verbal Fluency, Borkowski Verbal Fluency Test, Trail-
Making Test-B, MHVS, Mill-Hill Vocabulary Scale.  
a
model 1 + HDL cholesterol, total cholesterol, systolic blood pressure at clinic visit, diastolic blood pressure at clinic visit, smoking 
(ex/current/never), HbA1c at clinic visit, transient ischaemic attack, stroke, myocardial infarction, angina, retinopathy 
b





Selected analyses repeated with exclusion of patients with dementia (total n=19; ‘attenders’ with 
dementia n=4) 
 
Table D.9: Linear regression analyses of associations between macrovascular disease and MHVS at baseline, including and 




























































































Outcome measure is baseline MHVS. Analyses adjusted for age, sex.  *comparisons are made with subjects free of respective symptomatic MVD category. **as 
reported in the main text of this thesis (Chapter 6). Values are standardised β coefficients (p-values). MHVS, Mill-Hill Vocabulary Scale; MVD, macrovascular 
disease; TIA, transient ischaemic attack; MI, myocardial infarction; PAD, peripheral arterial disease; NT-proBNP, N-terminal pro-brain natriuretic peptide; carotid 








Table D.10: Linear regression analyses of statistically significant associations of macrovascular disease with four-year cognitive 



























cases   






























































































































Values are standardised β coefficients (p-values). Outcome variables are year 4 follow-up cognitive test scores. Data for individual cognitive tests 
are non-imputed; for g are imputed. Trail-Making variable is log-transformed.  *comparisons are made with subjects free of stroke *
*
as reported 
in the main text of this thesis (Chapter 6). Analyses adjusted for age, sex, baseline scores. Trail-Making, Trail-Making Test-B; Verbal Fluency, 
Borkowski Verbal Fluency Test; Letter-Number, Letter Number Sequencing; ABI, ankle brachial index; carotid IMT, carotid intima-media 
thickness. For stroke, n=784 to 822 in analyses of all subjects and n=780 to 818 in analyses excluding dementia patients. For NT-proBNP, n=773 
to 811 in analyses of all subjects and n=769 to 807 in analyses excluding dementia patients. For cIMT, n=734 to 768 for analyses of all subjects 
and n=730 to 764 for analyses excluding dementia patients. For ABI, n=762 to 797 in analyses of all subjects and n=759 to 794 for analyses 







Table D.11: Peak pre-morbid ability estimated by MHVS and baseline global ability as risk factors for severe hypoglycaemia, 
including and excluding dementia cases (n=19) 
 Odds ratio (95% CI, p-value) for baseline history of 
SH 
Odds ratio (95% CI, p-value) for incident SH 









(95% CI 1.04, 2.32, p=0.033) 
1.57 




(95% CI 0.69, 1.83, p=0.63) 
1.13 






(95% CI 1.26, 2.85, p=0.002) 
1.93 




(95% CI 1.25, 3.31, p=0.004) 
2.04 
(95% CI 1.26, 3.32, p=0.004) 
 
*compared with higher two tertiles of distribution. All analyses are age- and sex-adjusted. OR, odds ratio; CI, confidence interval; MHVS, Mill-Hill Vocabulary 
Scale; SH, severe hypoglycaemia. 
**
as reported in the main text of this thesis (Chapter 7) 
Table D.12: Lifetime history of severe hypoglycaemia and four-year cognitive change, including and excluding dementia cases 
(n=4*) 
 Including dementia cases
**
 Excluding dementia cases (n=4*) 
 No severe hypoglycaemia 
(n=739) 
Severe hypoglycaemia  
(≥1 episodes; n=77) 




Severe hypoglycaemia  











Logical Memory  
‘g’ 
11.78 (11.50 – 12.06) 
8.99 (8.81 – 9.17) 
37.09 (36.55 – 37.63) 
50.44 (49.76 – 51.11) 
109.73 (107.45 – 112.17) 
69.36 (68.88 – 69.84) 
27.40 (26.94 – 27.86) 
0.03 (-0.04 – 0.10) 
10.19 (9.30 – 11.08) 
8.72 (8.13 – 9.30) 
36.20 (34.50 – 37.89) 
48.54 (46.41 – 50.70) 
119.34 (111.39 – 127.74) 
69.39 (66.88 – 69.91) 
27.30 (25.85 – 28.74) 

















11.81 (11.52 – 12.09) 
9.01 (8.83 – 9.19) 
37.13 (36.59 – 37.67) 
50.51 (49.83 – 51.19) 
109.62 (107.23 – 111.94) 
69.41 (68.93 – 69.88) 
27.42 (26.97 – 27.88) 
0.03 (-0.04 – 0.10) 
10.21 (9.32 – 1.11) 
8.79 (8.20 – 9.37) 
36.33 (34.62 – 38.04) 
48.80 (46.66 – 50.95) 
118.04 (110.28 – 126.47) 
68.44 (66.91 – 69.96) 
27.35 (25.89 – 28.80) 

















Outcome variables are follow-up cognitive test scores. *data on history of severe hypoglycaemia missing for 3 subjects with dementia. 
**
as reported in the main text 
of this thesis (Chapter 7). Values are adjusted means (95% CI). N for analyses excluding dementia cases  = 767 to 804; N for analyses including dementia cases  = 
770 to 807. Data for g are imputed, for remaining cognitive tests are non-imputed. Trail-Making is log-transformed. Means for this test are geometric means. MR, 
Matrix Reasoning; Letter-Number, Letter Number Sequencing, Verbal Fluency, Borkowski Verbal Fluency Test, Digit Symbol, Digit Symbol Coding, Trail-







Table D.13: Incident severe hypoglycaemia and four-year cognitive change, including and excluding dementia cases (n=4*) 
 Including dementia cases** Excluding dementia cases (n=4*) 
 No severe 
hypoglycaemia (n=730) 
Severe hypoglycaemia  
(≥1 episodes; n=85) 




Severe hypoglycaemia  
(≥1 episodes; n=85) 








Logical Memory  
‘g’ 
11.78 (11.49 – 12.06) 
9.04 (8.86 – 9.22) 
37.20 (36.66 – 37.74) 
50.69 (50.01 – 51.37) 
108.96 (106.59 – 111.27) 
69.55 (69.08 – 70.03) 
27.45 (26.98 – 27.91) 
0.04 (-0.03 – 0.12) 
10.58 (9.72 – 11.44) 
8.56 (8.01 – 9.12) 
35.78 (34.17 – 37.93) 
48.06 (46.03 – 50.10) 
119.10 (111.61 – 127.10) 
37.38 (65.94 – 68.82) 
27.25 (25.85 – 28.65) 

















11.79 (11.51 – 12.08) 
9.05 (8.87 – 9.11) 
37.23 (36.67 – 37.78) 
50.74 (50.06 – 51.42) 
108.85 (106.48 – 111.27) 
69.59 (69.11 – 70.07) 
27.57 (27.00 – 27.93) 
0.04 (-0.03 – 0.12) 
10.60 (9.73 – 11.45) 
8.57 (8.02 – 9.11) 
35.81 (34.20 – 37.47) 
48.11 (46.08 – 50.14) 
119.10 (111.61 – 127.10) 
67.41 (65.97 – 68.85) 
27.26 (25.86 – 28.67) 

















Outcome variables are follow-up cognitive test scores. *data on incident severe hypoglycaemia missing for 2 subjects with dementia. 
**
as reported in the main text 
of this thesis (Chapter 7) 
Values are adjusted means (95% CI). N for analyses excluding dementia cases = 766 to 804; N for analyses including dementia cases = 768 to 806. Data for g are 
imputed, for remaining cognitive tests are non-imputed. Trail-Making is log-transformed. Means for this test are geometric means. MR, Matrix Reasoning; Letter-

















Table D.14: Linear regression model of follow-up g on risk factors, excluding 














Age* -0.27 0.01 <0.001 0.089 
Sex* 0.08 0.09 0.093 
+inflammation factor -0.14  0.04 <0.001 0.036 
+alcohol 0.19 0.03 <0.001 0.025 
+packyears -0.15 0.01 <0.001 0.024 
+waist-hip ratio -0.14 0.55 0.001 0.014 
+stroke -0.09 0.16 0.013 0.008 
Total R
2
    0.197 
 
Age* -0.27 0.01 <0.001 0.119 
Sex* 0.09 0.09 0.040 
HADS-D* -0.10 0.06 0.005 
+inflammation factor -0.13 0.04 0.001 0.028 
+alcohol 0.18 0.03 <0.001 0.024 
+packyears -0.13 0.01 <0.001 0.019 
+waist-hip ratio -0.12 0.56 0.004 0.011 
+stroke -0.08 0.16 0.027 0.006 
Total R
2
    0.206 
N=669 for both models. G has been imputed. 
a





change following addition of predictor into the respective previous model. 
*
entered in a first block. Log-transformed values were used for NT-proBNP; square root 
transformed values were used for packyears.  
Variables entered in stepwise procedure: PA (presence of claudication and/or ABI≤0.90), 
CHD (angina and/or MI), stroke, cIMT, NT-proBNP, DR, packyears, alcohol consumption 
(quintiles), waist-hip ratio, LDL:HDL, systolic blood pressure, HbA1c, inflammation 
factor, cortisol, baseline history of SH.   
CHD, coronary heart disease; PA, peripheral atherosclerosis; LDL:HDL, low-density 
lipoprotein to high-density lipoprotein ratio; ABI, ankle brachial pressure index; DR, 
diabetic retinopathy; SH, severe hypoglycaemia; HADS-D, Depression Subscale of the 






















Table D.15: Linear regression model of estimated lifetime change in g, excluding 













Age* -0.30 0.01 <0.001 0.116 
Sex* 0.16 0.07 <0.001 
+inflammation factor -0.11 0.03 <0.001 0.018 
+packyears -0.10 0.03  0.001 0.007 
+stroke -0.07 0.14 0.019 0.006 
+alcohol 0.08 0.02 0.011 0.005 
+DR severity -0.08 0.05 0.008 0.004 
Total R
2
    0.156 
Model 2 
Age* -0.30 0.01 <0.001 0.127 
Sex* 0.16 0.07 <0.001 
HADS-D* -0.06 0.05 0.036 
+inflammation factor -0.10 0.03 <0.001 0.015 
+DR severity -0.08 0.05 0.010 0.006 
+packyears -0.10 0.01 0.003 0.007 
+alcohol 0.08 0.02 0.013 0.006 
+stroke -0.06 0.14 0.034 0.004 
Total R
2
    0.165 
N=662 for both models. In model 1, HbA1c was initially included in the model (R
2
change 
= 0.007) but was ‘dropped’ as a predictor from the final model. Baseline MHVS was 
entered in a first block (R
2
 change = 0.271; this is not included in total R
2
 shown in Table), 
so that the outcome is follow-up g adjusted for baseline MHVS. 
a





change following addition of predictor into the respective previous 
model.*entered in a second block. G has been imputed. Log-transformed values were used 
for NT-proBNP; square root transformed values were used for packyears. Variables 
entered in stepwise procedure: PA (presence of claudication and/or ABI≤0.90), CHD 
(angina and/or MI), stroke, cIMT, NT-proBNP, DR, packyears, alcohol consumption 
(quintiles), waist-hip ratio, LDL:HDL, systolic blood pressure, HbA1c, inflammation 
factor, cortisol; baseline history of SH. 
CHD, coronary heart disease; PA, peripheral atherosclerosis; LDL:HDL, low-density 
lipoprotein to high-density lipoprotein ratio; ABI, ankle brachial pressure index; DR, 
diabetic retinopathy; SH, severe hypoglycaemia;  HADS-D, Depression Subscale of the 
















Table D.16: Linear regression model of four-year change in g, excluding 















Age* -0.10 0.01 0.015 0.022 
Sex* 0.05 0.08 0.227 
+inflammation -0.10 0.04 0.015 0.022 
+cIMT -0.12 0.22 0.003 0.016 
+packyears -0.11 0.01 0.006 0.011 
+HbA1c -0.09 0.04 0.013 0.009 
+NT-proBNP -0.08 0.03 0.037 0.006 
Total R
2
    0.086 
Model 2 
Age* -0.10 0.01 0.016 0.025 
Sex* 0.05 0.08 0.244 
HADS-D* 0.02 0.06 0.692 
+inflammation -0.10 0.04 0.014 0.020 
+cIMT -0.12 0.22 0.003 0.016 
+packyears  -0.11 0.01 0.006 0.011 
+HbA1c -0.10 0.04 0.012 0.009 
+NT-proBNP -0.09 0.03 0.034 0.006 
Total R
2
    0.086 
Model 3 
Age* -0.13 0.01 0.001 0.051 
Sex* 0.06 0.08 0.17 
MHVS* 0.15 0.01 <0.001 
+cIMT -0.13 0.22 0.001 0.019 
+inflammation -0.10 0.04 0.009 0.015 
+HbA1c -0.10 0.04 0.011 0.009 
+packyears -0.09 0.01 0.019 0.008 
+NT-proBNP -- -- -- -- 
Total R
2
    0.102 
N=668 for Model 1 and Model 2. N=662 for Model 3. Outcome variable is follow-
up g adjusted for baseline g. G has been imputed.
 a





change following addition of predictor into the respective previous 
model. *entered in a first block. Log-transformed values were used for NT-proBNP; 
square root transformed values were used for packyears. Variables entered in 
stepwise procedure: PAD (presence of claudication and/or ABI≤0.90), CHD 
(angina and/or MI), stroke, cIMT, NT-proBNP, DR, packyears, alcohol 
consumption (quintiles), waist-hip ratio, LDL:HDL, systolic blood pressure, 
HbA1c, inflammation factor, cortisol, baseline history of SH. CHD, coronary heart 
disease; PAD, peripheral arterial disease; LDL:HDL, low-density lipoprotein to 
high-density lipoprotein ratio; ABI, ankle brachial pressure index; DR, diabetic 




Appendix F:  Unadjusted mean cognitive test 
performance at year 4 according to hypoglycaemia 
groups 
 
Table F.1: Unadjusted follow-up cognitive test performance at year 4 according 
to severe hypoglycaemia 
 Baseline history of SH Incident SH 












Logical Memory 27.26 ± 8.20 27.95 ± 8.27 27.36 ± 2.26 27.37 ± 7.72 
Faces 69.31 ± 8.33 69.08 ± 9.02 69.51 ± 8.27 67.94 ± 9.17 
Letter-Number 9.00 ± 2.09 8.45 ± 2.72 9.05 ± 2.89 8.30 ± 2.53 
Trail-Making (s)    105.49 








(91.34 – 152.04) 
Verbal Fluency  37.21 ± 12.76 34.73 ± 12.75 37.19 ±12.60 35.63 ± 13.38 
Digit Symbol 
Coding 
50.59 ± 14.06 47.00 ± 14.34 50.65 ± 13.96 48.39 ± 14.09 
Matrix 
Reasoning  
11.77 ± 5.25 10.07 ± 4.77 11.81 ± 5.25 10.08 ± 4.63 
g 0.04 ± 0.99 -0.23 ± 1.03 0.05 ±0.98 -0.23 ± 1.02 
Values are mean ± SD or median (interquartile range). SH, severe hypoglycaemia; Trail-Making, 
Trail-Making Test-B; Letter-Number, Letter-Number Sequencing. 
 
 
Table F.2: Unadjusted reaction time test performance at year 4 according to 
severe hypoglycaemia 
 Baseline history of SH Incident SH 












(≥1 episodes; n=85) 
SRT mean 303.95 
(274.90 – 342.33) 
325.40 
(280.95 – 374.35) 
304.10 
(275.85 – 342.25) 
328.43 
(282.30 – 372.31) 
CRT mean 629.41 ± 117.83 665.81 ± 164.00 630.69 ± 117.98 656.02 ± 153.63 
Values are mean ± SD or median (interquartile range). SH, severe hypoglycaemia; SRT, simple 







Appendix G: Material of cognitive test battery and 
Hospital Anxiety and Depression Scale (HADS) 



























Mill-Hill Vocabulary Test 
 TOMATO 
fly  crack 
wood  dunce 
fruit  step 
11 CONNECT 
accident join 
lace  bean 




linger  compare 
2 REST 
lie down sing 
go away taste 




hurt  supply 
annoy  divide 
 
22 LAVISH 
unaccountable     selfish 
romantic        lawful 
extravagant        praise 
 
3 PATCH 
switch  watch 
hand  bang 




orderly            slack 
23 WHIM 
complain noise 
tonic  fancy 




tired  frightened 
14 SCHOONER 
building man 
ship  singer 






clean  green 
pretty  found 
water  unkind 
15 LIBERTY 
worry  freedom 
rich  serviette 







grass  roof 
coat  side 
16 COURTEOUS 
dreadful proud 




unwieldy        repelling 
reclining penitent 
7 ACHE 
screen             tree 
prize  pain 










quarrel             lift 
bubble    photo 
mould  saw 
18 THRIVE 
flourish try 
thrash  reap 
think  blame 
28 TRUMPERY 
worthless heraldry 
etiquette          highest 
amusement final 
9 RAGE 
crease             love 
invite  anger 
rain  hoist 
 19 PRECISE 
natural            stupid 
faulty  grand 




aerate  scowl 
10 SHRIVEL 
linger  heed 
volunteer haunt 
wither  shiver 
20 ELEVATE 
revolve             move 
raise  work 
















alacrity   tariff 
35 TEMERITY 
impermanence     
rashness 
nervousness        
stability 
punctuality     
submissiveness 
39 VAGARY  
































challenge    attenuate 
suspend    establish 





  43 ADUMBRATE 
foreshadow protect 
detect  eradicate 
elaborate approach 
 
  44 MINATORY 
implacable diminutive 
belittling quiescent 

















Mini-Mental State Examination   
Orientation-Time 
Score one point for each correct answer 
        Correct? 
1. What day of the week is it?    Yes  No 
 
 What date is it today? 
Day       Yes  No 
Month       Yes  No 
Year       Yes  No 
 
5. What is the season?     Yes  No 
 (Allow flexibility when season changes) 
        Total correct…………. 
 
Orientation-Place 
Score one point for each correct answer 
        Correct? 
6. Can you tell me where we are now? 
 For instance, what county or region we are in? Yes  No 
 
7. What is the name of this town (city)?   Yes  No 
 
8. Which country are we in?    Yes  No 
 
9. What floor of the building are we on?  Yes  No 
 
What is the name of this place? (or:  
What is this address? If the subject is  
tested at home)     Yes  No 
 
       Total correct…………. 
Memory-registration 
 
I am going to name three objects. After I have finished saying all three, I want you to 
repeat them. Remember what they are because I am going to ask you to name them 
again in a few minutes. 
 
Name the following three objects taking one second to say each:  
LEMON, KEY, BALL.  Go! 
 
 
Note items which are correct on the FIRST attempt and enter number correct under 
total. 
       Correct? 
     Lemon  Yes  No 
     Key  Yes  No 
     Ball  Yes  No 
 
       Total correct…………. 
 
Attention and Calculation 
 
Spell ‘world’ backwards    Correct? 
Yes  No 
 





Could you please tell me the three objects  
I named earlier     Correct? 
 
     Lemon  Yes  No 
     Key  Yes  No 
     Ball  Yes  No 
 
       Total correct………… 
 
 
Could you please tell me what this is   Correct? 
 
show WATCH     Yes  No 
show PENCIL      Yes  No 
 
      Total correct………… 
 
I would like you to repeat the following 
‘No ifs, ands or buts’     Correct? 
 
       Yes  No 
 





Please read and obey the following: 
Give the patient the paper with the printed sentence ‘Close your eyes’ 
Ask the patient to read it and do what it says (only score when patient actually closes 
eyes) 
       Correct? 
 
       Yes  No 
 
       Total correct……….. 
Praxis-ideational 
 
Read the following statement and then hand to the subject a sheet of paper. Make a 
point of handing to the subject’s midline. 
 
Please listen carefully to the instructions as I will explain it only once: 
I am going to give you a piece of paper. When I do, take the paper in your RIGHT 
hand. Fold the paper in half with both hands, and put the paper down in your lap. 
 
Do not repeat instructions or coach. Score a move as correct only if it takes place n 
the correct sequence. Note each correct move and enter total number correct 
(Maximum score=3 points). 
 
      Correct? 
 
   Right hand  Yes  No 
   Folds   Yes  No 
   On lap   Yes  No 
 
      Total correct…………… 
Praxis-copying and drawing 
 
      Correct? 
19. Copy this design (pattern)    Yes  No 
 




       Correct? 
Write a complete sentence in the space 
 
 
on the page indicated. It can be anything 
you like as long as it is a complete sentence.  Yes  No 
 




































Hospital Anxiety and Depression Scale (HADS) 
Tick the response which comes closest to how you have felt in the last few days. 
 
I feel tense or ‘wound up’.    I feel as if I am slowed down. 
 Most of the time………………….   Nearly all the time………….. 
 A lot of the time………………….   Very often…………………... 
 From time to time, occasionally….   Sometimes…………………... 
 Not at all………………………….   Not at all……………………. 
 
I still enjoy the things I used   I get a sort of frightened feeling  
to enjoy.      like ‘butterflies’ in the stomach. 
 Definitely as much………………   Not at all…………………… 
 Not quite so much……………….   Occasionally……………….. 
 Only a little………………………   Quite often…………………. 
 Hardly at all……………………...   Very often………………….. 
 
I get a sort of frightened feeling   I have lost interest in my appearance. 
as if something awful is about to happen. 
 Definitely…………………………….. 
 Very definitely and quite badly….   I don’t take so much care as I 
should... 
 Yes, but not too badly……………   I may not take quite as much 
care…… 
 A little, but it doesn’t worry me….   I take just as much care as 
ever……… 
 Not at all………………………….   
 
I can laugh and see the funny side of things. I feel restless as if I have to be  
on the move. 
 As much as I always could………   Very much indeed……………. 
 Not quite so much now…………..   Quite a lot……………………. 
 Definitely not so much now……...   Not very much……………….. 
 Not at all………………………….   Not at all……………………… 
 
Worrying thoughts go through my mind. I look forward with enjoyment to 
things. 
 A great deal of the time………….   As much as I ever did…………. 
 A lot of the time…………………   Rather less than I used to……… 
 From time to time but not too often….  Definitely less than I used to….. 
 Only occasionally………………..   Hardly at all……………………. 
 
I feel cheerful.     I get sudden feelings of panic. 
 Not at all………………………..   Very often indeed……………… 
 Not often………………………..   Quite often…………………….. 
 Sometimes………………………   Not very often…………………. 
 
 
 Most of the time………………...   Not at all………………………. 
 
I can sit at ease and feel relaxed. I can enjoy a good book or radio  
Definitely………………………  or TV programme. 
 Usually…………………………   Often………………………….. 
Not often……………………….   Sometimes…………………….. 
 Not at all………………………..   Not often……………………… 










































Appendix H: Questionnaires administered at baseline 
 
EDINBURGH TYPE 2 DIABETES STUDY 
(Baseline) 
 
Data Collection Form & Checklist 
 
 





PART 1 – Consent and venepuncture  
 
Recorder: DJ GB SL KB CM RM Other…….  (circle initials) 
 
  
General consent form signed? 
 
Genetic consent form signed?   
 
Urine sample received from subject and labelled? 
  
Questionnaire part 1 received from subject, checked and labelled?  
 
Patient fasted and still to take diabetic medication (if appropriate)?  
 
 








               Yes            
No 
   
1. Was venepuncture completed and all tubes filled? 
 
2. Was venepuncture difficult/slow? 
 
 







All samples labelled?  
 
Correct brown, yellow and red tubes placed in specimen bag with 
COMPLETED  
request form and urine specimen? 
 







   Subject reminded to take medication if necessary? 
 
   Questionnaire part 3 (and pen) given to subject? 
 
PART 2 – Cognitive function testing 
 





          
 YES NO 
Does subject normally wear glasses/contact lenses for distance vision? 
   
If YES, subject tested wearing glasses/contact lenses? 
 
Right eye    ………………. 
 
Left eye   ………………. 
 
Near vision  
          
 YES NO 
Does subject normally wear glasses for near vision? 
   
If YES, subject tested wearing glasses? 
 
Right eye    N  …. 
 




             . (If < 4.0, re-arrange appointment) 
 
 
Cognitive Test Battery: 
 
Time tests started………………am 
 
Tick box if complete     If test incomplete/difficulty 




Hospital Anxiety & Depression Scale 
 ………………………………………………………….. 
 
Mini-Mental State Examination 
 …………………………………………………………. 
 
Logical memory 1 (WMS-III)  
 …………………………………………………………. 
 
Trail-Making Test B (TMB)  
 ………………………………………………………….  
 
Faces 1 (WMS-III)    
 …………………………………………………………. 
 
Matrix Reasoning (WAIS-III)  
 …………………………………………………………. 
 
Digit symbol test (WAIS-III)   
 …………………………………………………………. 
 
Borkowski Verbal Fluency Task  
 …………………………………………………………. 
 
Mill Hill Vocabulary Scale  
 ………………………………………………………….  
 
Letter-number sequencing (WAIS-III) 
 …………………………………………………………. 
 
Logical memory 2 (WMS-III)  
 …………………………………………………………. 
 
Faces 2 (WMS-III)   





PART 3 –physiological testing 
 
Time physiological testing started ……………………………… 
 
Tester:  DJ GB SL KB CM Other…….   
 
Group A tests (subject lying down) 
 
ABPI 
BP measurements using doppler 
 
 Left Right  
Posterior tibial 
 









Circle lowest ankle and higher arm reading    
 ABPI =        .  
 
 
RESTING BLOOD PRESSURE 
 
Right arm, using stethoscope   
    Observed        
 
Systolic mmHg     mm/Hg 
 




Yes  No 
  ECG recorded and labelled      
 
     
           
 NEUROTHESIOMETRY 
        Right big toe  Left big toe 
     
   Reading 1         .          volts   .
 volts 
 
   Reading 2         .          volts   .
 volts  
 
   Reading 3         .          volts   .
 volts  
 





Is there any obvious FOOT ulceration?    Yes No 
  Right foot 
 
      Left foot 
 
 
Has subject ever had a FOOT ulcer?    Yes No 
  Right foot 
 











Circumference mid-way between lower rib and iliac crest (feet 30cm apart) 
 
          
Reading 1     . cm        (to 
nearest 0.5cm) 
 










Max circumference at hips (feet together) 
   
Reading 1     . cm (to 
nearest 0.5cm) 
 




  Average 




Height (without shoes)                                               .         cm 









(Shoes off, feet 30 cm apart) 
     % fat    
 
Reading 1  . %  
 
Reading 2  . %  
 
Reading 3  . % 
  
Average  . %  
 
 
PART 4 – questionnaire checks and departure 
 
 














































PLEASE NOTE:  ONE OF OUR RESEARCH NURSES WILL GO OVER 
THE QUESTIONNAIRE WITH YOU AT THE CLINIC AND MAY ASK A FEW 
ADDITIIONAL QUESTIONS 
 
THE INFORMATION IN THIS QUESTIONNAIRE IS HIGHLY 
CONFIDENTIAL AND IS PART OF A MEDICAL RESEARCH STUDY 
 
 
The information you give in this questionnaire will be treated as strictly 
confidential and will be available only to your own doctor and the study team.  
The results of the research will appear only in the form of general statistics 




Please complete the following: 
 
 








If you have any difficulties in answering some of the questions, you will have 



















1. Please tick one box:            Male    Female      
                                 
                 
                  Day    Month          Year 
2. Enter your date of birth:         
 
 
3.  Please tick the box showing your present marital status: 
 
  Married and/or living with long-term partner   
  Single        
  Widowed         
Divorced or separated     
 
 
4. Please enter your address (including postcode) and telephone no.   
 
  Address:   …………………………………………………………………. 
 
    …………………………………………………………………. 
 
  Postcode: ……………………………….. 
 
Telephone no: ………………………………… 
 
                        
5. Please enter the details of your GP       
 




  …………………………………………………………………. 
 
EDUCATION 
6. What is the HIGHEST level of education you and your spouse/ex-spouse or long-
term partner  have completed? 




           You         Spouse/ 
ex-spouse 
                                  
            University/college degree course                       
 Other professional/technical qualification after leaving school      
 Secondary school           





7. What is your ethnic group? 
 
 Please choose ONE section from 1 to 5, then tick the appropriate box to indicate your 
ethnic Group 
 
 (i)  White  
 
  
      British 
     
    Any Other White background, please write in   
__________________________________ 
 
 (ii)  Mixed 
 
     
    White and Black Caribbean 
     
    White and Black African 
     
    White and Asian 
     
    Any Other Mixed background, please write in  
__________________________________ 
 
 (iii)  Asian or Asian British 
 
     
    Indian 
     
    Pakistani 
     
    Bangladeshi 
     
    Any Other Asian background, please write in  
__________________________________ 
 
 (iv)  Black or Black British 
 
     
    Caribbean 
     
    African 
     
    Any Other Black background, please write in  
__________________________________ 
 
 (v)  Chinese or other ethnic group 
 
     
    Chinese 
     
    Any Other, please write in  __________________________________ 
 
CURRENT EMPOYMENT STATUS 
8. At the moment, what is the employment status of you and your spouse/ex-spouse or 
long-term  partner? 
 You                 Spouse/ex-spouse/partner 
 
 
 Employed, full-time           Employed, full-time    
  
 Employed, part-time    
        
Employed, part-time    
  
 Unemployed     
        
Unemployed      
 
 
 Retired      
          
Retired      
  
 A Housewife (full-time)    
          
A Housewife (full-time)    
  
 Other     
          
Other      
 
 








9. When was your diabetes diagnosed (if known)?    Year ……..…… 
 
10. What treatment do you receive currently for your diabetes? 
 
Yes No 
(i) Tablets        
 
If ‘yes’, please give name(s)  ……………………................................................. 
 
  Yes No 
(ii) Insulin injections    
 
If ‘yes’,  
 
(a) give total number of units per day                            
……………….…units/day 
(b) give date (year) when you started insulin       year   ………………… 
 
Yes No Don’t Know 
11. Have you ever had an episode of low blood glucose (hypoglycaemia)  
      
  
 when you have needed someone else to treat you eg. give sugary  
drink or glucagon?    
 
 If ‘yes’, how many times has this ever happened? 
 
  1-2    
3-4    
5 or over  
 
 
 How many times has this happened over the past year? 
 
  1-2    
  3-4    
             5 or over  
 
 
            
12.  Are you on any regular medical treatment from a doctor as follows:  
        Yes No Don’t 
Know 
   Aspirin?        
  
  
   Drugs for angina (including spray)?   
     
  
   Drugs to lower blood pressure?     
               
  
   Drugs to lower cholesterol?     
               
  
   
(If you have answered YES to any of these, please include details below) 
 
 
13. Give names of all current medication if possible (including regular skin creams, eye 
drops, inhalers, tablets and injections which may or may not be repeat prescriptions): 
  
……………………………………………  ……………………………………………….... 
……………………………………………  ……………………………………………….... 
 
……………………………………………  ……………………………………………….... 
……………………………………………  ……………………………………………….... 
 
              Yes   No
 Don’t Know 
14. Have you taken any oral steroids, used steroid inhalers or used       
  
   
       
  





15. Have you ever been told by a doctor that you have or have had any of the following? 
 
  
Yes   No  Don’t Know 
(i) Heart attack (coronary thrombosis, myocardial infarction)?   
    
(ii) Angina?         
    
(iii) Stroke?           
  
(iv) Hardening of the arteries in the legs?       
  
(v)    High blood pressure?         
  
 
If you have answered ‘yes’ to any of the above, please give the year in which the event 
occurred and/or condition was diagnosed (as near as you can remember) and the name of 
the hospital/GP surgery where you were/are treated for the condition 
 
Event/condition   Year of event/diagnosis  Hospital/GP surgery  
where treated 
 
 …………………………… ………………………. 
 …………………………. 
 







16. Have you ever undergone any of the following procedures/operations? 
           
 Don’t 
          Yes No
 Know 
(i) An operation or balloon treatment to relieve a blockage in   
      
the arteries of your heart (coronary by-pass or angioplasty)?     
 
(ii) An operation or balloon treatment to relieve a blockage in 
       
the arteries of your leg(s) , other than for varicose veins?  
 
(iii) Surgery to remove toes or leg (above or below the knee)?    
   
 
(iv)   An operation or balloon treatment to relieve a blockage in       
the arteries of your neck (carotid surgery/angioplasty/stenting)? 
 
 
If you have answered ‘yes’ to any of the above, please give the year in which the procedure 
was performed and the name of the hospital you attended 
 
Procedure/operation  Year performed   Hospital attended  
 
 …………………………… ………………………. 
 …………………………. 






17. Have you ever been told by a doctor that you have or have had any of the following? 
  
Yes  No      Don’t Know 
(i) Hepatitis?           
  
(ii) Cirrhosis of the liver?          
  
(iii) Any other disease/medical condition affecting the liver? 
 
    
  
            
 
If you have answered ‘yes’ to any of the above, please give the name of the condition, the 
year in which it was diagnosed (as near as you can remember) and the name of the hospital 
where you were/are treated for the condition 
 
Name of condition  Year of diagnosis  Hospital where treated 
 
 …………………………… ………………………. 
 …………………………. 
 




18. Have you ever had any of the following investigations of your liver 
   
Yes  No   Don’t Know 
(i)          Abnormal blood tests of liver function?        
 
(ii)          Liver biopsy?           
 
(iii)         Scan (ultrasound or CT etc.) of the liver?       
 




If you have answered ‘yes’ to any of the above, please give the name of the investigation, 
the year in which it was done (as near as you can remember) and the name of the hospital 
where the test/investigation was performed 
 
Name of investigation  Year done   Hospital where  
performed 
 
 …………………………… ………………………. 
 …………………………. 
 
 …………………………… ……………………….. 
 …………………………. 





Other Medical Conditions         
Yes No Don’t Know 
19. Do you suffer from disease of the thyroid gland?       
   
20. Do you have any other medical conditions not mentioned above?      
 





   






21. Current alcohol intake 
 
(i)  Think back carefully over the last seven days.  Please write in each column 
the exact number  of alcoholic drinks you consumed on each day during the past week.  
If none consumed write ‘0’  in the boxes. 
 
 Try to remember where and who you were with on each day.  This may help you 
remember what  you had to drink. 
 
            Pints of beer,       Single glasses of        Single glasses of 
           lager, cider etc      whisky, vodka, gin etc       martini, wine, sherry, etc 
 
        
Monday         
Tuesday   
Wednesday        
Thursday         
Friday                        
Saturday                        
Sunday          
          Yes No 
(ii) Would you say that last week was fairly typical of what you usually 
have to drink in a week? 
          
          More
 Less 
(iii) If last week was not typical, would you normally drink more or 
less in a week?  
 
  
22.   Alcohol intake over past year 
 
(i)   How often did you have a drink containing alcohol in the past year?  
 Consider a “drink” to be a can or bottle of beer, a glass of wine, or one cocktail or a 
measure of  spirits (like scotch, gin, or vodka).  
 
never        
monthly or less     
2 to 4 times a month    
2 to 3 times a week    
4 to 5 times a week    
6 or more times a week    
 
 (ii)  How many drinks did you have on a typical day when you were drinking in the past 
year?  
 
0 drinks      
1 to 2 drinks     
3 to 4 drinks     
5 to 6 drinks        
7 to 9 drinks     






(iii)  How often did you have 6 or more drinks on one occasion in the past year?  
 
never      
less than monthly     
monthly      
weekly      
daily or almost daily     
 
23.   Have you or your doctor ever considered that you suffer/have   Yes No 







Smoking has been linked with many health problems.  It is important that you answer the 
following section as accurately as possible. 
         Yes No 
24. Do you smoke at present?          
        
 
If no, proceed to Question 29 
 
25. What do you usually smoke now? 
Yes No 
 Cigarettes                  
Pipe             
Cigars             
         
 
26. How many do you usually smoke now? 
 
Cigarettes per day      ……… cigarettes 
 
Ozs. tobacco per week      ……… ozs. 
 
Cigars per week      ……… cigars 
 
 
27. For how many years during your life have you smoked cigarettes? ……… 
years            
 
28. How many cigarettes have you smoked on average per day during  
 the period you have smoked?     
 ………cigarettes        
 Now proceed to Question 34       
      Yes No  
 
 
29. Have you ever smoked regularly?         
     
   If no, proceed to Question 34 
           
30. What did you usually smoke?       Yes No 
Cigarettes            
Pipe             




   
 
31. How much did you smoke on average while you were a smoker? 
 
Cigarettes per day      ……… cigarettes 
 
Ozs. tobacco per week      ……… oz. 
 
Cigars per week      ……… cigars 
 
32. For how many years did you smoke cigarettes?    ……… 
years 
 
33.        If you smoked cigarettes, how long is it since you finally  
 gave up?   






34. Do you ever get pain or discomfort in your chest?       
  
                     
 
IF NO, PROCEED TO QUESTION 40 
         Yes No 
35. Do you get this pain or discomfort when you walk uphill or hurry?      
         
  
  IF NO, PROCEED TO QUESTION 40 
           
          
 Yes No 
36. Do you get it when you walk at an ordinary pace on the level?     
  
           
          
37. When you get any pain or discomfort in your chest what do you do?  
                      Tick one 
Stop           
 
Slow down         
 
Continue at the same pace        
   
        Yes No 
38. Does it go away when you stand still or sit down?       
 
How soon?                       Tick one 
10 minutes or less         
 
More than 10 minutes         
 
 
39. Where do you get this pain or discomfort?  Mark the place(s) 
with an ‘X’ on the diagram 
 
 
         Yes No 
40. (i) Have you ever had a severe pain across the front of your     




(ii)         What was the cause?  ……………………………………………………………… 
 
LEG PAIN 
Yes No I am unable 
   to walk 
 41.  Do you get a pain or discomfort in your leg(s) when you walk?     
      
 
If you answered ‘yes’ to question 41, please answer the following questions.   
 
          
 Yes No 
 (i) Does this pain ever begin when you are standing still or sitting?   
   
 (ii) Do you get it if you walk uphill or hurry?      
  
 (iii) Do you get it when you walk at an ordinary pace on the level?   
  
 
 (iv) Does the pain ever disappear while you are still walking?    
   
 (v) What do you do if you get it when you are walking?     
   
 
         Tick one 
  Stop          
  Slow down         
  Continue at same pace        
 
 
(vi) What happens to it if you stand still? 
        Tick one 
 Usually continues for more than 10 minutes     
 Usually disappears in 10 minutes or less     
 
  
(vii) Where do you get this pain or discomfort? 
          Yes No 
  (i) Do you get this pain in your calf (or calves)?      
    






























THE INFORMATION IN THIS QUESTIONNAIRE IS HIGHLY CONFIDENTIAL 
AND IS PART OF A MEDICAL RESEARCH STUDY 
 
 
The information you give in this questionnaire will be treated as strictly 
confidential and will be available only to your own doctor and the study team.  
The results of the research will appear only in the form of general statistics 




Please complete the following: 
 
 




DATE:            ……………………………………………………………….. 
 
EMPLOYMENT STATUS / OCCUPATION  
The following questions refer to your current main job, or (if you are not working now) to your 
last main job. Please complete for both yourself (I) and for your spouse/ex-spouse or long-
term partner (II) 
(I) Yourself   (Please tick one box only per question) 
1. What is (was) your employment status? 
Employee   
Self-employed with employees   
Self-employed / freelance without employees 
(go to question 4)    
Housewife 
(go to question 4)    
 
 
No previous paid employment (excluding housewife) 
(go to question 4)    
2. Number of employees 
For employees: indicate below how many people work (worked) for your employer at the place 
where you work (worked).  Then go to question 3. 
For self-employed: indicate below how many people you employ (employed). Then go to 
question 4. 
                                                     1 to 24                                             25 or more   
3. Do (did) you supervise any other employees? 
A supervisor or foreman is responsible for overseeing the work of other employees on a day-
to-day basis 
                                                            Yes   
  
                                                  No   
4. Please tick one box to show which best describes the sort of work you do. 
(If you are not working now, please tick a box to show what you did in your last job). 
PLEASE TICK ONE BOX ONLY 
Modern professional occupations 
such as: teacher - nurse - physiotherapist - social worker - welfare officer - artist - musician - 




Clerical and intermediate occupations 
such as: secretary - personal assistant - clerical worker - office clerk - call centre agent - nursing 
auxiliary - nursery nurse 
 
 
Senior managers or administrators) 
such as: finance manager - chief executive  
 
Technical and craft occupations 
such as: motor mechanic - fitter - inspector - plumber - printer - tool maker - electrician - 
gardener - train driver 
 
 
Semi-routine manual and service occupations 
such as: postal worker - machine operative - security guard - caretaker - farm worker - catering 
assistant - receptionist - sales assistant  
 
 
Routine manual and service occupations 
such as: HGV driver - van driver - cleaner - porter - packer - sewing machinist - messenger - 
labourer - waiter / waitress - bar staff 
 
 
Middle or junior managers 
such as: office manager - retail manager - bank manager - restaurant manager - warehouse 
manager - publican 
 
 
Traditional professional occupations 




EMPLOYMENT STATUS / OCCUPATION (cont.) 
(II) Your spouse/ex-spouse/long term partner   (Please tick one box only per question) 
5. What is (was) his (her) employment status? 
Employee   
Self-employed with employees   
Self-employed / freelance without employees 
(go to question 8)    
Housewife 
(go to question 8)    
No previous paid employment (excluding housewife) 
(go to question 8)    
6. Number of employees 
For employees: indicate below how many people work (worked) for his/her employer at the 
place where he/she work (worked).  Then go to question 7. 
For self-employed: indicate below how many people he/she employs (employed). Then go to 
question 8. 
                                                     1 to 24                                             25 or more   
7. Do (did) he/she supervise any other employees? 
A supervisor or foreman is responsible for overseeing the work of other employees on a day-
to-day basis 
                                                            No   
  
                                                  Yes   
8. Please tick one box to show which best describes the sort of work he/she does. 
(If not working now, please tick a box to show what he/she did in his/her last job). 
PLEASE TICK ONE BOX ONLY 
Modern professional occupations 
such as: teacher - nurse - physiotherapist - social worker - welfare officer - artist - musician - 
police officer (sergeant or above) - software designer 
 
 
Clerical and intermediate occupations 
such as: secretary - personal assistant - clerical worker - office clerk - call centre agent - nursing 
auxiliary - nursery nurse 
 
 
Senior managers or administrators 
(usually responsible for planning, organising and co-ordinating work and for finance) 





Technical and craft occupations 
such as: motor mechanic - fitter - inspector - plumber - printer - tool maker - electrician - 
gardener - train driver 
 
 
Semi-routine manual and service occupations 
such as: postal worker - machine operative - security guard - caretaker - farm worker - catering 
assistant - receptionist - sales assistant  
 
 
Routine manual and service occupations 
such as: HGV driver - van driver - cleaner - porter - packer - sewing machinist - messenger - 
labourer - waiter / waitress - bar staff 
 
 
Middle or junior managers 
such as: office manager - retail manager - bank manager - restaurant manager - warehouse 
manager - publican 
 
 
Traditional professional occupations 




































___________                                   
 
The Edinburgh Type 2 Diabetes Study 
Co-ordinating Centre Public Health Science University of 
Edinburgh 





Information Sheet  
 
What is the purpose of this part of the Edinburgh Type 2 Diabetes 
Study? 
 
We would like to know more about your experience of ‘severe’ 
hypoglycaemia (hypo) and what kind of help you needed during hypos. It will 
improve our understanding of hypoglycaemia among people with type 2 
diabetes if you complete the attached forms and send them back to us 
according to the instructions below.   
 
What is a ‘severe’ hypo? 
 
Hypoglycaemia (low blood sugar) can occur in people treated with diets, 
tablets and/or insulin.  Common symptoms include shakiness, pounding 
heartbeat, sweating and/or hunger.  If the hypo is not treated, then some 
people can develop dizziness, blurred vision or confusion.  A hypo may be 
treated by eating or drinking something sugary or by medical treatment 
(typically an injection).  We are interested in ‘severe’ episodes of 
hypoglycaemia (severe hypos).  This is defined as a hypo in which you 
require treatment to be administered by another person (e.g., family member, 
friend or health care worker) in order to recover from the hypo, because you 




1. If you have a severe hypo (in which you require help from someone 
else to recover) in the next 6 months, please either 
 
a. Complete one of the white forms in this slip-case and return it 
to us in one of the pre-paid envelopes provided 
OR 
b. Call us on (0131) 650 3242 and leave your telephone number 
with a short message and we will call you back to ask you 
about your hypo. 
 
2.  Even if you do not have a severe hypo over the next 6 months, we 
would still like to hear from you.  Therefore, please complete and 
 
 
return one of the yellow forms in this slipcase to us every 2 months for 
the next 6 months whether or not you have a severe hypo.  The 
month in which we would like to receive each of these yellow forms is 
given at the top of the form.  
 
Remember, we would like to receive a yellow form from you every two  
months, whether or not you have a severe hypo.  
  
However, do not worry if you forget to send in a form during the specified 
month – if we do not receive a form then we will telephone you to check 
whether you have had a ‘severe’ hypo 
 
Thank you very much for your help. 
White Form  
Please complete this form if you have a ‘severe’ hypo during the 6 
months after your last Edinburgh Type 2 Diabetes Study clinic 
appointment.  Please return it to us in one of the pre-paid envelopes 
provided as soon as possible after the hypo  
 











2.  When did you have the severe 
hypo when you needed someone 
else to treat you because you were 
not well enough to treat yourself 
during that hypo?              
    
…..…/…..…/……..     
(please enter day/month/year) 
 
…… am OR …….pm    




3. Who helped you to recover from 










Hospital staff        
 








4. How did you recover from the 
severe hypo? (please tick all that 
apply) 
 
By taking a sugary drink/food 
 
By having an injection of glucagon 
 
By having an injection of sugary  






(please specify) …………………………............ 
 
Don’t know    
   
 
5. Did you take a blood glucose 
reading during the hypo?    
 
 YES                NO
    
 
  
If YES  
 
a. Please enter your blood 
glucose reading:    
……………..mmol/l    
 
b. Was this reading taken before 
or after the treatment?  
 










Please complete and return this form, whether or not you have had a 
‘severe’ hypo over the past 2 months 
 










2. Have you had a ‘severe’ hypo 
(requiring help from someone else 
to recover from the hypo, such as 
a family member, friend or health 
care worker) over the past 2 
months? 
 
YES   ( Continue to 
Question 3) 
 
NO ( Go to end of 
form) 
 
3. Have you already informed the 
research office about this/these 
hypo(s) 
 
YES  ( Go to end of 
form) 
 
NO ( Question 4) 
 
4. When did you have the severe 
hypo when you needed someone 
else to treat you because you were 
not well enough to treat yourself 
during that hypo?                   
…..…/…..…/……..    
(please enter day/month/year) 
 
…… am OR …….pm   
(please enter approximate time of 
day) 
 
5. Who helped you to recover from 










Hospital staff        




Other         
(Please specify)…………………………… 
 
6. How did you recover from the 
severe hypo? (please tick all that 
apply) 
 
By taking a sugary drink/food 
 
By having an injection of glucagon 
 
 
By having an injection of sugary  
water (glucose) into a vein 
 
Other       






Don’t know    
   
7. Did you take a blood glucose 
reading during the hypo?    
 
YES        NO   
 
 If YES  
 
a. Please enter your blood glucose 
reading:    
……………..mmol/l    
 
b. Was this reading taken before or 
after the treatment?  
 




Appendix I: Publications made on the basis of this 
thesis, with permission from Diabetes Care® 
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Abstract
Background: Type 2 diabetes mellitus is associated with risk of congestive heart failure (CHF), cognitive dysfunction and
depression. CHF itself is linked both to poor cognition and depression. The ventricular N-terminal pro-brain natriuretic
peptide (NT-proBNP) is a marker of CHF, suggesting potential as a marker for cognitive impairment and/or depression. This
was tested in the Edinburgh Type 2 Diabetes Study (ET2DS).
Methodology and Principal Findings: Cross-sectional analysis of 1066 men and women aged 60–75 with type 2 diabetes.
Results from seven neuropsychological tests were combined in a standardised general cognitive ability factor, ‘g’. A
vocabulary-based test estimated pre-morbid cognitive ability. The Hospital Anxiety and Depression Scale (HADS) assessed
possible depression. After adjustment for age and sex, raised plasma NT-proBNP was weakly associated with lower ‘g’ and
higher depression scores (ß 20.09, 95% CI 20.13 to 20.03, p = 0.004 and ß 0.08, 95% CI 0.04 to 0.12, p,0.001, respectively).
Comparing extreme quintiles of NT-proBNP, subjects in the highest quintile were more likely to have reduced cognitive
ability (within the lowest tertile of ‘g’) and ‘possible’ depression (HADS depression $8) (OR 1.80; 95% CI: 1.20, 2.70; p = 0.005
and OR 2.18; 95% CI: 1.28, 3.71; p = 0.004, respectively). Associations persisted when pre-morbid ability was adjusted for, but
as expected were no longer statistically significant following the adjustment for diabetes-related and vascular co-variates (b
20.02, 95% CI 20.07 to 0.03, p.0.05 for ‘g’; b 0.03, 95% CI 20.02 to 0.07, p.0.05 for depression scores).
Conclusion: Raised plasma NT-proBNP was weakly but statistically significantly associated with poorer cognitive function
and depression. The prospective phases of the ET2DS will help determine whether or not NT-proBNP can be considered a
risk marker for subsequent cognitive impairment and incident depression and whether it provides additional information
over and above traditional risk factors for these conditions.
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Introduction
People with type 2 diabetes are at around 1.5 to 2.5-fold
increased risk of developing dementia [1,2], a disorder involving
progressive cognitive, behavioural and motor deficits. Type 2
diabetes is also associated with an increased risk of age-associated
cognitive decline, short of frank dementia [3], and with depression
[4,5], a condition closely related to cognitive dysfunction. The
underlying mechanisms responsible for these links are unclear.
Co-morbidity with congestive heart failure (CHF) is also
prevalent in diabetes [6,7]; there appears to be a poorly defined
bidirectional relationship between cardiac function and glucose
metabolism. Cardiac stress initiates secretion of natriuretic
peptides from the ventricles [8], including N-terminal pro-brain
natriuretic peptide (NT-proBNP) the inactive metabolite of the
proBNP hormone. Higher circulating NT-proBNP concentrations
in populations with diabetes compared with healthy adults have
been reported [9,10].
There is some evidence in predominantly non-diabetic popu-
lations to suggest that BNP (with which circulating NT-proBNP is
highly correlated [11]) is associated with poor cognitive ability.
Raised natriuretic peptide concentrations have been related to low
performance on measures screening for poor global cognitive
functioning potentially indicative of dementia [12–14]. Raised
natriuretic peptide concentrations are also found in cognitively
impaired individuals [15,16] and may correlate with severity of
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dementia [14,17]. In the only prospective investigation to date,
proBNP predicted dementia at 5-year follow-up [18].
Evidence also indicates raised NT-proBNP in individuals with
major depressive disorder (MDD) and correlations between NT-
proBNP and number of depressive symptoms in healthy popula-
tions [19] and in those with cardiovascular disease [20–22].
Further, left ventricular dysfunction has been associated with poor
cognition [23–25] and depression [25]. However, overall evidence
is inconclusive, with several studies failing to find a statistically
significant association of NT-proBNP with depression or quality of
life [26–29], with cognitive function [30,31], or dementia [15].
Given these findings, NT-proBNP could function as a
biomarker of accelerated cognitive aging and depression in people
with type 2 diabetes. High prevalence of cognitive and mood
disorders in type 2 diabetes offers an interesting and novel
opportunity to study the relationship between natriuretic peptides,
acting as a proxy for cardiac stress, and cognitive function and
depression. The present study aims to assess the association of NT-
proBNP with level of cognitive ability, with level of ability relative
to estimated peak pre-morbid ability, and with depressive
symptoms, in a large, representative cohort of elderly patients
with the full spectrum of severity of type 2 diabetes (the Edinburgh
Type 2 Diabetes Study, ET2DS).
Methods
Study Population
Data from the cross-sectional, baseline phase of the prospective
ET2DS were analysed. Details of the recruitment and examina-
tion for the ET2DS have been reported previously [32]. In brief,
in 2006/7, 1066 community-dwelling men and women with type 2
diabetes mellitus, aged 60 to 75 years and living in the Lothian
area of Scotland, UK, were selected at random from a
comprehensive register of patients with diabetes attending primary
or secondary care in this region. Subjects underwent detailed
physical and cognitive examinations in a dedicated research clinic
by specially trained nurses using standard operating procedures.
Ethics Statement
Assessments complied with the ethical rules of the Declaration
of Helsinki. Ethical approval for the study was obtained from the
Lothian Medical Research Ethics Committee, and all participants
gave written informed consent.
Physical Examination
Participants were assessed by self-completion questionnaire and
physical examination for a range of demographic and clinical
characteristics. Diabetes-related measurements included plasma
HbA1c, fasting glucose, duration of diabetes and mode of
treatment. Vascular measurements included systolic and diastolic
brachial blood pressure, body mass index (BMI), waist-hip ratio
(WHR), % body fat, smoking status, alcohol intake, total serum
cholesterol and ankle brachial index (ABI). ABI is the ratio of
systolic blood pressure in the ankle to the systolic blood pressure in
the arm, and has been used as a measure both of peripheral
arterial disease and more generalised subclinical atherosclerosis
[33,34]. Pre-specified criteria were used to define prior myocardial
infarction (MI), angina or stroke using a combination of self-report
of a doctor diagnosis, WHO chest pain questionnaire, 12-lead
ECG and linkage to hospital discharge records, as has been
described in detail previously [35].
Cognitive and Mood Assessment
Seven neuropsychological tests measured various dimensions of
cognitive ability. The Borkowski Verbal Fluency Test (BVFT)
examined executive function. Immediate and delayed recall was
assessed in the Logical Memory subtest (LM) of the Wechsler
Memory Scale 3rd Edition (WMS-III). The Faces subtest of the
WMS-III was a measure of non-verbal memory. Mental flexibility
and visual attention were examined by the Trail-Making Test B
(TMT-B). Several subtests of the Wechsler Adult Intelligence Scale
3rd Edition (WAIS-III) were administered: Digit Symbol Coding
(DSC; speed of information processing), Letter Number Sequenc-
ing (LNS; working memory) and the Matrix Reasoning test (MR;
non-verbal reasoning). Vocabulary (‘crystallised’ intelligence) was
measured using the combined junior and senior Mill Hill
Vocabulary scale (MHVS) synonyms. As the results of vocabulary
tests show very little mean decline with ageing, they can be used to
estimate peak, prior cognitive ability [36]. When late-life cognitive
ability scores are adjusted for vocabulary-based test scores, the
residuals correlate highly with actual measures of cognitive change
over a lifetime [37]. A score of below 24 out of 30 on the Mini-
Mental-State Examination (MMSE; [38]) indicated presence of
possible dementia. Presence of depression and anxiety was assessed
on the Hospital Anxiety and Depression Scale (HADS; [39]).
Responses were made on four-point scales, with maximum scores
of 21 on each of two subscales, the HADS-A and HADS-D. In
addition to the use of the HADS-D as a continuous outcome,
‘possible cases’ of clinical depression (HADS-D $8) were
identified. Both these applications of the HADS are widely
employed in the literature [40], and the cut-point of 8 has been
shown to have high sensitivity and specificity [41]. A majority of
participants completed the entire cognitive test battery and mood
assessment (n = 1048 to 1065 for individual tests), and provided
data on all physical measures (n = 1028 to 1066). Incompleteness
was mainly due to physical difficulty rather than test refusal.
Measurement of NT-proBNP
Fasting blood samples were taken at the research clinic, and
plasma was frozen for storage. Plasma NT-proBNP concentrations
were determined using the Elecsys 2010 electrochemiluminescence
method (Roche Diagnostics, Burgess Hill, UK) calibrated using
the manufacturer’s reagents. Manufacturer’s controls were used
with limits of acceptability defined by the manufacturer. Low
control CV was 6.7% and high control CV was 4.9%.
Statistical Methods
Distribution of values was skewed for NT-proBNP, HADS-D,
and TMT-B. These variables were transformed to their natural
logarithm values.
Individuals who perform well on one cognitive test tend to
perform well on another, so that different cognitive tests load on a
single common factor, ‘g’ [42]. Principal component analysis
revealed that all seven cognitive tests (LM, Faces, MR, DSC,
TMT-B, LNS, BVFT) could indeed be captured by the single
standardised factor, ‘g’.
Initial two-tailed Pearson correlations tested associations of NT-
proBNP with other clinical measures, cognitive outcome and
HADS depression scores. Mean NT-proBNP levels were com-
pared between groups with suspected dementia (MMSE,24), and
between those with suspected clinical depression (HADS-D score
$8) and those without.
In exploratory univariate analyses, mean ‘g’ and HADS
depression scores were compared between the highest and the
lower four quintile NT-proBNP groups. The likelihood of low
cognitive functioning (scoring in the lowest versus intermediate or
NT-proBNP Associations with Cognition/Depression
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highest tertiles of ‘g’) and of suspected clinical depression were
calculated for the highest quintile NT-proBNP as an example of a
group with raised NT-proBNP levels.
Scores on the different cognitive tests were also treated as
individual continuous outcome variables. NT-proBNP was mod-
elled on each of these, ‘g’, and HADS depression, adjusting for
potential confounders in staged and cumulative linear regression
analyses. Confounders were selected on the basis of results from
exploratory univariate analyses and reports in the literature of
confounding or mediating roles in the relationship of NT-proBNP
with cognition or depression. Results from the regression analyses
were presented as b regression coefficients to show the direction
and strength of the associations, signifying the change in cognitive
and depression scores for each unit increase in NT-proBNP.
For cognitive outcome variables, only age and sex were
controlled for in a first model. Estimated pre-morbid cognitive
ability (MHVS) was entered in a second stage, before the addition
of diabetes-related and cardiovascular risk factor variables
(smoking status, blood pressure, BMI, HbA1c, cholesterol and
mode of treatment). MI, angina, stroke and ankle brachial index
(ABI) were then entered, but had not previously been included in
order to avoid over-adjustment. HADS depression scores were
added in a final model in order to determine the potential
independence of NT-proBNP associations with cognition and
depression. The first two modelling steps were also followed for the
HADS depression outcome. In a third step, HbA1c and mode of
treatment were controlled for. Cardiovascular disease variables
were only added into the model in a final step, again in order to
avoid over-adjustment given the role of NT-proBNP as a marker
of cardiovascular disease. Analyses were performed using SPSS for
Windows, version 14.0 (IBM Corporation, New York).
Results
Cohort characteristics and classical risk factors
Characteristics of the ET2DS participants are shown in Table 1.
The study population (n = 1066) has been shown previously to be
largely representative of all people invited to participate in the
study (n = 5454) and therefore of the target population of older
men and women with type 2 diabetes living in the general
population [35]. Mean age was 67.9 years. Mean plasma NT-
proBNP levels were similar in men and women (geometric means
79 pg/ml 63 vs 84 pg/ml 63; p = 0.41 and correlated positively
with age (r = 0.25; p,0.001). Controlling for age and sex, NT-
proBNP was significantly associated with the following variables:
duration of diabetes (r = 0.14; p,0.001), diastolic blood pressure
(r = 20.09; p = 0.008), ABI (r = 20.14; p,0.001), BMI (r = 0.11;
p,0.001) and cholesterol (r = 20.10; p = 0.005), but not with
HbA1c, plasma glucose or systolic blood pressure (p.0.05). Mean
levels differed between individuals with MI, stroke or angina and
those without (p,0.001 respectively), but not between smokers
and non-smokers (p.0.05).
NT-proBNP associations with cognitive performance
After controlling for age and sex, NT-proBNP was weakly but
statistically significantly correlated with decreased performance on
MHVS, Logical Memory, TMT-B, DSC, MR, the general ability
factor ‘g’ and HADS depression. NT-proBNP levels accounted for
,1% of variance in cognitive test scores and ‘g’ (r2 = 0.005 to
0.008), and for 1.7% of depression scores. (r2 = 0.017; Table 2).
NT-proBNP was not significantly different in the small group of
participants with possible dementia (MMSE,24, n = 30) com-
pared with higher scoring individuals (geometric mean 106 pg/ml
63 vs 81 pg/ml 63, p = 0.24). However, the group with possible
clinical depression (HADS depression score $8, n = 78) had lower
mean MMSE scores (geometric means 27.8061.08 vs
28.2861.08, p = 0.052, Cohen’s d = 0.24) and higher NT-proBNP
levels (geometric mean 107 pg/ml 63 vs 80 pg/ml 63, p = 0.03,
Cohen’s d = 0.28) compared to the non-depressed group.
To further explore whether plasma NT-proBNP could be a
marker of reduced cognitive function irrespective of other possible
markers, we examined differences in cognitive ability across
quintiles of NT-proBNP (geometric cutpoints were 29.70, 59.15,
100.48 and 217.02 pg/ml). An analysis of covariance with
adjustment for age and sex suggested an overall trend across
quintiles (adjusted mean ‘g’ = 0.02, 0.14, 0.13, 20.09 and 20.18
respectively; p = 0.003). Subjects in the highest quintile of NT-
proBNP (n = 199) had lower ‘g’ than those in the remaining four
quintiles (n = 807; adjusted means 20.18 versus 0.05; 95% CI for
difference 20.39, 20.08; p = 0.003). In unadjusted analyses
comparing the highest quintile of NT-proBNP to all other
quintiles, the odds ratios for low cognitive ability (‘g’ in the lowest
tertile) was 2.14 (95% CI: 1.44, 3.18; p,0.001). After adjustment
for age and sex, the association was marginally attenuated to 1.80
(95% CI: 1.20, 2.70; p = 0.005).
For ‘g’ and each of the constituent cognitive tests, multiple
regression analyses were carried out (Table 3). The initial model
controlled for age and sex. Associations with NT-proBNP reached
statistical significance for a number of cognitive tests (Logical
Memory, TMT-B, DSC, MR), and ‘g’. In a second step, pre-
morbid cognitive ability (MHVS) was added into the model. The
associations with TMT-B, DSC, MR, and ‘g’ remained statistically
significant, and for Logical Memory approached significance.
When a range of potential confounding and/or mediating
variables, including conventional cardiovascular risk factors
together with HbA1c and treatment type were added in a third
model, only the association with Logical Memory remained
statistically significant and also survived the further adjustment for
previous cardiovascular disease and HADS depression in a final
step.
NT-proBNP associations with depression
Adjusting for age and sex, HADS depression scores gradually
increased across NT-proBNP quintiles (geometric mean scores
were 2.77, 2.94, 3.19, 3.25 and 3.56 respectively; p = 0.007). The
highest NT-proBNP quintile had higher mean depression scores
compared with the lower four quintiles (95% CI 0.05, 0.28;
p = 0.006). The age- and sex-adjusted odds ratio (OR) for possible
clinical depression, comparing the highest versus the lower four
quintiles, was 2.18 (95% CI 1.28, 3.71; p = 0.004).
Multivariable modelling was repeated for HADS depression.
The age and sex adjusted association reached significance and
survived additional adjustment for pre-morbid cognitive ability, as
well as diabetes-associated variables. The association became non-
significant following the addition of previous cardiovascular
disease into the model (Table 4).
Discussion
This epidemiological study investigated the contribution of NT-
proBNP levels to performance on a large battery of cognitive tests
and symptoms of depression in older people with type 2 diabetes
using one of the largest community-based study populations on
this topic. Cognitive ability, measured by the standardised factor
‘g’, was lower, and depression higher, in patients with raised
plasma NT-proBNP. Participants with peptide levels in the highest
quintile of NT-proBNP distribution were almost two times more
likely to have reduced cognitive ability (lowest tertile of ‘g’) and
NT-proBNP Associations with Cognition/Depression
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were more than two times more likely to have possible clinical
depression following the adjustment for age and sex, compared
with the remaining population, but associations of NT-proBNP
with ‘g’ and depression scores no longer reached statistical
significance when diabetes-related and vascular co-variates were
additionally controlled for.
Although not the main focus of the present investigation, raised
NT-proBNP was also found to be associated with poorer pre-
morbid cognitive ability. This finding could cast doubt over a
causal relationship between cardiac stress (as measured by
natriuretic peptides) and late-life cognitive ability in people with
diabetes, since ‘reverse causation’ and confounding are possible
explanations [43]. Low early life cognitive ability leads to lower
late-life ability, and exposes individuals to poor lifestyle choices,
health problems with associated raised biomarker levels, and
earlier death [44]. However, the reported weak associations
between NT-proBNP and current cognitive ability remained
significant when pre-morbid ability was controlled for.
The association between reduced late-life cognitive ability and
plasma NT-proBNP is consistent with previous studies on
predominantly non-diabetic populations [12–14]. However, pre-
vious studies have predominantly used simple screening instru-
ments, such as the MMSE, to measure cognitive function. Our use
of a general ability factor derived from a number of different
cognitive tests is unique in the literature on NT-proBNP and
cognition. Although the age- and sex-adjusted odds of reduced
cognitive ability for the high NT-proBNP group were comparable
to those reported by Daniels et al. [12], the multivariate
associations between NT-proBNP and cognitive scores were
relatively weak compared with some previous investigations
[13,14]. Peptide levels were also similar in subjects with and
without suspected dementia determined using the MMSE
(MMSE,24) compared with others. This finding is consistent
with previous studies [15,30,31], but may reflect flaws in the use of
the MMSE, designed to screen for dementia, as a measure of
milder forms of cognitive impairment [45].
Table 1. Baseline characteristics of the ET2DS population.
Variable Mean ± SD, median (quartile range) or n (%)
Age (years) 67.964.2
Male sex (%) 547 (51.3)
Duration of diabetes (years) 6 (3–11)
Treatment of diabetes with insulin +/2 tablets 186 (17)
Treatment with tablets alone 679 (64)
Treatment with dietary change alone 200 (19)
HbA1c (%) 7.461.1
Fasting plasma glucose (mmol/L) 7.662.1
Systolic BP (mmHg) 133616
Diastolic BP (mmHg) 6969





Total cholesterol (mmol/L) 4.360.9
Smoking (current) (%) 153 (14.4)
NT-proBNP (pg/ml) 75 (37–169)
Hospital Anxiety and Depression Questionnaire (HADS): Depression score 3 (1–6)
HADS depression score $8 78 (7.3)
Mini-Mental State Examination ,24/30 (%) 30 (2.9)
Trail-Making Test B 104 (81–138)
Matrix Reasoning 12.865.3
Digit Symbol Coding 49.2614.8
Verbal Fluency Test 36.9612.8




Mill Hill Vocabulary Scale 30.965.2
Mean 6 SD is given for normally distributed variables.
Median (quartile range) is given for non-normally distributed variables.
doi:10.1371/journal.pone.0044569.t001
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Associations between NT-proBNP and deficits in specific
cognitive domains were also explored. When age and sex were
controlled for, peptide levels were unrelated to performance on
BVFT, Faces or LNS, but were associated with poor performance
on Logical Memory, TMT-B, DSC and MR. Furthermore, these
relatively weak associations (except that for Logical Memory, for
which a trend was observed) remained statistically significant
following adjustment for estimated pre-morbid ability. The finding
of inverse associations between peptide levels and performance on
the TMT-B test of visual attention and the Matrix Reasoning test
of non-verbal reasoning is consistent with investigations in non-
diabetic populations [12,14]. NT-proBNP was unrelated to verbal
fluency (BVFT) both in the present study and in Gunstad et al.
[14]. Associations in Daniels et al. [12] also only reached statistical
significance when analyses were largely unadjusted. NT-proBNP
has not previously been investigated in relation to nonverbal
memory (Faces), speed of information processing (DSC) or
working memory (LNS), of which we found an association only
with speed of processing. It must be noted that since a large
number of analyses were carried out, it is possible that the
statistically significant associations arose through type I error.
Further studies are required to confirm or refute these findings.
For any disease, the identification of biomarkers indicating
increased risk of complications and co-morbidities is vital to allow
identification of high risk individuals. Despite high prevalence of
vascular disease and associated high average NT-proBNP levels in
people with type 2 diabetes [9,10], as well as high prevalences of
cognitive and mood disorders, to our knowledge, this is the first
investigation to focus on the relationship of NT-proBNP with
cognitive function and mood in type 2 diabetes.
The association of natriuretic peptides with late cognitive ability
may well reflect underlying cardiac stress and associated vascular
disease, rather than any direct causal relationship. This is
supported by the attenuation of the relationship between cognitive
ability and NT-proBNP following the adjustment for a range of
cardiovascular risk factors and cardiovascular disease, which
rendered it statistically non-significant. A weak association
between NT-proBNP and the Logical Memory test (which
measures verbal declarative memory through recall of a short
story and is particularly sensitive to progression of type 2 diabetes
[46]) was unique, in that it was not attenuated by the adjustment
for cardiovascular or diabetes-associated variables, or HADS
depression scores. Despite the possibility that the result represents
a type I error, it is an intriguing finding which merits further
investigation.
Raised NT-proBNP was also associated with high depression
scores, supporting previous findings from non-diabetic populations
[19–22]. The relative weakness of the associations is consistent
with one previous report [22], although associations overall tend to
be larger [19–21]. Despite predicting high risk of future vascular
disease and depression, low pre-morbid ability did not confound
the association. Pathways linking depression and NT-proBNP
levels have been suggested previously [19]. We found evidence
Table 2. Age and sex-adjusted two- tailed partial correlations









Logical Memory 20.08 0.015
Faces 20.05 0.139
ln(Trail-Making-Test-B) 0.08 0.012




Matrix Reasoning 20.08 0.010
g 20.09 0.007
ln(HADS depression) 0.13 ,0.001
doi:10.1371/journal.pone.0044569.t002
Table 3. Multivariate associations between NT-proBNP and cognitive test scores.
MHVS g BVFT LM FACES ln(TMT-B) DSC LNS MR
Model 1a b 20.26 20.09 0.02 20.49 20.31 0.03 20.96 20.10 20.35
95% CI 20.54, 0.01 20.13, –0.03** 20.65, 0.69 20.91, 20.06* 20.71, 0.10 0.01, 0.05* 21.71, 20.20** 20.25, 0.04 20.62, 20.08**
Model 2b b 20.05 0.28 20.36 20.20 0.02 20.69 20.04 20.25
95% CI 20.09, 0.00* 20.33, 20.8920.75, 0.04 20.59, 0.19 0.00, 0.04* 21.38, 0.00* 20.18, 0.90 20.50, 20.01*
Model 3c b 20.04 0.38 20.48 20.15 0.02 20.26 20.04 20.23
95% CI 20.08, 0.01 20.26, 1.01 20.89, 20.07* 20.56, 0.26 0.00, 0.04 20.98, 0.46 20.17, 0.10 20.48, 0.02
Model 4d b 20.02 0.18 20.57 20.01 0.02 0.19 20.01 20.15
95% CI 20.07, 0.03 20.52, 0.87 21.02, 20.11* 20.46, 0.44 20.01, 0.04 20.60, 0.98 20.16, 0.15 20.43, 0.13
Model 5e b 20.02 0.16 20.56 20.03 0.01 0.26 0.01 20.14
95% CI 20.06, 0.03 20.56, 0.88 21.03, 20.08* 20.50, 0.44 20.01, 0.04 20.54, 1.07 20.15, 0.16 20.42, 0.15
The b scores are regression coefficients.
aadjusted for age and sex.
badjusted for +MHVS.
cadjusted for + smoking status, blood pressure, BMI, HbA1c, cholesterol, mode of treatment.
dadjusted for + MI, angina, stroke, ABI.
eadjusted for + ln(HADS depression).
*significant at 0.05 level.
**significant at 0.01 level.
doi:10.1371/journal.pone.0044569.t003
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against this, as the association became non-significant when
previous cardiovascular disease was controlled for. Depression is
associated with a harmful lifestyle and subsequent endothelial
damage, and also accelerates the progression of cardiac illness
through effects on the hypothalamic-pituitary adrenal (HPA) axis,
increasing the risk of heart failure [47]. Conversely, heart failure
and other chronic illness initiate symptoms of depression,
including hypersomnia, fatigue and loss of energy [48], constructs
included in the HADS questionnaire.
Overall, the clinical relevance of natriuretic peptides as
biomarkers for poor cognitive function and depression is unclear.
Despite a relatively weak multivariate association, individuals in
the highest NT-proBNP quintile were substantially more likely to
have reduced cognitive ability and depression compared with the
remaining population. NT-proBNP may function as a biomarker
of subclinical cerebrovascular disease particularly in individuals
who experience cardiac stress. This extends its well-established
role as a predictor of cardiovascular and cerebrovascular events
[49]. Mirroring a greater ability of natriuretic peptides compared
with other biomarkers, such as c-reactive protein (CRP), to predict
these outcomes [50], the association of NT-proBNP with cognitive
function in the present study was also stronger than that of CRP
with cognitive function in a previous analysis [35].
A strength of the current study was the ability to adjust for a
wide variety of variables, both those which are commonly
controlled for (e.g., age), and those which may be confounding
or mediating factors underlying the relationship between NT-
proBNP and cognitive ability (e.g., vascular risk factors; cardio-
vascular disease). Due to the large size of the study, results are
more robust than those of previous investigations carried out on
smaller scales [15–17] and the analysis had high power to detect
even weak associations, although admittedly, the clinical relevance
of such associations is debatable. The latter was reflected in the
conservative interpretation of statistically significant results. The
cross-sectional nature of the study and the resulting unclear
direction of the reported associations is a weakness of the study,
although this was partly offset by our adjustment for pre-morbid
cognitive ability. The MHVS as a measure of pre-morbid ability is
advantageous over the often used level of education, which is
subject to self-report bias.
In conclusion, we found some evidence for NT-proBNP as a
biomarker of low cognitive ability and depression in elderly people
with type 2 diabetes, although the associations were relatively
weak and were largely explained by previous cardiovascular
disease. The value of NT-proBNP measurement over and above
the assessment of traditional markers of cognitive dysfunction and
depression remains unclear, and further studies on its relationship
with these disorders are needed. Analysis of the second wave of
data of the prospective ET2DS will provide an ideal opportunity
to investigate the associations of natriuretic peptide levels with risk
of subsequent cognitive decline and the development of depres-
sion.
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OBJECTIVEdMacrovascular disease may contribute to increased risk of accelerated cognitive
decline in patients with type 2 diabetes. We aimed to determine associations of measures of macro-
vascular disease with cognitive change in a cognitively healthy older population with type 2 diabetes.
RESEARCHDESIGNANDMETHODSdEight hundred thirty-onemen andwomen (aged
60–75 years) attended two waves of the prospective Edinburgh Type 2 Diabetes Study (ET2DS). At
baseline, clinical and subclinical macrovascular disease was measured, including cardiovascular event
history, carotid intima-media thickness (cIMT), ankle brachial index (ABI), and serum N-terminal
probrain natriuretic peptide (NT-proBNP). Seven neuropsychological tests were administered at base-
line and after 4 years; scores were combined to a standardized general ability factor (g). Adjustment of
follow-up g for baseline g assessed 4-year cognitive change. Adjustment for vocabulary (estimated
premorbid ability) was used to estimate lifetime cognitive change.
RESULTSdMeasures of cognitive decline were significantly associated with stroke, NT-
proBNP, ABI, and cIMT, but not with nonstroke vascular events. The association of stroke with
increased estimated lifetime cognitive decline (standardized b,20.12) and of subclinical mark-
ers with actual 4-year decline (standardizedb,20.12, 0.12, and20.15 for NT-proBNP, ABI, and
cIMT, respectively) reached the Bonferroni-adjusted level of statistical significance (P, 0.006).
Results altered only slightly on adjustment for vascular risk factors.
CONCLUSIONSdStroke and subclinical markers of cardiac stress and generalized atherosclero-
sis are associatedwith cognitive decline in older patientswith type2diabetes. Further investigation into
the potential use of subclinical vascular disease markers in predicting cognitive decline is warranted.
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Cognitive abilities are essential forindependent living in later life, andsome domains of cognitive func-
tioning decline in mean level from rela-
tively early adulthood (1). Age-related
cognitive decline is accompanied by path-
ological changes in the brain, including
cerebral microvascular changes, and al-
though individual differences exist in
the severity of age-related microvascular
damage in the brain, this is difficult to in-
vestigate noninvasively. Systemic athero-
sclerotic changes in the body may serve
as a marker of vascular-related changes in
the brain (2) that, in turn, lead to cogni-
tive deficits (3,4). However, the potential
of large vessel changes distant from the
brain itself to function as markers of cog-
nitive decline remains unclear. We aimed
to study a range of measures of clinical
and subclinical macrovascular disease
that focus on different areas of the vascu-
lature or different underlying pathophys-
iological mechanisms to assess which of
these might function as proxies of cogni-
tive decline.
Understanding the role of macrovas-
cular disease in age-related cognitive im-
pairment is particularly important in
diabetes, given the higher prevalence of
atherosclerotic large vessel disease as well
as the accelerated cognitive decline and
increased risk of cognitive impairment
(5,6) associated with this condition, and
the potentially modifiable nature of mac-
rovascular disease (7). The prevalence of
stroke, of transient ischemic attack (TIA)
(8), and of coronary heart disease (9) are
higher in diabetic populations than in
nondiabetic populations, and average na-
triuretic peptide levels, a marker of car-
diac stress, are increased (10). Markers of
subclinical atherosclerosis also are al-
tered, with increased average carotid
intima-media thickness (cIMT) (11) and
reduced mean ankle brachial index
(ABI) (12). Despite this, investigation
into the role of macrovascular disease in
age-related cognitive impairment in
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people with diabetes is limited compared
with investigation into this issue in the
general (predominantly nondiabetic)
population. We set out to determine the
association of a variety of measures of
subclinical macrovascular disease and
cardiovascular event categories with cog-
nitive decline in a sample of older people,
all of whom had diabetes (the Edinburgh
Type 2 Diabetes Study [ET2DS]). We did
so using two cognitive outcomes, actual
late-life cognitive change over a 4-year
period and estimated lifetime cognitive
change. These analyses are timely given
the increasing prevalence of diabetes at
younger ages (13) that, together with
greater survival (14) and greater lifetime
exposure to diabetes in current genera-
tions, is likely to contribute to increasing




In 2006, the ET2DS recruited a randomly
selected sample of older adults with type
2 diabetes from the Lothian Diabetes
Register, a population-based disease reg-
ister that contains details of nearly all
individuals with diagnosed diabetes living
in the Lothian region of Scotland, U.K.
The study had ethical approval from the
Lothian Medical Research Ethics Commit-
tee. Of 5,454 individuals aged 60–74 years
who were invited to participate, 1,066
were recruited. Details of recruitment
have been described previously (15) and
representativeness of the cohort has been
demonstrated by comparing demographic
and clinical characteristics of responders
and nonresponders (16).
At baseline in 2006–2007, all study
participants attended a dedicated re-
search clinic for extensive physical and
cognitive examination and 939 (88%) re-
turned for further examination after ;1
year (2007–2008). All participants were
considered for repeat cognitive testing af-
ter 4 years (2010–2011). Between base-
line and year 4, 88 participants had
died, 9 declined further participation,
and 26 were deemed unfit to continue
participation. Invitations were sent out
to 943 (88%) participants. Of these, 98
declined to attend and 14 could not be
contacted; 831 (78%) ultimately attended
the year 4 clinic (Fig. 1). Reasons for non-
attendance at follow-up included poor
health (including dementia), responsi-
bilities as a carer, and loss of interest
in participation. Nonattenders were
followed-up using subject or general
practitioner questionnaires, record link-
age to hospital discharge and death certif-
icate data, and review of hospital notes
when required. Informed consent was ob-
tained from all participants at each clinic
attendance.
Physical and cognitive examination
All assessments were performed by spe-
cially trained nurses following standard
operating procedures and have been de-
scribed in detail previously (15). At base-
line, fasting blood samples were taken for
measurement of total serum cholesterol,
HbA1c, glucose, and plasma N-terminal
probrain natriuretic peptide (NT-
proBNP). Participants completed a ques-
tionnaire with standard questions about
vascular disease and vascular risk factors,
including smoking history, doctor diag-
nosis of myocardial infarction (MI), an-
gina, and stroke, the World Health
Organization chest pain questionnaire,
and the Edinburgh Claudication Ques-
tionnaire (17).
Height and weight, brachial blood
pressure, and a standard 12-lead electro-
cardiogram were recorded and measure-
ment of right and left brachial, posterior
tibial, and dorsalis pedis systolic pres-
sures were used to calculate the ABI.
Scottish Morbidity Record (SMR01) data
on all medical and surgical discharges
from Scottish hospitals between 1981 and
2011 were obtained. Any ICD-10 or ICD-
9 codes for cardiovascular or cerebrovas-
cular disease recorded between 1981 and
2007 were extracted and used together
with questionnaire data on vascular dis-
ease and electrocardiogramfindings (aswell
as review of clinical notes when required)
to define MI, angina, stroke, and TIA, as
detailed previously (16,18). Peripheral arte-
rial disease was defined as presence of in-
termittent claudication on the Edinburgh
Claudication Questionnaire.
At year 1, carotid IMT was measured
bilaterally in three separate images of the
common carotid artery, 1 to 2 cm below
the bifurcation and in areas free of plaque
using a Sonoline Elegra Ultrasound Im-
aging System (Siemens Medical Systems).
Mean cIMT was calculated for the left and
right carotid arteries; the higher of the two
values was used for analyses.
At baseline and at 4-year follow-up,
seven neuropsychological tests were used
to measure several domains of cognitive
ability. The Borkowski Verbal Fluency
Test (BVFT) examined executive func-
tion. The Logical Memory (LM) subtest of
the Wechsler Memory Scale, third edi-
tion, assessed immediate and delayed
verbal declarative memory. Nonverbal
memory was measured by the Faces subtest
Figure 1dSubject participation in the ET2DS.
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of the same scale. The Trail-Making Test B
(TMT-B) examined mental flexibility and
executive function. The Digit Symbol
Coding (DSC) subtest of the Wechsler
Adult Intelligence Scale, third edition,
measured speed of information process-
ing. The Letter-Number Sequencing and
the Matrix Reasoning (MR) subtests from
the Wechsler Adult Intelligence Scale,
third edition, assessed working memory
and nonverbal reasoning, respectively.
Scores on the combined junior and senior
Mill Hill Vocabulary Scale (MHVS) for
synonyms, which correlate strongly with
scores on the more traditionally used
National Adult Reading Test (19), tested
vocabulary abilities. Symptoms of depres-
sion and anxiety were self-reported on the
Hospital Anxiety and Depression Scale
(20). The Mini-Mental-State Examination
(MMSE) (21) assessed global cognitive
function. A cut-point of ,24 out of 30 is
traditionally used to identify individuals
with possible dementia (22). However,
because of the low validity and reliability
of this method (23), we applied the fol-
lowing additional criteria to define de-
mentia: using medication for dementia at
baseline or year 4, or both; dementia cod-
ing (F00, F01, F02, F03, or G30) from
SMR01 or on death certificate between
1981 and completion of year 4 follow-up
in 2011; report of psychiatrist diagnosis of
dementia in a questionnaire sent to gen-
eral practitioners of all subjects with
MMSE ,24 at baseline or follow-up and
subjects who did not attend the year 4
clinic; a psychiatrist’s diagnosis of demen-
tia obtained from a review of psychiatry
or hospital notes performed after comple-
tion of year 4 follow-up; and self-reported
or relative-reported dementia. Dementia
was recorded if two of these criteria were
met or, in subjects with MMSE score,24
at baseline or follow-up, or missing at
follow-up, if one of the first four criteria
was met.
Statistical analysis
Preparation of data. Because of skewed
distributions, NT-proBNP and TMT-B
were transformed to their natural loga-
rithm values. When data for one, two, or
three out of the seven cognitive tests
were missing, multiple imputation ac-
counting for age and sex was performed.
In accordance with previous literature
(24), mild cognitive impairment (MCI)
was defined as scoring in the lowest fifth
percentile of memory scores (LM), with
MMSE $24 and failure to meet criteria
for dementia.
Univariate analyses. Exploratory anal-
yses determined associations among
baseline predictors, correlations between
cognitive scores measured at baseline and
at follow-up, and 4-year change in mean
cognitive scores. Mean ABI, cIMT, and
NT-proBNP and prevalence of macrovas-
cular disease were compared in partici-
pants with dementia, in those who had
conversion to MCI during follow-up, and
in the remaining sample.
Multivariate analyses. Multivariate re-
gression analyses tested for associations
between baseline macrovascular disease
and follow-up cognitive scores, estimated
lifetime, and 4-year cognitive change.
To estimate lifetime cognitive change,
follow-up cognitive scores were adjusted
for baseline MHVS scores. Because vo-
cabulary tests measure "crystallized" in-
telligence and show little age-related
declines, they may be used to estimate
peak previous cognitive ability (25). De-
tails of this approach have been published
previously (26); essentially, by control-
ling for a well-validated estimate of peak
cognitive ability, it was possible to assess
associations of macrovascular disease var-
iables with estimated decline from best-
ever level of cognitive function. To
measure actual 4-year cognitive change,
follow-up scores were adjusted for base-
line scores on the respective cognitive test.
General ability factor g. Principal com-
ponents analysis was performed on cog-
nitive test scores with extraction of
components with Eigen values .1 to
function as additional cognitive out-
comes. A single component of general
cognitive ability (usually referred to as g)
was determined for follow-up (factor
loading: Faces, 0.51; LM, 0.61; DSC,
0.62; BVFT, 0.62; MR, 0.69; Letter-
Number Sequencing, 0.75; DSC and
TMT-B, 0.81), which accounted for
47.4% of the total variance. Strictly speak-
ing, principal components analysis does
not extract "factors," but the usage is com-
mon and we adopted it here. It has been
found that individuals who perform well
on one cognitive test tend to perform well
on another (27). Adjustment of follow-up
g for baseline g to signify 4-year cognitive
change requires that both are standard-
ized in the same population. To achieve
this, cognitive data were arranged in the
statistical program so that each of seven
columns included cognitive scores ob-
tained at baseline and at follow-up, a sin-
gle principal components analysis was
performed, and saved regression scores
of the first principal component were
separated into two columns according to
time point. The resulting baseline g and
follow-up g, which therefore have identi-
cal factor loading (Faces, 0.43; LM, 0.55;
BVFT, 0.65; MR, 0.67, Letter-Number Se-
quencing, 0.72; DSC, 0.75; TMT-B,
0.79), were then used for all analyses of
4-year change in g.
Covariates and correction for multiple
comparisons. Linear regression analyses
were further adjusted for conventional
cardiovascular risk factors (brachial blood
pressure, serum total cholesterol, and
history of cigarette smoking). Post hoc
analyses controlling for baseline MHVS
determined the independence of associa-
tions with 4-year cognitive change from
premorbid ability. To counteract risk of
type I error, Bonferroni corrections are
commonly applied to the cut-point for
statistical significance, but this increases
the risk of accepting incorrect null hy-
potheses (type II error). To balance these
risks, and because all three cognitive out-
comes were derived from one variable, we
applied a Bonferroni correction on the
basis of nine individual analyses only (to
reflect nine predictor variables; cut-point
P, 0.006). Analyses were performed us-
ing SPSS for Windows version 19.0
(IBM).
RESULTSdA comparison of baseline
sociodemographic and physical charac-
teristics revealed modest differences be-
tween participants who returned for year
4 follow-up ("attenders") and those who
did not ("nonattenders") (Table 1). At-
tenders had significantly better cognitive
ability at baseline and were less likely to
have dementia by year 4 (n = 4, 0.5%)
compared with nonattenders (n = 15,
6.4%). Further analyses were performed
on data from attenders; in this group,
mean age at baseline was 67.7 years and
293 participants (35.3%) had had at least
one cardiovascular event (stroke, TIA,MI,
angina, or intermittent claudication).
Many measures of macrovascular dis-
ease were associated with each other;
participants with low ABI tended to
have higher cIMT (r = 20.10; P =
0.004) and increased plasma NT-proBNP
levels (r = 20.16; P , 0.001). NT-
proBNP correlated positively with cIMT
(r = 0.13; P , 0.001). Participants with
history of any cardiovascular disease
(CVD), stroke, or angina all had signifi-
cantly higher mean NT-proBNP and
cIMT, and lower mean ABI compared
with the remaining population (all asso-
ciations P, 0.001 for any CVD; P, 0.05
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Table 1dBaseline characteristics of ET2DS participants attending and not attending 4-year follow-up for cognitive testing
Attenders Nonattenders
N
Mean 6 SD, median
(quartile range), or n (%) N
Mean 6 SD, median
(quartile range), or n (%)
P for difference
or trend
Age, years 831 67.69 6 4.16 235 68.71 6 4.27 0.001
Male 831 430 (51.7) 235 117 (49.8) 0.596
Education 831 235 0.110
University degree 831 145 (17.4) 235 26 (11.1)
Professional 831 239 (28.8) 235 68 (28.9)
Secondary school 831 442 (53.2) 235 139 (59.1)
Primary school 831 5 (0.6) 235 2 (0.9)
SIMD rank 831 235 ,0.001
1st quintile 831 99 (11.9) 235 28 (11.9)
2nd quintile 831 143 (17.2) 235 65 (27.7)
3rd quintile 831 143 (17.2) 235 45 (19.1)
4th quintile 831 146 (17.6) 235 48 (20.4)
5th quintile 831 300 (36.1) 235 49 (20.9)
HADS anxiety 831 5 (3–8) 234 6 (4–9) ,0.001
HADS depression 831 3 (1–5) 234 4 (2–6) 0.002
Duration of diabetes, years 824 6 (3–11) 229 7 (3–12) 0.196
Current treatment 830 235 0.281
Insulin 6 tablets 830 139 (16.7) 235 47 (20.0)
Tablets alone 830 526 (63.4) 235 153 (64.8)
Diet alone 830 165 (19.9) 235 35 (14.9)
HbA1c, % 804 7.39 6 1.13 224 7.41 6 1.08 0.872
HbA1c, mmol/mol 804 57 6 12.4 224 57 6 11.8 0.872
Plasma glucose, mmol/L 821 7.54 6 2.09 228 7.66 6 2.13 0.425
Systolic BP, mmHg 829 132.51 6 15.87 235 136.09 6 18.09 0.006
Diastolic BP, mmHg 829 68.95 6 8.87 235 69.44 6 9.50 0.457
BMI, kg/m2 831 31.29 6 5.59 234 31.93 6 6.03 0.130
WHR 828 0.97 6 0.08 233 0.97 6 0.08 0.966
Total cholesterol, mmol/L 826 4.34 6 0.90 231 4.23 6 0.91 0.100
Current smoker 831 108 (13.0) 235 45 (19.1) 0.018
Former smoker 831 390 (46.9) 235 109 (46.4) 0.882
Never smoked 831 333 (40.1) 235 81 (34.5) 0.120
cIMT, mm 775 1.00 6 0.17 142 0.99 6 0.17 0.408
ABI 824 0.99 6 0.20 235 0.95 6 0.23 0.009
NT-proBNP, pg/mL 820 71 (35–158) 230 102 (48–216) 0.004
MI 831 111 (13.4) 235 39 (16.6) 0.207
Angina 831 222 (26.7) 235 76 (32.3) 0.090
Stroke 831 44 (5.3) 235 18 (7.7) 0.171
TIA 831 27 (3.2) 235 4 (1.7) 0.213
PAD 831 53 (6.4) 235 12 (5.1) 0.472
Any CVD 831 293 (35.3) 235 100 (42.2) 0.041
MMSE 830 29 (28–30) 233 28 (27–29) ,0.001
MMSE ,24 830 13 (1.6) 234 17 (7.3) ,0.001
Dementia 831 4 (0.5) 235 15 (6.4) ,0.001
MHVS 820 31.45 6 5.07 229 29.07 6 5.38 ,0.001
LM 830 25.82 6 7.97 232 22.94 6 8.54 ,0.001
Faces 829 66.35 6 7.66 232 63.95 6 8.40 ,0.001
MR 830 13.35 6 5.23 233 10.92 6 5.02 ,0.001
DSC 830 50.37 6 14.37 231 44.72 6 15.52 ,0.001
TMT-B, sec 830 101 (79–132) 232 124 (94–164) ,0.001
Letter-Number Sequencing 829 9.91 6 2.67 232 8.78 6 2.95 ,0.001
BVFS 828 37.77 6 12.53 232 33.93 6 13.47 ,0.001
g 829 0.13 6 0.93 231 20.44 6 1.11 ,0.001
Attenders (n = 831) vs. nonattenders (n = 235). Data for attenders include three patients who attended follow-up but did not provide cognitive data. At baseline, 1,021
of 1,066 participants completed all cognitive tests. Missing data were imputed for 39 participants. BP, blood pressure; HADS, Hospital Anxiety and Depression Scale;
PAD, peripheral arterial disease; SIMD, Scottish Index of Multiple Deprivation; WHR, waist-to-hip ratio.
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for stroke and angina). History of TIA was
associated with lower mean ABI (P =
0.009). Mean NT-proBNP (P , 0.001)
and cIMT (P = 0.012) were increased in
participants with MI.
Of all subjects attending follow-up
(n = 831), three were not cognitively
tested because of refusal or physical dis-
ability. Performance on each cognitive
test correlated significantly with perfor-
mance on all other cognitive tests at base-
line (r = 0.19–0.63; all P , 0.001) and at
follow-up (r = 0.26–0.65; all P, 0.001).
Individual cognitive test scores and g cor-
related strongly between baseline and
follow-up (Table 2). Mean scores declined
slightly but significantly (P , 0.001) for
all tests except Faces and LM, in which
scores improved (P , 0.001), and for
DSC (P = 0.150) (Table 2). Effect sizes
and significance levels were similar
when analyses were repeated using origi-
nal rather than imputed data (data not
shown).
At Bonferroni-corrected P = 0.006,
follow-up g was found to be significantly
lower in participants with a preexisting
cardiovascular event at baseline (b =
20.18; P , 0.001); for individual event
categories, findings were statistically sig-
nificant for angina (b =20.11; P = 0.002)
and stroke (b =20.16; P, 0.001). Lower
follow-up g also appeared to be associated
with measures of subclinical macrovascu-
lar disease, although only the association
with higher NT-proBNP reached statistical
significance at the Bonferroni-corrected
level (b = 20.10; P = 0.005) (Table 3).
In multivariate analyses adjusting for
baseline cognitive test scores or for MHVS
(and for vascular risk factors), the only
cardiovascular event category that re-
mained significantly associated with
lower g at follow-up was stroke (Table
3), suggesting that people with stroke ex-
perienced steeper cognitive decline com-
pared with stroke-free individuals. For
estimated lifetime cognitive change, the as-
sociation was statistically significant at the
Bonferroni-adjusted level of significance
(b = 20.12; P , 0.001) and persisted
after adjustment for cIMT (b = 20.10;
P = 0.001). In terms of individual test
scores, stroke appeared to affect predomi-
nantly processing speed (Supplementary
Tables).
All markers of subclinical macrovas-
cular disease were significantly associated
with 4-year decline in g, although the as-
sociation with ABI, which appeared to be
driven by processing speed (TMT-B: b =
20.08; P = 0.001; Supplementary Ta-
bles), only lost statistical significance at
the Bonferroni-adjusted level when vas-
cular risk factors were controlled for
(P = 0.009) (Table 3).
Further analyses of the individual
cognitive tests revealed statistically signif-
icant associations of NT-proBNP with
4-year decline in verbal fluency at
Bonferroni-corrected level (BVFT: b =
20.07; P = 0.001) (Supplementary Ta-
bles). Associations between increased
cIMT and 4-year decline in processing
speed (DSC: b = 20.08; P = 0.001) and
reasoning (MR: b = 20.08; P = 0.004)
appeared to be the main contributors to
the association with decline in g. All asso-
ciations of cIMT and NT-proBNP with g
and individual cognitive tests (except be-
tween cIMT andMR; P = 0.007) remained
statistically significant (P , 0.006) after
adjustment for vascular risk factors
(Table 3 and Supplementary Tables).
In post hoc analyses, the association of
cIMT with 4-year decline in g survived
the additional adjustment for MHVS
(b = 20.13; P = 0.001) as well as addi-
tion of stroke, ABI, and NT-proBNP into
the model (b = 20.12; P = 0.002). The
association of NT-proBNP with decline
in g lost statistical significance when
MHVS (P = 0.008) or when stroke,
ABI, and cIMT were controlled for (P =
0.055).
A similar pattern of associations was
found for the subclinical vascular markers
and MHVS-adjusted cognitive test per-
formance to signify estimated lifetime
cognitive change, although overall the
associations were weaker, such that only
the association with cIMT reached the
Bonferroni-adjusted level of statistical
significance (b = 20.09; P = 0.005). The
finding also became less significant when
stroke was additionally controlled for
(P = 0.011).
Only four subjects attending the year
4 follow-up had a diagnosis of dementia.
Effect sizes and P values changed only
marginally when analyses were repeated
with exclusion of these cases (data not
shown). Although there was a suggestion
that the prevalence of vascular events was
higher in all subjects with dementia, in-
cluding TIA (P = 0.046) and MI (P =
0.027), this group of subjects (n = 19)
was too small for further subgroup analysis.
Twenty-three participants experienced
conversion from normal functioning to
MCI during follow-up. One (4.3%)
had a history of TIA, three had stroke
or peripheral arterial disease (13.0%, re-
spectively), six (26.9%) had MI, 10
(43.5%) had angina, and 14 (60.9%)
had any CVD. Age- and sex-adjusted
analyses revealed increased prevalence
of any CVD (P = 0.039) and significantly
higher mean NT-proBNP levels (geomet-
ric mean: 131.1 pg/mL and 95% CI
81.1–211.7 vs. 74.07 pg/mL and 95%
CI 68.4–80.3; P = 0.021) in the "conver-
sion to MCI" group compared with the
remaining population. None of the re-
maining macrovascular predictors was
related to conversion to MCI (all P .
0.05).
CONCLUSIONSdIn this cohort of
initially cognitively healthy older people
with type 2 diabetes, markers of subclin-
ical macrovascular disease, including
higher circulating levels of the natriuretic
peptide NT-proBNP and increased cIMT






or median (IQR) P for difference†
MHVS 0.89 31.53 6 5.02 30.70 6 4.95 ,0.001
g 0.84 0.12 6 0.93 0.00 6 1.00 ,0.001
BVFT 0.81 37.83 6 12.53 36.83 6 12.75 ,0.001
DSC 0.74 50.52 6 14.30 50.01 6 14.12 0.150
TMT-B, sec 0.66 104 (81–139) 107 (83–144) ,0.001
MR 0.67 13.36 6 5.24 11.55 6 5.22 ,0.001
LNS 0.54 9.93 6 2.66 8.86 6 2.89 ,0.001
LM 0.63 25.85 6 7.97 27.27 6 8.26 ,0.001
Faces 0.61 66.41 6 7.63 69.25 6 8.38 ,0.001
MMSE 0.51 29 (28–30) 29 (28–30) 0.011
N = 810–825. IQR, interquartile range; LNS, Letter-Number Sequencing. *Two-tailed Pearson correlations of
baseline and follow-up cognitive scores (all P , 0.001). Data for the seven cognitive tests and g include
imputed values. At baseline, missing data were imputed for 39 participants. At follow-up, missing data were
imputed for 65 participants. †Between baseline and follow-up mean scores.
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as well as a history of stroke, were asso-
ciated with cognitive decline.
Stroke is a well-established risk factor
associated with cognitive dysfunction and
impairment (28), and also may contribute
to accelerated cognitive decline (29), al-
though the relationship in exclusively
diabetic populations has not been exten-
sively investigated. In the ET2DS, stroke
was associated with steeper cognitive de-
cline between peak premorbid ability,
which was estimated by vocabulary, and
late-life ability. Contrary to previous in-
vestigations in older adults with type 2
diabetes (30,31), stroke also appeared to
be associated with rate of actual late-life
cognitive decline over the 4-year follow-
up, although these associations were
weaker and less statistically significant,
suggesting that cognitive function deteri-
orates from prestroke to immediate post-
stroke levels, with preexisting stroke
having relatively lower impact on subse-
quent cognitive decline.
The associations of cognitive decline
with subclinical measures of macrovascu-
lar disease, including higher levels of NT-
proBNP, increased thickness of the cIMT,
and lower ankle brachial pressure (a
further measure of systemic atheroscle-
rotic disease as well as of lower limb
peripheral arterial disease) (32), appeared
slightly stronger for 4-year cognitive de-
cline compared with associations of these
vascular markers with estimated lifetime
cognitive decline. This pattern of results is
of interest because, in terms of identifying
elderly subjects at risk for subsequent
cognitive decline, information on a pa-
tient’s future decline may be more
valuable compared with information
that incorporates past decline. Higher na-
triuretic peptide levels as a marker of
cardiac stress previously have been asso-
ciated with low level of cognitive function
(33) and risk of future dementia (34).
However, to our knowledge, this was
the first prospective investigation of
NT-proBNP and cognitive decline in a
cognitively healthy population with
type 2 diabetes. In addition to associa-
tions with continuously measured de-
cline in ability, higher baseline peptide
levels also predicted increased risk of
conversion from normal cognitive func-
tioning to suspected MCI. Increased
cIMT has been shown to be a marker of
coexistent CVD, including cerebrovascu-
lar disease (35), and may indicate sys-
temic atherosclerosis as well as more
localized disease. Evidence for associa-
tions with cognitive decline is mixed
(36,37), however, and although our
finding of accelerated 4-year cognitive
decline in individuals with higher cIMT
is consistent with one previous study
performed in a nondiabetic population
(36), investigations of patients with
type 2 diabetes are lacking. For cIMT,
but not for NT-proBNP, associations in
the current study were unrelated to po-
tential effects of premorbid ability in late-
life cognitive decline and risk of late-life
subclinical vascular damage.
Contrary to previous investigations
performed in predominantly nondiabetic
populations (38,39), we found an associ-
ation between low ABI and steeper late-
life cognitive decline. Individuals exposed
to lifestyle-associated vascular risk, such
as cigarette smoking, hypertension, and
hypercholesterolemia, may develop sub-
clinical macrovascular disease, evident
in lower ABI, and also may experience
accelerated late-life cognitive decline.
However, the association of ABI with cog-
nitive decline was only partially depen-
dent on conventional cardiovascular risk
factors.
It is also possible that the ABI may
function as a vascular risk marker in a
slightly different manner in diabetic pop-
ulations because of effects of stiffened
arteries on the measurement of ankle
pressures (12), and this could contribute
to any disparity between findings for ABI
and cognitive decline in diabetic com-
pared with nondiabetic populations.
The assessment of links between vas-
cular disease and cognition is notoriously
difficult because of the interrelationships
between different vascular measures and
the problems associated with measuring
or estimating change in cognitive abilities
over appropriate time periods in relation
to the development of vascular disease
markers. This somewhat explains incon-
sistencies in the current literature on the
role of large and small vessel vascular
disease in the etiology of cognitive de-
cline. Compared with some previous
studies, the relatively large size, population-
based approach, and prospective design
are strengths of the current study. The
use of an exclusively diabetic older pop-
ulation and the measurement of a large
number of different but commonly used
markers of subclinical and clinical mac-
rovascular disease provides a unique con-
tribution to the existing literature that
Table 3dMacrovascular disease and generalized cognitive ability (g)
4-year cognitive change Estimated lifetime cognitive change
Age and
sex-adjusted b
b adjusted for age,
sex, and baseline score Fully adjusted b
b adjusted for
age, sex, and MHVS Fully adjusted b
Vascular events
Any vascular event (n = 393) 20.18 (,0.001) 20.09 (0.008) 20.09 (0.014) 20.06 (0.032) 20.07 (0.023)
Stroke (n = 62) 20.16 (,0.001) 20.07 (0.036) 20.07 (0.037) 20.12 (,0.001) 20.12 (,0.001)
TIA (n = 31) 20.04 (0.239) 20.05 (0.178) 20.05 (0.177) 20.02 (0.590) 20.02 (0.580)
MI (n = 150) 20.09 (0.014) 20.04 (0.293) 20.04 (0.278) 20.05 (0.112) 20.05 (0.096)
Angina (n = 298) 20.11 (0.002) 20.04 (0.237) 20.04 (0.294) 20.01 (0.752) 20.01 (0.626)
Peripheral arterial disease (n = 65) 20.06 (0.099) 20.02 (0.567) 20.01 (0.703) 20.03 (0.266) 20.03 (0.287)
Vascular markers
NT-proBNP 20.10 (0.005) 20.12 (0.001) 20.10 (0.005) 20.07 (0.013) 20.07 (0.017)
ABI 0.10 (0.007) 0.12 (0.001) 0.10 (0.009) 0.05 (0.062) 0.05 (0.130)
cIMT 20.09 (0.015) 20.15 (,0.001) 20.12 (0.001) 20.10 (0.002) 20.09 (0.005)
Outcome variable is follow-up g. b values are standardized regression coefficients. Values in parentheses are P values. Cognitive data include imputed values. N =
755–823. Final models additionally adjusted for baseline vascular risk factors (total cholesterol, brachial blood pressure, cigarette smoking).
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has neglected investigations in diabetes
patients despite increased prevalence of
macrovascular disease and cognitive im-
pairment (5,8,11). The general ability
factor is a universal empirical finding, a
robust measure of overall cognitive func-
tioning, and also the locus of much of the
age effects on cognition (1). A conserva-
tive Bonferroni correction was applied to
the cut-point for statistical significance;
results were discussed both in terms of
the corrected and the traditional cut-
point (P , 0.05) with the aim of offering
an overall interpretation of findings with
minimal risk of statistical error. Adjust-
ment for a vocabulary-based cognitive
test enabled estimation of long-term
change in ability, although the MHVS
only served as an estimate of peak pre-
morbid ability and caution is warranted
in the interpretation of this outcome.
Analyses of actual longitudinal change
in cognitive test scores were presumably
subject to some error. Practice effects and
selective attrition, which favor partici-
pants with slower rates of decline (40),
lead to underestimation of actual cogni-
tive decline in the population. Individu-
als with higher ability at baseline were
more likely to attend follow-up and over-
all 4-year cognitive decline for attenders
was small. Although we set out to
recruit a cognitively healthy population,
subsequent consideration of information
from a wide variety of sources revealed
that a very small number of subjects
were likely to have been experiencing de-
mentia at baseline. However, exclusion of
dementia cases from the analyses only
marginally changed the results reported
here.
Our results provide additional evi-
dence that the impact of vascular disease
on cognition may not be restricted to
localized cerebral small vessel disease or
altered blood flow and ischemic damage
as a consequence of stroke, and that
cognitive decline could reflect systemic
atherosclerotic changes. NT-proBNP and
cIMT both appear to function as bio-
markers of risk of late-life cognitive de-
cline, despite their strong associations
with subclinical macrovascular disease
in different areas of the vasculature (left
ventricle and carotid artery, respectively)
and may offer valuable information be-
yond traditional vascular risk factors.
Given that stroke was only weakly asso-
ciated with 4-year cognitive decline, and
that none of the remaining measures of
symptomatic macrovascular disease were
related to this outcome, determination of
subclinical macrovascular disease using
continuous measures may be preferable
over symptomatic categorically assessed
macrovascular disease for the early iden-
tification of individuals at risk for late-life
cognitive decline. However, it must be
recognized that the categorical nature of
"events" data compared with the contin-
uous distribution of the subclinical mea-
sures is likely to have influenced the
relative levels of statistical significance
for these variables. Ascertainment of sub-
clinical macrovascular diseasemay aid the
identification of not only individuals at
risk for future symptomatic macrovascu-
lar disease (and its cognitive consequen-
ces) but also those at risk for late-life
cognitive decline in absence of symptom-
atic disease. With the proximity of the ca-
rotid artery to the brain, cIMT could be
hypothesized to represent the most accu-
rate noninvasive marker of asymptomatic
cerebral vascular damage. Certainly, its
potential as a vascular risk marker seems
to exceed that of simply a risk factor for
stroke.
In conclusion, we have found confir-
matory evidence of a link between stroke
and cognitive decline in people with type
2 diabetes but, more importantly, we have
identified associations between a number
of different measures of subclinical mac-
rovascular disease and late-life cognitive
change. Further studies are warranted to
determine whether these markers could
be useful clinical measures as risk predic-
tors for cognitive impairment and sub-
sequent targeting of interventions aimed
at reducing cognitive decline.
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Severe Hypoglycemia and
Cognitive Decline in Older People
With Type 2 Diabetes: The
Edinburgh Type 2 Diabetes Study
OBJECTIVE
People with type 2 diabetes are at increased risk of age-related cognitive decline
and dementia. Hypoglycemia is a candidate risk factor, but the direction of as-
sociation between episodes of severe hypoglycemia and cognitive decline in type
2 diabetes remains uncertain.
RESEARCH DESIGN AND METHODS
In the Edinburgh Type 2 Diabetes Study, cognitive function was assessed in 831
adults with type 2 diabetes (aged 60–75 years) at baseline and after 4 years. Scores
on seven neuropsychological tests were combined into a standardized general
ability factor g. Self-reported history of severe hypoglycemia at baseline (history
of hypoglycemia) and at follow-up (incident hypoglycemia) was recorded.
RESULTS
A history of hypoglycemia was reported by 9.3% of subjects, and 10.2% reported
incident hypoglycemia. Incident hypoglycemia was associated with poorer cog-
nitive ability at baseline (age- and sex-adjusted odds ratio for lowest tertile of
g 2.04 [95% CI 1.25–3.31], P = 0.004). Both history of hypoglycemia and incident
hypoglycemia were also associated with greater cognitive decline during follow-
up (mean follow-up g adjusted for age, sex, and baseline g20.25 vs. 0.03 [P = 0.02]
and20.28 vs. 0.04 [P = 0.01], respectively), including after addition of vascular risk
factors and cardiovascular and microvascular disease to the models (20.23 vs.
0.03 [P = 0.04] and 20.21 vs. 0.05 [P = 0.03], respectively).
CONCLUSIONS
The relationship between cognitive impairment and hypoglycemia appeared
complex, with severe hypoglycemia associated with both poorer initial cognitive
ability and accelerated cognitive decline.
Diabetes Care 2014;37:507–515 | DOI: 10.2337/dc13-1384
Type 2 diabetes is associated with an increased risk of cognitive impairment, age-
related cognitive decline, and dementia (1). Given the increasing numbers of elderly
people with type 2 diabetes in the general population, the identification of
potentially modifiable risk factors and the prevention of cognitive decline during
older age in this group are of major importance to public health. Although the
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cognitive impairment are likely to be
multifactorial (2), cerebral insults
associated with diabetes-associated
episodes of severe hypoglycemia (those
in which a patient requires external
assistance to aid recovery) are possible
contributors. In studies of individuals
with type 1 diabetes, in whom relatively
frequent episodes of severe
hypoglycemia are well-recognized,
severe hypoglycemia has been
associated with lower cognitive ability
and implicated in provoking cognitive
decline in children (3) but not in adults
(4). However, severe hypoglycemia is
also relatively common in adults with
insulin-treated type 2 diabetes and to a
lesser extent in individuals treated with
sulfonylureas (5). Because type 2
diabetes is predominant in the older
population, the investigation of the
relationship between hypoglycemia and
age-related cognitive decline in this
group, which has received limited
attention, is particularly pressing.
Retrospective analyses of hospital
records have suggested that exposure to
one or more episodes of severe
hypoglycemia is associated with an
increase in the subsequent risk of
dementia in people with type 2 diabetes
(6–9). These findings may be inflated by
the higher incidence of hypoglycemia in
hospital inpatients than in patients in
community settings (10) but are
supported by observations of cross-
sectional links between a history of
severe hypoglycemia and impaired
cognitive function short of frank
dementia (11,12). However, the extent
to which these associations are
explained by hypoglycemia occurring
as a consequence of poor cognitive
ability leading to suboptimal glycemic
control (13) as opposed to
hypoglycemia preceding and possibly
causing decrements in cognitive ability
is unknown. The very few prospective
analyses performed to date (which
might help to resolve this question)
have not implicated severe
hypoglycemia as a risk factor for
negative cognitive outcome (14–16).
However, these studies either have
neglected relatively mild cognitive
decline (14) or have been part of
randomized controlled trials in which
the nature of the intervention itself
potentially affected the relationship
between severe hypoglycemia and
cognitive ability (15,16). The principal
aim of the current study was to
determine the association of both
prevalent and incident severe
hypoglycemia with cognitive decline
measured prospectively through a range
of age-sensitive cognitive tests in a
representative sample of older adults
with type 2 diabetes living
independently in the general population
and participating in a well-established
observational epidemiological study
(the Edinburgh Type 2 Diabetes Study
[ET2DS]).
RESEARCH DESIGN AND METHODS
Study Population
Recruitment and examination
procedures for the prospective ET2DS
have been reported previously (17). In
brief, in 2006/2007, a sample of 1,066
men and women with type 2 diabetes
(aged 60–75 years), largely representative
of all individuals invited at random
froma population-based diabetes register
(18), attended a baseline clinic. In 2010/
2011, 831 participants (attenders)
returned for a 4-year follow-up;
nonattenders were followed up
through postal questionnaires, linkage
to hospital records, death certificate
data, and review of hospital notes. All
participants gave written informed
consent.
Clinical Examination
At the baseline clinic and year-4 follow-
up, HDL cholesterol, total cholesterol,
and plasma HbA1c concentrations were
measured in fasting blood samples;
systolic and diastolic brachial blood
pressures were measured; and smoking
history (current, never, and former) was
self-reported. Diabetic retinopathy was
assessed at baseline as absent, mild, or
moderate/severe on the basis of seven-
field retinal photographs. History of
myocardial infarction (MI), angina,
stroke, and transient ischemic attack
(TIA) was determined at baseline
through self-report of a physician
diagnosis, World Health Organization
chest pain questionnaire, 12-lead
electrocardiogram, and linkage to
hospital discharge records, as detailed
previously (18). The same sources of
data and criteria were used to ascertain
incident MI, angina, stroke, and TIA
events between baseline and year 4.
Scores on the self-administered
depression subscale of the Hospital
Anxiety and Depression Scale (HADS-D)
(19) (score range 0–21) measured
symptoms of depression at baseline and
at year 4. Scores,24 of 30 on the Mini-
Mental State Examination (20) were
used together with additional criteria
(21) to identify participants with
dementia by year 4 follow-up.
Measurement of Hypoglycemia
Reporting of severe hypoglycemia in the
ET2DS is summarized in Fig. 1. At
baseline, a questionnaire determined
participants’ history of severe
hypoglycemia (history of hypoglycemia),
which was defined as an episode of
hypoglycemia requiring the assistance
of another person to effect recovery.
Participants were asked about the
number of episodes they had
experienced over their lifetime and
within the past year. A similar
questionnaire at the year 4 examination
determined severe hypoglycemia since
baseline (incident hypoglycemia),
including the number of episodes
experienced in total, and in the year
preceding the examination. Data from
participants who expressed uncertainty
were not used.
Additionally, 898 consenting participants
were enrolled in a detailed 6-month
survey of severe hypoglycemia,
commencing ;1 year after baseline.
Once every 2 months for a total of
6 months, participants returned self-
completed questionnaires based on the
Edinburgh Hypoglycemia scale (22) that
comprised items on symptoms, date
and time of any hypoglycemic episode,
loss of consciousness, help from
another person, treatment, and blood
glucose values, if measured. For those
who reported severe hypoglycemia or
who failed to return a questionnaire,
data were obtained and verified by
telephone.
Cognitive Assessment at Baseline and
Year 4
With the aim to minimize effects of
measurement error on the baseline and
year 4 cognitive test data (a prerequisite
for the validity of analyses of cognitive
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change), conditions for cognitive testing
were kept the same at the two time
points asmuch as possible. At both times,
the absence of current hypoglycemia
was confirmed by measuring blood
glucose before commencing each
testing session, which was only
undertaken if values were$4.0 mmol/L.
Participants were also reminded by
letter to bring their glasses or hearing
aids as required and were prompted to
use these at the clinic. Data from
participants with severe sensory
impairment were not used. The Logical
Memory (LM) and Faces subtests of the
Wechsler Memory ScaledThird
Edition (U.K.) assessed verbal and
nonverbal memory, respectively (23).
Executive function was measured with
the Borkowski Verbal Fluency Test
(BVFT) and the Trail Making Test B
(TMT-B). The Digit SymboldCoding
(DSC), Letter-Number Sequencing
(LNS), and Matrix Reasoning (MR)
subtests of the Wechsler Adult
Intelligence ScaledThird Edition (U.K.)
assessed speed of processing, working
memory, and nonverbal reasoning,
respectively (24). Peak premorbid
ability was estimated by the junior and
senior Mill Hill Vocabulary Scale (MHVS)
(25), a valid measure of crystallized
intelligence relatively immune to
age-related decline (26).
Statistical Analysis
TMT-B, HADS-D, and duration of
diabetes were transformed to their
natural logarithms because of skewed
distributions. Data were missing on the
seven age-sensitive cognitive tests (LM,
Faces, MR, DSC, TMT-B, LNS, BVFT) for
between 0.6% (BVFT) and 1.7% (LNS) of
participants at baseline and for between
0.8% (MR) and 4.7% (LNS) at year 4
follow-up. Multiple imputation
accounting for age and sex was carried
out for participants withmissing data on
one, two, or three cognitive tests.
Different cognitive tests tending to load
on a single factor of global cognitive
ability, which has been termed g (27), is
commonly observed. With the aim to
extract g, components with eigenvalues
.1 were extracted from a principal
components analysis of scores on the
seven cognitive tests after their
imputation. All seven cognitive tests
loaded on a single component with an
eigenvalue .1; inspection of the scree
plot also suggested a strong general
cognitive ability factor. The use of the
standardized factor g derived from this
method is advantageous because in
contrast to scores on individual
cognitive tests, it partly offsets test-
specific measurement error. In the
ET2DS, g has been found to capture
participants’ overall performance at
baseline and year 4 follow-up, as
described previously (21).
All analyses were adjusted for age and
sex. Initially, ANCOVA was used to
compare mean baseline g between
individuals with incident hypoglycemia
and the remaining sample. This method
does not entirely eliminate the influence
from potential confounders to allow
their dismissal, especially in
observational studies, but reduces
Figure 1—Reporting of severe hypoglycemia (SH) in the ET2DS.
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covariate-associated noise in the data
(28); therefore, it was used to address
the issue of confounding in the current
study. Additionally, odds ratios (ORs) for
incident hypoglycemia were calculated
in participants with low baseline g (i.e.,
who scored in the lowest tertile of g) in
logistic regression models. Analyses
were repeated with restriction to
incidence of first-ever incident
hypoglycemia.
Further logistic regression analyses
ascertained the OR for reduced follow-
up g and accelerated decline in g (both
scoring in the lowest tertiles of
distribution) according to history of
previous hypoglycemia at baseline and
of subsequent incident hypoglycemia
between baseline and year 4.
Additionally, ANCOVA was used to
determine hypoglycemia associations
with follow-up cognitive test performance
and cognitive change. Cognitive change
between baseline and year 4 was
represented by inclusion of baseline
cognitive test scores in the models of
follow-up scores. This method was
chosen over the alternative of raw
change scores because its parameter
estimates are more straightforward and
no assumptions are made regarding the
group difference in cognitive function at
baseline (29).
Cognitive change between estimated
peak premorbid ability and year 4 ability
was represented by inclusion of baseline
MHVS in models of year 4 cognitive test
scores. For all outcomes, vascular risk
factors (HDL and total cholesterol,
systolic and diastolic blood pressure,
smoking), HbA1c, cerebrovascular
disease (stroke, TIA), coronary heart
disease (angina, MI), and diabetic
retinopathy as a measure of
microvascular disease (vascular
covariates) were then added to the
models. Treatment modality, duration
of diabetes, and HADS-D were also
included in analyses performed post hoc
and presented in the text. Baseline
covariates were used for analyses of a
baseline history of hypoglycemia, and
year 4 covariates were used in analyses
of incident hypoglycemia. An exception
to this was smoking status, which was
found to be relatively stable over the
course of the study, and retinopathy,
which was measured only at baseline.
Analyses were performed with SPSS
version 19.0 (IBM Corporation, Armonk,
NY) statistical software.
RESULTS
Characteristics of Follow-up Study
Population
Characteristics of attenders of the year 4
follow-up are presented in Table 1.
Attenders were largely similar to
nonattenders in terms of baseline
clinical characteristics but had higher
baseline cognitive function (21). In
addition, nonattendance was
significantly associated with a baseline
history of hypoglycemia (31.3 and 20.5%
of participants with and without a
history of hypoglycemia at baseline,
respectively, were nonattenders; P =
0.01).
History of Hypoglycemia
In the total study population attending
follow-up (n = 831), 77 (9.3%)
participants reported a history of
hypoglycemia at baseline and 85
(10.2%) experienced incident
hypoglycemia. Of the latter, 27 (31.8%)
also had a baseline history of
hypoglycemia (P , 0.001 for risk of
recurrent severe hypoglycemia). Of 898
participants enrolled in the 6-month
hypoglycemia survey, 30 reported a
total of 45 episodes of severe
hypoglycemia. For 18 of the 45 episodes
in which blood glucose readings were
self-reported, all but 1 of 14
measurements made before treatment
were ,3.0 mmol/L, suggesting that
participants were reasonably accurate
at identifying hypoglycemia. Of the 30
participants reporting hypoglycemia in
the 6-month survey, 25 recovered after
treatment with a glucose drink or
ingesting food, 1 required injection with
glucagon, and 3 required intravenous
glucose (information was missing for 1
participant). Twenty-three of the 30
participants attended the year 4 follow-
up; most (74%) reported incident
hypoglycemia in the 4 years since
baseline, demonstrating a reasonable
level of recall of hypoglycemia at
follow-up.
Association of Baseline Cognitive
Function With Incident Hypoglycemia
Baseline global cognitive function was
lower in participants with incident
hypoglycemia than in those remaining
free of incident hypoglycemia (age- and
sex-adjusted mean g 20.08 [95% CI
20.27 to 0.12] vs. 0.17 [0.10–0.24], P =
0.019). Participants scoring in the
lowest tertile of g were at a twofold
higher risk of experiencing incident
hypoglycemia compared with higher-
scoring participants (age- and sex
adjusted OR 2.04 [95% CI 1.25–3.31],
P = 0.004). Results were largely
unchanged when restricted to
participants who experienced their
first-ever severe hypoglycemic episode
during the follow-up period (age- and
sex-adjusted OR 2.45 [1.37–4.39], P =
0.002; adjusted mean g 20.08 [20.33
to 0.16] vs. 0.18 [0.12–0.25], P = 0.038).
The presence of dementia in four
participants was not significantly
associated with incident hypoglycemia
(P . 0.05). Because their exclusion did
not alter P values and effect sizes (data
not shown), results are reported for the
entire sample.
Baseline History of Hypoglycemia,
Cognitive Function, and Cognitive
Change
Participants with a history of
hypoglycemia had lower performance
on MR, DSC, TMT-B, and g at year 4
(Table 2) and were marginally more
likely to score in the lowest tertile of g
(age- and sex-adjusted OR 1.65 [0.99–
2.76], P = 0.055) compared with the
remaining population. All associations
persisted when MHVS (which estimates
premorbid ability) was included in the
model (all P , 0.05) (data not shown).
All except DSC (P = 0.145) survived
further addition of baseline vascular
covariates, baseline HADS-D, duration
of diabetes, and baseline treatment
modality into the model (all P , 0.05)
(data not shown).
A history of hypoglycemia was also
associated with a steeper decline
between baseline and year 4 on MR,
TMT-B, and g (Table 2), although the OR
for cognitive decline (lowest tertile
of standardized residuals signifying a
4-year decline in g) was not statistically
significant (1.36 [0.82–2.24], P = 0.230).
Inclusion of baseline vascular covariates
marginally attenuated the associations
with MR and g (Table 2). For MR (P ,
0.05) but not g (P = 0.083), the
association remained statistically
significant when baseline HADS-D,
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baseline treatment, and disease
duration were added to the model (data
not shown).
Incident Hypoglycemia, Cognitive
Function, and Cognitive Change
Incident hypoglycemia was associated
with lower g, MR, LNS, TMT-B, DSC, and
Faces performance at year 4 (Table 3).
The risk of reduced cognitive function at
follow-up (scoring in the lowest tertile
g) was increased threefold for the
incident hypoglycemia group (age- and
sex-adjusted OR 2.97 [1.82–4.86], P ,
0.001). All associations remained
statistically significant when MHVS was
added to the respective models,
suggesting that participants with
incident hypoglycemia experienced a
steeper estimated lifetime decline
between their peak premorbid and
late-life ability than did the group free
of incident hypoglycemia (Table 3). All
associations except for DSC further
survived the inclusion of year 4 vascular
covariates (Table 3) and the inclusion of
HADS-D at year 4, treatment at year 4,
and disease duration in the respective
models (all P, 0.05) (data not shown).
Participants with incident hypoglycemia
also experienced a steeper decline
between baseline and year 4 in MR,
TMT-B, DSC, Faces, and g (Table 3).
Those with the highest rate of decline
(scoring in the lowest tertile of
standardized residuals signifying a
decline in g) were marginally more likely
to have experienced incident
hypoglycemia than the remaining
population (age- and sex-adjusted OR
1.53 [0.95–2.47], P = 0.084). The
associations with decline in MR, TMT-B,
Faces, and g survived inclusion of year 4
vascular covariates (Table 3). The
associationwith decline in Faces andMR
further survived addition of HADS-D at
year 4, treatment at year 4, and disease
duration to the model (both P , 0.05);
for TMT-B and g, the findings were just
short of statistical significance (P = 0.064
and 0.072, respectively) (data not
shown).
CONCLUSIONS
Lower cognitive ability at baseline was
associated with a twofold higher
incidence of severe hypoglycemia over 4
years. In addition, severe hypoglycemia
was associated with a steeper decline in
cognitive function. The latter was
observed when cognitive change was
Table 1—Characteristics of year 4 attenders according to incident hypoglycemia reported at follow-up
All attenders
(maximum n = 831)
Incident hypoglycemia
(maximum n = 85)
No incident hypoglycemia
(maximum n = 730)
P value for difference
or trend*
Age (years) 67.69 6 4.16 66.69 6 4.05 67.79 6 4.17 0.022
Male sex 430 (51.7) 32 (37.6) 939 (53.8) 0.005
Duration of diabetes (years) 6.00 (3.00–11.00) 9.50 (5.25–15.00) 6.00 (300–10.00) ,0.001
Baseline treatment ,0.001
Insulin 6 tablets 139 (16.7) 31 (36.5) 103 (14.1)
Sulfonylureas 6 other tablets 210 (25.3) 28 (32.9) 179 (24.6)
Other tablets 316 (38.0) 19 (22.4) 292 (40.1)
Diet alone 165 (19.9) 7 (8.2) 155 (21.3)
Year 4 treatment ,0.001
Insulin 6 tablets 178 (21.4) 40 (47.1) 133 (18.2)
Sulfonylureas 6 other tablets 255 (30.7) 25 (29.4) 228 (31.2)
Other tablets 283 (34.1) 16 (18.8) 261 (35.8)
Diet alone 115 (13.8) 4 (4.7) 108 (14.8)
Plasma HbA1c (%) 7.39 6 1.13 7.86 6 1.22 7.32 6 1.06 ,0.001
Plasma HbA1c (mmol/mol) 57 6 12.4 62 6 13.3 56 6 11.6 ,0.001
Systolic BP (mmHg) 133 6 16 130 6 15 132 6 16 0.086
Diastolic BP (mmHg) 69 6 9 67 6 6 69 6 9 0.002
Vascular disease
MI 111 (13.4) 12 (14.1) 98 (13.4) 0.860
Angina 222 (26.7) 22 (25.9) 197 (27.0) 0.828
Stroke 44 (5.3) 2 (2.4) 42 (5.8) 0.189
TIA 27 (3.2) 7 (8.2) 19 (2.6) 0.005
Retinopathy 266 (32.0) 33 (39.3) 227 (31.5) 0.150
Total cholesterol (mmol/L) 4.34 6 0.90 4.34 6 0.81 4.32 6 0.90 0.890
HDL cholesterol (mmol/L) 1.29 6 0.36 1.26 6 0.35 1.29 6 0.36 0.351
Smoking status
Current smoker 108 (13.0) 18 (21.2) 88 (12.1) 0.018
Ex-smoker 390 (46.9) 37 (43.5) 349 (47.8) 0.455
Never smoked 333 (40.1) 30 (35.3) 293 (40.1) 0.388
HADS-D 3 (1–6) 5 (2–7) 3 (1–5) ,0.001
MMSE 28.47 6 1.64 28.59 6 1.48 28.51 6 1.57 0.647
Dementia 4 (0.5) 0 (0.0) 2 (0.3) 0.629
MHVS 31.45 6 5.07 30.80 6 4.84 31.63 6 5.07 0.151
Data are mean 6 SD, median (interquartile range), or n (%). Data are from baseline unless otherwise indicated. BP, blood pressure; MMSE, Mini-
Mental State Examination. *Comparing the incident hypoglycemia with the no incident hypoglycemia group.
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measured subsequently to the
hypoglycemic events and, even more
strongly, when the two were occurring
simultaneously during the 4-year
follow-up period. Thus, the results
suggest that the experience of severe
hypoglycemia may be associated with
lesser prior cognitive ability and is a risk
factor for accelerated cognitive decline.
In addition to global cognitive ability
measured by g, associations with
cognitive outcome were most
consistently observed for processing
speed, nonverbal memory, executive
function, and reasoning.
Previous cross-sectional studies
demonstrated a relationship between
hypoglycemia and poorer cognitive
function in people with type 2 diabetes
(11,12,14). However, uncertainty
remains about the reasons for this
association and the direction of any
possible causal relationship between
hypoglycemia and cognitive
decrements. Evidence supports that
people with poorer cognitive ability
may be more susceptible to
hypoglycemia. Lower baseline scores
on a screening instrument for dementia
predicted 5-year incident severe
hypoglycemia in the Action in Diabetes
and Vascular Disease: Preterax and
Diamicron Modified Release Controlled
Evaluation (ADVANCE) trial (15).
Clinically diagnosed dementia has been
shown to predict a two- to threefold
increased risk of hospital admission or
emergency treatment for hypoglycemia
in the Fremantle Diabetes Study (14)
and in the Health, Aging and Body
Composition Study (9). In the Memory
in Diabetes study of the Action to
Control Cardiovascular Risk in Diabetes
(ACCORD-MIND) trial, lower baseline
cognitive test scores also predicted an
increased risk of a first-ever
hypoglycemic episode over 3.5 years of
follow-up (11). These findings are
consistent with the current study in
which baseline g predicted subsequent
severe hypoglycemia. It is possible that
people with lower or declining cognitive
ability are less able to recognize
hypoglycemia, to treat it appropriately
when it occurs, or to prevent it through
modification of diabetes therapy.
Less epidemiological evidence supports
the hypothesis that hypoglycemia may
have a direct or indirect effect on the
brain, resulting in cognitive decrements.
In type 1 diabetes, the balance of
evidence suggests that hypoglycemia
may not affect cognitive function in this
way (30). Incidence of severe
hypoglycemia over 18 years was not
associated with concurrent cognitive
decline in the Diabetes Control and
Complications Trial/Epidemiology of
Diabetes Interventions and
Complications cohort (4), and in a
smaller study, 10-year incidence of
severe hypoglycemia failed to predict






P value for group
difference
Effect size of group
difference (partial s2)
Model 1: age, sex
MR 11.76 (11.39 to 12.13) 10.14 (8.97 to 11.31) 0.009 0.008
LNS 8.96 (8.75 to 9.16) 8.33 (7.67 to 8.99) 0.076 0.004
BVFT 37.19 (36.27 to 38.11) 34.63 (31.72 to 37.54) 0.100 0.003
DSC 50.51 (49.53 to 51.49) 46.31 (43.19 to 49.44) 0.012 0.012
ln(TMT-B) 109.84 (106.70 to 113.07) 129.02 (117.68 to 141.60) 0.001 0.013
Faces 69.37 (68.78 to 69.96) 68.70 (66.85 to 70.56) 0.500 0.001
LM 27.28 (26.69 to 27.84) 27.71 (25.86 to 29.56) 0.661 ,0.001
g 0.04 (20.03 to 0.11) 20.26 (20.49 to 20.04) 0.009 0.008
Model 2: age, sex, baseline score
MR 11.75 (11.47 to 12.03) 10.22 (9.34 to 11.11) 0.001 0.013
LNS 8.92 (8.74 to 9.09) 866 (8.10 to 9.22) 0.394 0.001
BVFT 37.04 (36.50 to 37.59) 36.17 (34.45 to 37.89) 0.340 0.001
DSC 50.31 (49.63 to 50.99) 48.31 (46.14 to 50.49) 0.086 0.004
ln(TMT-B) 110.72 (108.20 to 113.18) 119.94 (111.72 to 128.90) 0.036 0.005
Faces 69.40 (68.92 to 69.87) 68.49 (66.98 to 70.00) 0.260 0.002
LM 27.31 (26.85 to 27.77) 27.34 (25.89 to 28.80) 0.966 ,0.001
g 0.03 (20.04 to 0.10) 20.25 (20.48 to 20.02) 0.020 0.007
Model 3*
MR 11.82 (11.53 to 12.11) 10.35 (9.41 to 11.29) 0.004 0.011
LNS 8.95 (8.77 to 9.13) 8.70 (8.12 to 9.29) 0.423 0.001
BVFT 37.33 (36.77 to 37.89) 36.47 (34.65 to 38.30) 0.381 0.001
DSC 50.38 (49.79 to 51.08) 48.73 (46.46 to 51.01) 0.176 0.002
ln(TMT-B) 109.95 (107.45 to 112.51) 117.57 (109.07 to 126.72) 0.097 0.004
Faces 69.52 (69.03 to 70.01) 68.81 (67.21 to 70.41) 0.409 0.001
LM 27.45 (26.98 to 27.91) 27.93 (26.42 to 29.45) 0.549 ,0.001
g 0.03 (20.04 to 0.11) 20.23 (20.47 to 0.01) 0.040 0.006
Data are adjusted mean (95% CI). n = 808–811 for model 1; n = 807–810 for model 2; n = 768–770 for model 3. Means for ln(TMT-B) are geometric
means. *Adjusted for age, sex, baseline score, and baseline data on HDL cholesterol, total cholesterol, systolic blood pressure, diastolic blood
pressure, smoking, HbA1c, stroke, TIA, angina, MI, and retinopathy.
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subsequent levels of cognitive function
(31). However, people with type 1
diabetes typically are younger and
have a lower prevalence of
comorbidities than those with type 2
diabetes (32). In addition, the Diabetes
Interventions and Complications Trial
cohort was atypical in that the
participants had been selected for
having high compliance with treatment
and a low risk of hypoglycemia such that
these findings may have been affected
by low prevalence of both the risk factor
(hypoglycemia) and the outcome (age-
related cognitive decline). In type 2






P value for group
difference
Effect size of group
difference (partial s2)
Cognitive ability at year 4
Model 1: age, sex
MR 11.82 (11.45 to 12.19) 10.02 (8.92 to 11.12) 0.003 0.011
LNS 9.02 (8.82 to 9.23) 8.00 (7.38 to 8.61) 0.002 0.012
BVFT 37.20 (36.27 to 38.12) 35.34 (32.60 to 38.09) 0.211 0.002
DSC 50.69 (49.70 to 51.67) 46.63 (43.69 to 49.57) 0.011 0.008
ln(TMT-B) 109.29 (106.16 to 112.51) 126.85 (116.28 to 138.52) 0.001 0.013
Faces 69.63 (69.05 to 70.22) 67.08 (65.33 to 68.83) 0.007 0.009
LM 27.42 (26.83 to 28.01) 26.77 (25.00 to 28.54) 0.493 0.001
g 0.07 (0.00 to 0.13) 20.33 (20.53 to 20.12) ,0.001 0.015
Four-year cognitive decline
Model 2*
MR 11.75 (11.47 to 12.04) 10.57 (9.72 to 11.41) 0.009 0.008
LNS 8.97 (8.79 to 9.14) 8.42 (7.89 to 8.94) 0.052 0.005
BVFT 37.15 (36.61 to 37.70) 35.77 (34.14 to 37.40) 0.116 0.003
DSC 50.51 (49.82 to 51.19) 48.21 (46.16 to 50.26) 0.038 0.005
ln(TMT-B) 109.95 (107.55 to 112.51) 119.82 (112.06 to 128.25) 0.019 0.007
Faces 69.59 (69.11 to 70.07) 67.53 (66.11 to 68.96) 0.008 0.009
LM 27.36 (26.90 to 27.83) 27.27 (25.87 to 28.66) 0.900 ,0.001
g 0.04 (20.03 to 0.12) 20.28 (20.49 to 20.06) 0.006 0.009
Model 3†
MR 11.78 (11.49 to 12.07) 10.65 (9.77 to 11.53) 0.017 0.007
LNS 8.98 (8.80 to 9.16) 8.54 (7.99 to 9.09) 0.140 0.003
BVFT 37.32 (36.76 to 37.88) 36.16 (34.46 to 37.86) 0.205 0.002
DSC 50.56 (49.86 to 51.26) 48.79 (46.66 to 50.92) 0.122 0.003
ln(TMT-B) 109.73 (107.23 to 112.28) 119.10 (111.05 to 127.74) 0.029 0.006
Faces 69.69 (69.20 to 70.18) 67.64 (66.15 to 69.12) 0.010 0.009
LM 27.46 (26.99 to 27.94) 27.33 (25.88 to 28.77) 0.860 ,0.001
g 0.05 (20.02 to 0.13) 20.21 (20.43 to 0.01) 0.028 0.006
Estimated lifetime cognitive decline
Model 4‡
MR 11.78 (11.45 to 12.11) 10.30 (9.24 to 11.22) 0.004 0.011
LNS 9.02 (8.83 to 9.21) 8.16 (7.60 to 8.73) 0.006 0.010
BVFT 37.11 (36.26 to 37.96) 35.95 (33.41 to 38.49) 0.394 0.001
DSC 50.61 (49.69 to 51.53) 47.22 (44.46 to 49.98) 0.023 0.007
ln(TMT-B) 109.29 (106.38 to 112.28) 124.71 (114.89 to 135.23) 0.003 0.011
Faces 69.60 (69.03 to 70.17) 67.24 (65.55 to 68.93) 0.010 0.008
LM 27.37 (26.84 to 27.90) 27.36 (25.77 to 28.95) 0.990 ,0.001
g 0.06 (0.00 to 0.12) 20.26 (20.43 to 20.09) 0.001 0.015
Model 5§
MR 11.81 (11.47 to 12.15) 10.28 (9.24 to 11.32) 0.007 0.010
LNS 9.03 (8.84 to 9.23) 8.24 (7.64 to 8.83) 0.013 0.008
BVFT 37.26 (36.94 to 38.13) 36.53 (33.89 to 39.17) 0.608 ,0.001
DSC 50.61 (49.68 to 51.55) 48.22 (45.38 to 51.08) 0.121 0.003
ln(TMT-B) 109.18 (106.17 to 112.28) 122.73 (112.73 to 133.49) 0.010 0.009
Faces 69.70 (69.13 to 70.28) 67.32 (65.56 to 69.08) 0.012 0.008
LM 27.47 (26.93 to 28.01) 27.51 (25.86 to 29.15) 0.963 ,0.001
g 0.07 (0.01 to 0.13) 20.22 (20.39 to 20.04) 0.003 0.012
Data are adjusted mean (95% CI). n = 807–810 for model 1; n = 806–809 for model 2; n = 775–777 for model 3; n = 798–801 for model 4; n = 767–769
for model 5. Means for ln(TMT-B) are geometric means. *Adjusted for age, sex, and baseline score. †Model 2 + baseline smoking, retinopathy, and
year 4 data on HDL cholesterol, total cholesterol, systolic blood pressure, diastolic blood pressure, HbA1c, stroke, TIA, angina, and MI. ‡Adjusted for
age, sex, and baseline MHVS. §Model 4 + baseline smoking, retinopathy, and year 4 data on HDL cholesterol, total cholesterol, systolic blood
pressure, diastolic blood pressure, HbA1c, stroke, TIA, angina, and MI.
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diabetes, one relatively small study
established no links between a baseline
history of severe hypoglycemia and
conversion among normal cognition,
impairment, and frank dementia over 18
months (14). Conversely, some evidence
suggests that the experience of
hypoglycemia may be a risk factor for
future dementia developing in type 2
diabetes (6,7,9). Dementia lies at an end
point of the continuum of age-related
cognitive impairment, and to our
knowledge, the current study has
supplemented the current literature by
providing the most robust evidence to
date that exposure to severe
hypoglycemia either preceding or
concurrent with change in cognition
during aging is associated with an
increase in the rate of age-related
cognitive decline in older people with
type 2 diabetes without frank dementia.
The finding of a relationship between
hypoglycemia and the memory domain
in particular is consistent with published
evidence for associations of
hypoglycemia with dementia, which
commonly is preceded by memory
impairment (33).
The findings contrast those of the
ACCORD-MIND and ADVANCE trials in
which patients in intensive treatment
groups (with higher incidence of
hypoglycemia) experienced cognitive
decline at similar rates over 40 months
and 5 years of follow-up, respectively,
compared with the respective standard
treatment groups (15,16). However,
both studies were randomized
controlled trials involving strict glycemic
control and with cognitive function as a
secondary end point. Because
improving glycemic control may
improve cognitive dysfunction when
glycemic control is suboptimal (34),
detrimental effects of hypoglycemia
were potentially counteracted by the
specific therapeutic interventions. The
ADVANCE trial also assessed cognitive
decline with a screening instrument for
dementia, which is likely to be
insensitive to subtle cognitive changes
(35), and annual incidence of
hypoglycemic episodes (defined on the
basis of criteria comparable to severe
hypoglycemia in the current study) was
low compared with the ET2DS and
ACCORD-MIND trials because none of its
participants were receiving insulin
treatment.
In addition to its prospective nature, the
strengths of the current study lie in the
relatively large size and in the
population being representative of the
full spectrum of people with type 2
diabetes living in the community, with
treatment modalities ranging from diet
to insulin, and with the inclusion of the
age range at which cognitive decline
often becomes apparent. A detailed
battery of validated cognitive tests
covered the major cognitive domains,
and a reasonably comprehensive list of
potential confounders was considered
in the analyses, although, of course,
residual confounding by any
unmeasured variable cannot be ruled
out. Despite potential weakness in the
self-reporting of severe hypoglycemia
given that not all severe episodes
generate symptoms, particularly in
people who have impaired awareness of
hypoglycemia (36), a short prospective
survey embedded into the main study
demonstrated that the participants
appeared to be identifying most, if not
all, episodes at least of symptomatic
severe hypoglycemia and that their
recall (even over a number of years) was
reasonably accurate. Although self-
reported episodes of severe
hypoglycemia may not represent all
episodes of hypoglycemia, including
milder episodes or symptom-free severe
episodes, the measure appears to be a
useful marker of a more generalized risk
of exposure to hypoglycemia. One
limitation of the study, which is inherent
to all observational studies, is the
inability to evaluate the potential for
causality in the reported associations.
Nonetheless, such observational studies
make important contributions to the
understanding of associations and
inform the design of future studies
aimed specifically at investigating the
issue of causality. The mechanism by
which hypoglycemia could potentially
disrupt cognitive function is unclear.
Although reports of permanent brain
damage or chronic severe cognitive
deficit are rare (37,38), glucose
deprivation has been directly linked to
neuronal death in vitro, and some
evidence in type 1 diabetes suggests
structural differences in the brain
between patients who have and those
who have not been exposed to
hypoglycemia (3).
In the current study, we show that low
cognitive ability is associated with an
increase in the risk of subsequent
episodes of severe hypoglycemia.
Moreover, severe hypoglycemia at
baseline and during follow-up was
associated with an increased risk of
subsequent and/or concurrent cognitive
decline. If the latter association is found
to be causal in nature, it will be
necessary to address the effect of strict
glycemic control on cognitive function
in the clinical management of older
people with type 2 diabetes. In the
meantime, change in cognitive function
should be considered as a clinical end
point in the design of all future
randomized trials of novel antidiabetes
agents that have the potential to induce
or augment the frequency of
hypoglycemia.
Funding. The sponsor for the ET2DS was the
University of Edinburgh. The study was funded
by the Medical Research Council (U.K.) and the
Chief Scientist Office of the Scottish Executive.
I.J.D., B.M.F., and J.F.P. are members of The
University of Edinburgh Centre for Cognitive
Ageing and Cognitive Epidemiology, part of the
cross-council Lifelong Health and Wellbeing
Initiative (which has funding from the
Biotechnology and Biological Sciences Research
Council, Engineering and Physical Sciences
Research Council, Economic and Social Research
Council, and Medical Research Council,
G0700704/84698).
Duality of Interest. This study has received
funding from Pfizer plc. M.W.J.S. has received
fees for speaking from Novo Nordisk, Eli Lilly,
Pfizer, and Bristol-Myers Squibb and has
received support for travel and
accommodations at a scientific meeting from
Sanofi. No other potential conflicts of interest
relevant to this article were reported.
The funder had no other role in the design,
analysis, or preparation of this article.
Author Contributions. I.F. performed the
literature search and statistical analysis,
contributed to the data collection, created the
figure, and drafted the manuscript with
supervision from I.J.D., M.W.J.S., and J.F.P. P.P.A.,
M.K., C.M.R., J.R.M., and S.M. contributed to
the data collection, interpretation offindings, and
preparation of the final manuscript. I.J.D. and
B.M.F. contributed to the interpretation of
findings and preparation of the final manuscript.
M.W.J.S. and J.F.P. contributed to the
interpretation of findings and preparation of the
final manuscript, conceived and designed the
ET2DS, and oversaw the data acquisition and
514 Severe Hypoglycemia and Cognitive Decline Diabetes Care Volume 37, February 2014
© 
analysis. I.F. and J.F.P. are the guarantors of this
work and, as such, had full access to all the data in
the study and take responsibility for the integrity
of the data and the accuracy of the data analysis.
References
1. Biessels GJ, Deary IJ, Ryan CM. Cognition
and diabetes: a lifespan perspective. Lancet
Neurol 2008;7:184–190
2. Strachan MWJ, Reynolds RM, Marioni RE,
Price JF. Cognitive function, dementia and
type 2 diabetes mellitus in the elderly. Nat
Rev Endocrinol 2011;7:108–114
3. Northam EA, Lin A. Hypoglycaemia in
childhood onset type 1 diabetesdpart
villain, but not the only one. Pediatr
Diabetes 2010;11:134–141
4. Jacobson AM, Musen G, Ryan CM, et al.;
Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions
and Complications Study Research Group.
Long-term effect of diabetes and its
treatment on cognitive function. N Engl J
Med 2007;356:1842–1852
5. UK Hypoglycaemia Study Group. Risk of
hypoglycaemia in types 1 and 2 diabetes:
effects of treatment modalities and their
duration. Diabetologia 2007;50:1140–1147
6. Lin CH, Sheu WH. Hypoglycaemic episodes
and risk of dementia in diabetes mellitus:
7-year follow-up study. J Intern Med 2013;
273:102–110
7. Whitmer RA, Karter AJ, Yaffe K,
Quesenberry CPJ Jr, Selby JV. Hypoglycemic
episodes and risk of dementia in older
patients with type 2 diabetes mellitus.
JAMA 2009;301:1565–1572
8. Feil DG, Rajan M, Soroka O, Tseng C-L,
Miller DR, Pogach LM. Risk of hypoglycemia
in older veterans with dementia and
cognitive impairment: implications for
practice and policy. J Am Geriatr Soc 2011;
59:2263–2272
9. Yaffe K, Falvey CM, Hamilton N, et al.; Health
ABC Study. Association between
hypoglycemia and dementia in a biracial
cohort of older adults with diabetesmellitus.
JAMA Intern Med 2013;173:1300–1306
10. Graveling AJ, Frier BM. Dementia and
hypoglycemic episodes in patients with
type 2 diabetes mellitus. JAMA 2009;302:
843–844; author reply 843–844
11. Punthakee Z, Miller ME, Launer LJ, et al.;
ACCORD Group of Investigators; ACCORD-
MIND Investigators. Poor cognitive
function and risk of severe hypoglycemia in
type 2 diabetes: post hoc epidemiologic
analysis of the ACCORD trial. Diabetes Care
2012;35:787–793
12. Aung PP, Strachan MWJ, Frier BM,
Butcher I, Deary IJ, Price JF; Edinburgh
Type 2 Diabetes Study Investigators.
Severe hypoglycaemia and late-life
cognitive ability in older people with type
2 diabetes: the Edinburgh Type 2
Diabetes Study. Diabet Med 2012;29:
328–336
13. Warren RE, Frier BM. Hypoglycaemia and
cognitive function. Diabetes Obes Metab
2005;7:493–503
14. Bruce DG, Davis WA, Casey GP, et al. Severe
hypoglycaemia and cognitive impairment in
older patients with diabetes: the Fremantle
Diabetes Study. Diabetologia 2009;52:
1808–1815
15. de Galan BE, Zoungas S, Chalmers J, et al.;
ADVANCE Collaborative Group. Cognitive
function and risks of cardiovascular disease
and hypoglycaemia in patients with type 2
diabetes: the Action in Diabetes and
Vascular Disease: Preterax and Diamicron
Modified Release Controlled Evaluation
(ADVANCE) trial. Diabetologia 2009;52:
2328–2336
16. Launer LJ, Miller ME, Williamson JD, et al.;
ACCORD MIND Investigators. Effects of
intensive glucose lowering on brain
structure and function in people with type 2
diabetes (ACCORD MIND): a randomised
open-label substudy. Lancet Neurol 2011;
10:969–977
17. Price JF, Reynolds RM, Mitchell RJ, et al.
The Edinburgh Type 2 Diabetes Study:
study protocol. BMC Endocr Disord 2008;8:
18–27
18. Marioni RE, Strachan MWJ, Reynolds
RM, et al. Association between
raised inflammatory markers and
cognitive decline in elderly people with
type 2 diabetes: the Edinburgh Type 2
Diabetes Study. Diabetes 2010;59:
710–713
19. Zigmond AS, Snaith RP. The hospital anxiety
and depression scale. Acta Psychiatr Scand
1983;67:361–370
20. Folstein MF, Folstein SE, McHugh PR.
“Mini-mental state”. A practical method
for grading the cognitive state of patients
for the clinician. J Psychiatr Res 1975;12:
189–198
21. Feinkohl I, Keller M, Robertson CM, et al.;
Edinburgh Type 2 Diabetes Study (ET2DS)
Investigators. Clinical and subclinical
macrovascular disease as predictors of
cognitive decline in older patients with
type 2 diabetes: the Edinburgh Type 2
Diabetes Study. Diabetes Care 2013;36:
2779–2786
22. Deary IJ, Crawford JR, Hepburn DA, Langan
SJ, Blackmore LM, Frier BM. Severe
hypoglycemia and intelligence in adult
patients with insulin-treated diabetes.
Diabetes 1993;42:341–344
23. Wechsler D. Manual of the Wechsler
Memory Scale- Revised. New York, The
Psychological Corporation Limited, 1987
24. Wechsler D. Wechsler Adult Intelligence
Scale. 3rd ed. London, The Psychological
Corporation; 1998.
25. Raven J, Raven JC, Court JH. Manual for
Raven’s Progressive Matrices and
Vocabulary Scales. Oxford, U.K., Oxford
Psychologists Press Ltd., 1998
26. Deary IJ, Whalley LJ, Crawford JR. An
‘instantaneous’ estimate of a lifetime’s
cognitive change. Intelligence 2004;32:
113–119
27. Spearman C. “General intelligence,”
objectively determined and measured. Am
J Psychol 1904;15:201–292
28. Miller GA, Chapman JP. Misunderstanding
analysis of covariance. J Abnorm Psychol
2001;110:40–48
29. Willett JB. Measuring change: what
individual growth modeling buys you. In
Change and Development: Issues of Theory,
Method, and Application. Amsel E, Renninger
KA, Eds. Mahwah, NJ, Lawrence Erlbaum
Associates, 1997, p. 213–243
30. Brands AMA, Biessels GJ, de Haan EHF,
Kappelle LJ, Kessels RPC. The effects of type
1 diabetes on cognitive performance:
a meta-analysis. Diabetes Care 2005;28:
726–735
31. Reichard P, Pihl M, Rosenqvist U, Sule J.
Complications in IDDM are caused by
elevated blood glucose level: the
Stockholm Diabetes Intervention Study
(SDIS) at 10-year follow up. Diabetologia
1996;39:1483–1488
32. Plotnikoff RC, Lippke S, Karunamuni N,
et al. Co-morbidity, functionality and time
since diagnosis as predictors of physical
activity in individuals with type 1 or type 2
diabetes. Diabetes Res Clin Pract 2007;78:
115–122
33. Petersen RC. Mild cognitive impairment
as a diagnostic entity. J Intern Med 2004;
256:183–194
34. Ryan CM, Freed MI, Rood JA, Cobitz AR,
Waterhouse BR, Strachan MW. Improving
metabolic control leads to better working
memory in adults with type 2 diabetes.
Diabetes Care 2006;29:345–351
35. Tombaugh TN, McIntyre NJ. The Mini-
Mental State Examination: a comprehensive
review. J Am Geriatr Soc 1992;40:922–
935
36. Graveling AJ, Frier BM. Impaired awareness
of hypoglycaemia: a review. Diabetes
Metab 2010;36(Suppl. 3):S64–S74
37. Ryan CM. Recurrent hypoglycemia and the
development of permanent brain damage
in diabetic adults. Diabetic Hypoglycemia
2009;1:3–7
38. McCrimmon RJ, Ryan CM, Frier BM.
Diabetes and cognitive dysfunction. Lancet
2012;379:2291–2299
care.diabetesjournals.org Feinkohl and Associates 515
© 
